
<html lang="en"     class="pb-page"  data-request-id="afc01de7-fe0a-4de8-963b-342bc053afa6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00443;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)" /></meta><meta name="dc.Creator" content="Ryan  Moslin" /></meta><meta name="dc.Creator" content="Yanlei  Zhang" /></meta><meta name="dc.Creator" content="Stephen T.  Wrobleski" /></meta><meta name="dc.Creator" content="Shuqun  Lin" /></meta><meta name="dc.Creator" content="Michael  Mertzman" /></meta><meta name="dc.Creator" content="Steven  Spergel" /></meta><meta name="dc.Creator" content="John S.  Tokarski" /></meta><meta name="dc.Creator" content="Joann  Strnad" /></meta><meta name="dc.Creator" content="Kathleen  Gillooly" /></meta><meta name="dc.Creator" content="Kim W.  McIntyre" /></meta><meta name="dc.Creator" content="Adriana  Zupa-Fernandez" /></meta><meta name="dc.Creator" content="Lihong  Cheng" /></meta><meta name="dc.Creator" content="Huadong  Sun" /></meta><meta name="dc.Creator" content="Charu  Chaudhry" /></meta><meta name="dc.Creator" content="Christine  Huang" /></meta><meta name="dc.Creator" content="Celia  D’Arienzo" /></meta><meta name="dc.Creator" content="Elizabeth  Heimrich" /></meta><meta name="dc.Creator" content="Xiaoxia  Yang" /></meta><meta name="dc.Creator" content="Jodi K.  Muckelbauer" /></meta><meta name="dc.Creator" content="ChiehYing  Chang" /></meta><meta name="dc.Creator" content="Jeffrey  Tredup" /></meta><meta name="dc.Creator" content="Dawn  Mulligan" /></meta><meta name="dc.Creator" content="Dianlin  Xie" /></meta><meta name="dc.Creator" content="Nelly  Aranibar" /></meta><meta name="dc.Creator" content="Manoj  Chiney" /></meta><meta name="dc.Creator" content="James R.  Burke" /></meta><meta name="dc.Creator" content="Louis  Lombardo" /></meta><meta name="dc.Creator" content="Percy H.  Carter" /></meta><meta name="dc.Creator" content="David S.  Weinstein" /></meta><meta name="dc.Description" content="As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 inter..." /></meta><meta name="Description" content="As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 inter..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 17, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00443" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00443" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00443" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00443" /></link>
        
    
    

<title>Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00443" /></meta><meta property="og:title" content="Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0023.jpeg" /></meta><meta property="og:description" content="As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 interferons. The nicotinamide 4, identified by a SPA-based high-throughput screen targeting the TYK2 pseudokinase domain, potently inhibits IL-23 and IFNα signaling in cellular assays. The described work details the optimization of this poorly selective hit (4) to potent and selective molecules such as 47 and 48. The discoveries described herein were critical to the eventual identification of the clinical TYK2 JH2 inhibitor (see following report in this issue). Compound 48 provided robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model. These results demonstrate the ability of TYK2 JH2 domain binders to provide a highly selective alternative to conventional TYK2 orthosteric inhibitors." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 interferons. The nicotinamide 4, identified by a SPA-based high-throughput screen targeting the TYK2 pseudokinase domain, potently inhibits IL-23 and IFNα signaling in cellular assays. The described work details the optimization of this poorly selective hit (4) to potent and selective molecules such as 47 and 48. The discoveries described herein were critical to the eventual identification of the clinical TYK2 JH2 inhibitor (see following report in this issue). Compound 48 provided robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model. These results demonstrate the ability of TYK2 JH2 domain binders to provide a highly selective alternative to conventional TYK2 orthosteric inhibitors." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0023.jpeg" /></meta><meta name="twitter:title" content="Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00443"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00443">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00443&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00443&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00443&amp;href=/doi/10.1021/acs.jmedchem.9b00443" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8953-8972</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01612" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/acs.jmedchem.9b00444" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ryan Moslin</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ryan Moslin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#cebcb7afa0e0a3a1bda2a7a08eaca3bde0ada1a3"><span class="__cf_email__" data-cfemail="116368707f3f7c7e627d787f51737c623f727e7c">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ryan++Moslin">Ryan Moslin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0332-4778" title="Orcid link">http://orcid.org/0000-0002-0332-4778</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanlei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanlei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanlei++Zhang">Yanlei Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen T. Wrobleski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen T. Wrobleski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+T.++Wrobleski">Stephen T. Wrobleski</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7793-1530" title="Orcid link">http://orcid.org/0000-0001-7793-1530</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuqun Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuqun Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuqun++Lin">Shuqun Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Mertzman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Mertzman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Mertzman">Michael Mertzman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven Spergel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven Spergel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Spergel">Steven Spergel</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5190-3942" title="Orcid link">http://orcid.org/0000-0002-5190-3942</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John S. Tokarski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John S. Tokarski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+S.++Tokarski">John S. Tokarski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joann Strnad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joann Strnad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joann++Strnad">Joann Strnad</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kathleen Gillooly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kathleen Gillooly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Gillooly">Kathleen Gillooly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kim W. McIntyre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kim W. McIntyre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kim+W.++McIntyre">Kim W. McIntyre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adriana Zupa-Fernandez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adriana Zupa-Fernandez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adriana++Zupa-Fernandez">Adriana Zupa-Fernandez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lihong Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lihong Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lihong++Cheng">Lihong Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huadong Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huadong Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huadong++Sun">Huadong Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charu Chaudhry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charu Chaudhry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lead Discovery and Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charu++Chaudhry">Charu Chaudhry</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christine Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christine Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Huang">Christine Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Celia D’Arienzo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Celia D’Arienzo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Celia++D%E2%80%99Arienzo">Celia D’Arienzo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elizabeth Heimrich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elizabeth Heimrich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth++Heimrich">Elizabeth Heimrich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoxia Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoxia Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoxia++Yang">Xiaoxia Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jodi K. Muckelbauer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jodi K. Muckelbauer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jodi+K.++Muckelbauer">Jodi K. Muckelbauer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">ChiehYing Chang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">ChiehYing Chang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=ChiehYing++Chang">ChiehYing Chang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey Tredup</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey Tredup</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Tredup">Jeffrey Tredup</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dawn Mulligan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dawn Mulligan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dawn++Mulligan">Dawn Mulligan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dianlin Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dianlin Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dianlin++Xie">Dianlin Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nelly Aranibar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nelly Aranibar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nelly++Aranibar">Nelly Aranibar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manoj Chiney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manoj Chiney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manoj++Chiney">Manoj Chiney</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James R. Burke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James R. Burke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Burke">James R. Burke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Louis Lombardo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Louis Lombardo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Louis++Lombardo">Louis Lombardo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Percy H. Carter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Percy H. Carter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Percy+H.++Carter">Percy H. Carter</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-1164" title="Orcid link">http://orcid.org/0000-0002-5880-1164</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">David S. Weinstein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David S. Weinstein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+S.++Weinstein">David S. Weinstein</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00443&amp;href=/doi/10.1021%2Facs.jmedchem.9b00443" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8953–8972</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 17, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 March 2019</li><li><span class="item_label"><b>Published</b> online</span>17 July 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 October 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00443" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00443</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8953%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRyan%2BMoslin%252C%2BYanlei%2BZhang%252C%2BStephen%2BT.%2BWrobleski%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D20%26contentID%3Dacs.jmedchem.9b00443%26title%3DIdentification%2Bof%2BN-Methyl%2BNicotinamide%2Band%2BN-Methyl%2BPyridazine-3-Carboxamide%2BPseudokinase%2BDomain%2BLigands%2Bas%2BHighly%2BSelective%2BAllosteric%2BInhibitors%2Bof%2BTyrosine%2BKinase%2B2%2B%2528TYK2%2529%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8972%26publicationDate%3DOctober%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00443"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5115</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00443" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;Moslin&quot;},{&quot;first_name&quot;:&quot;Yanlei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;T. Wrobleski&quot;},{&quot;first_name&quot;:&quot;Shuqun&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Mertzman&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Spergel&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;S. Tokarski&quot;},{&quot;first_name&quot;:&quot;Joann&quot;,&quot;last_name&quot;:&quot;Strnad&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Gillooly&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;W. McIntyre&quot;},{&quot;first_name&quot;:&quot;Adriana&quot;,&quot;last_name&quot;:&quot;Zupa-Fernandez&quot;},{&quot;first_name&quot;:&quot;Lihong&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Huadong&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Charu&quot;,&quot;last_name&quot;:&quot;Chaudhry&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Celia&quot;,&quot;last_name&quot;:&quot;D’Arienzo&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;Heimrich&quot;},{&quot;first_name&quot;:&quot;Xiaoxia&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Jodi&quot;,&quot;last_name&quot;:&quot;K. Muckelbauer&quot;},{&quot;first_name&quot;:&quot;ChiehYing&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Tredup&quot;},{&quot;first_name&quot;:&quot;Dawn&quot;,&quot;last_name&quot;:&quot;Mulligan&quot;},{&quot;first_name&quot;:&quot;Dianlin&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Nelly&quot;,&quot;last_name&quot;:&quot;Aranibar&quot;},{&quot;first_name&quot;:&quot;Manoj&quot;,&quot;last_name&quot;:&quot;Chiney&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Burke&quot;},{&quot;first_name&quot;:&quot;Louis&quot;,&quot;last_name&quot;:&quot;Lombardo&quot;},{&quot;first_name&quot;:&quot;Percy&quot;,&quot;last_name&quot;:&quot;H. Carter&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;S. Weinstein&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;8953-8972&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00443&quot;},&quot;abstract&quot;:&quot;As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 interferons. The nicotinamide 4, identified by a SPA-based high-throughput screen targeting the TYK2 pseudokinase domain, potently inhibits IL-23 and IFNα signaling in cellular assays. The described work details the optimization of this poorly selective hit (4) to potent and selective molecules such as 47 and 48. The discoveries described herein were critical to the eventual identification of the clinical TYK2 JH2 inhibitor (see following report in this issue). Compound 48 provided robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model. These results demonstrate the ability of TYK2 JH2 domain binders to provide a highly selective alternative to conventional TYK2 orthosteric inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00443&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00443" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00443&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00443" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00443&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00443" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00443&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00443&amp;href=/doi/10.1021/acs.jmedchem.9b00443" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00443" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00443" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00443%26sid%3Dliteratum%253Aachs%26pmid%3D31314518%26genre%3Darticle%26aulast%3DMoslin%26date%3D2019%26atitle%3DIdentification%2Bof%2BN-Methyl%2BNicotinamide%2Band%2BN-Methyl%2BPyridazine-3-Carboxamide%2BPseudokinase%2BDomain%2BLigands%2Bas%2BHighly%2BSelective%2BAllosteric%2BInhibitors%2Bof%2BTyrosine%2BKinase%2B2%2B%2528TYK2%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D20%26spage%3D8953%26epage%3D8972%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/20" title="Go to Volume 62, Issue 20"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/jmcmar.2019.62.issue-20/20191024/jmcmar.2019.62.issue-20.largecover.jpg" alt="Go to Volume 62, Issue 20"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">As a member of the Janus (JAK) family of nonreceptor tyrosine kinases, TYK2 plays an important role in mediating the signaling of pro-inflammatory cytokines including IL-12, IL-23, and type 1 interferons. The nicotinamide <b>4</b>, identified by a SPA-based high-throughput screen targeting the TYK2 pseudokinase domain, potently inhibits IL-23 and IFNα signaling in cellular assays. The described work details the optimization of this poorly selective hit (<b>4</b>) to potent and selective molecules such as <b>47</b> and <b>48</b>. The discoveries described herein were critical to the eventual identification of the clinical TYK2 JH2 inhibitor (see following report in this issue). Compound <b>48</b> provided robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model. These results demonstrate the ability of TYK2 JH2 domain binders to provide a highly selective alternative to conventional TYK2 orthosteric inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60733" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60733" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Janus family of kinases (JAK1, JAK2, JAK3, and TYK2) are nonreceptor tyrosine kinases that bind to the intracellular portion of cell surface cytokine receptors. In response to the stimulation of these receptors, the Janus kinases phosphorylate signal transducer and activator of transcription (STAT) proteins, which then dimerize, translocate to the nucleus, and activate gene transcription. Different pairs of Janus kinase family members are responsible for propagating the signaling of the different cytokines and their receptors. TYK2 partners with JAK2 to mediate signaling by IL-12 and IL-23 (p40 subunit containing cytokines) and with JAK1 for type 1 interferons. Because of the involvement of the JAK/STAT pathway in inflammation, the Janus family of kinases have generated significant recent interest as targets for immunological disorders.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Speaking to TYK2 specifically, a significant body of evidence supports it as a target within the field of autoimmune diseases. TYK2-deficient mice are viable and develop normally, in contrast, JAK1<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> or JAK2<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> deficiencies are lethal in mice while JAK3-deficient mice display severe B cell and T cell lymphopenia.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Furthermore, TYK2 deficiency has been shown to be protective in various models of experimental autoimmunity.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> A small number of patients with a TYK2 deficiency have been identified. They demonstrate increased susceptibility to mycobacterial and/or viral infections, consistent with the role of TYK2 in normal immune homeostasis.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition, a recent meta-analysis of genome-wide association studies showed that a deactivating TYK2 variant provided high protection from several autoimmune diseases including multiple sclerosis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriasis. Intriguingly, homozygosity for this variant was not associated with an increased risk for hospitalization due to mycobacterial, viral, or fungal infections, suggesting that preventing TYK2 activation with novel therapeutics may strike an optimal balance between efficacy and safety.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a></div><div class="NLM_p">The value of inhibiting the TYK2-involved pathways in the treatment of autoimmune diseases has been demonstrated clinically with a number of antibodies. The blocking p40 antibody, ustekinumab inhibits the IL-12 and IL-23 pathways and is currently marketed for the treatment of psoriasis, psoriatic arthritis, and Crohn’s disease.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Ustekinumab has also recently shown efficacy in patients with systemic lupus erythematosus (SLE).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The anti-p19 antibody guselkumab, which blocks IL-23 but not IL-12 signaling, has also proven to be an effective treatment for psoriasis.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Several studies have implicated the pathogenic role of type 1 IFNs in SLE,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and the success of targeting this pathway in lupus has recently been demonstrated in phase 2 trials with sifalimumab and anifrolumab.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Sifalimumab is a monoclonal antibody that binds to and blocks many of the isoforms of IFNα, while anifrolumab blocks the type 1 interferon receptor (anti-IFNAR), thus impacting both IFNα and IFNβ. However, it should be noted that one of the two current phase 3 studies evaluating anifrolumab recently failed to meet its primary end point in lupus patients.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Given the support that exists for TYK2 as a therapeutic target, it is not surprising that many efforts have been made to identify selective inhibitors of TYK2.<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25">(21−25)</a> However, achieving this selectivity has been challenging due to high sequence homology within the catalytic domains (Janus homology 1 or JH1) of the JAK family kinases.<a onclick="showRef(event, 'cit25a'); return false;" href="javascript:void(0);" class="ref cit25a">(25a)</a> Interestingly the TYK2 and Janus family kinases possess a catalytically inactive pseudokinase domain (Janus homology 2 or JH2) adjacent to the JH1 domain, a striking and highly unusual feature. Structures of the JH2 domains of JAK1,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> JAK2,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and TYK2<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> reveal that the JH2 domains bear the overall structure of a kinase but each with unique features depriving it of full catalytic activity. In the case of TYK2, there is some evidence that the JH2 domain exerts regulatory functions as several deletions or mutations have been demonstrated to impair catalytic activity.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We have recently demonstrated that potent and selective allosteric inhibition of TYK2 is afforded by ligands that bind to the TYK2 pseudokinase (JH2) domain.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The mechanism by which binding to the “catalytic” pocket of the pseudokinase domain inhibits TYK2 is not known, but given that the JH2 and JH1 domains form a significant interface, about 1460 Å<sup>2</sup>, that appears to be auto inhibitory, we postulate that the binding of these allosteric inhibitors to the TYK2 JH2 domain stabilizes an inhibitory conformation thereby preventing activation.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> It has also been shown that TYK2 JH2 binders prevent the phosphorylation of the Tyr1054 and Tyr1055 residues, an activating event that is necessary for the catalytic function of the TYK2 protein.<a onclick="showRef(event, 'ref29 ref33'); return false;" href="javascript:void(0);" class="ref ref29 ref33">(29,33)</a> While there have been few reports of optimized small molecules targeting pseudokinases outside of our TYK2 efforts,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> the interest in pseudokinases as targets in drug discovery is growing.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">As reported previously, a high-throughput screen (HTS) using a cellular reporter assay led to the identification of allosteric inhibitors of TYK2, among them compounds <b>1</b> and <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref29 cit32a'); return false;" href="javascript:void(0);" class="ref ref29 cit32a">(29,32a)</a> The imidazo[1,2-<i>b</i>]pyridazine <b>2</b> was subsequently optimized to improve potency resulting in <b>3</b>. Compound <b>3</b> showed good functional potency and excellent kinase selectivity, but it had poor metabolic stability, modest pharmacokinetic properties (in mouse), and was potent against phosphodiesterase 4 (PDE4, IC<sub>50</sub> = 43 nM).<a onclick="showRef(event, 'cit32a'); return false;" href="javascript:void(0);" class="ref cit32a">(32a)</a> In an effort to identify a new TYK2 JH2-binding scaffold, a corporate compound collection-wide screen was initiated by utilizing a scintillation proximity assay (SPA) that employed a tritiated version of <b>1</b>, resulting in the identification of nicotinamide <b>4</b>. The binding affinity of <b>4</b>, and subsequently prepared analogues, exceeded the sensitivity limits of the SPA assay used in the HTS, which was thus replaced with a more sensitive homogeneous time-resolved fluorescence (HTRF) assay. In the IL-23 and IFNα-stimulated reporter assays, <b>4</b> was about twice as potent as <b>3</b>; however, <b>4</b> was not selective over the catalytic (JH1) domains of the four JAK family members. The observed inhibition of IL-23-signaling by <b>4</b> may have resulted from direct inhibition of JH1 domains of JAK2, TYK2, or a combination of both. Similarly, the inhibition of IFNα could be rationalized to be a consequence of JAK1 and/or TYK2 JH1 binding. Furthermore, <b>4</b> was found to be fairly promiscuous, inhibiting 85 of 261 kinases tested by at least 50% (at 1 μM concentration) in the HTRF assay. Although <b>4</b> had poor kinase selectivity, it was inactive against PDE4 (IC<sub>50</sub> > 2 μM) and IKKβ (off-targets of previously reported chemotypes), had good metabolic stability (>80% remaining in incubations with human and mouse liver microsomes),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and had high ligand efficiency (LE = 0.30, LLE = 5.8).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Consequently, lead optimization efforts were initiated to improve the selectivity of <b>4</b> for the TYK2 JH2 domain.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported TYK2 JH2 ligands and deck hit <b>4</b>. (a) SPA-binding assay. (b) HTRF displacement assay potency reported throughout the remainder of the communication. (c) <i>K</i><sub><i>i</i>,app</sub> determined using a Morrison titration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80584" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80584" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A series of amides were prepared at the C3 position of <b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). While methyl amide <b>5</b> maintained most of the affinity of <b>4</b>, extending the amide by a single carbon to ethyl amide <b>6</b> reduced the potency by an order of magnitude relative to <b>5</b>. The trend continued with further loss in potency for cyclopropyl amide <b>7</b>. The dimethyl amide <b>8</b> was similarly weakly active, suggesting a potential hydrogen-bonding role for the secondary amide NH (vide infra). The methyl amide maintained submicromolar potency in the IL-23 and IFNα cellular assays, consistent with the primary amide <b>4</b>. Importantly, the methyl substituent provided a remarkable improvement in selectivity relative to <b>4</b>, as <b>5</b> proved to be inactive against the JAK (including TYK2) JH1 domains at the concentrations tested. This improved JAK family selectivity was reflected in the cellular assays, with <b>5</b> showing no measurable (limit of quantitation = 12.5 μM) activity in IL-2 (JAK 1 and JAK3 dependent) and GM-CSF (JAK2 dependent) assays. In general, the methyl group had a significant impact on selectivity across the kinome. Amide <b>5</b> at 1 μM concentration inhibited only 4 of 265 kinases tested by more than 50%,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> representing a vast improvement in selectivity relative to <b>4</b>, which inhibited 85 out of 261 tested kinases by 50% or more.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationship of C3 Amide</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All data represents an average of <i>n</i> ≥ 3 test occasions, standard deviations as shown.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">IL-23 is dependent upon TYK2 as well as JAK2; IFNα is dependent upon TYK2 as well as JAK1.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Control assays (TYK2 independent): IL-2 is dependent upon JAK1 and JAK3; GM-CSF is dependent upon JAK1 and JAK2.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last"><i>n</i> = 1.</p></div></div><div></div></div><div class="NLM_p">Synthesis of C3 amides was possible following the procedure detailed in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The C4 chloride of the commercially available 4,6-dichloronicotinic acid (<b>9</b>) was selectively displaced with 2-aminobenzamide to give <b>10</b>. Following a palladium-catalyzed <i>N</i>-arylation reaction, the acid <b>11</b> was condensed with various amines using hexafluorophosphate azabenzotriaxole tetramethyl uranium (HATU) to provide the desired amides.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) NaHMDS, THF, room temperature 1 h; (b) Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 145 °C, 30–60 min; (c) RR′NH hydrochloride salt, <i>N</i>,<i>N</i>-diisopropylethylamine, HATU, DMF, 1 h (12–39%).</p></p></figure><div class="NLM_p">The selectivity provided by methyl amide <b>5</b> could be rationalized on the basis of a cocrystal structure obtained with the TYK2 JH2 domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZE">6NZE</a>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The ligand was found to be anchored to the “hinge” through a donor–acceptor–donor motif of hydrogen bonding interactions involving the core pyridine, C6 pendant aminopyridine, and C3 methylamide and backbone amides of Val690 and Glu688. These interactions effectively lock the core in place to project the methyl of the C3 amide toward, and in close proximity to, the adjacent Ala671. It is notable that alanine in this position is found in only nine other kinases,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> with a majority of kinases having much larger residues such as valine, leucine, or isoleucine at this position. We postulate that while kinases with these larger residues can more readily accommodate the C3 primary amide of deck hit <b>4</b> (consistent with its very modest selectivity profile), only the space provided by an adjacent alanine (“alanine pocket”) tolerates the C3 methyl amide of <b>5</b>. The small threonine gatekeeper is unique among the kinases possessing this alanine pocket and also contributes to high ligand selectivity. In addition, Pro694 (not shown) in the extended hinge is a relatively rare residue to have in that position as it is typically a polar residue in the majority of the kinome. The steric effect of Pro694 likely influences the nearly planar conformation of the C4 aniline and the nicotinamide core.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of <b>5</b> bound to TYK2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZE">6NZE</a>). (a) Close-up of the binding site, highlighting hinge interactions. TYK2 JH2 ribbon and carbons in green. Carbons of <b>5</b> in magenta. Hydrogen bonds shown as dashed lines. (b) Rotated view of the binding site highlighting interactions of C2′ amide and the location of Ala671.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To examine the effect of the C6 substituent, <b>9</b> was first converted to the corresponding amide, via the acid chloride, and then coupled with 2-aminobenzamide, as described previously. The final step, a palladium-catalyzed <i>N</i>-arylation, provided the target compounds (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, in addition to the observed series of hydrogen bonding interactions involving the two amides, coplanarity of the two pyridine rings was also noted. A presumed intramolecular hydrogen bond between the C5 hydrogen of the pyridine core and the ring nitrogen of the pendant C6 aminopyridine as well as the observed interaction of the C6 amine NH with Val690 are consistent with structure–activity relationship (SAR) findings for close analogues (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Replacement of the pendant pyridine with a phenyl group (<b>16</b>) led to a more than 10-fold loss in binding and functional potency, consistent with this requirement for coplanarity. A preference for hydrogen at the C3′′ position of the pendant aminopyridine was also revealed by these studies. Consistent with this, replacement of the C3′′ hydrogen with fluorine (<b>18</b>) or replacement of the pyridine with pyrimidine (<b>19</b>) led to losses in potency.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) (COCl)<sub>2</sub>, DMF, chloroform, 0 °C, 1 h; (b) (i) methylamine, chloroform, 0 °C, (76%), (ii) methyl-<i>d</i><sub>3</sub>-amine hydrochloride, triethylamine, DCM, 0 °C, 30 min, (74%), (iii) NH<sub>3</sub>, chloroform, 0 °C, (80%); (c) NaHMDS, THF, room temperature 1 h, (80%); (d) arylamine, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 145 °C, (12–33%).</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship of C6 Substituent</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0015.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All data represents an average of <i>n</i> ≥ 3 test occasions, standard deviations as shown.</p></div></div><div></div></div><div class="NLM_p">The potency of compounds was established in human (hWB) and mouse whole blood (mWB) assays of IFNα-induced STAT5 phosphorylation. The early lead <b>5</b> maintained potency in hWB (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), with the observed translation of potency from reporter assay to hWB being related to its relatively high polarity (cLogP = 3.10) and low protein binding in human plasma (26.3% free). Stability to oxidative metabolism was deemed acceptable, with at least 82% remaining after 10 min incubations with liver microsomes from human, mouse, and rat. Permeability in the Caco-2 assay was determined to be quite low, with a high efflux ratio, which may explain the low serum exposures of <b>5</b> after administration as a single 10 mg/kg oral solution dose (<i>C</i><sub>max</sub> = 0.036 μM; AUC<sub>last</sub> = 0.15 μM·h).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Impact of C4-Substituents on Potency and Permeability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0016.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0017.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All data represents an average of <i>n</i> ≥ 3 test occasions, standard deviations as shown.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">LM %rem refers to liver microsomal stability as measured by % remaining.</p></div></div><div></div></div><div class="NLM_p">To screen the C4 position of the nicotinamide core, a synthesis was devised to allow the C4 aniline addition to be the final coupling (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). 4,6-Dichloronicotinic acid was reacted with methanol under basic conditions to provide the C4 methyl ether <b>26</b>, which was then coupled to 2-amino-5-fluoropyridine using palladium catalysis as described previously. Cleavage of the ether followed by chlorination and amide formation converted the intermediate acid <b>27</b> to the penultimate amide <b>28</b>. Addition of the aniline to the chloronicotinamide could be accomplished under acidic or neutral conditions depending upon the substrate. In general, these analogues showed a high degree of selectivity against PDE4, but binding affinity to the TYK2 pseudokinase varied with the choice of aniline (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Simply removing the polar C2′ amide substituent (<b>20</b>) resulted in a significant loss of potency. Therefore, groups which could engage in a hydrogen bonding interaction with the neighboring Lys642 residue were prioritized for evaluation. Within that constraint, a methoxy replacement for the primary amide <b>21</b> was prepared and found to be well tolerated both in terms of binding and cell potency. Moreover, <b>21</b> provided the desired decrease in polarity (cLogP = 4.1 for <b>21</b> vs 3.1 for <b>5</b>), correlating with an improvement in Caco-2 permeability. A significant trade-off in microsomal stability was observed, however. Some stability could be recovered by fluorinating the C4 aryl ring at the C3′ and C4′ positions of compound <b>22</b>, with relatively little impact on hWB potency relative to <b>21</b>. The improvements in both permeability and metabolic stability for <b>22</b> translated to increased serum exposures relative to <b>5</b> in the mouse oral pharmacokinetic (PK) study (10 mg/kg: <i>C</i><sub>max</sub> = 1.6 μM, AUC<sub>last</sub> = 4.0 μM·h); however, further improvement in human metabolic stability was still required. Replacing the 2′ amide with a methyl sulfonyl group resulted in a significant breakthrough (sulfones prepared following <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Sulfone <b>23</b> maintained the affinity of amide <b>5</b> and was slightly more potent in the reporter and hWB assays (0.5 μM for <b>5</b> vs 0.2 μM for <b>23</b>). Homologation to ethyl sulfone <b>24</b> led to a significant decrease in binding and functional potency. With regard to potential for acceptable pharmacokinetics, the microsomal stability of <b>23</b> matched that of <b>5</b> and the Caco-2 cell permeability was improved, with both an increased apical-to-basolateral flux and decreased efflux. A single 10 mg/kg oral solution dose of <b>23</b> to mice provided a very encouraging 1.62 μM <i>C</i><sub>max</sub> and 9.83 μM·h AUC<sub>last</sub>. The corresponding sulfide <b>25</b> failed to show any potency improvement in the reporter assays, relative to the methoxy, illustrating the potential involvement of the sulfone oxygens in binding.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) LiOH, THF, MeOH, rt 1 h; (b) Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 145 °C, 30 min; (c) HBr, AcOH, 110 °C, 4 h; (d) POCl<sub>3</sub>, NEt<sub>3</sub>, 110 °C, 2 h; (e) methylamine, THF, 0 °C, 1 h; (f) arylamine, NMP, HCl (for <b>20</b> and <b>22</b>), 120 °C, 16 h, (15–51%).</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) NaHMDS, THF, 15 min, (62–80%); (b) sodium tungstate dihydrate, AcOH, H<sub>2</sub>O<sub>2</sub>, 30 min, (68–89%); (c) NH<sub>2</sub>R″, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 145 °C, (7–62%).</p></p></figure><div class="NLM_p">An X-ray cocrystal structure of <b>23</b> with TYK2 JH2 showed that it maintains the critical hydrogen bond with the Lys642 residue (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZF">6NZF</a>; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). An additional intramolecular hydrogen bond with the C4 amino hydrogen further stabilizes the active conformation of <b>23</b>. A notable difference is that while <b>5</b> projects the polar −NH<sub>2</sub> of its amide toward the Arg–Asn backbone, the sulfone orients its methyl substituent into a lipophilic pocket underneath the ligand. The loss of activity of the ethyl sulfone <b>24</b> is consistent with a steric limitation of this pocket.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of TYK2 JH2 bound with <b>23</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZF">6NZF</a>). (a) Close-up of the binding site, highlighting interactions between the C4 aniline and C2′ sulfone group. TYK2 JH2 ribbon and carbons in green. Carbons of <b>23</b> in magenta. Hydrogen bonds shown as dashed lines. (b) Surface representation of protein highlighting C2′sulfone methyl pocket. (c) Superposition of TYK2 JH2 structures bound with <b>5</b> (cyan) and <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the potency, and lack of selectivity, of the primary amide <b>4</b>, we were concerned that an anticipated primary amide metabolite of <b>23</b> could confound interpretation of in vivo efficacy data and potentially lead to off-target effects. Preparation and testing of the putative metabolite <b>29</b> gave confirmation of its potency and poor selectivity profile, consistent with the profile of <b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). An analysis of plasma samples from the aforementioned mouse oral PK study showed that <b>29</b> was circulating at levels up to 5% of parent <b>23</b>, with a maximum plasma concentration of 47 (±18) nM at 5 h post dose, an exposure close to the IC<sub>50</sub> values determined against the JAK JH1 domains (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Tables <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). The pharmacokinetic profile of <b>23</b> in mice after an intravenous 3 mg/kg dose was also determined (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Clearance was determined to be low (15 mL/min/kg) with overall exposure (AUC<sub>last</sub> = 7.0 μM·h) such that oral bioavailability for <b>23</b> in the mouse was determined to be 35%. Formation of the primary amide metabolite was determined to be even more pronounced after IV administration of <b>23</b>, with up to 29% of parent circulating as <b>29</b> at 7 h postdose.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Profiles of Methylnicotinamide <b>23</b>, Primary Amide Metabolite <b>29</b>, and Deuteromethyl Amide <b>30</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0018.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">TYK2 JH2 (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">IL23/IFNα (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">TYK2/JAK1/JAK2 JH1 (IC<sub>50</sub>, μM)</th><th class="colsep0 rowsep0" align="center">IL2/GM CSF (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">hWB IFNα (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">mWB IFNα (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">LM %rem (h/r/m)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">%kinases with IC<sub>50</sub> ≤1 μM (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="center">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="center">0.00092 ± 0.0004</td><td class="colsep0 rowsep0" align="center">0.063/0.063 ± 0.04/0.02</td><td class="colsep0 rowsep0" align="center">>50/>50/>50</td><td class="colsep0 rowsep0" align="center">>12.5/>12.5</td><td class="colsep0 rowsep0" align="center">0.18 ± 0.05</td><td class="colsep0 rowsep0" align="center">0.45 ± 0.3</td><td class="colsep0 rowsep0" align="center">90/85/87</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">0.00032 ± 0.00006</td><td class="colsep0 rowsep0" align="center">0.046/0.035 ± 0.03/0.02</td><td class="colsep0 rowsep0" align="center">0.042/0.043/0.018</td><td class="colsep0 rowsep0" align="center">0.96/0.26</td><td class="colsep0 rowsep0" align="center">0.033 ± 0.02</td><td class="colsep0 rowsep0" align="center">0.083 ± 0.02</td><td class="colsep0 rowsep0" align="center">77/3/80</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="center">CD<sub>3</sub></td><td class="colsep0 rowsep0" align="center">0.00049 ± 0.0002</td><td class="colsep0 rowsep0" align="center">0.11/0.053 ± 0.04/0.02</td><td class="colsep0 rowsep0" align="center">>50/>2/>50</td><td class="colsep0 rowsep0" align="center">>12.5/>12.5</td><td class="colsep0 rowsep0" align="center">0.16 ± 0.09</td><td class="colsep0 rowsep0" align="center">0.60 ± 0.07</td><td class="colsep0 rowsep0" align="center">85/91/81</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All data represents an average of <i>n</i> ≥ 3 test occasions, standard deviations as shown.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Control assays (TYK2 independent): IL-2 is dependent upon JAK1 and JAK3; GM-CSF is dependent upon JAK1 and JAK2.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">LM %rem refers to liver microsomal stability as measured by % remaining.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Exposures (nM) of Parent (<b>23</b>/<b>30</b>) and Metabolite (<b>29</b>) in Mouse PK Studies</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><b>23</b> (3 mg/kg IV) (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center"><b>23</b> (10 mg/kg po) (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center"><b>30</b> (3 mg/kg IV) (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center"><b>30</b> (10 mg/kg po) (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">time (h)</th><th class="colsep0 rowsep0" align="center"><b>23</b></th><th class="colsep0 rowsep0" align="center"><b>29</b></th><th class="colsep0 rowsep0" align="center"><b>23</b></th><th class="colsep0 rowsep0" align="center"><b>29</b></th><th class="colsep0 rowsep0" align="center"><b>30</b></th><th class="colsep0 rowsep0" align="center"><b>29</b></th><th class="colsep0 rowsep0" align="center"><b>30</b></th><th class="colsep0 rowsep0" align="center"><b>29</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.05</td><td class="colsep0 rowsep0" align="center">3500</td><td class="colsep0 rowsep0" align="center">51 [1%]</td><td class="colsep0 rowsep0" align="center">780</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">2800</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">750</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="center">2100</td><td class="colsep0 rowsep0" align="center">110 [5%]</td><td class="colsep0 rowsep0" align="center">1400</td><td class="colsep0 rowsep0" align="center">14 [1%]</td><td class="colsep0 rowsep0" align="center">2400</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">1400</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="center">2100</td><td class="colsep0 rowsep0" align="center">84 [4%]</td><td class="colsep0 rowsep0" align="center">1600</td><td class="colsep0 rowsep0" align="center">21 [1%]</td><td class="colsep0 rowsep0" align="center">1500</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">1400</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="center">530</td><td class="colsep0 rowsep0" align="center">33 [6%]</td><td class="colsep0 rowsep0" align="center">1500</td><td class="colsep0 rowsep0" align="center">28 [2%]</td><td class="colsep0 rowsep0" align="center">470</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">1300</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="center">440</td><td class="colsep0 rowsep0" align="center">41 [9%]</td><td class="colsep0 rowsep0" align="center">1400</td><td class="colsep0 rowsep0" align="center">47 [3%]</td><td class="colsep0 rowsep0" align="center">270</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">1300</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="center">190</td><td class="colsep0 rowsep0" align="center">54 [29%]</td><td class="colsep0 rowsep0" align="center">450</td><td class="colsep0 rowsep0" align="center">24 [5%]</td><td class="colsep0 rowsep0" align="center">47</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">260</td><td class="colsep0 rowsep0" align="center"><LLQ<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>last</sub> (nM·h)</td><td class="colsep0 rowsep0" align="center">7000</td><td class="colsep0 rowsep0" align="center">360 [5%]</td><td class="colsep0 rowsep0" align="center">8100</td><td class="colsep0 rowsep0" align="center">200 [3%]</td><td class="colsep0 rowsep0" align="center">5000</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">7800</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL·min<sup>–1</sup>·kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" colspan="2" align="center">15</td><td class="colsep0 rowsep0" colspan="2" align="center"> </td><td class="colsep0 rowsep0" colspan="2" align="center">25</td><td class="colsep0 rowsep0" colspan="2" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L·kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" colspan="2" align="center">2.8</td><td class="colsep0 rowsep0" colspan="2" align="center"> </td><td class="colsep0 rowsep0" colspan="2" align="center">2.7</td><td class="colsep0 rowsep0" colspan="2" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" colspan="2" align="center">3</td><td class="colsep0 rowsep0" colspan="2" align="center"> </td><td class="colsep0 rowsep0" colspan="2" align="center">1.2</td><td class="colsep0 rowsep0" colspan="2" align="center"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">5 mL/kg, 5% DMAC, 76% PEG 400, 19% water.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">10 mL/kg, 5% DMAC, 9.5% EtOH, 76% PEG 300, 9.5% TPGS.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">LLQ = 4.9 nM.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">LLQ = 9.8 nM.</p></div></div></div><div class="NLM_p">It has been shown that metabolic demethylation of tertiary amides can be significantly attenuated by the kinetic isotope effect.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> We prepared the trideuteromethyl secondary amide <b>30</b> in an attempt to minimize formation of the primary amide (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). To assess the effect of <b>30</b> in vivo, male Balb/c mice were administered <b>23</b> or <b>30</b> orally (10 mg/kg) or intravenously (3 mg/kg), and the exposures of <b>23</b>/<b>30</b> as well as the metabolite <b>29</b> were monitored over time (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Deuteromethyl amide <b>30</b> proved to be sufficient to render in vivo formation of the primary amide <b>29</b> below its lower limit of quantification (LLQ) at all time points (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The stability of <b>30</b> in liver microsome incubations was also very similar to that of <b>23</b>, suggesting that the deuterium incorporation was serving to shunt metabolism away from the C3 amide than to increase the overall stability of the molecule toward oxidative metabolism. As expected, the potency and selectivity profile was unchanged relative to <b>23</b>.</div><div class="NLM_p">Preparation of <b>30</b>, as well as the metabolite <b>29</b>, was accomplished following the general route for accessing C6 substituents with C4-sulfonyl anilines, differing only in the starting amides (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Base promoted displacement of the C4-chloride on the methyl (CH<sub>3</sub>/CD<sub>3</sub>) or primary amide proceeded efficiently to provide the corresponding sulfide. This was oxidized using sodium tungstate to the sulfone. The purified sulfone could then be coupled to various anilines (or amides) following standard palladium catalyzed <i>N</i>-arylation conditions.</div><div class="NLM_p">While deuterium incorporation addressed the formation of an active, but nonselective, primary metabolite, additional liabilities associated with <b>23</b> were identified. Despite its otherwise excellent selectivity profile across the kinome (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), <b>23</b> was determined to be potent inhibitor of cKit (IC<sub>50</sub> = 0.10 μM). Because cKit plays an important role in cellular proliferation and differentiation in the hematopoietic system, this represented an unacceptable liability.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Fortunately, the cKit affinity was highly sensitive to substitution on the C6 aromatic ring (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Substitution off of the position <i>para</i> to the pyridine nitrogen (C4″) proved to be a generally reliable method of eliminating cKit affinity (<b>35</b>); however, other structural modifications such as significant bulk at the C5″ position or inclusion of additional heteroatoms in the ring also eliminated cKit affinity (<b>36</b>, <b>37</b>). Some activity for <b>23</b> in a hERG fluorescence polarization (flux) assay (IC<sub>50</sub> = 25 μM) also raised a concern for potential QT interval prolongation. When <b>23</b> was evaluated for inhibition of hERG tail currents in a whole cell patch clamp assay, the measured IC<sub>50</sub> was 2.5 μM, much lower than had been observed in the hERG flux assay. To establish in vitro to in vivo correlations for hERG, deuteromethyl amide <b>30</b> was evaluated for effects on cardiac electrophysiology in anesthetized rabbits. After an intravenous infusion representing cumulative doses of 1, 3, and 10 mg/kg, a maximal QTc prolongation of 38 ms was recorded. With a plasma <i>C</i><sub>max</sub> exposure of 20.2 (±3.9) μM, the circulating free fraction in rabbit was calculated to be ∼2.6 μM (13% unbound), this effect was consistent with the IC<sub>50</sub> measured in the hERG patch clamp assay (2.5 μM), which suggested a narrow therapeutic window toward undesirable cardiovascular effects.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Effects of Different C6 Substituents on Potency, Permeability, and hERG Activity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0019.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0020.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">All data represents an average of <i>n</i> ≥ 3 test occasions, standard deviations as shown.</p></div></div><div></div></div><div class="NLM_p">To address the hERG liability, simple substituent modifications on the 2-aminopyridine were extensively explored, with minimal success (examples <b>35</b>–<b>39</b>). Removing peripheral aryl rings to disrupt potential π-stacking within the aromatic residue-rich hERG channel is a common strategy to reduce hERG affinity,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and as such we expanded our exploration to C6 amides. Replacing the 2-aminopyridine with cyclopropylamide <b>40</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> greatly improved the hERG selectivity (hERG flux IC<sub>50</sub> > 80 μM). The decrease in hERG activity was confirmed in the hERG patch clamp assay (IC<sub>50</sub> > 30 μM). A cocrystal structure of <b>40</b> in TYK2 JH2 revealed a binding mode consistent with the 2-aminopyridines (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZH">6NZH</a>; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The carbonyl oxygen preserves the hydrogen bond with the C4 hydrogen, orienting the C6 amine hydrogen toward the hinge. The α-hydrogen on the cyclopropyl ring is similarly coplanar with both the carbonyl oxygen and the C6-amine hydrogen, in a manner analogous to the C3′′ hydrogen of the 2-aminopyridines, possibly explaining the similar binding potency between <b>40</b> and many of the 2-aminopyridines.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of TYK2 JH2 bound with <b>40</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZH">6NZH</a>). (a) View mainly of hinge area. TYK2 JH2 ribbon and carbons in green. Carbons of <b>40</b> in magenta. Distances between the α-hydrogen of the cyclopropyl ring and the protein that are approximately 3 Å or less (and likely are favorable) are shown as dashed lines. (b) Cyclopropylamide as an isostere for 2-aminopyridine. Superposition of TYK2 JH2 structures bound with <b>23</b> (green) and <b>40</b>, only protein from complex with <b>40</b> is shown. (c) Surface representation of protein highlighting complementary binding groove for the cyclopropyl group (<b>40</b> shown in spherical representation).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a mouse 7 h oral PK study, exposures of <b>40</b> were much lower than those achieved with <b>23</b> and <b>30</b>, both with regard to <i>C</i><sub>max</sub> (0.19 μM) and AUC<sub>last</sub> (0.56 μM·h). This was attributed to the poor permeability of <b>40</b>, as measured in a Caco-2 assay. An important advance was realized with replacement of the central pyridine ring with the less basic and more lipophilic pyridazine core.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Despite its lower basicity than pyridine, pyridazine is a strong hydrogen bond acceptor, which has been attributed to the α-effect.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">Synthesis of the pyridazine core initiated with diazo transfer to diethyl malonate to provide <b>43</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). A diaza-Wittig reaction followed by hydrolysis and saponification provided the crude acid diol <b>44</b>. Chlorination with POCl<sub>3</sub> converted the C4 and C6 alcohols to the corresponding chlorides and provided the intermediate acyl chloride, which was trapped as the amide using methyl-<i>d</i><sub>3</sub>-amine hydrochloride in the presence of Hunig’s base to provide <b>45</b>. Base-promoted displacement with 2-(methylthio)aniline and subsequent oxidation as described previously provided the penultimate <b>46</b>, which could be converted to the target compounds using palladium catalyzed <i>N</i>-arylation as before.</div><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) MeCN, 1 h; (b) PPh<sub>3</sub>, Et<sub>2</sub>O, 16 h; (c) AcOH, H<sub>2</sub>O, reflux, 6 h; (d) LiOH, THF, MeOH, H<sub>2</sub>O, 16 h; (e) POCl<sub>3</sub>, NEt<sub>3</sub>, 110 °C, 2 h; (f) methyl-<i>d</i><sub>3</sub>-amine hydrochloride, <i>N</i>,<i>N</i>′-diisopropylethylamine, THF, rt; (g) 2-(methylthio)aniline, NaHMDS, THF, 15 min; (h) sodium tungstate dihydrate, AcOH, H<sub>2</sub>O<sub>2</sub>, 30 min; (i) NH<sub>2</sub>R, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 130 °C, (44–88%).</p></p></figure><div class="NLM_p">Several pairs of compounds with the central pyridine and corresponding pyridazine were evaluated in 7 h mouse PK experiments. The pyridazine analogues consistently provided improved exposures without sacrificing potency compared to their pyridine counterpart (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). The improved exposures correlated well with increased permeability and diminished efflux ratios, consistent with the higher lipophilicity of the pyridazine compounds. On the basis of its increased lipophilicity relative to pyridine <b>40</b>, pyridazine cyclopropyl amide <b>47</b> provided more than 10-fold higher exposures in the coarse mouse PK experiment at the same 10 mg/kg dose. Pyridazine <b>47</b> also presented an improvement in cardiovascular safety profile over earlier compounds (such as <b>23</b>, vide infra), with an IC<sub>50</sub> > 30 μM in the hERG patch clamp assay.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Permeability and PK Exposures for Several Nicotinamides and Corresponding Pyridazine Amides<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0021.gif" alt="" id="fx10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0022.gif" alt="" id="fx11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Unless noted otherwise, values were obtained from the <i>d</i><sub>3</sub>-methyl amide.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">All data represents an average of <i>n</i> ≥ 3 test occasions (except mWB for <b>49</b>), standard deviations as shown.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">HPLC log <i>P</i> value is for the nondeuterium form (<b>23</b>)</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">C3 amide nondeuterium form</p></div></div><div></div></div><div class="NLM_p">As compound <b>48</b> had the best mouse whole blood potency and the greatest exposure, in mouse PK studies it was selected to assess the in vivo activity of pyridazine amides in a pharmacodynamic model of IL-12 signaling (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In this model, the test compound was administered orally to female C57BL/6 mice 1 h prior to being challenged with IL-12 followed by a subsequent challenge by IL-18 to induce IFNγ production, measured in the serum 3 h after the IL-18 dose. A robust, dose-responsive suppression of IFNγ production was provided by <b>48</b>. The 10 mg/kg dose provided a similar level of efficacy (91% suppression relative to vehicle control) as a single 10 mg/kg dose of anti-p40 positive control antibody. The average serum exposure of <b>48</b> (10 mg/kg) at the end of study (5 h) was found to be nearly 4-fold above its mouse whole blood IC<sub>50</sub> of 0.13 μM. The lowest dose of <b>48</b> that provided statistically significant suppression (56%) of IFNγ production was 1 mg/kg, with a terminal exposure equivalent to 0.5× the mouse whole blood IC<sub>50</sub>. No primary amide metabolite of <b>48</b> could be detected in the plasma samples from the PD study at any dose.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Dose–response of <b>48</b> in IL-12/IL-18 induced serum IFNγ production; vehicle, 5:5:90 EtOH:TPGS:PEG 300. (b) Exposures, multiples (mWB IC<sub>50</sub> = 130 nM), and % suppression relative to vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having demonstrated robust pharmacodynamic activity for inhibition of IL-12 signaling, nicotinamide <b>48</b> was then evaluated in the CD40-agonist induced colitis mouse model of inflammatory bowel disease (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In this model, male B6.CB17 mice were administered an agonistic α-CD40 antibody to induce experimental colitis. The test compound, <b>48</b>, was administered orally as a nanosuspension twice daily. The measured terminal serum exposures of <b>48</b> from this study (24 h post final dose) were determined to be 12 ± 9, 67 ± 89, and 77 ± 24 nM at the 25, 80, and 250 mg/kg doses, respectively. The induction of disease in this model led to significant body wasting, as evidenced by the nearly 20% loss in weight in the diseased animals treated only with the vehicle control. A dose dependent inhibition of this wasting was provided by <b>48</b>. The wasting component of the disease is driven by IL-12,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> so its inhibition was additional evidence of selective pathway inhibition by <b>48</b>. With regard to histological evaluation of damage and inflammation to the colon, previously shown to be an IL-23 driven effect,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> a semiquantitative score was assigned to each parameter of damage, infiltrate, and percent tissue involvement in proximal, medial, and distal sections of colon examined for each animal. A composite score was calculated, and <b>48</b> was shown to significantly reduce inflammation and damage of colitis at 250 mg/kg dose compared to vehicle using one-way analysis of variance (ANOVA) and Dunnett’s post-test. In addition, 250 mg/kg of <b>48</b> reduced the severity of colitis to a comparable level as the positive control, anti-p40 Ab dosed at 10 mg/kg. All of the compounds tested in biological assays were electronically filtered for structural attributes consistent with classification as pan-assay interference compounds (PAINS) and were found to be negative.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Dose-dependent response of inhibitor <b>48</b> in α-CD40 Ab induced IBD in SCID mice. (b) Histological evaluation dose–response of <b>48</b> in α-CD40 Ab induced colitis.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a><b>48</b> was dosed as a nanosuspension at 6, 19.2, and 60 mg/mL at the 25, 80, and 250 mg/kg doses, respectively. N/group = 5; *** <i>p</i> < 0.01 using one-way ANOVA and Dunnett’s post-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12300" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12300" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The finding that ligands of the pseudokinase domain of TYK2 stabilize an unphosphorylated, unactivated state of the protein and inhibit receptor-mediated kinase activation represented a fundamental advance in the study of JAK kinases.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This result provided the confidence to search for a potent and selective chemotype that could be optimized for improved functional potency and pharmacokinetics in order to enable in vivo proof of concept. Despite its lack of selectivity for the TYK2 JH2 domain, the ligand efficiency and lipophilic ligand efficiency of nicotinamide deck hit <b>4</b> were encouraging and a modification to the methyl amide (<b>5</b>) imparted nearly complete selectivity for binding to the TYK2 JH2 domain over the JAK JH1 domains and excellent general selectivity within the kinome. Structure–activity relationships for binding affinity were rationalized on the basis of cocrystal structures, with coplanarity of the C6 substituent with pyridine core, and the unique pocket provided by Ala671 occupied by the C3 methyl amide selectivity handle as key structural features. Further optimization of the methyl amide <b>5</b> resulted in the identification of a highly selective lead <b>48</b>, which showed effective inhibition in an in vivo colitis model, albeit at a high dose. Along with the high dose requirement, another drawback associated with <b>48</b> was it was a fairly potent hERG inhibitor. Compound <b>48</b> had a measured IC<sub>50</sub> of 10.9 μM in the hERG patch clamp assay. Compound <b>47</b>, with an IC<sub>50</sub> = >30 μM in the hERG patch clamp assay, represented a promising alternative starting point for further optimization. However, compound <b>47</b> demonstrated reduced potency and lower exposures than <b>48</b> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), which would need to be addressed.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In conclusion, several key discoveries made in the described hit-to-lead work are featured in the eventual clinical candidate (see following report in this issue):<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The identification and utilization, by way of a methyl amide, of the “alanine pocket” to achieve kinase selectivity and the use of the deuterium kinetic isotope effect to prevent metabolism to a nonselective primary nicotinamide. The validation of this strategy was realized by a lack of observed circulating primary amide metabolite as determined in a PK study of <b>30</b> and during a pharmacodynamic study of <b>48</b>. Second, a cyclopropyl carboxamide at C6 served to reduce the observed affinity for the hERG potassium channel while maintaining the selectivity and much of the potency of the 2-aminopyridine substituents, as evidenced by compounds <b>40</b> and <b>47</b>. Lastly, as the cyclopropyl amide containing nicotinamides demonstrated poor exposures in mouse PK studies, the conversion of the nicotinamide core to the pyridazine amide proved critical. The resulting pyridazine amides maintained consistently higher log <i>P</i> values, higher Caco-2 permeabilities and improved exposures in vivo.</div><div class="NLM_p last">This novel class of allosteric TYK2 inhibitors served as the foundation for further optimization, ultimately leading to the first clinical pseudokinase inhibitor.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All animal research was conducted in accordance with institutional guidelines as defined by Institutional Animal Care and Use Committee for U.S. institutions and with the approval of the Bristol-Myers Squibb Animal Care and Use Committee. Mice were housed under a 12 h/12 h light/dark cycle and provided standard access to rodent chow diet and fresh drinking water ad libitum.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> TYK2 JH2 Homogeneous Time Resolved Fluorescence (HTRF) Assay</h3><div class="NLM_p last">Binding assays contained 0.5 nM TYK2 (His-TVMV-TYK2 JH2 (575–869)), 0.2 nM terbium-anti-His antibody, fluorescein-labeled kinase tracer at the respective kinase <i>K</i><sub>d</sub>, and test compounds in assay buffer consisting of 20 mM Hepes pH 7.5, 10 mM MgCl<sub>2</sub>, 0.015% Brij-35, 2 mM DTT, and 50 μg/mL BSA. Assays were performed in black, flat-bottom, 1536-well plates. The reactions were incubated at room temperature for 90 min, following which the HTRF signal, ratio of fluorescence intensities at emission wavelengths for fluorescein acceptor (520 nm) and terbium donor (495 nm), the 520/495 ratio, generated were then measured on the Envision plate reader. Inhibition data were calculated from the 520/495 ratio generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Dose–response curves were generated to determine the concentration required for inhibiting 50% of the HTRF signal (IC<sub>50</sub>). Compounds were dissolved at 10 mM in dimethyl sulfoxide (DMSO) and evaluated at 11 concentrations (3-fold dilutions). For very potent compounds with affinities nearing assay bottom (IC<sub>50</sub> ∼ [TYK2JH2]/2), Morrison fitting of the experimental data to the equation below was carried out to determine apparent <i>K</i><sub>i</sub>; for these experiments, compounds were evaluated at 20 concentrations (2 fold dilutions).<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_m001.gif" alt="" id="_i14" /></img></span>where <i>F</i><sub>i</sub> and <i>F</i><sub>max</sub> are the fluorescent signal in the presence and absence of inhibitor, respectively; [E] and [I] are the total enzyme and inhibitor concentration, respectively.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> IL-23/IFNα Cell Assay</h3><div class="NLM_p last">Kit225 T cells with a stably integrated STAT-dependent luciferase reporter were plated in RPMI (Gibco) containing 10% heat-inactivated FBS (Gibco) and 100 U/mL PenStrep (Gibco). The cells were then stimulated with either 20 ng/mL human recombinant IL-23 or 200 U/mL human recombinant IFN-α (PBL InterferonSource) for 5–6 h. Luciferase expression was measured using the STEADY-GLO Luciferase Assay System (PROMEGA) according to the manufacturer’s instructions. Inhibition data were calculated by comparison to no inhibitor control wells for 0% inhibition and nonstimulated control wells for 100% inhibition. Dose–response curves were generated to determine the concentration required to inhibit 50% of cellular response (IC<sub>50</sub>) as derived by nonlinear regression analysis.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> IFNα-Induced STAT Phosphorylation in Mouse Whole Blood</h3><div class="NLM_p last">Following incubation with various concentrations of compound for 1 h, ACD-A-treated mouse whole blood was stimulated with 5000 U/mL of mouse IFNα (Miltenyi Biotech 130-093-131) for 15 min at 37 °C in a CO<sub>2</sub> incubator. The stimulation was stopped by adding Fix/Lyse buffer (BD 558049). Cells were stained with a rat antimouse CD32/CD16 Fc blocker (BD 553142) and CD3 FITC (eBioscience 11-0031-85) for 30 min, washed, and permeabilized on ice using Perm III buffer (BD 558050). Cells were then stained with an anti-pSTAT1 PE antibody (BD 612564) for 30 min prior to analysis using the FACS (fluorescence activated cell sorting) Canto II. The amount of pSTAT1 expression was quantitated by median fluorescence intensity after gating on the CD3 positive population.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> IFNα-Induced STAT Phosphorylation in Human Whole Blood</h3><div class="NLM_p last">After an hour long incubation with compound, human whole blood (drawn with either EDTA or ACD-A as anticoagulant) was stimulated with 1000 U/mL recombinant human IFNα A/D (R&D Systems 11200-2) for 15 min. The stimulation was stopped by adding Fix/Lyse buffer (BD 558049). Cells were stained with a CD3 FITC antibody (BD 555916), washed, and permeabilized on ice using Perm III buffer (BD 558050). Cells were then stained with an Alexa-Fluor 647 pSTAT5 (pY694) antibody (BD 612599) for 30 min prior to analysis on the FACS Canto II. The amount of pSTAT5 expression was quantitated by median fluorescence intensity after gating on the CD3 positive population.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Radiometric [<sup>3</sup>H]cAMP SPA Binding Assay with PDE4</h3><div class="NLM_p last">Binding of compounds to PDE4 enzyme was assessed by a radiometric competition assay measuring their inhibitory activity on [<sup>3</sup>H]cAMP binding. The PDE4 construct encoding His-Tb-hPDE4D2(86-413) was expressed in <i>Escherichia coli</i>, and purified by nickel affinity and gel filtration chromatography. Assays were performed in 384-well Proxiplates (PerkinElmer). The purified His-Tb-hPDE4D2(86-413) protein was diluted to 0.5 ng/mL in assay buffer (25 mM HEPES, pH 7.4, 2.5 mM MgCl<sub>2</sub>, 0.1% BSA). Test compounds were preincubated for 10 min with the diluted His-Tb-hPDE4D2(86-413) protein in a concentration series from 0.5 nM to 30 μM in 3-fold serial dilutions for 11 points. An equal volume of [<sup>3</sup>H]cAMP (isotopically diluted to 0.6 μM) was added and further incubated for 1 h. Subsequently, a mixture containing YtO beads (GE Healthcare, RPNQ1280, 10 mg/mL), IBMX (2 mM), and glycerol (20%) was added as twice the original volume. The final reaction mixtures were incubated for another 3 h. Radioactivity was measured on the Leadseeker (GE Healthcare). Competition data was fitted to a four-parameter logistic equation. IC<sub>50</sub> was determined as the concentration of compound that yielded 50% inhibition to the [<sup>3</sup>H]cAMP binding.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry General Methods</h3><div class="NLM_p">All reagents and starting materials were obtained from commercial suppliers and used without further purification unless otherwise stated. Reaction progress was monitored using a variety of liquid chromatography (LC) instruments equipped with electrospray positive ionization detectors. Unless otherwise noted the purity and retention time of final compounds was established using the following conditions: Column, Waters Acquity UPLC BEH C18, 2.1 mm × 50 mm, 1.7 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Temperature: 50 °C. Gradient: 0–100% B over 3 min, then a 0.75 min hold at 100% B. Flow: 1.11 mL/min. Detection: MS and UV (220 nm). Intermediates were isolated to >95% purity (determined by <sup>1</sup>H NMR) unless otherwise noted.</div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 4-((2-Carbamoylphenyl)amino)-6-((5-fluoropyridin-2-yl)amino)nicotinamide (<b>4</b>)</h4><div class="NLM_p last"><b>11</b> (35 mg, 0.10 mmol) was dissolved in <i>N</i>,<i>N</i>-dimethylformamide (DMF) (1 mL) and combined with ammonium chloride (10 mg, 0.19 mmol) as well as <i>N</i>,<i>N</i>′-diisopropylethylamine (52 μL, 0.48 mmol). To this was added HATU (44 mg, 0.11 mmol), and the reaction was stirred for 1 h. The crude reaction was filtered through a micropore frit and purified using preparative high-performance liquid chromatography (pHPLC) to provide <b>4</b> as the TFA salt (6 mg, 12% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.01 (s, 1H), 9.72 (s, 1H), 8.46 (s, 1H), 8.07 (d, <i>J</i> = 3.0 Hz, 1H), 7.97–7.82 (m, 2H), 7.69–7.65 (m, 1H), 7.65–7.60 (m, 2H), 7.59–7.53 (m, 2H), 7.52–7.45 (m, 1H), 7.38 (s, 1H), 7.14–7.08 (m, 1H). MS (E+) <i>m</i>/<i>z</i>: 367.2 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.09 min, purity = 96.6%.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-((2-Carbamoylphenyl)amino)-6-((5-fluoropyridin-2-yl)amino)-<i>N</i>-methylnicotinamide (<b>5</b>)</h4><div class="NLM_p last">5-Fluoropyridin-2-amine (74 mg, 0.66 mmol) was combined with <b>15</b> (100 mg, 0.328 mmol). To the vessel was added dimethylacetamide (DMA, 3 mL) followed by tris(dibenzylideneacetone)dipalladium(0) (Pd<sub>2</sub>dba<sub>3</sub>) (30 mg, 0.033 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) (38 mg, 0.066 mmol), and cesium carbonate (Cs<sub>2</sub>CO<sub>3</sub>, 214 mg, 0.656 mmol). The vessel was then evacuated and backfilled with nitrogen three times and then heated to 145 °C for 45 min. The crude product was diluted with DMF and filtered before being purified using preparative HPLC providing 16.4 mg (12.5% yield) of <b>5</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.89 (s, 1H), 9.73 (s, 1H), 8.37 (s, 1H), 8.33 (d, <i>J</i> = 4.5 Hz, 1H), 8.08 (d, <i>J</i> = 3.0 Hz, 1H), 7.92 (s, 1H), 7.68 (s, 1H), 7.67–7.62 (m, 1H), 7.62–7.59 (m, 1H), 7.57 (d, <i>J</i> = 7.9 Hz, 2H), 7.52–7.45 (m, 1H), 7.40 (s, 1H), 7.13–7.06 (m, 1H), 4.05 (s, 1H), 3.90 (s, 1H), 2.75 (d, <i>J</i> = 4.5 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 381.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.24 min, purity = 100%.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-((2-Carbamoylphenyl)amino)-<i>N</i>-ethyl-6-((5-fluoropyridin-2-yl)amino)nicotinamide (<b>6</b>)</h4><div class="NLM_p last">Prepared in a manner analogous to <b>4</b>, using 6.7 mg of ethylamine hydrochloride, 20 mg of <b>11</b>, 38 μL of <i>N</i>,<i>N</i>′-diisopropylethylamine, and HATU (27 mg) to provide <b>6</b> (6.9 mg, 32%). <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.26 (s, 1H), 8.18 (br s, 1H), 7.73 (d, <i>J</i> = 7.4 Hz, 1H), 7.58–7.50 (m, 2H), 7.43–7.29 (m, 1H), 7.02 (br s, 1H), 3.42 (q, <i>J</i> = 7.3 Hz, 2H), 1.27–1.20 (m, 3H). MS (E+) <i>m</i>/<i>z</i>: 395.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.24 min, purity = 96.4%.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-((2-Carbamoylphenyl)amino)-<i>N</i>-cyclopropyl-6-((5-fluoropyridin-2-yl)amino)nicotinamide (<b>7</b>)</h4><div class="NLM_p last">Prepared in a manner analogous to <b>4</b>, using cyclopropanamine (4.7 mg, 0.082 mmol), <i>N</i>,<i>N</i>′-diisopropylethylamine (38 μL, 0.22 mmol), and HATU (27 mg, 0.071 mmol) with <b>11</b> (20 mg, 0.054 mmol) to provide <b>7</b> (6 mg, 27% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>/methanol-<i>d</i><sub>4</sub>) δ 8.21 (s, 1H), 7.94 (d, <i>J</i> = 3.0 Hz, 1H), 7.67 (dd, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 1H), 7.51 (s, 1H), 7.49–7.43 (m, 1H), 7.39–7.33 (m, 1H), 7.32–7.26 (m, 1H), 7.19–7.13 (m, 1H), 2.81 (tt, <i>J</i> = 7.3, 3.8 Hz, 1H), 0.81–0.74 (m, 2H), 0.65–0.58 (m, 2H). MS (E+) <i>m</i>/<i>z</i>: 407.2 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.25 min, purity = 100%.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-((2-Carbamoylphenyl)amino)-6-((5-fluoropyridin-2-yl)amino)-<i>N</i>,<i>N</i>-dimethylnicotinamide (<b>8</b>)</h4><div class="NLM_p last">Prepared in a manner analogous to <b>4</b>, using dimethylamine (4.6 mg, 0.10 mmol), <i>N</i>,<i>N</i>′-diisopropylethylamine (48 μL, 0.27 mmol), and HATU (34 mg, 0.088 mmol) with <b>11</b> (25 mg, 0.068 mmol) to provide <b>8</b> (11 mg, 39% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>/methanol-<i>d</i><sub>4</sub>) δ 8.01 (d, <i>J</i> = 3.0 Hz, 1H), 7.96 (s, 1H), 7.75 (s, 1H), 7.67 (s, 1H), 7.66 (s, 1H), 7.50–7.43 (m, 1H), 7.43–7.37 (m, 1H), 7.37–7.30 (m, 1H), 7.07 (t, <i>J</i> = 7.7 Hz, 1H), 3.10 (s, 6H). MS (E+) <i>m</i>/<i>z</i>: 395.2 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.20 min, purity = 96.1%.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4-((2-Carbamoylphenyl)amino)-6-chloronicotinic Acid (<b>10</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (500 mg, 2.60 mmol) in DMA (5 mL) was added 2-aminobenzamide (425 mg, 3.13 mmol) followed by sodium bis(trimethylsilyl)amide solution (1 M in THF, 9.1 mL, 9.1 mmol). The reaction was stirred at room temperature for 1 h. The reaction was concentrated under reduced pressure to remove the THF and then water (∼30 mL) was added, resulting in a clear solution. To this was added HCl (6 M, aqueous) until the pH was ∼1–2, and a white precipitate prevailed. The solid was collected by filtration and rinsed with water (4 × 20 mL) and then dried overnight to provide <b>10</b> (630 mg, 83% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.31 (br s, 1H), 8.53 (s, 1H), 7.74 (br s, 1H), 7.53 (dd, <i>J</i> = 7.6, 1.4 Hz, 1H), 7.48–7.42 (m, 1H), 7.42–7.38 (m, 1H), 7.36 (br s, 1H), 7.18 (td, <i>J</i> = 7.4, 1.3 Hz, 2H), 6.68 (s, 1H). MS (E+) <i>m</i>/<i>z</i>: 292.1 (MH<sup>+</sup>).</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-((2-Carbamoylphenyl)amino)-6-((5-fluoropyridin-2-yl)amino)nicotinic Acid (<b>11</b>)</h4><div class="NLM_p last"><b>10</b> (380 mg, 1.30 mmol) was combined with 5-fluoropyridin-2-amine (219 mg, 1.95 mmol) within a reaction vessel. To the vessel was added DMA (15 mL) followed by Pd<sub>2</sub>dba<sub>3</sub> (119 mg, 0.13 mmol), Xantphos (151 mg, 0.26 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (849 mg, 2.61 mmol). The vessel was then evacuated and backfilled with nitrogen three times and then heated to 145 °C for 35 min. The reaction mixture was filtered, absorbed onto silica gel, and then purified using automated column chromatography (0–100% MeOH/DCM) to provide <b>11</b> (350 mg, 73% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.85 (br s, 1H), 9.87 (s, 1H), 8.62 (s, 1H), 8.08 (s, 1H), 7.98 (br s, 1H), 7.74 (br s, 1H), 7.67–7.57 (m, 4H), 7.54 (t, <i>J</i> = 7.4 Hz, 1H), 7.44 (br s, 1H), 7.16 (t, <i>J</i> = 7.4 Hz, 1H). MS (E+) <i>m</i>/<i>z</i>: 368.2 (MH<sup>+</sup>).</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4,6-Dichloro-<i>N</i>-methylnicotinamide (<b>12</b>)</h4><div class="NLM_p last">To a round bottomed flask containing <b>9</b> (60 g, 313 mmol) was added chloroform (500 mL) and a single drop of DMF. The reaction was cooled to 0 °C, and oxalyl chloride (82 mL, 938 mmol) was subsequently added over 5 min. The reaction was maintained at 0 °C for 1 h and then concentrated under reduced pressure. The reaction vessel was recharged with chloroform and reconcentrated, and this was repeated one additional time, yielding a brown oil. The oil was dissolved in chloroform (500 mL) and cooled to 0 °C. To the chilled reaction vessel was added methylamine (2 M in THF, 390 mL, 780 mmol) in a gradual manner. Stirring was maintained at 0 °C for 1 h and then the reaction was quenched via the addition of water. The product was extracted with chloroform, and the combined organic layers were washed with water and brine and then dried over sodium sulfate, filtered, and concentrated. The crude product (52 g) was combined with another batch of crude material (27 g) and then purified using flash chromatography eluting with 40–50% ethyl acetate in petroleum ether, providing 73 g of <b>12</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (bm, 1H), δ 8.47 (s, 1H), δ 7.89 (s, 1H), δ 2.78 (d, <i>J</i> = 4.6 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 204.9 (MH<sup>+</sup>).</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4,6-Dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)nicotinamide (<b>13</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (5 g, 26 mmol) in DCM (50 mL) was added oxalyl chloride (2.7 mL, 31.3 mmol) followed by 4 drops of DMF. The reaction was run at room temperature for 30 min and then concentrated under reduced pressure. The crude product was redissolved in DCM (50 mL), and triethylamine (10.9 mL, 78 mmol) was added, followed by methyl-<i>d</i><sub>3</sub>-amine hydrochloride (2.76 g, 39.1 mmol). The reaction was run at room temperature overnight and then diluted with water. The product was extracted using DCM (×2), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude product was triturated with diethyl ether and collected (4 g, 74% yield). <sup>1</sup>H NMR (300 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.45 (s, 1H), δ 7.71 (s, 1H). MS (E+) <i>m</i>/<i>z</i>: 207.9 (MH<sup>+</sup>).</div></div><div id="sec4_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4,6-Dichloronicotinamide (<b>14</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (5 g, 26 mmol) in DCM (20 mL) was added oxalyl chloride (3.0 mL, 33.9 mmol) followed by 6 drops of DMF. The reaction was stirred at room temperature until aliquot with methanol indicated complete conversion by liquid chromatography–mass spectrometry (LCMS). The reaction was concentrated and then redissolved in DCM and cooled to 0 °C. To this was added aqueous ammonia (7.4 mL, 104 mmol), resulting in a white precipitate. The reaction was filtered, collecting the filter cake, and the biphasic filtrate was separated and the organic phase was concentrated to dryness and combined with the filter cake to provide <b>14</b> (4.2 g, 84% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.49 (s, 1H), 8.10 (br s, 1H), 7.93–7.78 (m, 2H). MS (E+) <i>m</i>/<i>z</i>: 191.4 (MH<sup>+</sup>).</div></div><div id="sec4_6_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-((2-Carbamoylphenyl)amino)-6-chloro-<i>N</i>-methylnicotinamide (<b>15</b>)</h4><div class="NLM_p last">To a stirred solution of <b>12</b> (800 mg, 3.90 mmol) was added 2-aminobenzamide (1.59 g, 11.7 mmol) followed by sodium bis(trimethylsilyl)amide (NaHMDS) (1 M in THF, 23.4 mL, 23.4 mmol) at 0 °C. The reaction was warmed to room temperature and stirred for 2 h, at which point methanol was added to quench the reaction. The solvents were removed in vacuo and the crude material purified using flash chromatography (5–10% MeOH/chloroform) to provide <b>15</b> (950 mg, 80% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.90 (s, 1H), 8.62 (d, <i>J</i> = 3.3 Hz, 1H), 8.41 (s, 1H), 7.95 (br s, 1H), 7.62 (d, <i>J</i> = 7.7 Hz, 1H), 7.53–7.38 (m, 3H), 7.29–7.15 (m, 1H), 6.92 (s, 1H), 2.78 (d, <i>J</i> = 4.4 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 305.0 (MH<sup>+</sup>).</div></div><div id="sec4_6_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-((2-Carbamoylphenyl)amino)-<i>N</i>-methyl-6-(pyridin-2-ylamino)nicotinamide (<b>16</b>)</h4><div class="NLM_p last">Prepared according to the procedure described for <b>5</b>, using Pd<sub>2</sub>dba<sub>3</sub> (9 mg, 0.010 mmol), Xantphos (11.4 mg, 0.020 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (64 mg, 0.20 mmol) with <b>15</b> (30 mg, 0.098 mmol) and aniline (18 mg, 0.20 mmol) to provide <b>16</b> (11.5 mg, 33% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>/methanol-<i>d</i><sub>4</sub>) δ 8.29 (s, 1H), 8.12 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.73–7.61 (m, 3H), 7.54–7.45 (m, 1H), 7.29 (d, <i>J</i> = 8.4 Hz, 1H), 7.18 (t, <i>J</i> = 7.2 Hz, 1H), 6.88 (dd, <i>J</i> = 6.9, 5.4 Hz, 1H), 4.29 (s, 1H), 2.94 (s, 3H). Purity = 94.7%.</div></div><div id="sec4_6_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-((2-Carbamoylphenyl)amino)-<i>N</i>-methyl-6-(pyridin-2-ylamino)nicotinamide (<b>17</b>)</h4><div class="NLM_p last">Prepared according to the procedure described for <b>5</b>, using Pd<sub>2</sub>dba<sub>3</sub> (9 mg, 0.010 mmol), Xantphos (11.4 mg, 0.020 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (64 mg, 0.20 mmol) with <b>15</b> (30 mg, 0.098 mmol) and 2-aminopyridine (19 mg, 0.20 mmol) to provide <b>17</b> (10.8 mg, 30% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>/methanol-<i>d</i><sub>4</sub>) δ 8.25 (s, 1H), 8.08 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.66 (dd, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.63–7.57 (m, 2H), 7.52–7.41 (m, 1H), 7.26 (d, <i>J</i> = 8.4 Hz, 1H), 7.15 (t, <i>J</i> = 7.2 Hz, 1H), 6.84 (dd, <i>J</i> = 6.9, 5.4 Hz, 1H), 2.90 (s, 3H). <i>R</i><sub>T</sub> = 1.02 min, purity = 98.8%.</div></div><div id="sec4_6_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-((2-Carbamoylphenyl)amino)-6-((3-fluoropyridin-2-yl)amino)-<i>N</i>-methylnicotinamide (<b>18</b>)</h4><div class="NLM_p last">Prepared according to the procedure described for <b>5</b>, using Pd<sub>2</sub>dba<sub>3</sub> (9 mg, 0.010 mmol), Xantphos (11.4 mg, 0.020 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (64 mg, 0.20 mmol) with <b>15</b> (30 mg, 0.098 mmol) and 2-amino-3-fluoropyridine (22 mg, 0.20 mmol) to provide <b>18</b> (12 mg, 32% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.96 (s, 1H), 9.05 (s, 1H), 8.42–8.33 (m, 2H), 8.05–7.84 (m, 3H), 7.67–7.54 (m, 3H), 7.48 (t, <i>J</i> = 7.7 Hz, 1H), 7.40 (br s, 1H), 7.09 (t, <i>J</i> = 7.4 Hz, 1H), 6.96 (ddd, <i>J</i> = 7.9, 4.5, 3.5 Hz, 1H), 2.78–2.74 (m, 3H). <i>R</i><sub>T</sub> = 1.10 min, purity = 100%.</div></div><div id="sec4_6_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-((2-Carbamoylphenyl)amino)-<i>N</i>-methyl-6-(pyrimidin-2-ylamino)nicotinamide (<b>19</b>)</h4><div class="NLM_p last">Prepared according to the procedure described for <b>5</b>, using Pd<sub>2</sub>dba<sub>3</sub> (9 mg, 0.010 mmol), Xantphos (11.4 mg, 0.020 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (64 mg, 0.20 mmol) with <b>15</b> (30 mg, 0.098 mmol) and 2-amino-pyrimidine (19 mg, 0.20 mmol) to provide <b>19</b> (11.4 mg, 32% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.00 (s, 1H), 9.78 (s, 1H), 8.46 (d, <i>J</i> = 5.0 Hz, 2H), 8.40 (s, 1H), 8.38 (d, <i>J</i> = 4.5 Hz, 1H), 8.29 (s, 1H), 7.94 (br s, 1H), 7.64 (d, <i>J</i> = 8.4 Hz, 1H), 7.58 (dd, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.53–7.47 (m, 1H), 7.40 (br s, 1H), 7.10 (t, <i>J</i> = 7.4 Hz, 1H), 6.92 (t, <i>J</i> = 5.0 Hz, 1H), 2.77 (d, <i>J</i> = 4.5 Hz, 3H). Purity = 100%.</div></div><div id="sec4_6_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 6-((5-Fluoropyridin-2-yl)amino)-<i>N</i>-methyl-4-(phenylamino)nicotinamide (<b>20</b>)</h4><div class="NLM_p last"><b>28</b> (20 mg, 0.071 mmol) was combined with aniline (13 mg, 0.4 mmol) in <i>N</i>-methyl-2-pyrrolidone (NMP) (1 mL), and to this was added hydrochloric acid (4 M in dioxane, 14 μL, 0.057 mmol) and the vessel was sealed and heated to 120 °C overnight. The crude reaction was filtered and purified using preparative HPLC, providing 8.7 mg (36% yield) of <b>20</b>. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.29 (s, 1H), 8.00 (d, <i>J</i> = 3.0 Hz, 1H), 7.58 (s, 1H), 7.45–7.37 (m, 3H), 7.35–7.29 (m, 3H), 7.20–7.14 (m, 1H), 2.93 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 338.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.62 min, purity = 100%.</div></div><div id="sec4_6_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 6-((5-Fluoropyridin-2-yl)amino)-4-((2-methoxyphenyl)amino)-<i>N</i>-methylnicotinamide (<b>21</b>)</h4><div class="NLM_p last"><b>28</b> (20 mg, 0.071 mmol) was dissolved in NMP (0.5 mL) along with 2-methoxyaniline (35 mg, 0.28 mmol). The solution was heated to 130 °C for 15 h, cooled to room temperature, filtered, and purified using pHPLC to provide <b>21</b> (9.8 mg, 37% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H), 8.41 (s, 1H), 8.28 (m, 1H), 7.80 (bs, 1H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 7.28–7.20 (m, 3H), 7.07 (m, 1 H), 3.86 (s, 3H), 2.82 (d, <i>J</i> = 4.4 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 368.2 (MH<sup>+</sup>). *<i>R</i><sub>T</sub> = 6.25 min, purity = 98.3%. *Conditions: Column, Waters Sunfire C18 (4.6 mm × 150 mm), 3.5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 0.1% TFA. Mobile phase B: 95:5 acetonitrile:water with 0.1% TFA. Temperature: 50 °C. Gradient: 0–100% B over 12 min. Flow: 4 mL/min. Detection: UV (220 and 254 nm).</div></div><div id="sec4_6_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-((3,4-Difluoro-2-methoxyphenyl)amino)-6-((5-fluoropyridin-2-yl)amino)-<i>N</i>-methylnicotinamide (<b>22</b>)</h4><div class="NLM_p last">Prepared according to the procedure described for <b>20</b>, using <b>28</b> (35 mg, 0.12 mmol), 3,4-difluoro-2-methoxyaniline (50 mg, 0.31 mmol), and HCl (31 μL, 0.12 mmol) to give <b>22</b> (6.4 mg, 13% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>/methanol-<i>d</i><sub>4</sub>) δ 8.29 (s, 1H), 8.02 (d, <i>J</i> = 3.0 Hz, 1H), 7.48 (s, 1H), 7.40 (td, <i>J</i> = 8.4, 3.0 Hz, 1H), 7.28 (dd, <i>J</i> = 9.2, 3.7 Hz, 1H), 7.24 (ddd, <i>J</i> = 9.2, 5.2, 2.5 Hz, 1H), 7.00–6.92 (m, 1H), 3.97 (d, <i>J</i> = 1.5 Hz, 3H), 2.90 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 404.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.78 min, purity = 98.1%.</div></div><div id="sec4_6_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 6-((5-Fluoropyridin-2-yl)amino)-<i>N</i>-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>23</b>)</h4><div class="NLM_p last">5-Fluoropyridin-2-amine (40 mg, 0.35 mmol) was combined with <b>33</b> (80 mg, 0.24 mmol). To the vessel was added DMA (1 mL) followed by Pd<sub>2</sub>dba<sub>3</sub> (22 mg, 0.024 mmol), Xantphos (27 mg, 0.047 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (153 mg, 0.47 mmol). The vessel was then evacuated and backfilled with nitrogen three times and then heated to 145 °C for 2 h. The crude product was diluted with DMF and filtered before being purified using preparative HPLC providing 50 mg (51% yield) of <b>23</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.82 (s, 1H), 9.82 (s, 1H), 8.57–8.48 (m, 2H), 8.09 (d, <i>J</i> = 2.5 Hz, 1H), 7.93 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.83–7.77 (m, 1H), 7.76–7.73 (m, 1H), 7.69–7.60 (m, 2H), 7.59 (s, 1H), 7.40–7.34 (m, 1H), 3.15 (s, 3H), 2.77 (d, <i>J</i> = 4.5 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 416.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.23 min, purity = 100%.</div></div><div id="sec4_6_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-((2-(Ethylsulfonyl)phenyl)amino)-6-((5-fluoropyridin-2-yl)amino)-<i>N</i>-methylnicotinamide (<b>24</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>23</b> using <b>34</b> (30 mg, 0.085 mmol), 5-fluoropyridin-2-amine (12 mg, 0.11 mmol), Pd<sub>2</sub>dba<sub>3</sub> (7.8 mg, 0.008 mmol), Xantphos (9.8 mg, 0.017 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (55 mg, 0.17 mmol) in DMA (1 mL) at 145 °C to give <b>24</b> (12 mg, 33% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>/methanol-<i>d</i><sub>4</sub>) δ 8.34 (s, 1H), 7.96 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.94 (d, <i>J</i> = 3.0 Hz, 1H), 7.77 (d, <i>J</i> = 8.4 Hz, 1H), 7.73 (s, 1H), 7.70–7.64 (m, 1H), 7.41–7.35 (m, 1H), 7.33–7.26 (m, 2H), 3.22 (q, <i>J</i> = 7.4 Hz, 2H), 2.90 (s, 3H), 1.20 (t, <i>J</i> = 7.4 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 430.0 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.30 min, purity = 98.8%.</div></div><div id="sec4_6_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-((5-Fluoropyridin-2-yl)amino)-<i>N</i>-methyl-4-((2-(methylthio)phenyl)amino)nicotinamide (<b>25</b>)</h4><div class="NLM_p last"><b>31</b> (50 mg, 0.16 mmol) and 5-fluoropyridin-2-amine were combined in a 2 dram vial with dioxane (1 mL). To this was added in a single portion, Pd<sub>2</sub>dba<sub>3</sub> (15 mg, 0.016 mmol), Xantphos (0.014 mg, 0.024 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (132 mg, 0.41 mmol). The vial was evacuated and backfilled with N<sub>2</sub> three times and then warmed to 130 °C and stirred for 90 min. The reaction was cooled to room temperature, filtered through sand, eluting with ethyl acetate, concentrated, redissolved in DMF, and purified using pHPLC to provide <b>25</b> (21.4 mg, 34% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.37 (s, 1H), 9.71 (s, 1H), 8.54–8.38 (m, 2H), 8.05 (d, <i>J</i> = 2.8 Hz, 1H), 7.72–7.64 (m, 1H), 7.61 (td, <i>J</i> = 8.7, 2.9 Hz, 1H), 7.43 (d, <i>J</i> = 7.9 Hz, 1H), 7.39–7.33 (m, 2H), 7.27 (t, <i>J</i> = 7.4 Hz, 1H), 7.23–7.10 (m, 1H), 2.77 (d, <i>J</i> = 4.3 Hz, 3H), 2.42 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 384.2 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.72 min, purity = 100%.</div></div><div id="sec4_6_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 6-Chloro-4-methoxynicotinic Acid (<b>26</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (4 g, 20.8 mmol) in methanol (8 mL) and tetrahydrofuran (16 mL) was added lithium hydroxide monohydrate (2.62 g, 62.5 mmol), and the reaction was stirred at room temperature for 1 h. The reaction was concentrated under reduced pressure, and 12 mL of water was added, the solution was cooled to 0 °C, and 1 N hydrochloric acid (aqueous) was added while the solution was agitated, resulting in a precipitate. Gradual addition of the acid was continued until the pH measured (litmus paper) to be ∼4. The suspension was then filtered and the solid collected and triturated with diethyl ether for 1 h. The solid was filtered, dried, and collected, yielding <b>26</b> (2.84 g, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.23 (br s, 1H), 8.54 (s, 1H), 7.32 (s, 1H), 3.94 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 187.9 (MH<sup>+</sup>).</div></div><div id="sec4_6_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-((5-Fluoropyridin-2-yl)amino)-4-methoxynicotinic Acid (<b>27</b>)</h4><div class="NLM_p last">5-Fluoropyridin-2-amine (1.195 g, 10.66 mmol) was combined with <b>26</b> (1.00 g, 5.33 mmol). To the vessel was added DMA (20 mL), followed by Pd<sub>2</sub>dba<sub>3</sub> (488 mg, 0.533 mmol), Xantphos (617 mg, 1.07 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (3.47 g, 107 mmol). The vessel was then evacuated and backfilled with nitrogen three times and then heated to 145 °C for 30 min. The crude reaction was diluted with methanol and filtered (rinsing with methanol). The filtrate was concentrated to minimal volume using a rotary evaporator connected to an oil pump. To the viscous oil was added 1 N HCl (aqueous) to a pH ∼ 2, resulting in a precipitate which was then sonicated and filtered off, rinsing with cold water. The solid was collected, dried, and suspended in diethyl ether. The slurry was sonicated and subsequently filtered, rinsing with diethyl ether. The solid was once again collected and this time suspended in 1:1 dichloromethane:ether and again sonicated. Filtration followed by a 1:1 dichloromethane:ether rinse and a hexanes rinse yielded <b>27</b> (1.31 g, 94%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 8.35 (d, <i>J</i> = 3.1 Hz, 1H), 7.86 (td, <i>J</i> = 8.6, 2.8 Hz, 1H), 7.57 (d, <i>J</i> = 5.9 Hz, 1H), 7.16 (s, 1H), 3.96 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 264.1 (MH<sup>+</sup>).</div></div><div id="sec4_6_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 6-((5-Fluoropyridin-2-yl)amino)-4-hydroxynicotinic Acid (<b>28</b>)</h4><div class="NLM_p last">To a suspension of <b>27</b> (1.53 g, 5.81 mmol) in glacial acetic acid (50 mL) was added hydrobromic acid (48% in AcOH, 9.86 mL, 87 mmol)). The vessel was sealed and heated to 110 °C for 4 h. The reaction was cooled to room temperature, and the solvent was removed under reduced pressure, and the crude product was coevaporated with toluene and then suspended in diethyl ether and filtered rinsing with ether. The resulting red powder was carried on without further purification. To 1.1 g (∼4.4 mmol) of the crude product was added phosphorus oxychloride (25 mL) and triethylamine (0.61 mL, 4.4 mmol). The reaction was heated to 110 °C for 2 h and then concentrated under reduced pressure. The resulting residue was dissolved in THF (20 mL). The solution was cooled to 0 °C, and methylamine (2 M in THF, 4.42 mL, 8.84 mmol) was gradually added. The reaction was stirred at 0 °C for 1 h, concentrated, and then purified using flash chromatography providing <b>28</b> (500 mg, 40% yield). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.20 (s, 1H), 8.36 (m, 1H), 8.29 (m, 2H), 7.90 (s, 1H), 7.69 (m, 2H), 2.76 (d, <i>J</i> = 4.5 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 281.0 (MH<sup>+</sup>).</div></div><div id="sec4_6_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 6-((5-Fluoropyridin-2-yl)amino)-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>29</b>)</h4><div class="NLM_p last">Prepared following the exact sequence for <b>23</b> but initiating from <b>14</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.01 (s, 1H), 9.81 (br s, 1H), 8.59 (s, 1H), 8.15–7.99 (m, 2H), 7.93 (d, <i>J</i> = 7.8 Hz, 1H), 7.83–7.73 (m, 2H), 7.64 (d, <i>J</i> = 9.3 Hz, 2H), 7.53 (br s, 1H), 7.38 (t, <i>J</i> = 7.4 Hz, 2H), 3.14 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 402.2 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.30 min, purity = 99.0%.</div></div><div id="sec4_6_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 6-((5-Fluoropyridin-2-yl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>30</b>)</h4><div class="NLM_p last">Prepared following the exact sequence for <b>23</b> but initiating from <b>13</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.83 (br s, 1H), 9.83 (br s, 1H), 8.57–8.50 (m, 1H), 8.48 (br s, 1H), 8.09 (d, <i>J</i> = 3.0 Hz, 1H), 7.93 (dd, <i>J</i> = 7.9, 3.0 Hz, 1H), 7.82–7.71 (m, 2H), 7.69–7.60 (m, 2H), 7.59 (br s, 1H), 7.42–7.28 (m, 1H), 3.20–3.11 (m, 3H). MS (E+) <i>m</i>/<i>z</i>: 419.0 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.38 min, purity = 100%.</div></div><div id="sec4_6_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 6-Chloro-<i>N</i>-methyl-4-((2-(methylthio)phenyl)amino)nicotinamide (<b>31</b>)</h4><div class="NLM_p last">To a solution of <b>12</b> (1.8 g, 8.78 mmol) in tetrahydrofuran (THF, 68 mL) was added 2-(methylthio)aniline (1.83 g, 13.2 mmol), followed by NaHMDS solution (1 M in THF, 61 mL, 61 mmol). The reaction was stirred at room temperature for 30 min and then quenched with water. The crude product was extracted with ethyl acetate, dried over sodium sulfate, filtered, concentrated, and purified by automated chromatography (0–100% EtOAc/hexanes) to provide <b>31</b> (2.16 g, 80% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 8.77 (d, <i>J</i> = 4.4 Hz, 1H), 8.51 (s, 1H), 7.44–7.22 (m, 4H), 6.51 (s, 1H), 2.80 (d, <i>J</i> = 4.6 Hz, 3H), 2.43 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 307.9 (MH<sup>+</sup>).</div></div><div id="sec4_6_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 6-Chloro-4-((2-(ethylthio)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>32</b>)</h4><div class="NLM_p last">Prepared in an analogous manner to <b>31</b>, using 2-(ethylthio)aniline (336 mg, 2.20 mmol), <b>12</b> (300 mg, 1.46 mmol), and NaHMDS (10 mL, 10 mmol) in THF (10 mL), providing <b>32</b> (290 mg, 62% yield). MS (E+) <i>m</i>/<i>z</i>: 322.1 (MH<sup>+</sup>).</div></div><div id="sec4_6_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 6-Chloro-<i>N</i>-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>33</b>)</h4><div class="NLM_p last"><b>31</b> (900 mg, 2.92 mmol) was suspended in acetic acid (AcOH, 9.7 mL), and hydrogen peroxide (30% aqueous solution, 6.0 mL, 58.5 mmol) and sodium tungstate dihydrate (964 mg, 2.92 mmol) were subsequently added. The reaction was complete after 30 min and was then diluted with water and ethyl acetate. The layers were separated and the aqueous layer extracted once with ethyl acetate. The combined organic layers were washed once with saturated aqueous sodium bisulfite and once with water. The combined organic layers were then dried over sodium sulfate, filtered, concentrated under reduced pressure and purified with automated silica gel chromatography (0–100% EtOAc/hexanes), yielding the sulfone product <b>33</b> (678 mg, 68%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (s, 1H), 8.79 (d, <i>J</i> = 4.0 Hz, 1H), 8.57 (s, 1H), 7.96 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.79–7.73 (m, 1H), 7.70–7.66 (m, 1H), 7.46 (t, <i>J</i> = 7.6 Hz, 1H), 6.97 (s, 1H), 3.17 (s, 3H), 2.79 (d, <i>J</i> = 4.4 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 340.1 (MH<sup>+</sup>).</div></div><div id="sec4_6_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-Chloro-4-((2-(ethylsulfonyl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>34</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>33</b>, using <b>32</b> (290 mg, 0.90 mmol), hydrogen peroxide (2.76 mL, 27 mmol), and sodium tungstate dihydrate (300 mg, 0.90 mmol) to provide <b>34</b> (283 mg, 89% yield). MS (E+) <i>m</i>/<i>z</i>: 354.0 (MH<sup>+</sup>).</div></div><div id="sec4_6_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-Methyl-6-((4-methylpyridin-2-yl)amino)-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>35</b>)</h4><div class="NLM_p last">4-Methyl-2-aminopyridine (19 mg, 0.18 mmol) was combined with <b>33</b> (30 mg, 0.088 mmol). To the vessel was added dioxane (0.9 mL) followed by Pd<sub>2</sub>dba<sub>3</sub> (8 mg, 0.009 mmol), BrettPhos (7 mg, 0.01 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (72 mg, 0.22 mmol). The vessel was then evacuated and backfilled with nitrogen three times and then heated to 130 °C overnight. The crude product was diluted with DMF and filtered before being purified using preparative HPLC, providing 22.5 mg (62% yield) of <b>35</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.80 (s, 1H), 9.63 (br s, 1H), 8.58–8.43 (m, 2H), 8.02–7.86 (m, 2H), 7.76 (d, <i>J</i> = 3.3 Hz, 3H), 7.36 (br s, 1H), 7.30 (br s, 1H), 6.71 (br s, 1H), 3.15 (s, 3H), 2.77 (d, <i>J</i> = 3.7 Hz, 3H), 2.23 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 412.2 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.31 min, purity = 98.7%.</div></div><div id="sec4_6_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-Methyl-4-((2-(methylsulfonyl)phenyl)amino)-6-((5-morpholinopyridin-2-yl)amino)nicotinamide (<b>36</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>23</b>, from <b>33</b> (45 mg, 0.13 mmol), 5-morpholinopyridin-2-amine (36 mg, 0.20 mmol), Pd<sub>2</sub>dba<sub>3</sub> (12 mg, 0.013 mmol), Xantphos (15 mg, 0.026 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (86 mg, 0.26 mmol) in DMA (1 mL) at 145 °C for 90 min to provide <b>36</b> (4.8 mg, 7% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.82 (s, 1H), 9.51 (s, 1H), 8.49 (s, 1H), 8.46 (d, <i>J</i> = 4.0 Hz, 1H), 7.96–7.89 (m, 1H), 7.81–7.72 (m, 3H), 7.60 (br s, 1H), 7.47 (d, <i>J</i> = 8.9 Hz, 1H), 7.42–7.32 (m, 2H), 3.76–3.68 (m, 4H), 3.16 (s, 3H), 3.07–2.98 (m, 4H), 2.77 (d, <i>J</i> = 4.5 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 483.3 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.20 min, purity = 97.9%.</div></div><div id="sec4_6_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-Methyl-6-((6-methylpyridazin-3-yl)amino)-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>37</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>23</b>, from <b>33</b> (25 mg, 0.13 mmol), 6-methylpyridazin-3-amine (16 mg, 0.15 mmol), Pd<sub>2</sub>dba<sub>3</sub> (7 mg, 0.007 mmol), Xantphos (8.5 mg, 0.015 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (48 mg, 0.15 mmol) in DMA (1 mL) at 145 °C for 4 h to provide <b>37</b> (14.7 mg, 48% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>/methanol-<i>d</i><sub>4</sub>) δ 8.40 (s, 1H), 8.00 (d, <i>J</i> = 7.9 Hz, 1H), 7.82 (d, <i>J</i> = 9.4 Hz, 1H), 7.77–7.73 (m, 1H), 7.72–7.66 (m, 1H), 7.34 (d, <i>J</i> = 9.4 Hz, 1H), 7.30 (t, <i>J</i> = 7.2 Hz, 1H), 3.11 (s, 3H), 2.91 (s, 3H), 2.54 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 413.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.08 min, purity = 99.2%.</div></div><div id="sec4_6_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-Methyl-4-((2-(methylsulfonyl)phenyl)amino)-6-(pyridin-2-ylamino)nicotinamide (<b>38</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>23</b>, from <b>33</b> (30 mg, 0.088 mmol), 2-aminopyridine (12.5 mg, 0.13 mmol), Pd<sub>2</sub>dba<sub>3</sub> (8.1 mg, 0.009 mmol), Xantphos (10 mg, 0.018 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (58 mg, 0.18 mmol) in DMA (1 mL) at 145 °C for 1 h to provide <b>38</b> (15.5 mg, 44% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.84 (s, 1H), 9.77 (br s, 1H), 8.53 (s, 2H), 8.10 (br s, 1H), 7.94 (d, <i>J</i> = 7.9 Hz, 1H), 7.78 (d, <i>J</i> = 3.5 Hz, 2H), 7.65 (br s, 1H), 7.49 (br s, 1H), 7.38 (br s, 1H), 6.86 (br s, 1H), 3.17 (s, 3H), 2.78 (d, <i>J</i> = 4.5 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 398.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.23 min, purity = 100%.</div></div><div id="sec4_6_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 6-((5-Methoxypyridin-2-yl)amino)-<i>N</i>-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>39</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>23</b>, from <b>33</b> (25 mg, 0.074 mmol), 2-amino-5-methoxypyridine (14 mg, 0.11 mmol), Pd<sub>2</sub>dba<sub>3</sub> (6.7 mg, 0.007 mmol), Xantphos (8.5 mg, 0.015 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (48 mg, 0.15 mmol) in DMA (0.7 mL) at 145 °C for 1 h to provide <b>39</b> (14.3 mg, 44% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.80 (s, 1H), 9.56 (br s, 1H), 8.55–8.42 (m, 2H), 7.97–7.89 (m, 1H), 7.83 (d, <i>J</i> = 3.0 Hz, 1H), 7.81–7.71 (m, 2H), 7.63–7.50 (m, 2H), 7.42–7.29 (m, 2H), 3.76 (s, 3H), 3.15 (s, 3H), 2.77 (d, <i>J</i> = 4.5 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 428.0 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.18 min, purity = 98.9%.</div></div><div id="sec4_6_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 6-(Cyclopropanecarboxamido)-<i>N</i>-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>40</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>23</b>, from <b>33</b> (30 mg, 0.088 mmol), cyclopropanecarboxamide (22.5 mg, 0.26 mmol), Pd<sub>2</sub>dba<sub>3</sub> (8.1 mg, 0.009 mmol), Xantphos (10 mg, 0.018 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (115 mg, 0.35 mmol) in DMA (0.6 mL) at 145 °C for 1 h to provide <b>40</b> (16.3 mg, 48% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.82 (d, <i>J</i> = 4.4 Hz, 2H), 8.60 (d, <i>J</i> = 4.6 Hz, 1H), 8.58 (s, 1H), 7.95 (s, 1H), 7.93 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.74–7.67 (m, 1H), 7.66–7.61 (m, 1H), 7.41–7.33 (m, 1H), 3.14 (s, 3H), 2.78 (d, <i>J</i> = 4.4 Hz, 3H), 2.06–1.87 (m, 1H), 0.87–0.62 (m, 4H). MS (E+) <i>m</i>/<i>z</i>: 389.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.11 min, purity = 97.3%.</div></div><div id="sec4_6_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 6-Butyramido-<i>N</i>-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>41</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>23</b>, from <b>33</b> (20 mg, 0.059 mmol), butyramide (15 mg, 0.18 mmol), Pd<sub>2</sub>dba<sub>3</sub> (5.4 mg, 0.006 mmol), Xantphos (6.8 mg, 0.012 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (77 mg, 0.24 mmol) in DMA (0.5 mL) at 145 °C for 2 h to provide <b>41</b> (6.1 mg, 26% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.92 (br s, 1H), 10.65 (br s, 1H), 8.70 (br s, 1H), 8.54 (d, <i>J</i> = 3.5 Hz, 1H), 7.96 (d, <i>J</i> = 7.9 Hz, 1H), 7.83–7.57 (m, 3H), 7.44 (t, <i>J</i> = 7.4 Hz, 1H), 3.17 (d, <i>J</i> = 3.5 Hz, 3H), 2.85–2.73 (m, 3H), 2.37–2.19 (m, 2H), 1.62–1.45 (m, 2H), 0.85 (td, <i>J</i> = 7.4, 3.5 Hz, 3H). MS (E+) <i>m</i>/<i>z</i>: 391.0 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.24 min, purity = 100%.</div></div><div id="sec4_6_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 6-Isobutyramido-<i>N</i>-methyl-4-((2-(methylsulfonyl)phenyl)amino)nicotinamide (<b>42</b>)</h4><div class="NLM_p last">Prepared according to the procedure for <b>23</b>, from <b>33</b> (20 mg, 0.059 mmol), isobutyramide (15 mg, 0.18 mmol), Pd<sub>2</sub>dba<sub>3</sub> (5.4 mg, 0.006 mmol), Xantphos (6.8 mg, 0.012 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (77 mg, 0.24 mmol) in DMA (0.5 mL) at 145 °C for 2 h to provide <b>42</b> (11.7 mg, 51% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.86 (br s, 1H), 10.47 (br s, 1H), 8.62 (br s, 1H), 8.57 (s, 1H), 7.99 (s, 1H), 7.94 (d, <i>J</i> = 7.9 Hz, 1H), 7.79–7.70 (m, 1H), 7.66 (d, <i>J</i> = 7.4 Hz, 1H), 7.39 (t, <i>J</i> = 7.2 Hz, 1H), 3.15 (s, 3H), 2.77 (br s, 3H), 2.74–2.64 (m, 1H), 1.01 (dd, <i>J</i> = 6.7, 2.2 Hz, 6H). MS (E−) <i>m</i>/<i>z</i>: 389.0 (M<sup>–</sup>). <i>R</i><sub>T</sub> = 1.24 min, purity = 100%.</div></div><div id="sec4_6_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Diethyl 2-Diazo-3-oxopentanedioate (<b>43</b>)</h4><div class="NLM_p last">To a cooled (0 °C) mixture of diethyl 1,3-acetonedicarboxylate (12.4 mL, 68.3 mmol) and triethylamine (10.5 mL, 75 mmol) in acetonitrile (270 mL) was added 4-acetamidobenzenesulfonylazide (16.74 g, 69.7 mmol) in portions. The reaction was warmed to room temperature and stirred for 1 h, at which point the solids were removed by filtration, rinsing with 1:1 heptanes:diethyl ether. The filtrate was concentrated and then redissolved in 1:1 heptanes:diethyl ether. The slurry was stirred for 30 min, filtered, and the filtrate concentrated once more to provide the crude product <b>43</b> (12.2 g, 50.8 mmol, 74%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 4.31 (q, <i>J</i> = 7.2 Hz, 2H), 4.21 (q, <i>J</i> = 7.1 Hz, 2H), 3.87 (s, 2H), 1.33 (t, <i>J</i> = 7.2 Hz, 3H), 1.28 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_6_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4,6-Dihydroxypyridazine-3-carboxylic Acid (<b>44</b>)</h4><div class="NLM_p last"><b>43</b> (41.6 g, 182 mmol) was dissolved in diethyl ether (300 mL), and triphenylphosphine (47.8 g, 182 mmol) was added. The reaction was stirred overnight at room temperature and then concentrated in vacuo. To the residual sludge was added acetic acid (300 mL) and water (30 mL), and the vessel was equipped with a condenser and heated to reflux for 6 h. The reaction was concentrated and then dissolved in 1,2-dichloroethane (300 mL) and reconcentrated. The resultant slurry was dissolved in THF (600 mL) and MeOH (200 mL), and then LiOH (3 M aq 201 mL, 602 mmol) was added in portions over 5 min. After overnight stirring, the reaction was concentrated to remove the organic solvents. Water and 1 M NaOH were added to generate a homogeneous solution (total volume = 400 mL, pH ∼ 12). The aqueous layer was washed 2× with diethyl ether and 2× with dichloromethane. Concentrated HCl was added until pH ∼ 7, and then the water was removed under reduced pressure, leaving a volume of ∼50 mL, and to this was added, at 0 °C, concentrated HCl until the suspension became a densely packed solid. This solid was filtered, rinsing with 1 M HCl and then dichloromethane. After air drying (pulling air through the material on the filter pad) overnight, the solid was dried for 3–5 days under vacuum in a desiccator over phosphorus pentoxide, providing 27.5 g (97%) of <b>44</b>. <sup>1</sup>H NMR (400 MHz, deuterium oxide) δ 6.05 (s, 1H).</div></div><div id="sec4_6_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4,6-Dichloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>45</b>)</h4><div class="NLM_p last"><b>44</b> (10 g, 64.1 mmol) was placed in a 1 L round-bottom flask and triethylamine (8.9 mL, 64.1 mmol) was added, followed by phosphorus oxychloride (50 mL, 546 mmol). A water cooled condenser equipped with a drying tube (24/40 joint size) was then attached. The flask was placed in a room temperature oil bath, and once self-reflux ceased, the temperature was raised to 80 °C. Once that temperature was reached and the vigorous reflux subsided, the temperature was raised again to 110 °C and the reaction run for 120 min. The heating was stopped and the reaction allowed to cool to ∼90 °C (oil bath temperature), at which point 200 mL of anhydrous 1,2-dichloroethane was added and the flask was concentrated under reduced pressure. Caution was taken in the disposal of the condensate, which contained phosphorus oxychloride. Thus, all of the distillates were poured slowly and portionwise into a rapidly stirred ethanol/ice bath. Next, 200 mL of anhydrous 1,2-dichloroethane was added to the residue and the mixture sonicated and then concentrated. Finally 300 mL of anhydrous 1,2-dichloroethane was added, and the sides of the vessel were scraped into the liqueur, the system was sonicated and stirred for ∼10 min and then filtered through Celite packed with dichloromethane and the pad rinsed with dichloromethane until the total filtrate volume was ∼800 mL. This was transferred to a 2 L RBF, and the solvent was removed. Next the residue was dissolved in THF (200 mL), deuteromethylamine (HCl salt, 2.26 g, 32 mmol) was then added followed by <i>N</i>,<i>N</i>′-diisopropylethylamine (18 mL, 103 mmol). After 1 h the reaction was concentrated, and the residue adsorbed onto Celite using dichloromethane. The Celite was dried and transferred onto a medium-grade glass frit, and the crude product was flushed off of the Celite using EtOAc and the filtrate reconcentrated and then reabsorbed onto Celite using dichloromethane. This material could then be purified using automated chromatography with dry loading. Pure fractions were combined to provide 4.56 g (33%) of <b>45</b>. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.72 (s, 1H). MS (E+) <i>m</i>/<i>z</i>: 208.9 (MH<sup>+</sup>).</div></div><div id="sec4_6_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 6-Chloro-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)-4-((2-(methylsulfonyl)phenyl)amino)pyridazine-3-carboxamide (<b>46</b>)</h4><div class="NLM_p last"><b>45</b> (11.6 g, 55 mmol) was dissolved in THF (200 mL), and 2-(methylthio)aniline (7.6 mL, 61 mmol) was added. To this solution at room temperature was added NaHMDS (1 M in THF, 138 mL, 138 mmol) in a rapid dropwise manner (<10 min) using an addition funnel. The reaction was stirred for 15 min, and then 83 mL of 1 M (aq) HCl was added to quench the reaction. The reaction vessel was concentrated to ∼150 mL and then poured slowly into rapidly stirring water (∼1 L). The suspension was stirred for 15 min and then filtered, rinsing with water and then hexanes. The powder was collected and coevaporated from DCM and dichloroethane to remove residual water. The crude product was dried and carried on as is (<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (s, 1H), 9.34 (s, 1H), 7.47–7.41 (m, 2H), 7.37 (td, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.32–7.25 (m, 1H), 6.80 (s, 1H), 2.46 (s, 3H)). MS (E+) <i>m</i>/<i>z</i>: 312.1 (MH<sup>+</sup>). The intermediate powder was dissolved in acetic acid (210 mL), and hydrogen peroxide (30 weight%, 50 mL, 294 mmol) was added, followed by sodium tungstate dihydrate (17.35 g, 52.6 mmol). The reaction was stirred for 40 min at room temperature and then diluted with water and DCM. The two layers were separated and the aqueous layer extracted twice with DCM. The combined organic layers were washed with water, sodium thiosulfate (saturated aqueous solution), and brine. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified using automated chromatography by absorbing it onto Celite using DCM/MeOH. Isolation of pure fractions provided <b>46</b> (12.5 g, 66% yield). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 11.49 (s, 1H), 8.20 (br s, 1H), 8.16 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.72 (td, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.56 (d, <i>J</i> = 7.9 Hz, 1H), 7.50–7.43 (m, 1H), 7.15 (s, 1H), 3.11 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 344.3 (MH<sup>+</sup>).</div></div><div id="sec4_6_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 6-(Cyclopropanecarboxamido)-<i>N</i>-(methyl-d<sub>3</sub>)-4-((2-(methylsulfonyl)phenyl)amino)pyridazine-3-carboxamide (<b>47</b>)</h4><div class="NLM_p last"><b>46</b> (50 mg, 0.14 mmol) was combined with cyclopropanecarboxamide (37 mg, 0.44 mmol) in DMA (1 mL). To this was added Pd<sub>2</sub>dba<sub>3</sub> (20 mg, 0.022 mmol), Xantphos (25 mg, 0.044 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (190 mg, 0.58 mmol) in a single portion. The vessel was evacuated and backfilled with N<sub>2</sub> three times and then heated to 145 °C for 4 h. The reaction was cooled to room temperature, diluted with DMF, and purified by pHPLC. The combined pure fractions were concentrated, diluted with saturated aqueous NaHCO<sub>3</sub>, and extracted with ethyl acetate. The combined organic fractions were dried over sodium sulfate, filtered, concentrated, and freeze-dried from acetonitrile/water to provide <b>47</b> (26 mg, 44% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.37 (s, 1H), 11.09 (s, 1H), 9.10 (s, 1H), 8.08 (s, 1H), 7.98 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.79–7.73 (m, 1H), 7.73–7.68 (m, 1H), 7.51–7.42 (m, 1H), 3.17 (s, 3H), 2.11–2.03 (m, 1H), 0.88–0.71 (m, 4H). MS (E+) <i>m</i>/<i>z</i>: 393.3 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.22 min, purity = 97.6%.</div></div><div id="sec4_6_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-(Methyl-<i>d</i><sub>3</sub>)-4-((2-(methylsulfonyl)phenyl)amino)-6-(pyridin-2-ylamino)pyridazine-3-carboxamide (<b>48</b>)</h4><div class="NLM_p last"><b>46</b> (5 g, 14.5 mmol) was combined with 2-aminopyridine (2.74 g, 29 mmol), Pd<sub>2</sub>dba<sub>3</sub> (1.33 g, 1.45 mmol), Xantphos (1.26 g, 2.18 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (9.48 g, 29.1 mmol) in a 500 mL Schlenk flask. To this was added dioxane (145 mL) and the vessel evacuated and backfilled with N<sub>2</sub> five times. The flask was heated to 130 °C in an oil bath and stirred for 75 min. The reaction was filtered through Celite while still hot, eluting with ethyl acetate. The filtrate was concentrated to an oily residue then coevaporated with dichloroethane and then methanol, the latter resulting in a yellow solid. The solid was sonicated with 30 mL of methanol and then placed at −18 °C (freezer) for 30 min. The solid was filtered off and rinsed with cold methanol (20 mL × 2) and then room temperature methanol (8 mL × 4). The solid was dissolved in hot DCM/MeOH and absorbed onto Celite. The Celite was dried and the crude product purified using automated chromatography (0–5% MeOH/DCM). Pure fractions were combined to provide <b>48</b> (4.4 g, 75% yield). Several combined samples (18 g) were slurried with hot DCM (∼200 mL), cooled in a freezer overnight, and then filtered collecting <b>48</b> as a white solid (15.17 g, 84% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.08 (s, 1H), 10.23 (s, 1H), 9.08 (s, 1H), 8.16–8.07 (m, 2H), 7.98 (d, <i>J</i> = 7.5 Hz, 1H), 7.89–7.76 (m, 2H), 7.73–7.65 (m, 1H), 7.52 (d, <i>J</i> = 8.6 Hz, 1H), 7.45 (ddd, <i>J</i> = 8.0, 5.8, 2.6 Hz, 1H), 6.91 (dd, <i>J</i> = 6.9, 5.3 Hz, 1H), 3.18 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.4, 157.6, 153.8, 147.2, 143.5, 137.9, 137.2, 134.6, 134.0, 133.0, 129.2, 124.9, 124.4, 116.8, 112.7, 96.0, 42.2, 24.5 (m, 1C). Karl Fischer titration −0.16 wt % water. EA measured (theory) C/H/N: 53.08(53.52)/4.32(4.64)/20.61(20.81). MS (E+) <i>m</i>/<i>z</i>: 402.4 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.30 min, purity = 99.8%.</div></div><div id="sec4_6_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 6-((5-Fluoropyridin-2-yl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)-4-((2-(methylsulfonyl)phenyl)amino)pyridazine-3-carboxamide (<b>49</b>)</h4><div class="NLM_p last"><b>46</b> (50 mg, 0.14 mmol) was combined with 5-fluoropyridin-2-amine (65 mg, 0.58 mmol) in DMA (1.2 mL). To this was added Pd<sub>2</sub>dba<sub>3</sub> (20 mg, 0.022 mmol), Xantphos (25 mg, 0.044 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (190 mg, 0.58 mmol) in a single portion. The vessel was evacuated and backfilled with N<sub>2</sub> three times and then heated to 145 °C for 4.5 h. The reaction was cooled to room temperature and diluted with ethyl acetate and water. The layers were separated and the aqueous layer extracted twice with ethyl acetate. The combined organic layers were washed with water and brine and then dried over Na<sub>2</sub>SO<sub>4</sub>. The desiccant was removed via filtration, and the filtrate was concentrated and purified via pHPLC. The combined pure fractions were concentrated, diluted with saturated aqueous NaHCO<sub>3</sub>, and extracted with ethyl acetate. The combined organic fractions were dried over sodium sulfate, filtered, concentrated, and freeze-dried from acetonitrile/water to provide <b>49</b> (30 mg, 49% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.05 (s, 1H), 10.22 (s, 1H), 9.05 (s, 1H), 8.13 (d, <i>J</i> = 2.8 Hz, 1H), 7.98 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.88 (s, 1H), 7.86–7.79 (m, 2H), 7.72–7.63 (m, 2H), 7.45 (t, <i>J</i> = 6.8 Hz, 1H), 3.18 (s, 3H). MS (E+) <i>m</i>/<i>z</i>: 420.0 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 1.42 min, purity = 100%.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Protein Production and X-ray Crystallography</h3><div class="NLM_p last">Protein production, purification, and crystallization of TYK2 pseudokinase domain (575–869) were carried out as previously reported.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00443" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00443" class="ext-link">10.1021/acs.jmedchem.9b00443</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">X-ray crystallographic data and refinement statistics for compounds <b>5</b>, <b>23</b>, and <b>40</b> in TYK2 JH2 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00443/suppl_file/jm9b00443_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings available for all compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00443/suppl_file/jm9b00443_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00443/suppl_file/jm9b00443_si_001.pdf">jm9b00443_si_001.pdf (147.33 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00443/suppl_file/jm9b00443_si_002.csv">jm9b00443_si_002.csv (2.72 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structures of compound <b>5</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZE">6NZE</a>), <b>23</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZF">6NZF</a>), and <b>40</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZH">6NZH</a>) in TYK2 JH2 are available from the RCSB Protein Data Bank (<a href="http://www.rscb.org" class="extLink">www.rscb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00443" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan Moslin</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0332-4778" title="Orcid link">http://orcid.org/0000-0002-0332-4778</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#43313a222d6d2e2c302f2a2d03212e306d202c2e"><span class="__cf_email__" data-cfemail="c5b7bca4abeba8aab6a9acab85a7a8b6eba6aaa8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanlei Zhang</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen T. Wrobleski</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7793-1530" title="Orcid link">http://orcid.org/0000-0001-7793-1530</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuqun Lin</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Mertzman</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Spergel</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5190-3942" title="Orcid link">http://orcid.org/0000-0002-5190-3942</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John S. Tokarski</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joann Strnad</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Gillooly</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim W. McIntyre</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adriana Zupa-Fernandez</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lihong Cheng</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huadong Sun</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charu Chaudhry</span> - <span class="hlFld-Affiliation affiliation">Lead Discovery and Optimization, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Huang</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celia D’Arienzo</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth Heimrich</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoxia Yang</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jodi K. Muckelbauer</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">ChiehYing Chang</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Tredup</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dawn Mulligan</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dianlin Xie</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nelly Aranibar</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manoj Chiney</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic
Department, Pharmaceutical Candidate Optimization, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Burke</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louis Lombardo</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Percy H. Carter</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-1164" title="Orcid link">http://orcid.org/0000-0002-5880-1164</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David S. Weinstein</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d7e5150-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86456" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86456" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This paper is dedicated to Prof. François Diederich on the occasion of his retirement. This work was funded by Bristol-Myers Squibb Company. We thank Sylwia Stachura and Lauren Haque for library synthesis, Paul Elzinga for formulation of samples for mouse PK experiments, Sarah C. Traeger for assistance with NMR experiments, and Robert Borzilleri, Joseph Tino, and William Pitts for assistance in preparation of this article. Thank you also to Dr. Andrew Tebben and Charlotte Raymond for their assistance in the design of the proposed cover art illustration. Thank you to Prof. Phil Baran for helpful discussions regarding synthesis.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">JH1</td><td class="NLM_def"><p class="first last">Janus homology 1</p></td></tr><tr><td class="NLM_term">JH2</td><td class="NLM_def"><p class="first last">Janus homology 2</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">pSTAT</td><td class="NLM_def"><p class="first last">phospho signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">hWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">mWB</td><td class="NLM_def"><p class="first last">mouse whole blood</p></td></tr><tr><td class="NLM_term">IC</td><td class="NLM_def"><p class="first last">Inhibitory concentration</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">μM</td><td class="NLM_def"><p class="first last">micromolar</p></td></tr><tr><td class="NLM_term">mM</td><td class="NLM_def"><p class="first last">millimolar</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte-macrophage colony-stimulatory factor</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">mg</td><td class="NLM_def"><p class="first last">milligram</p></td></tr><tr><td class="NLM_term">g</td><td class="NLM_def"><p class="first last">gram</p></td></tr><tr><td class="NLM_term">CD40</td><td class="NLM_def"><p class="first last">cluster of differentiation 40</p></td></tr><tr><td class="NLM_term">cmpd</td><td class="NLM_def"><p class="first last">compound</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">SPA</td><td class="NLM_def"><p class="first last">scintillation proximity assay</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">inflammatory bowel disease</p></td></tr><tr><td class="NLM_term">Ab</td><td class="NLM_def"><p class="first last">antibody</p></td></tr><tr><td class="NLM_term">Pro</td><td class="NLM_def"><p class="first last">proline</p></td></tr><tr><td class="NLM_term">Leu</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">Asn</td><td class="NLM_def"><p class="first last">asparagine</p></td></tr><tr><td class="NLM_term">Lys</td><td class="NLM_def"><p class="first last">lysine</p></td></tr><tr><td class="NLM_term">Gln</td><td class="NLM_def"><p class="first last">glutamine</p></td></tr><tr><td class="NLM_term">Thr</td><td class="NLM_def"><p class="first last">threonine</p></td></tr><tr><td class="NLM_term">Val</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term">Ala</td><td class="NLM_def"><p class="first last">alanine</p></td></tr><tr><td class="NLM_term">Arg</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">s</td><td class="NLM_def"><p class="first last">seconds</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>c</sub></td><td class="NLM_def"><p class="first last">permeability coefficient</p></td></tr><tr><td class="NLM_term">Å</td><td class="NLM_def"><p class="first last">angstroms</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether a-go-go-related gene</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome p450</p></td></tr><tr><td class="NLM_term">mL</td><td class="NLM_def"><p class="first last">milliliter</p></td></tr><tr><td class="NLM_term">kg</td><td class="NLM_def"><p class="first last">kilogram</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">L</td><td class="NLM_def"><p class="first last">liter</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour</p></td></tr><tr><td class="NLM_term">A</td><td class="NLM_def"><p class="first last">apical</p></td></tr><tr><td class="NLM_term">B</td><td class="NLM_def"><p class="first last">basal</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous administration</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">oral administration</p></td></tr><tr><td class="NLM_term">TPGS</td><td class="NLM_def"><p class="first last">tocopheryl polyethylene glycol</p></td></tr><tr><td class="NLM_term">PCR</td><td class="NLM_def"><p class="first last">quantitative chain reaction</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe-combined immunodeficient</p></td></tr><tr><td class="NLM_term">IFNαR</td><td class="NLM_def"><p class="first last">interferon-α receptor</p></td></tr><tr><td class="NLM_term">ng</td><td class="NLM_def"><p class="first last">nanogram</p></td></tr><tr><td class="NLM_term">WB</td><td class="NLM_def"><p class="first last">whole blood</p></td></tr><tr><td class="NLM_term">LLQ</td><td class="NLM_def"><p class="first last">lower limit of detection</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">mpk</td><td class="NLM_def"><p class="first last">milligrams per kilogram</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice-daily administration</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once-daily administration</p></td></tr><tr><td class="NLM_term">Ar</td><td class="NLM_def"><p class="first last">aryl</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term"><i>R</i><sub>T</sub></td><td class="NLM_def"><p class="first last">retention times</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">LC</td><td class="NLM_def"><p class="first last">liquid chromatography</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">pHPLC</td><td class="NLM_def"><p class="first last">preparative high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high resolution mass spectrometer</p></td></tr><tr><td class="NLM_term">MHz</td><td class="NLM_def"><p class="first last">megahertz</p></td></tr><tr><td class="NLM_term">K</td><td class="NLM_def"><p class="first last">Kelvin</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometer</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">br</td><td class="NLM_def"><p class="first last">broad</p></td></tr><tr><td class="NLM_term">s</td><td class="NLM_def"><p class="first last">singlet</p></td></tr><tr><td class="NLM_term">d</td><td class="NLM_def"><p class="first last">doublet</p></td></tr><tr><td class="NLM_term">dd</td><td class="NLM_def"><p class="first last">doublet of doublet</p></td></tr><tr><td class="NLM_term">m</td><td class="NLM_def"><p class="first last">multiplet</p></td></tr><tr><td class="NLM_term">Hz</td><td class="NLM_def"><p class="first last">hertz</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">conc</td><td class="NLM_def"><p class="first last">concentration</p></td></tr><tr><td class="NLM_term">MH<sup>+</sup></td><td class="NLM_def"><p class="first last">molecular ion</p></td></tr><tr><td class="NLM_term">mmol</td><td class="NLM_def"><p class="first last">millimolar</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">Xantphos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriaxole tetramethyl uranium</p></td></tr><tr><td class="NLM_term">cKit</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase kit</p></td></tr><tr><td class="NLM_term">NaHMDS</td><td class="NLM_def"><p class="first last">sodium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">QTc</td><td class="NLM_def"><p class="first last">corrected QT interval.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63056" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63056" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0liLPXR4dkfTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=R.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+Inhibition+as+a+Therapeutic+Strategy+for+Immune+and+Inflammatory+Diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0liLPXR4dkfTxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DR.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Immune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Type I/II Cytokines, JAKs, and New Strategies for Treating Autoimmune Diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+M.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Type+I%2FII+Cytokines%2C+JAKs%2C+and+New+Strategies+for+Treating+Autoimmune+Diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0lg2Uf6sH1uC9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DType%2520I%252FII%2520Cytokines%252C%2520JAKs%252C%2520and%2520New%2520Strategies%2520for%2520Treating%2520Autoimmune%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span>; <span class="NLM_string-name">Moslin, R.</span>; <span class="NLM_string-name">Lin, S.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Spergel, S.</span>; <span class="NLM_string-name">Kempson, J.</span>; <span class="NLM_string-name">Pitts, W. J.</span>; <span class="NLM_string-name">Tokarski, J.</span>; <span class="NLM_string-name">Strnad, J.</span>; <span class="NLM_string-name">Shuster, D.</span>; <span class="NLM_string-name">Gillooly, K.</span>; <span class="NLM_string-name">McIntyre, K. W.</span>; <span class="NLM_string-name">Zupa-Fernandez, A.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Chaudhry, C.</span>; <span class="NLM_string-name">Huang, C.</span>; <span class="NLM_string-name">D’Arienzo, C.</span>; <span class="NLM_string-name">Heimrich, E.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Muckelbauer, J. K.</span>; <span class="NLM_string-name">Chang, C.</span>; <span class="NLM_string-name">Tredup, J.</span>; <span class="NLM_string-name">Mulligan, D.</span>; <span class="NLM_string-name">Xia, D.</span>; <span class="NLM_string-name">Aranibar, N.</span>; <span class="NLM_string-name">Chimalakonda, A.</span>; <span class="NLM_string-name">Chiney, M.</span>; <span class="NLM_string-name">Carter, P. H.</span>; <span class="NLM_string-name">Burke, J. R.</span>; <span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span> <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00443</span> .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+T.+Wrobleski&author=R.+Moslin&author=S.+Lin&author=Y.+Zhang&author=S.+Spergel&author=J.+Kempson&author=W.+J.+Pitts&author=J.+Tokarski&author=J.+Strnad&author=D.+Shuster&author=K.+Gillooly&author=K.+W.+McIntyre&author=A.+Zupa-Fernandez&author=L.+Cheng&author=H.+Sun&author=C.+Chaudhry&author=C.+Huang&author=C.+D%E2%80%99Arienzo&author=E.+Heimrich&author=X.+Yang&author=J.+K.+Muckelbauer&author=C.+Chang&author=J.+Tredup&author=D.+Mulligan&author=D.+Xia&author=N.+Aranibar&author=A.+Chimalakonda&author=M.+Chiney&author=P.+H.+Carter&author=J.+R.+Burke&author=D.+S.+Weinstein&title=Highly+Selective+Inhibition+of+Tyrosine+Kinase+2+%28TYK2%29+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of+the+Allosteric+Inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26atitle%3DHighly%2520Selective%2520Inhibition%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2520the%2520Allosteric%2520Inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26doi%3D10.1021%2Facs.jmedchem.9b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span> JAK1 deficient
mice die perinatally and suffer from neurological deficits:<span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meraz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, K. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennica, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R. D.</span></span> <span> </span><span class="NLM_article-title">Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81166-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2FS0092-8674%2800%2981166-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=9590172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=373-383&author=S.+J.+Rodigauthor=M.+A.+Merazauthor=J.+M.+Whiteauthor=P.+A.+Lampeauthor=J.+K.+Rileyauthor=C.+D.+Arthurauthor=K.+L.+Kingauthor=K.+C.+F.+Sheehanauthor=L.+Yinauthor=D.+Pennicaauthor=E.+M.+Johnsonauthor=R.+D.+Schreiber&title=Disruption+of+the+Jak1+Gene+Demonstrates+Obligatory+and+Nonredundant+Roles+of+the+Jaks+in+Cytokine-Induced+Biologic+Responses&doi=10.1016%2FS0092-8674%2800%2981166-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</span></div><div class="casAuthors">Rodig, Scott J.; Meraz, Marco A.; White, J. Michael; Lampe, Pat A.; Riley, Joan K.; Arthur, Cora D.; King, Kathleen L.; Sheehan, Kathleen C. F.; Yin, Li; Pennica, Diane; Johnson, Eugene M., Jr.; Schreiber, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">373-383</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Herein we report the generation of mice lacking the ubiquitously expressed Janus kinase, Jak1.  Jak1-/- mice are runted at birth, fail to nurse, and die perinatally.  Although Jak1-/- cells are responsive to many cytokines, they fail to manifest biol. responses to cytokines that bind to three distinct families of cytokine receptors.  These include all class II cytokine receptors, cytokine receptors that utilize the γc subunit for signaling, and the family of cytokine receptors that depend on the gp130 subunit for signaling.  Our results thus demonstrate that Jak1 plays an essential and nonredundant role in promoting biol. responses induced by a select subset of cytokine receptors, including those in which Jak utilization was thought to be nonspecific.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxGavQ7H-weLVg90H21EOLACvtfcHk0lg2Uf6sH1uC9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLs%253D&md5=c96007f46457346d3446a6ed2c2e0e07</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981166-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981166-6%26sid%3Dliteratum%253Aachs%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMeraz%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DLampe%26aufirst%3DP.%2BA.%26aulast%3DRiley%26aufirst%3DJ.%2BK.%26aulast%3DArthur%26aufirst%3DC.%2BD.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSheehan%26aufirst%3DK.%2BC.%2BF.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DPennica%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DDisruption%2520of%2520the%2520Jak1%2520Gene%2520Demonstrates%2520Obligatory%2520and%2520Nonredundant%2520Roles%2520of%2520the%2520Jaks%2520in%2520Cytokine-Induced%2520Biologic%2520Responses%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D373%26epage%3D383%26doi%3D10.1016%2FS0092-8674%2800%2981166-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span> JAK2 deficient mouse embryos are anemic
and die 12–13 days postcoitum:<span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffstadt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, K.</span></span> <span> </span><span class="NLM_article-title">Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81168-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2FS0092-8674%2800%2981168-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=9590174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+M%C3%BCllerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+Deficiency+Defines+an+Essential+Developmental+Checkpoint+in+Definitive+Hematopoiesis&doi=10.1016%2FS0092-8674%2800%2981168-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span></div><div class="casAuthors">Neubauer, Hans; Cumano, Ana; Muller, Mathias; Wu, Hong; Huffstadt, Ulrike; Pfeffer, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors.  A targeted inactivation of Jak2 was performed.  Jak2-/- embryos are anemic and die around day 12.5 postcoitum.  Primitive erythrocytes are found, but definitive erythropoiesis is absent.  Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe.  Fetal liver BFU-E and CFU-E colonies are completely absent.  However, multilineage hematopoietic stem cells (CD34low, c-kitpos) can be found, and B lymphopoiesis appears intact.  In contrast to IFNα stimulation, Jak2-/- cells do not respond to IFNγ.  Jak2-/- embryonic stem cells are competent for LIF signaling.  The data provided demonstrate that Jak2 has pivotal functions for signal transduction of a set of cytokine receptors required in definitive erythropoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8oeTh0n3FcbVg90H21EOLACvtfcHk0ljRvNTNpCD-Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D&md5=74275b73c807331170c096145e69af94</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981168-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981168-X%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520Deficiency%2520Defines%2520an%2520Essential%2520Developmental%2520Checkpoint%2520in%2520Definitive%2520Hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D397%26epage%3D409%26doi%3D10.1016%2FS0092-8674%2800%2981168-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Deursen, J. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thierfelder, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witthuhn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMickle, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosveld, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, J. N.</span></span> <span> </span><span class="NLM_article-title">Defective Lymphoid Development in Mice Lacking Jak3</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">800</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1126/science.270.5237.800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1126%2Fscience.270.5237.800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=7481769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK2MXptV2isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=800-802&author=T.+Nosakaauthor=J.+M.+A.+van+Deursenauthor=R.+A.+Trippauthor=W.+E.+Thierfelderauthor=B.+A.+Witthuhnauthor=A.+P.+McMickleauthor=P.+C.+Dohertyauthor=G.+C.+Grosveldauthor=J.+N.+Ihle&title=Defective+Lymphoid+Development+in+Mice+Lacking+Jak3&doi=10.1126%2Fscience.270.5237.800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Defective lymphoid development in mice lacking Jak3</span></div><div class="casAuthors">Nosaka, Tetsuya; van Deursen, Jan M. A.; Tripp, Ralph A.; Thierfelder, William E.; Witthuhn, Bruce A.; McMickle, Anthony P.; Doherty, Peter C.; Grosveld, Gerard; Ihle, James N.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5237</span>),
    <span class="NLM_cas:pages">800-2</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The Janus tyrosine kinases (Jaks) play a central role in signaling through cytokine receptors.  Although Jak1, Jak2, and Tyk2 are widely expressed, Jak3 is predominantly expressed in hematopoietic cells and is known to assoc. only with the common γ (γc) chain of the interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15 receptors.  Homozygous mutant mice in which the Jak3 gene had been disrupted were generated by gene targeting.  Jak3-deficient mice had profound redns. in thymocytes and severe B cell and T cell lymphopenia similar to severe combined immunodeficiency disease (SCID), and the residual T cells and B cells were functionally deficient.  Thus, Jak3 plays a crit. role in γc signaling and lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop_pvDKJAxprVg90H21EOLACvtfcHk0lh5MmwRJUbFBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptV2isr0%253D&md5=5b96bcb02a748be8b4df4a3ea7337867</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5237.800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5237.800%26sid%3Dliteratum%253Aachs%26aulast%3DNosaka%26aufirst%3DT.%26aulast%3Dvan%2BDeursen%26aufirst%3DJ.%2BM.%2BA.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26aulast%3DThierfelder%26aufirst%3DW.%2BE.%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DMcMickle%26aufirst%3DA.%2BP.%26aulast%3DDoherty%26aufirst%3DP.%2BC.%26aulast%3DGrosveld%26aufirst%3DG.%2BC.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DDefective%2520Lymphoid%2520Development%2520in%2520Mice%2520Lacking%2520Jak3%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D800%26epage%3D802%26doi%3D10.1126%2Fscience.270.5237.800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyamada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikebe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itsumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiwai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, H.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">7539</span>– <span class="NLM_lpage">7546</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0902740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.4049%2Fjimmunol.0902740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=19917699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVehtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=7539-7546&author=A.+Oyamadaauthor=H.+Ikebeauthor=M.+Itsumiauthor=H.+Saiwaiauthor=S.+Okadaauthor=K.+Shimodaauthor=Y.+Iwakuraauthor=K.+I.+Nakayamaauthor=Y.+Iwamotoauthor=Y.+Yoshikaiauthor=H.+Yamada&title=Tyrosine+Kinase+2+Plays+Critical+Roles+in+the+Pathogenic+CD4+T+Cell+Responses+for+the+Development+of+Experimental+Autoimmune+Encephalomyelitis&doi=10.4049%2Fjimmunol.0902740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis</span></div><div class="casAuthors">Oyamada, Akiko; Ikebe, Hiori; Itsumi, Momoe; Saiwai, Hirokazu; Okada, Seiji; Shimoda, Kazuya; Iwakura, Yoichiro; Nakayama, Keiichi I.; Iwamoto, Yukihide; Yoshikai, Yasunobu; Yamada, Hisakata</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7539-7546</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2), a member of the JAK family, is involved in IL-12- and IL-23-mediated signaling.  In the present study, we examd. the roles of Tyk2 in the development of myelin oligodendrocyte glycoprotein (MOG)-induced exptl. autoimmune encephalomyelitis (EAE) by using Tyk2 knockout (KO) mice.  In vitro differentiation of Th1 but not Th17 cells was severely impaired in Tyk2 KO CD4 T cells, although Tyk2 KO Th17 cells did not respond to IL-23.  Tyk2 KO mice showed complete resistance against EAE with no infiltration of CD4 T cells in the spinal cord.  Surprisingly, the no. of MOG-specific Th17 cells in the periphery was comparable between KO and wild-type (WT) mice, whereas Th1 cells were greatly reduced in Tyk2 KO mice.  Adoptive transfer of MOG-primed WT T cells induced EAE in Tyk2 KO recipients, indicating that Tyk2 in the environment was dispensable for the infiltration of effector T cells into the spinal cord.  A reduced but significant no. of Tyk2 KO T cells were detected in the spinal cord of mice with EAE, which had been reconstituted with bone marrow cells of WT and KO mice.  Furthermore, MOG-immunized Tyk2 KO mice developed EAE after adoptive transfer of MOG-primed WT Th1 cells, which might trigger local inflammation that recruits Th17 cells.  Taken together, these results indicate that Tyk2 is critically involved in the pathogenic CD4 T cell responses and thus could be a target mol. for the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0gM6rPFuApLVg90H21EOLACvtfcHk0lh5MmwRJUbFBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVehtrrE&md5=05bba19010fbdffbb10b751a1dda16fb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902740%26sid%3Dliteratum%253Aachs%26aulast%3DOyamada%26aufirst%3DA.%26aulast%3DIkebe%26aufirst%3DH.%26aulast%3DItsumi%26aufirst%3DM.%26aulast%3DSaiwai%26aufirst%3DH.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DIwakura%26aufirst%3DY.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26aulast%3DIwamoto%26aufirst%3DY.%26aulast%3DYoshikai%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DH.%26atitle%3DTyrosine%2520Kinase%25202%2520Plays%2520Critical%2520Roles%2520in%2520the%2520Pathogenic%2520CD4%2520T%2520Cell%2520Responses%2520for%2520the%2520Development%2520of%2520Experimental%2520Autoimmune%2520Encephalomyelitis%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D7539%26epage%3D7546%26doi%3D10.4049%2Fjimmunol.0902740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeltz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevach, E. M.</span></span> <span> </span><span class="NLM_article-title">A Heritable Defect in IL-12 Signaling in B10.Q/J Mice. I. In Vitro Analysis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">5712</span>– <span class="NLM_lpage">5719</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.166.9.5712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.4049%2Fjimmunol.166.9.5712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=11313413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFyqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2001&pages=5712-5719&author=R.+Ortmannauthor=R.+Smeltzauthor=G.+Yapauthor=A.+Sherauthor=E.+M.+Shevach&title=A+Heritable+Defect+in+IL-12+Signaling+in+B10.Q%2FJ+Mice.+I.+In+Vitro+Analysis&doi=10.4049%2Fjimmunol.166.9.5712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis</span></div><div class="casAuthors">Ortmann, Robert; Smeltz, Ronald; Yap, George; Sher, Alan; Shevach, Ethan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5712-5719</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">B10.Q mice are normally susceptible to the induction of collagen-induced arthritis.  The authors noted that one subline of B10.Q mice, B10.Q/J, was completely resistant to disease induction when immunized with collagen in CFA.  B10.Q/J mice have a global defect in the generation of Th1 responses, and antigen-specific T cells derived from this strain failed to produce IFN-γ.  Because T cells from these mice could produce normal amts. of IFN-γ when activated by IL-12/IL-18-independent stimuli, the defect appeared to be a failure to respond to IL-12.  This defect extended to NK cells, which also failed to produce IFN-γ when stimulated by IL-12.  The capacity of NK cells, but not activated T cells, to produce IFN-γ in response to IL-12 could be partially restored by IL-18.  The expression of the IL-12R β1- and β2-chains on T cells and NK cells from B10.Q/J mice was normal.  However, activated T cells from B10.Q/J mice did not signal normally through the IL-12R and manifested a defect in their capacity to phosphorylate Stat4.  This defect was partial in that it could be overcome by increasing both the concn. of IL-12 and the incubation times in the Stat4 phosphorylation assays.  Because Stat4 function is apparently intact in B10.Q/J mice, the defect in IL-12 signaling can be localized between the IL-12R complex and Stat4.  This subtle abnormality in IL-12 responsiveness results in a profound defect in the generation of Th1 cells and the development of autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnzWn-o1wME7Vg90H21EOLACvtfcHk0lh5MmwRJUbFBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFyqsr4%253D&md5=bf724d444e9db709a3a40fc251b73d40</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.166.9.5712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.166.9.5712%26sid%3Dliteratum%253Aachs%26aulast%3DOrtmann%26aufirst%3DR.%26aulast%3DSmeltz%26aufirst%3DR.%26aulast%3DYap%26aufirst%3DG.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DShevach%26aufirst%3DE.%2BM.%26atitle%3DA%2520Heritable%2520Defect%2520in%2520IL-12%2520Signaling%2520in%2520B10.Q%252FJ%2520Mice.%2520I.%2520In%2520Vitro%2520Analysis%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D166%26spage%3D5712%26epage%3D5719%26doi%3D10.4049%2Fjimmunol.166.9.5712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agematsu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuge, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yachie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessho, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujieda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakiguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abinun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belohradsky, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyawaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasuyama, H.</span></span> <span> </span><span class="NLM_article-title">Human Tyrosine Kinase 2 Deficiency Reveals its Requisite Roles in Multiple Cytokine Signals Involved in Innate and Acquired Immunity</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2006.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.immuni.2006.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=17088085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&author=Y.+Minegishiauthor=M.+Saitoauthor=T.+Morioauthor=K.+Watanabeauthor=K.+Agematsuauthor=S.+Tsuchiyaauthor=H.+Takadaauthor=T.+Haraauthor=N.+Kawamuraauthor=T.+Arigaauthor=H.+Kanekoauthor=N.+Kondoauthor=I.+Tsugeauthor=A.+Yachieauthor=Y.+Sakiyamaauthor=T.+Iwataauthor=F.+Besshoauthor=T.+Ohishiauthor=K.+Johauthor=K.+Imaiauthor=K.+Kogawaauthor=M.+Shinoharaauthor=M.+Fujiedaauthor=H.+Wakiguchiauthor=S.+Pasicauthor=M.+Abinunauthor=H.+D.+Ochsauthor=E.+D.+Rennerauthor=A.+Janssonauthor=B.+H.+Belohradskyauthor=A.+Metinauthor=N.+Shimizuauthor=S.+Mizutaniauthor=T.+Miyawakiauthor=S.+Nonoyamaauthor=H.+Karasuyama&title=Human+Tyrosine+Kinase+2+Deficiency+Reveals+its+Requisite+Roles+in+Multiple+Cytokine+Signals+Involved+in+Innate+and+Acquired+Immunity&doi=10.1016%2Fj.immuni.2006.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span></div><div class="casAuthors">Minegishi, Yoshiyuki; Saito, Masako; Morio, Tomohiro; Watanabe, Ken; Agematsu, Kazunaga; Tsuchiya, Shigeru; Takada, Hidetoshi; Hara, Toshiro; Kawamura, Nobuaki; Ariga, Tadashi; Kaneko, Hideo; Kondo, Naomi; Tsuge, Ikuya; Yachie, Akihiro; Sakiyama, Yukio; Iwata, Tsutomu; Bessho, Fumio; Ohishi, Tsutomu; Joh, Kosuke; Imai, Kohsuke; Kogawa, Kazuhiro; Shinohara, Miwa; Fujieda, Mikiya; Wakiguchi, Hiroshi; Pasic, Srdjan; Abinun, Mario; Ochs, Hans D.; Renner, Eleonore D.; Jansson, Annette; Belohradsky, Bernd H.; Metin, Ayse; Shimizu, Norio; Mizutani, Shuki; Miyawaki, Toshio; Nonoyama, Shigeaki; Karasuyama, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2) is a nonreceptor tyrosine kinase that belongs to the Janus kinase (Jak) family.  Here we identified a homozygous Tyk2 mutation in a patient who had been clin. diagnosed with hyper-IgE syndrome.  This patient showed unusual susceptibility to various microorganisms including virus, fungi, and mycobacteria and suffered from atopic dermatitis with elevated serum IgE.  The patient's cells displayed defects in multiple cytokine signaling pathways including those for type I interferon (IFN), interleukin (IL)-6, IL-10, IL-12, and IL-23.  The cytokine signals were successfully restored by transducing the intact Tyk2 gene.  Thus, the Tyk2 deficiency is likely to account for the patient's complex clin. manifestations, including the phenotype of impaired T helper 1 (Th1) differentiation and accelerated Th2 differentiation.  This study identifies human Tyk2 deficiency and demonstrates that Tyk2 plays obligatory roles in multiple cytokine signals involved in innate and acquired immunity of humans, which differs substantially from Tyk2 function in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TTbAIzXM-bVg90H21EOLACvtfcHk0lh-hFTjt3n8gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI&md5=debec30b44a7e1dc111d7cfb1c92f7dd</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2006.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2006.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAgematsu%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DAriga%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DTsuge%26aufirst%3DI.%26aulast%3DYachie%26aufirst%3DA.%26aulast%3DSakiyama%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DT.%26aulast%3DBessho%26aufirst%3DF.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DKogawa%26aufirst%3DK.%26aulast%3DShinohara%26aufirst%3DM.%26aulast%3DFujieda%26aufirst%3DM.%26aulast%3DWakiguchi%26aufirst%3DH.%26aulast%3DPasic%26aufirst%3DS.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DRenner%26aufirst%3DE.%2BD.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DBelohradsky%26aufirst%3DB.%2BH.%26aulast%3DMetin%26aufirst%3DA.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DS.%26aulast%3DMiyawaki%26aufirst%3DT.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DKarasuyama%26aufirst%3DH.%26atitle%3DHuman%2520Tyrosine%2520Kinase%25202%2520Deficiency%2520Reveals%2520its%2520Requisite%2520Roles%2520in%2520Multiple%2520Cytokine%2520Signals%2520Involved%2520in%2520Innate%2520and%2520Acquired%2520Immunity%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26spage%3D745%26epage%3D755%26doi%3D10.1016%2Fj.immuni.2006.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kreins, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciancanelli, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramírez-Alejo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Baghdadi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahdaviani, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ailal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousfiha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nievas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehn, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deveau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Azbaoui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halwani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogunovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moncada-Velez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Barricarte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migaud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deswarte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotlarz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Fleckenstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleckenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cormier-Daire, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose-John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarstrom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Muhsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaussabel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangye, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustamante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisson-Dupuis, S.</span></span> <span> </span><span class="NLM_article-title">Human TYK2 Deficiency: Mycobacterial and Viral Infections Without Hyper-IgE Syndrome</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">1641</span>– <span class="NLM_lpage">1662</span>, <span class="refDoi"> DOI: 10.1084/jem.20140280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1084%2Fjem.20140280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=26304966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Wjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=1641-1662&author=A.+Y.+Kreinsauthor=M.+J.+Ciancanelliauthor=S.+Okadaauthor=X.-F.+Kongauthor=N.+Ram%C3%ADrez-Alejoauthor=S.+S.+Kilicauthor=J.+El+Baghdadiauthor=S.+Nonoyamaauthor=S.+A.+Mahdavianiauthor=F.+Ailalauthor=A.+Bousfihaauthor=D.+Mansouriauthor=E.+Nievasauthor=C.+S.+Maauthor=G.+Raoauthor=A.+Bernasconiauthor=H.+S.+Kuehnauthor=J.+Niemelaauthor=J.+Stoddardauthor=P.+Deveauauthor=A.+Cobatauthor=S.+El+Azbaouiauthor=A.+Sabriauthor=C.+K.+Limauthor=M.+Sundinauthor=D.+T.+Averyauthor=R.+Halwaniauthor=A.+V.+Grantauthor=B.+Boissonauthor=D.+Bogunovicauthor=Y.+Itanauthor=M.+Moncada-Velezauthor=R.+Martinez-Barricarteauthor=M.+Migaudauthor=C.+Deswarteauthor=L.+Alsinaauthor=D.+Kotlarzauthor=C.+Kleinauthor=I.+Muller-Fleckensteinauthor=B.+Fleckensteinauthor=V.+Cormier-Daireauthor=S.+Rose-Johnauthor=C.+Picardauthor=L.+Hammarstromauthor=A.+Puelauthor=S.+Al-Muhsenauthor=L.+Abelauthor=D.+Chaussabelauthor=S.+D.+Rosenzweigauthor=Y.+Minegishiauthor=S.+G.+Tangyeauthor=J.+Bustamanteauthor=J.-L.+Casanovaauthor=S.+Boisson-Dupuis&title=Human+TYK2+Deficiency%3A+Mycobacterial+and+Viral+Infections+Without+Hyper-IgE+Syndrome&doi=10.1084%2Fjem.20140280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome</span></div><div class="casAuthors">Kreins, Alexandra Y.; Ciancanelli, Michael J.; Okada, Satoshi; Kong, Xiao-Fei; Ramirez-Alejo, Noe; Kilic, Sara Sebnem; El Bagjhdadi, Jamila; Nonoyama, Shigeaki; Mahdaviani, Seyed Alireza; Ailal, Fatima; Bousfiha, Aziz; Mansouri, Davood; Nievas, Elma; Ma, Cindy S.; Rao, Geetha; Bernasconi, Andrea; Kuehn, Hye Sun; Niemela, Julie; Stoddard, Jennifer; Deveau, Paul; Cobat, Aurelie; El Azbaoui, Safe; Sabri, Ayoub; lim, Che Kang; Sundin, Mikael; Avery, Danielle T.; Halwani, Rabih; Grant, Audrey V.; Boisson, Bertrand; Bogunovic, Dusan; Itan, Yuval; Moncada-Velez, Marcela; Martinez-Barricarte, Ruben; Migaud, Melanie; Deswarte, Caroline; Alsina, Laia; Kotlarz, Daniel; Klein, Christoph; Muller-Fleckenstein, Ingrid; Fleckenstein, Bernhard; Cormier-Daire, Valerie; Rose-John, Stefen; Picard, Capucine; Hammarstrom, Lennart; Puel, Anne; Al-Muhsen, Saleh; Abel, Laurent; Chaussabel, Damien; Rosenzweig, Sergio D.; Minegishi, Yoshiyuki; Tangye, Stuart G.; Bustamante, Jacinta; Casanova, Jean-Laurent; Boisson-Dupuis, Stephanie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1641-1662</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Autosomal recessive, complete TYK2 deficiency was previously described in a patient (P1) with intracellular bacterial and viral infections and features of hyper-IgE syndrome (HIES), including atopic dermatitis, high serum IgE levels, and staphylococcal abscesses.  We identified seven other TYK2-deficient patients from five families and four different ethnic groups.  These patients were homozygous for one of five null mutations, different from that seen in P1.  They displayed mycobacterial and/or viral infections, but no HIES.  All eight TYK2-deficient patients displayed impaired but not abolished cellular responses to (a) IL-12 and IFN-α/ β, accounting for mycobacterial and viral infections, resp.; (b) IL-23, with normal proportions of circulating IL-17+ T cells, accounting for their apparent lack of mucocutaneous candidiasis; and (c) IL-10, with no overt clin. consequences, including a lack of inflammatory bowel disease.  Cellular responses to IL-21, IL-27, IFN-γ, IL-28/29 (IFN-λ), and leukemia inhibitory factor (LIF) were normal.  The leukocytes and fibroblasts of all seven newly identified TYK2-deficient patients, unlike those of P1, responded normally to IL-G, possibly accounting for the lack of HIES in these patients.  The expression of exogenous wild-type TYK2 or the silencing of endogenous TYK2 did not rescue IL-6 hyporesponsiveness, suggesting that this phenotype was not a consequence of the TYK2 genotype.  The core clin. phenotype of TYK2 deficiency is mycobacterial and/or viral infections, caused by impaired responses to IL-12 and IFN-α/β.  Moreover, impaired IL-6 responses and HIES do not appear to be intrinsic features of TYK2 deficiency in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcrqmRKkmKbVg90H21EOLACvtfcHk0lh-hFTjt3n8gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Wjtbo%253D&md5=d5916cdd4b0ebe7f613a824292cf1c6c</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1084%2Fjem.20140280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20140280%26sid%3Dliteratum%253Aachs%26aulast%3DKreins%26aufirst%3DA.%2BY.%26aulast%3DCiancanelli%26aufirst%3DM.%2BJ.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DX.-F.%26aulast%3DRam%25C3%25ADrez-Alejo%26aufirst%3DN.%26aulast%3DKilic%26aufirst%3DS.%2BS.%26aulast%3DEl%2BBaghdadi%26aufirst%3DJ.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DMahdaviani%26aufirst%3DS.%2BA.%26aulast%3DAilal%26aufirst%3DF.%26aulast%3DBousfiha%26aufirst%3DA.%26aulast%3DMansouri%26aufirst%3DD.%26aulast%3DNievas%26aufirst%3DE.%26aulast%3DMa%26aufirst%3DC.%2BS.%26aulast%3DRao%26aufirst%3DG.%26aulast%3DBernasconi%26aufirst%3DA.%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DNiemela%26aufirst%3DJ.%26aulast%3DStoddard%26aufirst%3DJ.%26aulast%3DDeveau%26aufirst%3DP.%26aulast%3DCobat%26aufirst%3DA.%26aulast%3DEl%2BAzbaoui%26aufirst%3DS.%26aulast%3DSabri%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DC.%2BK.%26aulast%3DSundin%26aufirst%3DM.%26aulast%3DAvery%26aufirst%3DD.%2BT.%26aulast%3DHalwani%26aufirst%3DR.%26aulast%3DGrant%26aufirst%3DA.%2BV.%26aulast%3DBoisson%26aufirst%3DB.%26aulast%3DBogunovic%26aufirst%3DD.%26aulast%3DItan%26aufirst%3DY.%26aulast%3DMoncada-Velez%26aufirst%3DM.%26aulast%3DMartinez-Barricarte%26aufirst%3DR.%26aulast%3DMigaud%26aufirst%3DM.%26aulast%3DDeswarte%26aufirst%3DC.%26aulast%3DAlsina%26aufirst%3DL.%26aulast%3DKotlarz%26aufirst%3DD.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DMuller-Fleckenstein%26aufirst%3DI.%26aulast%3DFleckenstein%26aufirst%3DB.%26aulast%3DCormier-Daire%26aufirst%3DV.%26aulast%3DRose-John%26aufirst%3DS.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DHammarstrom%26aufirst%3DL.%26aulast%3DPuel%26aufirst%3DA.%26aulast%3DAl-Muhsen%26aufirst%3DS.%26aulast%3DAbel%26aufirst%3DL.%26aulast%3DChaussabel%26aufirst%3DD.%26aulast%3DRosenzweig%26aufirst%3DS.%2BD.%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DTangye%26aufirst%3DS.%2BG.%26aulast%3DBustamante%26aufirst%3DJ.%26aulast%3DCasanova%26aufirst%3DJ.-L.%26aulast%3DBoisson-Dupuis%26aufirst%3DS.%26atitle%3DHuman%2520TYK2%2520Deficiency%253A%2520Mycobacterial%2520and%2520Viral%2520Infections%2520Without%2520Hyper-IgE%2520Syndrome%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2015%26volume%3D212%26spage%3D1641%26epage%3D1662%26doi%3D10.1084%2Fjem.20140280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Couturier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucciarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurtdinov, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debouverie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrun-Frenay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Confavreux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukusic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cournu-Rebeix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goertsches, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zettl, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comabella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieckmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Myhsok, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mars, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saoudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksenberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clanet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liblau, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassat, D.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2 Variant Influences T Lymphocyte Polarization and Multiple Sclerosis Susceptibility</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1093/brain/awr010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1093%2Fbrain%2Fawr010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=21354972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A280%3ADC%252BC3M3it1alsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2011&pages=693-703&author=N.+Couturierauthor=F.+Bucciarelliauthor=R.+N.+Nurtdinovauthor=M.+Debouverieauthor=C.+Lebrun-Frenayauthor=G.+Deferauthor=T.+Moreauauthor=C.+Confavreuxauthor=S.+Vukusicauthor=I.+Cournu-Rebeixauthor=R.+H.+Goertschesauthor=U.+K.+Zettlauthor=M.+Comabellaauthor=X.+Montalbanauthor=P.+Rieckmannauthor=F.+Weberauthor=B.+M%C3%BCller-Myhsokauthor=G.+Edanauthor=B.+Fontaineauthor=L.+T.+Marsauthor=A.+Saoudiauthor=J.+R.+Oksenbergauthor=M.+Clanetauthor=R.+S.+Liblauauthor=D.+Brassat&title=Tyrosine+Kinase+2+Variant+Influences+T+Lymphocyte+Polarization+and+Multiple+Sclerosis+Susceptibility&doi=10.1093%2Fbrain%2Fawr010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility</span></div><div class="casAuthors">Couturier Nicolas; Bucciarelli Florence; Nurtdinov Ramil N; Debouverie Marc; Lebrun-Frenay Christine; Defer Gilles; Moreau Thibault; Confavreux Christian; Vukusic Sandra; Cournu-Rebeix Isabelle; Goertsches Robert H; Zettl Uwe K; Comabella Manuel; Montalban Xavier; Rieckmann Peter; Weber Frank; Muller-Myhsok Bertram; Edan Gilles; Fontaine Bertrand; Mars Lennart T; Saoudi Abdelhadi; Oksenberg Jorge R; Clanet Michel; Liblau Roland S; Brassat David</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">Pt 3</span>),
    <span class="NLM_cas:pages">693-703</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tyrosine kinase 2 variant rs34536443 has been established as a genetic risk factor for multiple sclerosis in a variety of populations.  However, the functional effect of this variant on disease pathogenesis remains unclear.  This study replicated the genetic association of tyrosine kinase 2 with multiple sclerosis in a cohort of 1366 French patients and 1802 controls.  Furthermore, we assessed the functional consequences of this polymorphism on human T lymphocytes by comparing the reactivity and cytokine profile of T lymphocytes isolated from individuals expressing the protective TYK2(GC) genotype with the disease-associated TYK2(GG) genotype.  Our results demonstrate that the protective C allele infers decreased tyrosine kinase 2 activity, and this reduction of activity is associated with a shift in the cytokine profile favouring the secretion of Th2 cytokines.  These findings suggest that the rs34536443 variant effect on multiple sclerosis susceptibility might be mediated by deviating T lymphocyte differentiation toward a Th2 phenotype.  This impact of tyrosine kinase 2 on effector differentiation is likely to be of wider importance because other autoimmune diseases also have been associated with polymorphisms within tyrosine kinase 2.  The modulation of tyrosine kinase 2 activity might therefore represent a new therapeutic approach for the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAUtIRbYJEbJp6t8nS6Nc3fW6udTcc2eYnxIZEd8mktbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3it1alsA%253D%253D&md5=f5a12ce5f485067a22d821552f1a1bde</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawr010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawr010%26sid%3Dliteratum%253Aachs%26aulast%3DCouturier%26aufirst%3DN.%26aulast%3DBucciarelli%26aufirst%3DF.%26aulast%3DNurtdinov%26aufirst%3DR.%2BN.%26aulast%3DDebouverie%26aufirst%3DM.%26aulast%3DLebrun-Frenay%26aufirst%3DC.%26aulast%3DDefer%26aufirst%3DG.%26aulast%3DMoreau%26aufirst%3DT.%26aulast%3DConfavreux%26aufirst%3DC.%26aulast%3DVukusic%26aufirst%3DS.%26aulast%3DCournu-Rebeix%26aufirst%3DI.%26aulast%3DGoertsches%26aufirst%3DR.%2BH.%26aulast%3DZettl%26aufirst%3DU.%2BK.%26aulast%3DComabella%26aufirst%3DM.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DRieckmann%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DM%25C3%25BCller-Myhsok%26aufirst%3DB.%26aulast%3DEdan%26aufirst%3DG.%26aulast%3DFontaine%26aufirst%3DB.%26aulast%3DMars%26aufirst%3DL.%2BT.%26aulast%3DSaoudi%26aufirst%3DA.%26aulast%3DOksenberg%26aufirst%3DJ.%2BR.%26aulast%3DClanet%26aufirst%3DM.%26aulast%3DLiblau%26aufirst%3DR.%2BS.%26aulast%3DBrassat%26aufirst%3DD.%26atitle%3DTyrosine%2520Kinase%25202%2520Variant%2520Influences%2520T%2520Lymphocyte%2520Polarization%2520and%2520Multiple%2520Sclerosis%2520Susceptibility%26jtitle%3DBrain%26date%3D2011%26volume%3D134%26spage%3D693%26epage%3D703%26doi%3D10.1093%2Fbrain%2Fawr010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 Locus Genotype-to-Phenotype Differences in Autoimmunity</span>. <i>Science Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=27807284" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.+A.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+Locus+Genotype-to-Phenotype+Differences+in+Autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520Locus%2520Genotype-to-Phenotype%2520Differences%2520in%2520Autoimmunity%26jtitle%3DScience%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span> For a review of the use of Ustekinumab in psoriasis and psoriatic
arthritis, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Croxtall, J. D.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab: A Review of its use in the Management of Moderate to Severe Plaque Psoriasis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1733</span>– <span class="NLM_lpage">1753</span>, <span class="refDoi"> DOI: 10.2165/11207530-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.2165%2F11207530-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=21902296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1733-1753&author=J.+D.+Croxtall&title=Ustekinumab%3A+A+Review+of+its+use+in+the+Management+of+Moderate+to+Severe+Plaque+Psoriasis&doi=10.2165%2F11207530-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis</span></div><div class="casAuthors">Croxtall, Jamie D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1733-1753</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Ustekinumab (Stelara) is a human monoclonal antibody that binds to the p40 subunit common to both interleukin (IL)-12 and IL-23.  It is indicated in the US for use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.  In the EU, it is indicated for those who failed to respond to, have a contraindication to or are intolerant of other systemic therapies or phototherapy.  This article reviews the efficacy and tolerability of ustekinumab in patients with moderate to severe plaque psoriasis, as well as summarizing its pharmacol. properties.  Ustekinumab attenuates the immune cell activation properties of IL-12 and IL-23.  It interrupts the abnormal activation of signalling and cytokine cascades that underlie the pathol. of psoriasis by reducing the expression of IL-12- and IL-23-induced cell surface markers that mediate skin homing, activation and cytokine release.  In well designed, randomized clin. trials, regimens of s.c. ustekinumab 45 or 90 mg provided a rapid and durable improvement in psoriasis area severity index (PASI) scores for patients with moderate to severe plaque psoriasis.  A significantly greater proportion of patients receiving ustekinuman 45 or 90 mg compared with those receiving placebo achieved a ≥75% improvement from baseline in PASI score following 12 wk' treatment (primary endpoint).  Improvements in PASI scores were evident following 2 wk' treatment with ustekinumab and were sustained for up to 3 years.  Treatment with ustekinumab 45 or 90 mg also improved health-related quality-of-life scores from baseline.  Following 12 wk' treatment, ustekinumab 45 or 90 mg was more effective than etanercept 50 mg twice weekly in providing symptomatic relief for patients with moderate to severe plaque psoriasis.  Furthermore, ustekinumab treatment provided effective symptomatic improvement for almost half of the patients who showed no response to 12 wk' treatment with etanercept.  More limited data indicate that ustekinumab also improves the symptoms of arthritis in patients with plaque psoriasis and psoriatic arthritis.  S.c. ustekinumab was generally well tolerated in clin. trials; most adverse events were mild in intensity and did not require dosage adjustment.  A pooled anal. of clin. trial data indicated no specific patterns of infection for recipients of ustekinumab and that infection rates remained stable following cumulative exposure to the agent.  In conclusion, s.c. ustekinumab provides an effective and well tolerated alternative for the symptomatic treatment of patients with moderate to severe plaque psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Ypb6QpOVSrVg90H21EOLACvtfcHk0ljNBpbmZvw2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtr7E&md5=adc553a889d647c9fd00aea59040c01b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2165%2F11207530-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11207530-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DCroxtall%26aufirst%3DJ.%2BD.%26atitle%3DUstekinumab%253A%2520A%2520Review%2520of%2520its%2520use%2520in%2520the%2520Management%2520of%2520Moderate%2520to%2520Severe%2520Plaque%2520Psoriasis%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D1733%26epage%3D1753%26doi%3D10.2165%2F11207530-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feagan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johanns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adedokun, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanauer, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Villiers, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombel, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulassay, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzberg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desreumaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loftus, E. V.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieleman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutgeerts, P.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1960</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1056%2FNEJMoa1602773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=27959607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1946-1960&author=B.+G.+Feaganauthor=W.+J.+Sandbornauthor=C.+Gasinkauthor=D.+Jacobsteinauthor=Y.+Langauthor=J.+R.+Friedmanauthor=M.+A.+Blankauthor=J.+Johannsauthor=L.-L.+Gaoauthor=Y.+Miaoauthor=O.+J.+Adedokunauthor=B.+E.+Sandsauthor=S.+B.+Hanauerauthor=S.+Vermeireauthor=S.+Targanauthor=S.+Ghoshauthor=W.+J.+de+Villiersauthor=J.-F.+Colombelauthor=Z.+Tulassayauthor=U.+Seidlerauthor=B.+A.+Salzbergauthor=P.+Desreumauxauthor=S.+D.+Leeauthor=E.+V.+Loftusauthor=L.+A.+Dielemanauthor=S.+Katzauthor=P.+Rutgeerts&title=Ustekinumab+as+Induction+and+Maintenance+Therapy+for+Crohn%E2%80%99s+Disease&doi=10.1056%2FNEJMoa1602773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab as induction and maintenance therapy for Crohn's disease</span></div><div class="casAuthors">Feagan, B. G.; Sandborn, W. J.; Gasink, C.; Jacobstein, D.; Lang, Y.; Friedman, J. R.; Blank, M. A.; Johanns, J.; Gao, L.-L.; Miao, Y.; Adedokun, O. J.; Sands, B. E.; Hanauer, S. B.; Vermeire, S.; Targan, S.; Ghosh, S.; de Villiers, W. J.; Colombel, J.-F.; Tulassay, Z.; Seidler, U.; Salzberg, B. A.; Desreumaux, P.; Lee, S. D.; Loftus, E. V. Jr.; Dieleman, L. A.; Katz, S.; Rutgeerts, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1946-1960</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin- 23, was evaluated as an i.v. induction therapy in two populations with moderately to severely active Crohn's disease.  Ustekinumab was also evaluated as s.c. maintenance therapy.  Methods: We randomly assigned patients to receive a single i.v. dose of ustekinumab (either 130 mg or approx. 6 mg per kg of body wt.) or placebo in two induction trials.  The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects.  The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred.  Patients who completed these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive s.c. maintenance injections of 90 mg of ustekinumab (either every 8 wk or every 12 wk) or placebo.  The primary end point for the induction trials was a clin. response at week 6 (defined as a decrease from baseline in the Crohn's Disease Activity Index [CDAI] score of ≥100 points or a CDAI score <150).  The primary end point for the maintenance trial was remission at week 44 (CDAI score <150).  Results: The rates of response at week 6 among patients receiving i.v. ustekinumab at a dose of either 130 mg or approx. 6 mg per kg were significantly higher than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, resp., with P≤0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, resp., with P<0.001 for both doses).  In the groups receiving maintenance doses of ustekinumab every 8 wk or every 12 wk, 53.1% and 48.8%, resp., were in remission at week 44, as compared with 35.9% of those receiving placebo (P = 0.005 and P = 0.04, resp.).  Within each trial, adverse-event rates were similar among treatment groups.  Conclusions: Among patients with moderately to severely active Crohn's disease, those receiving i.v. ustekinumab had a significantly higher rate of response than did those receiving placebo.  S.c. ustekinumab maintained remission in patients who had a clin. response to induction therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmRR8xWwu5_7Vg90H21EOLACvtfcHk0lgc2ZjT0zLcOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrfO&md5=fe0fe2ba66261e94acdd1ce816d40ab8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602773%26sid%3Dliteratum%253Aachs%26aulast%3DFeagan%26aufirst%3DB.%2BG.%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGasink%26aufirst%3DC.%26aulast%3DJacobstein%26aufirst%3DD.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFriedman%26aufirst%3DJ.%2BR.%26aulast%3DBlank%26aufirst%3DM.%2BA.%26aulast%3DJohanns%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DL.-L.%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DAdedokun%26aufirst%3DO.%2BJ.%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DHanauer%26aufirst%3DS.%2BB.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DTargan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3Dde%2BVilliers%26aufirst%3DW.%2BJ.%26aulast%3DColombel%26aufirst%3DJ.-F.%26aulast%3DTulassay%26aufirst%3DZ.%26aulast%3DSeidler%26aufirst%3DU.%26aulast%3DSalzberg%26aufirst%3DB.%2BA.%26aulast%3DDesreumaux%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DS.%2BD.%26aulast%3DLoftus%26aufirst%3DE.%2BV.%26aulast%3DDieleman%26aufirst%3DL.%2BA.%26aulast%3DKatz%26aufirst%3DS.%26aulast%3DRutgeerts%26aufirst%3DP.%26atitle%3DUstekinumab%2520as%2520Induction%2520and%2520Maintenance%2520Therapy%2520for%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D1946%26epage%3D1960%26doi%3D10.1056%2FNEJMoa1602773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van Vollenhoven, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsokos, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werth, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevrier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Ustekinumab, an IL-12 and IL-23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Multicenter, Double-blind, Phase 2, Randomised, Controlled Study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1330</span>– <span class="NLM_lpage">1339</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)32167-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2FS0140-6736%2818%2932167-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=30249507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOhurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1330-1339&author=R.+F.+van+Vollenhovenauthor=B.+H.+Hahnauthor=G.+C.+Tsokosauthor=C.+L.+Wagnerauthor=P.+Lipskyauthor=Z.+Toumaauthor=V.+P.+Werthauthor=R.+M.+Gordonauthor=B.+Zhouauthor=B.+Hsuauthor=M.+Chevrierauthor=M.+Triebelauthor=J.+L.+Jordanauthor=S.+Rose&title=Efficacy+and+Safety+of+Ustekinumab%2C+an+IL-12+and+IL-23+Inhibitor%2C+in+Patients+with+Active+Systemic+Lupus+Erythematosus%3A+Results+of+a+Multicenter%2C+Double-blind%2C+Phase+2%2C+Randomised%2C+Controlled+Study&doi=10.1016%2FS0140-6736%2818%2932167-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study</span></div><div class="casAuthors">van Vollenhoven, Ronald F.; Hahn, Bevra H.; Tsokos, George C.; Wagner, Carrie L.; Lipsky, Peter; Touma, Zahi; Werth, Victoria P.; Gordon, Robert M.; Zhou, Bei; Hsu, Benjamin; Chevrier, Marc; Triebel, Manon; Jordan, Jarrat L.; Rose, Shawn</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10155</span>),
    <span class="NLM_cas:pages">1330-1339</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease.  IL-12 and IL-23 have been implicated in systemic lupus erythematosus.  We aimed to assess the efficacy and safety of ustekinumab for the treatment of systemic lupus erythematosus in patients with moderate-to-severe disease activity despite conventional treatment.  This was a multicentre, double-blind, phase 2, randomised, controlled trial of adult patients with active, seropos. systemic lupus erythematosus, done at 44 private practices and academic centers in Argentina, Australia, Germany, Hungary, Mexico, Poland, Spain, Taiwan, and the USA.  Eligible adults were aged 18-75 years, weighed at least 35 kg, and had a diagnosis of systemic lupus erythematosus at least 3 mo before the first administration of study drug.  Eligible patients were randomly assigned (3:2) to the ustekinumab or placebo group using an interactive web response system with stratification by skin biopsy, lupus nephritis presence, baseline systemic lupus erythematosus medications and systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score combined factor, site, region, and race.  Patients and investigators were masked to treatment allocation.  Patients received an i.v. infusion of ustekinumab (260 mg for patients weighing 35-55 kg, 390 mg for patients weighing >55 kg and ≤85 kg, and 520 mg for patients weighing >85 kg) followed by s.c. injections of ustekinumab 90 mg every 8 wk or i.v. infusion of placebo at week 0 followed by s.c. injections of placebo every 8 wk, both in addn. to std.-of-care therapy.  The primary endpoint was the proportion of patients achieving a SLEDAI-2K responder index-4 (SRI-4) response at week 24.  Efficacy analyses were done in a modified intention-to-treat population of patients who received at least one dose (partial or complete, i.v. or s.c.) of their randomly assigned study treatment.  Safety analyses were done in all patients who received at least one dose of study treatment, regardless of group assignment.  This study is registered at ClinicalTrials.gov, no. NCT02349061.  Between Oct 6, 2015, and Nov 30, 2016, 166 patients were screened, of whom 102 were randomly assigned to receive ustekinumab (n=60) or placebo (n=42).  At week 24, 37 (62%) of 60 patients in the ustekinumab group and 14 (33%) of 42 patients in the placebo group achieved an SRI-4 response (percentage difference 28% [95% CI 10-47], p=0·006).  Between week 0 and week 24, 47 (78%) of 60 patients in the ustekinumab group and 28 (67%) of 42 patients in the placebo group had at least one adverse event.  Infections were the most common type of adverse event (27 [45%] in the ustekinumab group vs 21 [50%] in the placebo group).  No deaths or treatment-emergent opportunistic infections, herpes zoster, tuberculosis, or malignancies occurred between weeks 0-24.  The addn. of ustekinumab to std.-of-care treatment resulted in better efficacy in clin. and lab. parameters than placebo in the treatment of active systemic lupus erythematosus and had a safety profile consistent with ustekinumab therapy in other diseases.  The results of this study support further development of ustekinumab as a novel treatment in systemic lupus erythematosus.  Janssen Research & Development, LLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKMNv-uXP8PbVg90H21EOLACvtfcHk0lhiniy_Sys8vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOhurzE&md5=f037f3161cea1b76fb83e68e12ed9e48</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2932167-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252932167-6%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%2BF.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DTsokos%26aufirst%3DG.%2BC.%26aulast%3DWagner%26aufirst%3DC.%2BL.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DTouma%26aufirst%3DZ.%26aulast%3DWerth%26aufirst%3DV.%2BP.%26aulast%3DGordon%26aufirst%3DR.%2BM.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHsu%26aufirst%3DB.%26aulast%3DChevrier%26aufirst%3DM.%26aulast%3DTriebel%26aufirst%3DM.%26aulast%3DJordan%26aufirst%3DJ.%2BL.%26aulast%3DRose%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Ustekinumab%252C%2520an%2520IL-12%2520and%2520IL-23%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Active%2520Systemic%2520Lupus%2520Erythematosus%253A%2520Results%2520of%2520a%2520Multicenter%252C%2520Double-blind%252C%2520Phase%25202%252C%2520Randomised%252C%2520Controlled%2520Study%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1330%26epage%3D1339%26doi%3D10.1016%2FS0140-6736%2818%2932167-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blauvelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randazzo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasfi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, A. B.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared with Adalimumab for the Continuous Treatment of Patients with Moderate to Severe Psoriasis: Results from the Phase III, Double-blinded, Placebo- and Active Comparator-Controlled VOYAGE 1 Trial</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2016.11.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.jaad.2016.11.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=28057360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1SksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=405-417&issue=3&author=A.+Blauveltauthor=K.+A.+Pappauthor=C.+E.+M.+Griffithsauthor=B.+Randazzoauthor=Y.+Wasfiauthor=Y.-K.+Shenauthor=S.+Liauthor=A.+B.+Kimball&title=Efficacy+and+Safety+of+Guselkumab%2C+an+Anti-Interleukin-23+Monoclonal+Antibody%2C+Compared+with+Adalimumab+for+the+Continuous+Treatment+of+Patients+with+Moderate+to+Severe+Psoriasis%3A+Results+from+the+Phase+III%2C+Double-blinded%2C+Placebo-+and+Active+Comparator-Controlled+VOYAGE+1+Trial&doi=10.1016%2Fj.jaad.2016.11.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial</span></div><div class="casAuthors">Blauvelt, Andrew; Papp, Kim A.; Griffiths, Christopher E. M.; Randazzo, Bruce; Wasfi, Yasmine; Shen, Yaung-Kaung; Li, Shu; Kimball, Alexa B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-417</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial.  We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 yr.  Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 wk; n = 329); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20, then every 8 wk; n = 174); or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 wk through week 47; n = 334).  Physician-reported outcomes (Investigator Global Assessment, Psoriasis Area and Severity Index [PASI]), patient-reported outcomes (Dermatol. Life Quality Index, Psoriasis Symptoms and Signs Diary), and safety were evaluated through week 48.  Guselkumab was superior (P < .001) to placebo at week 16 (85.1% vs 6.9% [Investigator Global Assessment score of 0/1 (cleared/minimal)] and 73.3% vs 2.9% [90% or greater improvement in PASI score from baseline (PASI 90)]).  Guselkumab was also superior (P < .001) to adalimumab for Investigator Global Assessment 0/1 and PASI 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4% and 76.3% vs 47.9%).  Furthermore, guselkumab significantly improved patient-reported outcomes through week 48.  Adverse event rates were comparable between treatments.  Analyses were limited to 48 wk.  Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 yr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_St0MQ2YFlrVg90H21EOLACvtfcHk0lgUCZULgncp8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1SksA%253D%253D&md5=296388a810106b5dbced2f689be04fc3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.11.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.11.041%26sid%3Dliteratum%253Aachs%26aulast%3DBlauvelt%26aufirst%3DA.%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DRandazzo%26aufirst%3DB.%26aulast%3DWasfi%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.-K.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKimball%26aufirst%3DA.%2BB.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Guselkumab%252C%2520an%2520Anti-Interleukin-23%2520Monoclonal%2520Antibody%252C%2520Compared%2520with%2520Adalimumab%2520for%2520the%2520Continuous%2520Treatment%2520of%2520Patients%2520with%2520Moderate%2520to%2520Severe%2520Psoriasis%253A%2520Results%2520from%2520the%2520Phase%2520III%252C%2520Double-blinded%252C%2520Placebo-%2520and%2520Active%2520Comparator-Controlled%2520VOYAGE%25201%2520Trial%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2017%26volume%3D76%26issue%3D3%26spage%3D405%26epage%3D417%26doi%3D10.1016%2Fj.jaad.2016.11.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sozzani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosisio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tincani, A.</span></span> <span> </span><span class="NLM_article-title">Type I Interferons in Systemic Immunity</span>. <i>Autoimmunity</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.3109/08916930903510872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.3109%2F08916930903510872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=20298124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFehtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=196-203&author=S.+Sozzaniauthor=D.+Bosisioauthor=M.+Scarsiauthor=A.+Tincani&title=Type+I+Interferons+in+Systemic+Immunity&doi=10.3109%2F08916930903510872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Type I interferons in systemic autoimmunity</span></div><div class="casAuthors">Sozzani, Silvano; Bosisio, Daniela; Scarsi, Mirko; Tincani, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Autoimmunity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">196-203</span>CODEN:
                <span class="NLM_cas:coden">AUIMEI</span>;
        ISSN:<span class="NLM_cas:issn">0891-6934</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Type I IFN (IFN-I) was firstly described in 1957 as a sol. factor responsible for viral resistance in vitro.  Today, it is well known that the IFN-I family comprises a wide no. of cytokines with different modulatory effects on angiogenesis, cell growth, fibrosis, and apoptosis.  However, one of the most important functions of IFN-I is the capability to trigger a complex array of cellular responses that result in a host-protective antiviral response.  For this reason, IFN-I can be considered a "director" of protective immune responses.  The recent finding of the so-called interferon signature in patients suffering from different autoimmune diseases has underlined its possible role in the pathogenesis of these diseases.  On the other hand, IFN-α/β is reported to be efficacious in the treatment of some autoimmune and infectious diseases not responsive to conventional therapy.  On these occasions, the treated patients often start or increase autoantibody prodn. supporting the role of IFN as inducer of an autoimmune response.  In this review, we will underline recent acquisitions about IFN-I biol., with a focus on the relevance of the induction of some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, dermato/polymiositis, and Sjogren's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOfl71Vv3xQbVg90H21EOLACvtfcHk0lgUCZULgncp8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFehtrw%253D&md5=1571043015d55361f6412b1dfe0659e3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3109%2F08916930903510872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08916930903510872%26sid%3Dliteratum%253Aachs%26aulast%3DSozzani%26aufirst%3DS.%26aulast%3DBosisio%26aufirst%3DD.%26aulast%3DScarsi%26aufirst%3DM.%26aulast%3DTincani%26aufirst%3DA.%26atitle%3DType%2520I%2520Interferons%2520in%2520Systemic%2520Immunity%26jtitle%3DAutoimmunity%26date%3D2010%26volume%3D43%26spage%3D196%26epage%3D203%26doi%3D10.3109%2F08916930903510872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khamashta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werth, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalunian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illei, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drappa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greth, W.</span></span> <span> </span><span class="NLM_article-title">Sifalimumab, An Anti-Interferon-α Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus: A Randomised, Double-Blind, Placebo-Controlled Study</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1909</span>– <span class="NLM_lpage">1916</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2015-208562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1136%2Fannrheumdis-2015-208562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=27009916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFahtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=1909-1916&issue=11&author=M.+Khamashtaauthor=J.+T.+Merrillauthor=V.+P.+Werthauthor=R.+Furieauthor=K.+Kalunianauthor=G.+G.+Illeiauthor=J.+Drappaauthor=L.+Wangauthor=W.+Greth&title=Sifalimumab%2C+An+Anti-Interferon-%CE%B1+Monoclonal+Antibody%2C+in+Moderate+to+Severe+Systemic+Lupus+Erythematosus%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Study&doi=10.1136%2Fannrheumdis-2015-208562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study</span></div><div class="casAuthors">Khamashta, Munther; Merrill, Joan T.; Werth, Victoria P.; Furie, Richard; Kalunian, Kenneth; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei; Greth, Warren</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1909-1916</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: The efficacy and safety of sifalimumab were assessed in a phase IIb, randomized, double-blind, placebo-controlled study (NCT01283139) of adults with moderate to severe active systemic lupus erythematosus (SLE).  Methods: 431 patients were randomized and received monthly i.v. sifalimumab (200 mg, 600 mg or 1200 mg) or placebo in addn. to std.-of-care medications.  Patients were stratified by disease activity, interferon gene-signature test (high vs low based on the expression of four genes) and geog. region.  The primary efficacy end point was the percentage of patients achieving an SLE responder index response at week 52.  Results: Compared with placebo, a greater percentage of patients who received sifalimumab (all dosages) met the primary end point (placebo: 45.4%; 200 mg: 58.3%; 600 mg: 56.5%; 1200 mg 59.8%).  Other improvements were seen in Cutaneous Lupus Erythematosus Disease Area and Severity Index score (200 mg and 1200 mg monthly), Physician's Global Assessment (600 mg and 1200 mg monthly), British Isles Lupus Assessment Group-based Composite Lupus Assessment (1200 mg monthly), 4-point redns. in the SLE Disease Activity Index-2000 score and redns. in counts of swollen joints and tender joints.  Serious adverse events occurred in 17.6% of patients on placebo and 18.3% of patients on sifalimumab.  Herpes zoster infections were more frequent with sifalimumab treatment.  Conclusions: Sifalimumab is a promising treatment for adults with SLE.  Improvement was consistent across various clin. end points, including global and organ specific measures of disease activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDXKlIdXLL6bVg90H21EOLACvtfcHk0liiEcSaIZCOJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFahtL4%253D&md5=13decd12e183bf27cb0dc808d23ff345</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2015-208562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2015-208562%26sid%3Dliteratum%253Aachs%26aulast%3DKhamashta%26aufirst%3DM.%26aulast%3DMerrill%26aufirst%3DJ.%2BT.%26aulast%3DWerth%26aufirst%3DV.%2BP.%26aulast%3DFurie%26aufirst%3DR.%26aulast%3DKalunian%26aufirst%3DK.%26aulast%3DIllei%26aufirst%3DG.%2BG.%26aulast%3DDrappa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGreth%26aufirst%3DW.%26atitle%3DSifalimumab%252C%2520An%2520Anti-Interferon-%25CE%25B1%2520Monoclonal%2520Antibody%252C%2520in%2520Moderate%2520to%2520Severe%2520Systemic%2520Lupus%2520Erythematosus%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Study%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2016%26volume%3D75%26issue%3D11%26spage%3D1909%26epage%3D1916%26doi%3D10.1136%2Fannrheumdis-2015-208562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werth, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamashta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalunian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohawn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drappa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S.</span></span> <span> </span><span class="NLM_article-title">Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1002/art.39962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1002%2Fart.39962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=28130918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=376-386&author=R.+Furieauthor=J.+Merrillauthor=V.+Werthauthor=M.+Khamashtaauthor=K.+Kalunianauthor=P.+Brohawnauthor=G.+Illeiauthor=J.+Drappaauthor=L.+Wangauthor=S.+Yoo&title=Anifrolumab%2C+an+Anti-Interferon-%CE%B1+Receptor+Monoclonal+Antibody%2C+in+Moderate-to-Severe+Systemic+Lupus+Erythematosus&doi=10.1002%2Fart.39962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus</span></div><div class="casAuthors">Furie, Richard; Khamashta, Munther; Merrill, Joan T.; Werth, Victoria P.; Kalunian, Kenneth; Brohawn, Philip; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei; Yoo, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">376-386</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE).  Methods: Patients (n = 305) were randomized to receive i.v. anifrolumab (300 mg or 1,000 mg) or placebo, in addn. to std. therapy, every 4 wk for 48 wk.  Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or ≥10), oral corticosteroid dosage (<10 or ≥10 mg/day), and type I IFN gene signature test status (high or low) based on a 4-gene expression assay.  The primary end point was the percentage of patients achieving an SLE Responder Index (SRI[4]) response at week 24 with sustained redn. of oral corticosteroids (<10 mg/day and less than or equal to the dose at week 1 from week 12 through 24).  Other end points (including SRI[4], British Isles Lupus Assessment Group [BILAG]-based Composite Lupus Assessment [BICLA], modified SRI[6], and major clin. response) were assessed at week 52.  The primary end point was analyzed in the modified intent-to-treat (ITT) population and type I IFN-high subpopulation.  The study result was considered pos. if the primary end point was met in either of the 2 study populations.  The Type I error rate was controlled at 0.10 (2-sided), within each of the 2 study populations for the primary end point anal.  Results: The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, vs. placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo-treated patients vs. 36.0% [P = 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, resp.  At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% vs. 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, resp.), BICLA (25.7% vs. 53.5% [P < 0.001] and 41.2% [P = 0.018], resp.), modified SRI(6) (28.4% vs. 49.5% [P = 0.002] and 44.7% [P = 0.015], resp.), major clin. response (BILAG 2004 C or better in all organ domains from week 24 through week 52) (6.9% vs. 19.2% [P = 0.012] and 17.3% [P = 0.025], resp.), and several other global and organ-specific end points.  Herpes zoster was more frequent in the anifrolumab-treated patients (2.0% with placebo treatment vs. 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, resp.), as were cases reported as influenza (2.0% vs. 6.1% and 7.6%, resp.), in the anifrolumab treatment groups.  Incidence of serious adverse events was similar between groups (18.8% vs. 16.2% and 17.1%, resp.).  Conclusion: Anifrolumab substantially reduced disease activity compared with placebo across multiple clin. end points in the patients with moderate-to-severe SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOnuGe2pgO6LVg90H21EOLACvtfcHk0ljeq3v72-L7iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrs7Y%253D&md5=c7f5b70586a8cbc0fafb2651a5f98b32</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fart.39962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39962%26sid%3Dliteratum%253Aachs%26aulast%3DFurie%26aufirst%3DR.%26aulast%3DMerrill%26aufirst%3DJ.%26aulast%3DWerth%26aufirst%3DV.%26aulast%3DKhamashta%26aufirst%3DM.%26aulast%3DKalunian%26aufirst%3DK.%26aulast%3DBrohawn%26aufirst%3DP.%26aulast%3DIllei%26aufirst%3DG.%26aulast%3DDrappa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYoo%26aufirst%3DS.%26atitle%3DAnifrolumab%252C%2520an%2520Anti-Interferon-%25CE%25B1%2520Receptor%2520Monoclonal%2520Antibody%252C%2520in%2520Moderate-to-Severe%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D376%26epage%3D386%26doi%3D10.1002%2Fart.39962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span> </span><span class="NLM_article-title">Update on TULIP 1 Phase III Trial for Anifrolumab
in Systemic Lupus Erythematosus</span>.  <i>AstraZeneca
News Release</i>; <span class="NLM_publisher-name">AstraZenica</span>, Aug 31, <span class="NLM_year">2018</span>; <a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html" class="extLink">https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html</a> (accessed Oct 17, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Update+on+TULIP+1+Phase+III+Trial+for+Anifrolumab%0Ain+Systemic+Lupus+Erythematosus.+AstraZeneca%0ANews+Release%3B+AstraZenica%2C+Aug+31%2C+2018%3B+https%3A%2F%2Fwww.astrazeneca.com%2Fcontent%2Fastraz%2Fmedia-centre%2Fpress-releases%2F2018%2Fupdate-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html+%28accessed+Oct+17%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DUpdate%2520on%2520TULIP%25201%2520Phase%2520III%2520Trial%2520for%2520Anifrolumab%250Ain%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DAstraZeneca%250ANews%2520Release%26pub%3DAstraZenica%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delarosa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menghrajani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, Am.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold to Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4521</span>– <span class="NLM_lpage">4536</span>, <span class="refDoi"> DOI: 10.1021/jm400266t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400266t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4521-4536&author=J.+Liangauthor=A+van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=Y.+Liuauthor=J.+Lyssikatosauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=I.+Pengauthor=Am.+Sambroneauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=L.+C.+Wuauthor=Y.+Xiaoauthor=W.+Yangauthor=J.+Youngauthor=B.+Zhangauthor=B.-y.+Zhuauthor=S.+Magnuson&title=Lead+Optimization+of+a+4-Aminopyridine+Benzamide+Scaffold+to+Identify+Potent%2C+Selective%2C+and+Orally+Bioavailable+TYK2+Inhibitors&doi=10.1021%2Fjm400266t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span></div><div class="casAuthors">Liang, Jun; van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade; Chang, Christine; Delarosa, Donnie; DeVoss, Jason; Driscoll, Jim; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liu, Yanzhou; Lyssikatos, Joseph; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Peng, Ivan; Sambrone, Amy; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Wu, Lawren C.; Xiao, Yisong; Yang, Wenqian; Young, Judy; Zhang, Birong; Zhu, Bing-yan; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4521-4536</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the authors' lead optimization effort to identify potent, selective, and orally bioavailable TYK2 inhibitors, starting with lead mol. 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  The authors used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  Further optimization eventually led to 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-fluorocyclopropanecarboxamido)pyridin-4-yl)benzamide that showed good TYK2 enzyme and interleukin-12 (IL-12) cell potency, as well as acceptable cellular JAK1 and JAK2 selectivity and excellent oral exposure in mice.  When tested in a mouse IL-12 PK/PD model, 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-ffluorocyclopropanecarboxamido)pyridin-4-yl)benzamide showed statistically significant knockdown of cytokine interferon-γ (IFNγ), suggesting that selective inhibition of TYK2 kinase activity might be sufficient to block the IL-12 pathway in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCinZ75WrtObVg90H21EOLACvtfcHk0lg4lL1aC6QMVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D&md5=290ee5f1e3e093136ac5fbb418323421</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400266t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400266t%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DAm.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DB.-y.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520Optimization%2520of%2520a%25204-Aminopyridine%2520Benzamide%2520Scaffold%2520to%2520Identify%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520TYK2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4521%26epage%3D4536%26doi%3D10.1021%2Fjm400266t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagamiya, H.</span>; <span class="NLM_string-name">Yoshida, M.</span>; <span class="NLM_string-name">Seto, M.</span>; <span class="NLM_string-name">Marui, S.</span>; <span class="NLM_string-name">Oda, T.</span>; <span class="NLM_string-name">Ishichi, Y.</span>; <span class="NLM_string-name">Suzuki, H.</span>; <span class="NLM_string-name">Kusumoto, T.</span>; <span class="NLM_string-name">Yogo, T.</span>; <span class="NLM_string-name">Rhim, C. Y.</span>; <span class="NLM_string-name">Yoon, C.</span>; <span class="NLM_string-name">Lee, G. N.</span>; <span class="NLM_string-name">Kang, H. B.</span>; <span class="NLM_string-name">Kim, K. O.</span>; <span class="NLM_string-name">Jeoh, H. S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazolopyridines as Tyrosine Kinase 2 (Tyk2) Inhibitors and Pharmaceuticals Containing them</span>. PCT Int. Appl. <span class="NLM_patent">WO2013/125543 A1</span>,  <span class="NLM_patent">20130829</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Nagamiya&author=M.+Yoshida&author=M.+Seto&author=S.+Marui&author=T.+Oda&author=Y.+Ishichi&author=H.+Suzuki&author=T.+Kusumoto&author=T.+Yogo&author=C.+Y.+Rhim&author=C.+Yoon&author=G.+N.+Lee&author=H.+B.+Kang&author=K.+O.+Kim&author=H.+S.+Jeoh&title=Preparation+of+Pyrazolopyridines+as+Tyrosine+Kinase+2+%28Tyk2%29+Inhibitors+and+Pharmaceuticals+Containing+them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagamiya%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520Pyrazolopyridines%2520as%2520Tyrosine%2520Kinase%25202%2520%2528Tyk2%2529%2520Inhibitors%2520and%2520Pharmaceuticals%2520Containing%2520them%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delarosa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menghrajani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Identification of an Imidazopyridine Scaffold to Generate Potent and Selective TYK2 Inhibitors that Demonstrate Activity in an In Vivo Psoriasis Model</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4370</span>– <span class="NLM_lpage">4376</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.bmcl.2017.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=28830649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOku7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4370-4376&author=J.+Liangauthor=A.+Van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+S.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=S.+Goodacreauthor=N.+Ghilardiauthor=C.+MacLeodauthor=A.+Johnsonauthor=P.+Bir+Kohliauthor=Y.+Laiauthor=Z.+Linauthor=P.+Mantikauthor=K.+Menghrajaniauthor=H.+Nguyenauthor=I.+Pengauthor=A.+Sambroneauthor=S.+Shiaauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=K.+Williamsauthor=L.+C.+Wuauthor=W.+Yangauthor=B.+Zhangauthor=S.+Magnuson&title=Identification+of+an+Imidazopyridine+Scaffold+to+Generate+Potent+and+Selective+TYK2+Inhibitors+that+Demonstrate+Activity+in+an+In+Vivo+Psoriasis+Model&doi=10.1016%2Fj.bmcl.2017.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model</span></div><div class="casAuthors">Liang, Jun; Van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade S.; Chang, Christine; Delarosa, Donnie; De Voss, Jason; Driscoll, Jim; Eigenbrot, Charles; Goodacre, Simon; Ghilardi, Nico; MacLeod, Calum; Johnson, Adam; Bir Kohli, Pawan; Lai, Yingjie; Lin, Zhonghua; Mantik, Priscilla; Menghrajani, Kapil; Nguyen, Hieu; Peng, Ivan; Sambrone, Amy; Shia, Steven; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Williams, Karen; Wu, Lawren C.; Yang, Wenqian; Zhang, Birong; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4370-4376</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compd. 1.  Further optimization led to generation of compd. 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties.  In mice, compd. 30 demonstrated dose-dependent redn. of IL-17 prodn. in a PK/PD model as well as in an imiquimod-induced psoriasis model.  In this efficacy model, the IL-17 decrease was accompanied by a redn. of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe2FqArjLnebVg90H21EOLACvtfcHk0lhR6Y5jw046Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOku7bJ&md5=d132566f504626660c52c680399c9a09</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DMacLeod%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520an%2520Imidazopyridine%2520Scaffold%2520to%2520Generate%2520Potent%2520and%2520Selective%2520TYK2%2520Inhibitors%2520that%2520Demonstrate%2520Activity%2520in%2520an%2520In%2520Vivo%2520Psoriasis%2520Model%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4370%26epage%3D4376%26doi%3D10.1016%2Fj.bmcl.2017.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.-B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+Inhibition+of+TYK2+and+JAK1+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29-pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lhR6Y5jw046Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520Inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529-pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">For reviews of TYK2 selective inhibitors, see:</p></div><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span> <span> </span><span class="NLM_article-title">Toward Selective TYK2 Inhibitors as Therapeutic Agents for the Treatment of Inflammatory Diseases</span>. <i>Pharm. Pat. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.4155/ppa.14.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.4155%2Fppa.14.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=25291316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=449-466&issue=4&author=C.+J.+Menet&title=Toward+Selective+TYK2+Inhibitors+as+Therapeutic+Agents+for+the+Treatment+of+Inflammatory+Diseases&doi=10.4155%2Fppa.14.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Menet, Christel J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Patent Analyst</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-466</span>CODEN:
                <span class="NLM_cas:coden">PPAHCN</span>;
        ISSN:<span class="NLM_cas:issn">2046-8954</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The family of JAK comprises four members and has received significant attention in recent years from the pharmaceutical industry as a therapeutic target.  The role of JAK is central to cytokine signaling pathways.  It is believed that selective modulation of one specific JAK can lead to the inhibition of a restricted set of cytokines, which should avoid undesired side effects and get closer to the profile of biol. therapies.  Consequently, selective JAK inhibition has become a major focus area of drug discovery research.  A review of the TYK2 patents indicates that industry attention has recently turned toward the development of specific inhibitors.  Importantly, despite the increasing no. of published patents, none of these drugs have yet made it to the clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmMgH3Z8Ff7Vg90H21EOLACvtfcHk0lh4mIt9_N7wdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF&md5=0a79df697117246c840c559260d8e7ba</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.4155%2Fppa.14.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fppa.14.23%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26atitle%3DToward%2520Selective%2520TYK2%2520Inhibitors%2520as%2520Therapeutic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DPharm.%2520Pat.%2520Anal.%26date%3D2014%26volume%3D3%26issue%3D4%26spage%3D449%26epage%3D466%26doi%3D10.4155%2Fppa.14.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span></span> <span> </span><span class="NLM_article-title">Advances in the Discovery and Development of Selective Tyrosine Kinase 2 (TYK2) Inhibitors</span>. <i>Medicinal Chemistry Reviews</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.29200/acsmedchemrev-v53.ch10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.29200%2Facsmedchemrev-v53.ch10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlyjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=177-200&author=D.+W.+Weinsteinauthor=R.+M.+Moslin&title=Advances+in+the+Discovery+and+Development+of+Selective+Tyrosine+Kinase+2+%28TYK2%29+Inhibitors&doi=10.29200%2Facsmedchemrev-v53.ch10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery and development of selective tyrosine kinase 2 (TYK2) inhibitors</span></div><div class="casAuthors">Weinstein, David S.; Moslin, Ryan M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-200</span>CODEN:
                <span class="NLM_cas:coden">MCREGD</span>;
        ISSN:<span class="NLM_cas:issn">2575-9175</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society, Division of Medicinal Chemistry</span>)
        </div><div class="casAbstract">A review discussing the advances in the discovery and development of selective tyrosine kinase 2 (TYK2) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm_EO5ig1UTrVg90H21EOLACvtfcHk0lh4mIt9_N7wdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlyjsb8%253D&md5=1ae794f8190d9c312e67fcdd2e06b793</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.29200%2Facsmedchemrev-v53.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.29200%252Facsmedchemrev-v53.ch10%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DD.%2BW.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26atitle%3DAdvances%2520in%2520the%2520Discovery%2520and%2520Development%2520of%2520Selective%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520Inhibitors%26jtitle%3DMedicinal%2520Chemistry%2520Reviews%26date%3D2018%26volume%3D53%26spage%3D177%26epage%3D200%26doi%3D10.29200%2Facsmedchemrev-v53.ch10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure of a Pseudokinase Domain Switch that Controls Oncogenic Activation of Jak Kinases</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1223</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnsmb.2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24013208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ktrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1221-1223&issue=10&author=A.+V.+Tomsauthor=A.+Deshpandeauthor=R.+McNallyauthor=Y.+Jeongauthor=J.+M.+Rogersauthor=C.+U.+Kimauthor=S.+M.+Grunerauthor=S.+B.+Ficarroauthor=J.+A.+Martoauthor=M.+Sattlerauthor=J.+D.+Griffinauthor=M.+J.+Eck&title=Structure+of+a+Pseudokinase+Domain+Switch+that+Controls+Oncogenic+Activation+of+Jak+Kinases&doi=10.1038%2Fnsmb.2673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases</span></div><div class="casAuthors">Toms, Angela V.; Deshpande, Anagha; McNally, Randall; Jeong, Youngjee; Rogers, Julia M.; Kim, Chae Un; Gruner, Sol M.; Ficarro, Scott B.; Marto, Jarrod A.; Sattler, Martin; Griffin, James D.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1221-1223</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The V617F mutation in the Jak2 pseudokinase domain causes myeloproliferative neoplasms, and the equiv. mutation in Jak1 (V658F) is found in T-cell leukemias.  Crystal structures of wild-type and V658F-mutant human Jak1 pseudokinase reveal a conformational switch that remodels a linker segment encoded by exon 12, which is also a site of mutations in Jak2.  This switch is required for V617F-mediated Jak2 activation and possibly for physiol. Jak activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5DpUPWQk57Vg90H21EOLACvtfcHk0lh4mIt9_N7wdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ktrnO&md5=e38a60cb1460c113ba8460319902c493</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2673%26sid%3Dliteratum%253Aachs%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DMcNally%26aufirst%3DR.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DRogers%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DC.%2BU.%26aulast%3DGruner%26aufirst%3DS.%2BM.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructure%2520of%2520a%2520Pseudokinase%2520Domain%2520Switch%2520that%2520Controls%2520Oncogenic%2520Activation%2520of%2520Jak%2520Kinases%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26issue%3D10%26spage%3D1221%26epage%3D1223%26doi%3D10.1038%2Fnsmb.2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandaranayake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of the JAK2 Pseudokinase Domain and the Pathogenic Mutant V617F</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnsmb.2348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=22820988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=754-759&issue=8&author=R.+M.+Bandaranayakeauthor=D.+Ungureanuauthor=Y.+Shanauthor=D.+E.+Shawauthor=O.+Silvennoinenauthor=S.+R.+Hubbard&title=Crystal+Structures+of+the+JAK2+Pseudokinase+Domain+and+the+Pathogenic+Mutant+V617F&doi=10.1038%2Fnsmb.2348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</span></div><div class="casAuthors">Bandaranayake, Rajintha M.; Ungureanu, Daniela; Shan, Yibing; Shaw, David E.; Silvennoinen, Olli; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">754-759</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protein tyrosine kinase JAK2 mediates signaling through numerous cytokine receptors.  JAK2 possesses a pseudokinase domain (JH2) and a tyrosine kinase domain (JH1).  Through unknown mechanisms, JH2 regulates the catalytic activity of JH1, and hyperactivating mutations in the JH2 region of human JAK2 cause myeloproliferative neoplasms (MPNs).  We showed previously that JAK2 JH2 is, in fact, catalytically active.  Here we present crystal structures of human JAK2 JH2, including both wild type and the most prevalent MPN mutant, V617F.  The structures reveal that JH2 adopts the fold of a prototypical protein kinase but binds Mg-ATP noncanonically.  The structural and biochem. data indicate that the V617F mutation rigidifies α-helix C in the N lobe of JH2, facilitating trans-phosphorylation of JH1.  The crystal structures of JH2 afford new opportunities for the design of novel JAK2 therapeutics targeting MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGj9DoN3fj37Vg90H21EOLACvtfcHk0lgouBm4yEq3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM&md5=da64398430cd3279e131b2569cdc7391</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2348%26sid%3Dliteratum%253Aachs%26aulast%3DBandaranayake%26aufirst%3DR.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520JAK2%2520Pseudokinase%2520Domain%2520and%2520the%2520Pathogenic%2520Mutant%2520V617F%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26issue%3D8%26spage%3D754%26epage%3D759%26doi%3D10.1038%2Fnsmb.2348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the Pseudokinase-Kinase Domains from Protein Kinase TYK2 Reveals a Mechanism for Janus Kinase (JAK) Autoinhibition</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8025</span>– <span class="NLM_lpage">8030</span>, <span class="refDoi"> DOI: 10.1073/pnas.1401180111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1073%2Fpnas.1401180111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24843152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8025-8030&issue=22&author=P.+J.+Lupardusauthor=M.+Ultschauthor=H.+Wallweberauthor=P.+Bir+Kohliauthor=A.+R.+Johnsonauthor=C.+Eigenbrot&title=Structure+of+the+Pseudokinase-Kinase+Domains+from+Protein+Kinase+TYK2+Reveals+a+Mechanism+for+Janus+Kinase+%28JAK%29+Autoinhibition&doi=10.1073%2Fpnas.1401180111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition</span></div><div class="casAuthors">Lupardus Patrick J; Ultsch Mark; Wallweber Heidi; Eigenbrot Charles; Bir Kohli Pawan; Johnson Adam R</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8025-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinases (JAKs) are receptor-associated multidomain tyrosine kinases that act downstream of many cytokines and interferons.  JAK kinase activity is regulated by the adjacent pseudokinase domain via an unknown mechanism.  Here, we report the 2.8-ÅA structure of the two-domain pseudokinase-kinase module from the JAK family member TYK2 in its autoinhibited form.  We find that the pseudokinase and kinase interact near the kinase active site and that most reported mutations in cancer-associated JAK alleles cluster in or near this interface.  Mutation of residues near the TYK2 interface that are analogous to those in cancer-associated JAK alleles, including the V617F and "exon 12" JAK2 mutations, results in increased kinase activity in vitro.  These data indicate that JAK pseudokinases are autoinhibitory domains that hold the kinase domain inactive until receptor dimerization stimulates transition to an active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsxgEXiV6j3TQLBVDQn4bCfW6udTcc2ebqC-dpM2ostLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D&md5=47f1d528f736376c9e02add92839ac67</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1401180111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1401180111%26sid%3Dliteratum%253Aachs%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Pseudokinase-Kinase%2520Domains%2520from%2520Protein%2520Kinase%2520TYK2%2520Reveals%2520a%2520Mechanism%2520for%2520Janus%2520Kinase%2520%2528JAK%2529%2520Autoinhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26issue%3D22%26spage%3D8025%26epage%3D8030%26doi%3D10.1073%2Fpnas.1401180111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edavettal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2-Mediated Signal Transduction in T Lymphocytes is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">11061</span>– <span class="NLM_lpage">11074</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.619502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1074%2Fjbc.M114.619502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=25762719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=11061-11074&author=J.+S.+Tokarskiauthor=A.+Zupa-Fernandezauthor=J.+A.+Tredupauthor=K.+Pikeauthor=C.+Changauthor=D.+Xieauthor=L.+Chengauthor=D.+Pedicordauthor=J.+Muckelbauerauthor=S.+R.+Johnsonauthor=S.+Wuauthor=S.+C.+Edavettalauthor=Y.+Hongauthor=M.+R.+Witmerauthor=L.+L.+Elkinauthor=Y.+Blatauthor=W.+J.+Pittsauthor=D.+S.+Weinsteinauthor=J.+R.+Burke&title=Tyrosine+Kinase+2-Mediated+Signal+Transduction+in+T+Lymphocytes+is+Blocked+by+Pharmacological+Stabilization+of+Its+Pseudokinase+Domain&doi=10.1074%2Fjbc.M114.619502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain</span></div><div class="casAuthors">Tokarski, John S.; Zupa-Fernandez, Adriana; Tredup, Jeffrey A.; Pike, Kristen; Chang, Chieh Ying; Xie, Dianlin; Cheng, Lihong; Pedicord, Donna; Muckelbauer, Jodi; Johnson, Stephen R.; Wu, Sophie; Edavettal, Suzanne C.; Hong, Yang; Witmer, Mark R.; Elkin, Lisa L.; Blat, Yuval; Pitts, William J.; Weinstein, David S.; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11061-11074</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibition of signal transduction downstream of the IL-23 receptor represents an intriguing approach to the treatment of autoimmunity.  Using a chemogenomics approach marrying kinome-wide inhibitory profiles of a compd. library with the cellular activity against an IL-23-stimulated transcriptional response in T lymphocytes, a class of inhibitors was identified that bind to and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of receptor-mediated activation of the adjacent catalytic domain.  These Tyk2 pseudokinase domain stabilizers were also shown to inhibit Tyk2-dependent signaling through the Type I interferon receptor but not Tyk2-independent signaling and transcriptional cellular assays, including stimulation through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high functional selectivity of this approach.  A crystal structure of the pseudokinase domain liganded with a representative example showed the compd. bound to a site analogous to the ATP-binding site in catalytic kinases with features consistent with high ligand selectivity.  The results support a model where the pseudokinase domain regulates activation of the catalytic domain by forming receptor-regulated inhibitory interactions.  Tyk2 pseudokinase stabilizers, therefore, represent a novel approach to the design of potent and selective agents for the treatment of autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwSl_Zer56d7Vg90H21EOLACvtfcHk0lgouBm4yEq3TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D&md5=49e10a7c3e430c8be198c119b26bb16b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.619502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.619502%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DTredup%26aufirst%3DJ.%2BA.%26aulast%3DPike%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DMuckelbauer%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DEdavettal%26aufirst%3DS.%2BC.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DElkin%26aufirst%3DL.%2BL.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DTyrosine%2520Kinase%25202-Mediated%2520Signal%2520Transduction%2520in%2520T%2520Lymphocytes%2520is%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520Its%2520Pseudokinase%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D11061%26epage%3D11074%26doi%3D10.1074%2Fjbc.M114.619502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillert, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">27261</span>– <span class="NLM_lpage">27270</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.672048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1074%2Fjbc.M115.672048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=26359499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=27261-27270&issue=45&author=X.+Minauthor=D.+Ungureanuauthor=S.+Maxwellauthor=H.+Hammar%C3%A9nauthor=S.+Thibaultauthor=E.-K.+Hillertauthor=M.+Ayresauthor=B.+Greenfieldauthor=J.+Eksterowiczauthor=C.+Gabelauthor=N.+Walkerauthor=O.+Silvennoinenauthor=Z.+Wang&title=Structural+and+Functional+Characterization+of+the+JH2+Pseudokinase+Domain+of+JAK+Family+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1074%2Fjbc.M115.672048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span></div><div class="casAuthors">Min, Xiaoshan; Ungureanu, Daniela; Maxwell, Sarah; Hammaren, Henrik; Thibault, Steve; Hillert, Ellin-Kristina; Ayres, Merrill; Greenfield, Brad; Eksterowicz, John; Gabel, Chris; Walker, Nigel; Silvennoinen, Olli; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">27261-27270</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation.  JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2).  The majority of disease-assocd. mutations in JAKs map to JH2, demonstrating its central regulatory function.  JH2s were considered catalytically inactive, but JAK2 JH2 was found to have low autoregulatory catalytic activity.  Whether the other JAK JH2s share ATP binding and enzymic activity has been unclear.  Here we report the crystal structure of TYK2 JH2 in complex with adenosine 5'-O-(thiotriphosphate) (ATP-γS) and characterize its nucleotide binding by biochem. and biophys. methods.  TYK2 JH2 did not show phosphotransfer activity, but it binds ATP and the nucleotide binding stabilizes the protein without inducing major conformational changes.  Mutation of the JH2 ATP-binding pocket increased basal TYK2 phosphorylation and downstream signaling.  The overall structural characteristics of TYK2 JH2 resemble JAK2 JH2, but distinct stabilizing mol. interactions around helix αAL in the activation loop provide a structural basis for differences in substrate access and catalytic activities among JAK family JH2s.  The structural and biochem. data suggest that ATP binding is functionally important for both TYK2 and JAK2 JH2s, whereas the regulatory phosphorylation appears to be a unique property of JAK2.  Finally, the co-crystal structure of TYK2 JH2 complexed with a small mol. inhibitor demonstrates that JH2 is accessible to ATP-competitive compds., which offers novel approaches for targeting cytokine signaling as well as potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ZJIkM0pXXbVg90H21EOLACvtfcHk0lhwpuPfuYn0qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO&md5=2933fa07a5bdbea19f3d434591613070</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.672048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.672048%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DX.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DMaxwell%26aufirst%3DS.%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DHillert%26aufirst%3DE.-K.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DGreenfield%26aufirst%3DB.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGabel%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructural%2520and%2520Functional%2520Characterization%2520of%2520the%2520JH2%2520Pseudokinase%2520Domain%2520of%2520JAK%2520Family%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26issue%3D45%26spage%3D27261%26epage%3D27270%26doi%3D10.1074%2Fjbc.M115.672048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzé, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">A Dual Role for the Kinase-Like Domain of the Tyrosine Kinase Tyk2 in Interferon-α Signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">8991</span>– <span class="NLM_lpage">8996</span>, <span class="refDoi"> DOI: 10.1073/pnas.160130297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1073%2Fpnas.160130297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10908660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls12lu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=8991-8996&issue=16&author=T.+C.+Yehauthor=E.+Dondiauthor=G.+Uz%C3%A9author=S.+Pellegrini&title=A+Dual+Role+for+the+Kinase-Like+Domain+of+the+Tyrosine+Kinase+Tyk2+in+Interferon-%CE%B1+Signaling&doi=10.1073%2Fpnas.160130297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-α signaling</span></div><div class="casAuthors">Yeh, Tammie C.; Dondi, Elisabetta; Uze, Gilles; Pellegrini, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8991-8996</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tyrosine kinases of the Janus kinase family initiate cellular responses through their assocn. with receptors for α-helical cytokines.  In addn. to a tyrosine kinase domain, these enzymes possess a kinase-like (KL) domain, whose function remains elusive.  To investigate the role of the KL domain of Tyk2 in interferon-α/β signaling, we transfected a library of Tyk2 cDNAs contg. random point mutations in KL into Tyk2-neg. cells and selected for loss-of-function Tyk2 mutants.  Four such mutants, V584D, G596V, H669P, and R856G, were identified through this screen.  Like the wild-type Tyk2, the mutant proteins were able to sustain the level of IFNAR1 receptor protein.  However, all four mutants were incapable of restoring high-affinity interferon-α binding in Tyk2-neg. cells and were also catalytically impaired, even when transiently overexpressed.  Interferon-α induced phosphorylation, and gene expression could be detected in V584D- or G596V-expressing cells, but not in H669P- or R856G-expressing cells.  Furthermore, H669P and R856G proteins were constitutively highly phosphorylated.  All together, these our findings demonstrate that an intact KL domain is essential for the intrinsic catalytic activity of Tyk2 and for the establishment of a high-affinity interferon-α receptor complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Si0cKeITxbVg90H21EOLACvtfcHk0lhwpuPfuYn0qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls12lu74%253D&md5=da8f555ea9811971e6f4734e1d73de79</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.160130297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.160130297%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DT.%2BC.%26aulast%3DDondi%26aufirst%3DE.%26aulast%3DUz%25C3%25A9%26aufirst%3DG.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DA%2520Dual%2520Role%2520for%2520the%2520Kinase-Like%2520Domain%2520of%2520the%2520Tyrosine%2520Kinase%2520Tyk2%2520in%2520Interferon-%25CE%25B1%2520Signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26issue%3D16%26spage%3D8991%26epage%3D8996%26doi%3D10.1073%2Fpnas.160130297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogensen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzé, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">Distinct Domains of the Protein Tyrosine Kinase Tyk2 Required for Binding of Interferon-alpha/beta and for Signal Transduction</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3327</span>– <span class="NLM_lpage">3334</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.7.3327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1074%2Fjbc.270.7.3327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=7531704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK2MXjslagsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=3327-3334&issue=7&author=L.+Velazquezauthor=K.+E.+Mogensenauthor=G.+Barbieriauthor=M.+Fellousauthor=G.+Uz%C3%A9author=S.+Pellegrini&title=Distinct+Domains+of+the+Protein+Tyrosine+Kinase+Tyk2+Required+for+Binding+of+Interferon-alpha%2Fbeta+and+for+Signal+Transduction&doi=10.1074%2Fjbc.270.7.3327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-α/β and for signal transduction</span></div><div class="casAuthors">Velazquez, Laura; Mogensen, Knud E.; Barbieri, Giovanna; Fellous, Marc; Uze, Gilles; Pellegrini, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3327-34</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tyk2 belongs to the JAK family of nonreceptor protein tyrosine kinases recently found implicated in signaling through a large no. of cytokine receptors.  These proteins are characterized by a large amino-terminal region and two tandemly arranged kinase domains, a kinase-like and a tyrosine kinase domain.  Genetic and biochem. evidence supports the requirement for tyk2 in interferon-α/β binding and signaling.  To study the role of the distinct domains of tyk2, constructs lacking one or both kinase domains were stably transfected in recipient cells lacking the endogenous protein.  Removal of either or both kinase domains resulted in loss of the in vitro kinase activity.  The mutant form truncated of the tyrosine kinase domain was found to reconstitute binding of interferon-α8 and partial signaling.  While no contribution of this protein toward interferon-β binding was evident, increased signaling could be measured.  The mutant form lacking both kinase domains did not exhibit any detectable activity.  Altogether, thus, a sequential deletion of domains engenders a sequential loss of function and that the different domains of tyk2 have distinct functions, all essential for full interferon-α and -β binding and signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhuTslOF05xrVg90H21EOLACvtfcHk0lhwpuPfuYn0qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjslagsrs%253D&md5=7da85d93af787ea1b643f284a9935d31</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.7.3327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.7.3327%26sid%3Dliteratum%253Aachs%26aulast%3DVelazquez%26aufirst%3DL.%26aulast%3DMogensen%26aufirst%3DK.%2BE.%26aulast%3DBarbieri%26aufirst%3DG.%26aulast%3DFellous%26aufirst%3DM.%26aulast%3DUz%25C3%25A9%26aufirst%3DG.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DDistinct%2520Domains%2520of%2520the%2520Protein%2520Tyrosine%2520Kinase%2520Tyk2%2520Required%2520for%2520Binding%2520of%2520Interferon-alpha%252Fbeta%2520and%2520for%2520Signal%2520Transduction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26issue%3D7%26spage%3D3327%26epage%3D3334%26doi%3D10.1074%2Fjbc.270.7.3327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of Imidazo[1,2-b]pyridazine TYK2 Pseudokinase Ligands as Potent and Selective Allosteric Inhibitors of TYK2 Signalling</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1039/C6MD00560H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1039%2FC6MD00560H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=30108788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=700-712&author=R.+Moslinauthor=D.+Gardnerauthor=J.+Santellaauthor=Y.+Zhangauthor=J.+V.+Dunciaauthor=C.+Liuauthor=J.+Linauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=D.+Pedicordauthor=J.+Chenauthor=Y.+Blatauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=H.+Sunauthor=C.+Chaudhryauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=D.+S.+Weinstein&title=Identification+of+Imidazo%5B1%2C2-b%5Dpyridazine+TYK2+Pseudokinase+Ligands+as+Potent+and+Selective+Allosteric+Inhibitors+of+TYK2+Signalling&doi=10.1039%2FC6MD00560H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</span></div><div class="casAuthors">Moslin, R.; Gardner, D.; Santella, J.; Zhang, Y.; Duncia, J. V.; Liu, C.; Lin, J.; Tokarski, J. S.; Strnad, J.; Pedicord, D.; Chen, J.; Blat, Y.; Zupa-Fernandez, A.; Cheng, L.; Sun, H.; Chaudhry, C.; Huang, C.; D'Arienzo, C.; Sack, J. S.; Muckelbauer, J. K.; Chang, C.; Tredup, J.; Xie, D.; Aranibar, N.; Burke, J. R.; Carter, P. H.; Weinstein, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">700-712</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">As a member of the Janus (JAK) family of non-receptor tyrosine kinases, TYK2 mediates the signaling of pro-inflammatory cytokines including IL-12, IL-23 and type 1 interferon (IFN), and therefore represents an attractive potential target for treating the various immuno-inflammatory diseases in which these cytokines have been shown to play a role.  Following up on our previous report that ligands to the pseudokinase domain (JH2) of TYK2 suppress cytokine-mediated receptor activation of the catalytic (JH1) domain, the imidazo[1,2-b]pyridazine (IZP) 7 was identified as a promising hit compd.  Through iterative modification of each of the substituents of the IZP scaffold, the cellular potency was improved while maintaining selectivity over the JH1 domain.  These studies led to the discovery of the JH2-selective TYK2 inhibitor 29, which provided encouraging systemic exposures after oral dosing in mice.  Phosphodiesterase 4 (PDE4) was identified as an off-target and potential liability of the IZP ligands, and selectivity for TYK2 JH2 over this enzyme was obtained by elaborating along selectivity vectors detd. from analyses of X-ray co-crystal structures of representative ligands of the IZP class bound to both proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobX5_XfvLHsLVg90H21EOLACvtfcHk0lg6GRe3nYKnSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN&md5=67b06413866ee6096810903f62edd901</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1039%2FC6MD00560H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00560H%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DD.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520TYK2%2520Pseudokinase%2520Ligands%2520as%2520Potent%2520and%2520Selective%2520Allosteric%2520Inhibitors%2520of%2520TYK2%2520Signalling%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D700%26epage%3D712%26doi%3D10.1039%2FC6MD00560H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mückelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=383-388&author=C+Liuauthor=J.+Linauthor=R.+Moslinauthor=J.+S.+Tokarskiauthor=J.+M%C3%BCckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=H.+Parkauthor=P.+Liauthor=D.-R.+Wuauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=C.+Chaudryauthor=J.+Chenauthor=C.+Chenauthor=H.+Sunauthor=P.+Elzingaauthor=C.+D%27arienzoauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=L.+J.+Lombardoauthor=P.+H.+Carterauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Identification+of+Imidazo%5B1%2C2-b%5Dpyridazine+Derivatives+as+Potent%2C+Selective%2C+and+Orally+Active+Tyk2+JH2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors</span></div><div class="casAuthors">Liu, Chunjian; Lin, James; Moslin, Ryan; Tokarski, John S.; Muckelbauer, Jodi; Chang, ChiehYing; Tredup, Jeffrey; Xie, Dianlin; Park, Hyunsoo; Li, Peng; Wu, Dauh-Rurng; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Chaudhry, Charu; Chen, Jing; Chen, Cliff; Sun, Huadong; Elzinga, Paul; Darienzo, Celia; Gillooly, Kathleen; Taylor, Tracy L.; McIntyre, Kim W.; Salter-Cid, Luisa; Lombardo, Louis J.; Carter, Percy H.; Aranibar, Nelly; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-388</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stability.  The N1-substituent on 2-oxo-1,2-dihydropyridine ring can be a variety of alkyl, aryl, and heteroaryl groups, but among them, 2-pyridyl provided much enhanced Caco-2 permeability, attributed to its ability to form intramol. hydrogen bonds.  Further structure-activity relationship studies at the C3 position led to the identification of highly potent and selective Tyk2 JH2 inhibitor 6, which proved to be highly effective in inhibiting IFNγ prodn. in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKahxaaZZWtbVg90H21EOLACvtfcHk0lg6GRe3nYKnSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsV2qu7w%253D&md5=65c8d8dccfcc2cf73175aef902df9fa2</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DM%25C3%25BCckelbauer%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DChaudry%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DElzinga%26aufirst%3DP.%26aulast%3DD%2527arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520Derivatives%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Active%2520Tyk2%2520JH2%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D383%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauzzi, M.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKendry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogensen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">Interferon-α-Dependent Activation of Tyk2 Requires Phosphorylation of Positive Regulatory Tyrosines by Another Kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">20494</span>– <span class="NLM_lpage">20500</span>, <span class="refDoi"> DOI: 10.1074/jbc.271.34.20494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1074%2Fjbc.271.34.20494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=8702790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK28Xlt1ygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=20494-20500&author=M.%0AC.+Gauzziauthor=L.+Velazquezauthor=R.+McKendryauthor=K.+E.+Mogensenauthor=M.+Fellousauthor=S.+Pellegrini&title=Interferon-%CE%B1-Dependent+Activation+of+Tyk2+Requires+Phosphorylation+of+Positive+Regulatory+Tyrosines+by+Another+Kinase&doi=10.1074%2Fjbc.271.34.20494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-α-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase</span></div><div class="casAuthors">Gauzzi, M. Cristina; Velazquez, Laura; McKendry, Roslyn; Mogensen, Knud E.; Fellous, Marc; Pellegrini, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20494-20500</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tyk2 and JAK1, members of the Janus kinase (JAK) family of protein tyrosine kinases, are required for interferon-α/β binding and signaling.  Both enzymes are assocd. with the interferon-α/β receptor, and upon ligand binding, they undergo tyrosine phosphorylation and catalytic activation in an interdependent manner.  To identify residues involved in Tyk2 regulation and to understand the basis of the interdependence of Tyk2 and JAK1, six mutated versions of Tyk2 bearing single or multiple point mutations in the tyrosine kinase domain were studied in a cell line lacking endogenous Tyk2.  The Y1054F/Y1055F substitutions in the putative activation loop prevented ligand-dependent activation of Tyk2, without abolishing its catalytic potential.  The K930R mutation in the ATP binding site generated a kinase-neg. protein, which however, still became phosphorylated upon interferon-α treatment.  The Y1054F/Y1055F substitutions in this kinase-neg. Tyk2 abolished the induced phosphorylation.  These results indicate that Tyk2 is activated by phosphorylation on Tyr-1054 and/or Tyr-1055 and that this phosphorylation requires another kinase, most likely JAK1.  While the Tyk2 forms mutated on Tyr-1054 and Tyr-1055 or on Lys-930 allowed some inducible gene expression, the combination of the three point mutations totally abolished signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPWGWPmMOHpbVg90H21EOLACvtfcHk0lg6GRe3nYKnSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xlt1ygu7w%253D&md5=934c554dfd8648a157193f82d4166dcd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.34.20494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.34.20494%26sid%3Dliteratum%253Aachs%26aulast%3DGauzzi%26aufirst%3DM.%2BC.%26aulast%3DVelazquez%26aufirst%3DL.%26aulast%3DMcKendry%26aufirst%3DR.%26aulast%3DMogensen%26aufirst%3DK.%2BE.%26aulast%3DFellous%26aufirst%3DM.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DInterferon-%25CE%25B1-Dependent%2520Activation%2520of%2520Tyk2%2520Requires%2520Phosphorylation%2520of%2520Positive%2520Regulatory%2520Tyrosines%2520by%2520Another%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D20494%26epage%3D20500%26doi%3D10.1074%2Fjbc.271.34.20494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of Small Molecules Targeting the Pseudokinase Her3</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3382</span>– <span class="NLM_lpage">3389</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.bmcl.2015.04.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=26094118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3382-3389&author=S.+M.+Limauthor=T.+Xieauthor=K.+D.+Westoverauthor=S.+B.+Ficarroauthor=H.+S.+Taeauthor=D.+Gurbaniauthor=T.+Simauthor=J.+A.+Martoauthor=P.+A.+J%C3%A4nneauthor=C.+M.+Crewsauthor=N.+S.+Gray&title=Development+of+Small+Molecules+Targeting+the+Pseudokinase+Her3&doi=10.1016%2Fj.bmcl.2015.04.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of small molecules targeting the pseudokinase Her3</span></div><div class="casAuthors">Lim, Sang Min; Xie, Ting; Westover, Kenneth D.; Ficarro, Scott B.; Tae, Hyun Seop; Gurbani, Deepak; Sim, Taebo; Marto, Jarrod A.; Janne, Pasi A.; Crews, Craig M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3382-3389</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Her3 is a member of the human epidermal growth factor receptor (EGFR) tyrosine kinase family, and it is often either overexpressed or deregulated in many types of human cancer.  Her3 has not been the subject of small-mol. inhibitor development because it is a pseudokinase and does not possess appreciable kinase activity.  We recently reported on the development of the first selective irreversible Her3 ligand (TX1-85-1) that forms a covalent bond with cysteine 721 which is unique to Her3 among all kinases.  We also developed a bi-functional compd. (TX2-121-1) contg. a hydrophobic adamantane moiety and the same warhead of TX1-85-1 that is capable of inhibiting Her3-dependent signaling and growth.  Here we report on the structure-based medicinal chem. effort that resulted in the discovery of these two compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTq9SbGZsuHLVg90H21EOLACvtfcHk0lhpxFyXJd1pyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGmtr0%253D&md5=3c96eda91b3747000aaf0796fc20e357</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.103%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BM.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DTae%26aufirst%3DH.%2BS.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520Small%2520Molecules%2520Targeting%2520the%2520Pseudokinase%2520Her3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3382%26epage%3D3389%26doi%3D10.1016%2Fj.bmcl.2015.04.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Novel Approaches for Targeting Kinases: Allosteric Inhibition, Allosteric Activation and Pseudokinases</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.4155/fmc.13.216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.4155%2Ffmc.13.216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24649957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=541-561&author=S.+W.+Cowan-Jacobauthor=W.+Jahnkeauthor=S.+Knapp&title=Novel+Approaches+for+Targeting+Kinases%3A+Allosteric+Inhibition%2C+Allosteric+Activation+and+Pseudokinases&doi=10.4155%2Ffmc.13.216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Jahnke, Wolfgang; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">541-561</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in many essential cellular processes and their deregulation can lead to a variety of diseases, including cancer.  The pharmaceutical industry has invested heavily in the identification of kinase inhibitors to modulate these disease-promoting pathways, resulting in several successful drugs.  However, the field is challenging as it is difficult to identify novel selective inhibitors with good pharmacokinetic/pharmacodynamic properties.  In addn., resistance to kinase inhibitor treatment frequently arises.  The identification of non-ATP site targeting ('allosteric') inhibitors, the identification of kinase activators and the expansion of kinase target space to include the less studied members of the family, including atypical- and pseudo-kinases, are potential avenues to overcome these challenges.  In this perspective, the opportunities and challenges of following these approaches and others will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQaQbATcjnLVg90H21EOLACvtfcHk0lhpxFyXJd1pyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyiurk%253D&md5=74a540a959200628a065e287ea6e48d3</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.216%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DNovel%2520Approaches%2520for%2520Targeting%2520Kinases%253A%2520Allosteric%2520Inhibition%252C%2520Allosteric%2520Activation%2520and%2520Pseudokinases%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D541%26epage%3D561%26doi%3D10.4155%2Ffmc.13.216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reiterer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhan, H.</span></span> <span> </span><span class="NLM_article-title">Day of the Dead: Pseudokinases and Pseudophosphatases in Physiology and Disease</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2014.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.tcb.2014.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24818526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVals7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=489-505&author=V.+Reitererauthor=P.+A.+Eyersauthor=H.+Farhan&title=Day+of+the+Dead%3A+Pseudokinases+and+Pseudophosphatases+in+Physiology+and+Disease&doi=10.1016%2Fj.tcb.2014.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">Day of the dead: pseudokinases and pseudophosphatases in physiology and disease</span></div><div class="casAuthors">Reiterer, Veronika; Eyers, Patrick A.; Farhan, Hesso</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">489-505</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pseudophosphatases and pseudokinases are increasingly viewed as integral elements of signaling pathways, and there is mounting evidence that they have frequently retained the ability to interact with cellular 'substrates', and can exert important roles in different diseases.  However, these pseudoenzymes have traditionally received scant attention compared to classical kinases and phosphatases.  In this review we explore new findings in the emerging pseudokinase and pseudophosphatase fields, and discuss their different modes of action which include exciting new roles as scaffolds, anchors, spatial modulators, traps, and ligand-driven regulators of canonical kinases and phosphatases.  Thus, it is now apparent that pseudokinases and pseudophosphatases both support and drive a panoply of signaling networks.  Finally, we highlight recent evidence on their involvement in human pathologies, marking them as potential novel drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQhlAbeCzFT7Vg90H21EOLACvtfcHk0lhpxFyXJd1pyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVals7Y%253D&md5=ab7719e24a3080439997957ba889ffd7</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2014.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2014.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DReiterer%26aufirst%3DV.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DFarhan%26aufirst%3DH.%26atitle%3DDay%2520of%2520the%2520Dead%253A%2520Pseudokinases%2520and%2520Pseudophosphatases%2520in%2520Physiology%2520and%2520Disease%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2014%26volume%3D24%26spage%3D489%26epage%3D505%26doi%3D10.1016%2Fj.tcb.2014.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span> <span> </span><span class="NLM_article-title">Dawn of the Dead: Protein Pseudokinases Signal New Adventures in Cell Biology</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">969</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1042/BST20130115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1042%2FBST20130115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=23863165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2msrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=969-974&author=P.+A.+Eyersauthor=J.+M.+Murphy&title=Dawn+of+the+Dead%3A+Protein+Pseudokinases+Signal+New+Adventures+in+Cell+Biology&doi=10.1042%2FBST20130115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35cR"><div class="casContent"><span class="casTitleNuber">35c</span><div class="casTitle"><span class="NLM_cas:atitle">Dawn of the dead: protein pseudokinases signal new adventures in cell biology</span></div><div class="casAuthors">Eyers, Patrick A.; Murphy, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">969-974</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent studies of proteins contg. kinase-like domains that lack catalytic residue(s) classically required for phosphotransfer, termed pseudokinases, have uncovered important roles in cell signalling across the kingdoms of life.  Addnl., mutations within pseudokinase domains are known to underlie human diseases, suggesting that these proteins may represent new and unexplored therapeutic targets.  To date, few pseudokinases have been studied in intricate detail, but as described in the present article and in the subsequent papers in this issue of Biochem. Society Transactions, several new studies have provided an advanced template and an improved framework for interrogating the roles of pseudokinases in signal transduction.  In the present article, the authors review landmarks in the establishment of this field of study, highlight some exptl. challenges and propose a simple scheme for definition of these domains based on their primary sequences, rather than exptl. defined nucleotide-binding or catalytic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJmZ4zTA9gZbVg90H21EOLACvtfcHk0lhAchXedIYRvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2msrrL&md5=8fd95f237debc9da4f61cd303fde39b0</span></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1042%2FBST20130115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20130115%26sid%3Dliteratum%253Aachs%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26atitle%3DDawn%2520of%2520the%2520Dead%253A%2520Protein%2520Pseudokinases%2520Signal%2520New%2520Adventures%2520in%2520Cell%2520Biology%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2013%26volume%3D41%26spage%3D969%26epage%3D974%26doi%3D10.1042%2FBST20130115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span> <span> </span><span class="NLM_article-title">Kinase Drug Discovery--What’s Next in the Field?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/cb300610s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvF2q" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&issue=1&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+Drug+Discovery%2D%2DWhat%E2%80%99s+Next+in+the+Field%3F&doi=10.1021%2Fcb300610s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35dR"><div class="casContent"><span class="casTitleNuber">35d</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Drug Discovery - What's Next in the Field?</span></div><div class="casAuthors">Cohen, Philip; Alessi, Dario R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-104</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past 15 years protein kinases have become the pharmaceutical industry's most important class of drug target in the field of cancer.  Some 20 drugs that target kinases have been approved for clin. use over the past decade, and hundreds more are undergoing clin. trials.  However, the recent approval of the first protein kinase inhibitors for the treatment of inflammatory diseases, coupled with an enhanced understanding of the signaling networks that control the immune system, suggests that there will be a surge of interest in this area over the next 10 years.  In this connection, we discuss opportunities for targeting protein kinases in the MyD88 signaling network for the development of drugs to treat chronic inflammatory and autoimmune diseases.  Activating mutations in protein kinases underlie many other diseases and conditions, and we also discuss why the protein kinases SPAK/OSR1 and LRRK2 have recently become interesting targets for the treatment of hypertension and Parkinson's disease, resp., and the progress that has been made in developing LRRK2 inhibitors.  Finally we suggest that more focus on the identification of inhibitors of kinase activation, rather than kinase activity, may pay dividends in identifying exquisitely specific inhibitors of signal transduction cascades, and we also highlight "pseudo-kinases" as an attractive and unexplored area for drug development that merits much more attention in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qmfkcqZ3ILVg90H21EOLACvtfcHk0lhAchXedIYRvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvF2q&md5=5bf2ced4163b6ae70e604b2916a6a068</span></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520Drug%2520Discovery--What%25E2%2580%2599s%2520Next%2520in%2520the%2520Field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26issue%3D1%26spage%3D96%26epage%3D104%26doi%3D10.1021%2Fcb300610s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span> <span> </span><span class="NLM_article-title">Prospects for Pharmacological Targeting of Pseudokinases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">526</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fs41573-019-0018-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=30850748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1GjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=501-526&author=J.+E.+Kungauthor=N.+Jura&title=Prospects+for+Pharmacological+Targeting+of+Pseudokinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35eR"><div class="casContent"><span class="casTitleNuber">35e</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for pharmacological targeting of pseudokinases</span></div><div class="casAuthors">Kung, Jennifer E.; Jura, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">501-526</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Pseudokinases are members of the protein kinase superfamily but signal primarily through noncatalytic mechanisms.  Many pseudokinases contribute to the pathologies of human diseases, yet they remain largely unexplored as drug targets owing to challenges assocd. with modulation of their biol. functions.  Our understanding of the structure and physiol. roles of pseudokinases has improved substantially over the past decade, revealing intriguing similarities between pseudokinases and their catalytically active counterparts.  Pseudokinases often adopt conformations that are analogous to those seen in catalytically active kinases and, in some cases, can also bind metal cations and/or nucleotides.  Several clin. approved kinase inhibitors have been shown to influence the noncatalytic functions of active kinases, providing hope that similar properties in pseudokinases could be pharmacol. regulated.  In this Review, we discuss known roles of pseudokinases in disease, their unique structural features and the progress that has been made towards developing pseudokinase-directed therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUFxQnlHTnn7Vg90H21EOLACvtfcHk0lhAchXedIYRvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1GjtLw%253D&md5=f3414770154e8d6449b454f9bc3f19bd</span></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0018-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0018-3%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DJ.%2BE.%26aulast%3DJura%26aufirst%3DN.%26atitle%3DProspects%2520for%2520Pharmacological%2520Targeting%2520of%2520Pseudokinases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D501%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kieltyka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W. Z.</span></span> <span> </span><span class="NLM_article-title">A High-Throughput Bioanalytical Platform Using Automated Infusion for Tandem Mass Spectrometric Method Optimization and its Application in a Metabolic Stability Screen</span>. <i>Rapid Commun. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1579</span>– <span class="NLM_lpage">1591</span>, <span class="refDoi"> DOI: 10.1002/rcm.4037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1002%2Frcm.4037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=19399765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1579-1591&author=K.+Kieltykaauthor=J.+Zhangauthor=S.+Liauthor=M.+Vathauthor=C.+Baglieriauthor=C.+Ferraroauthor=T.+A.+Zvyagaauthor=D.+M.+Drexlerauthor=H.+N.+Wellerauthor=W.+Z.+Shou&title=A+High-Throughput+Bioanalytical+Platform+Using+Automated+Infusion+for+Tandem+Mass+Spectrometric+Method+Optimization+and+its+Application+in+a+Metabolic+Stability+Screen&doi=10.1002%2Frcm.4037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span></div><div class="casAuthors">Kieltyka, Kasia; Zhang, Jun; Li, Shu; Vath, Marianne; Baglieri, Chris; Ferraro, Cheryl; Zvyaga, Tatyana A.; Drexler, Dieter M.; Weller, Harold N.; Shou, Wilson Z.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1579-1591</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Liq. chromatog./tandem mass spectrometry (LC/MS/MS) is the bioanal. method of choice to support plate-based, in vitro early ADME (Absorption, Distribution, Metab. and Excretion) screens such as metabolic stability (Metstab) assessment.  MS/MS method optimization has historically been the bottleneck in this environment, where samples from thousands of discrete compds. are analyzed on a monthly basis, mainly due to the lack of a high-quality com. available platform to handle the necessary MS/MS method optimization steps for sample anal. by selected reaction monitoring (SRM) on triple quadrupole mass spectrometers.  To address this challenge, we recently developed a highly automated bioanal. platform by successfully integrating QuickQuan 2.0, a unique high-throughput soln. featuring MS/MS method optimization by automated infusion, with a customized inhouse software tool in support of a Metstab screen.  In this platform, a dual-column setup running parallel chromatog. was also implemented to reduce the bioanal. cycle time for LC/MS/MS sample anal.  A set of 45 validation compds. was used to demonstrate the speed, quality and reproducibility of MS/MS method optimization, sample anal., and data processing using this automated platform.  Metstab results for the validation compds. in microsomes from multiple species (human, rat, mouse) showed good consistency within each batch, and also between batches conducted on different days.  We have achieved and maintained a monthly throughput of 1300 compd. assays representing 500 discrete compds. per instrument per mo on this platform, and it has been used to generate metabolic stability data for more than 25 000 compds. to date with an overall success rate of more than 95%.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8W1PNTqYnALVg90H21EOLACvtfcHk0lhAchXedIYRvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D&md5=57977322942dc41955c1d9cf015e5b05</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Frcm.4037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.4037%26sid%3Dliteratum%253Aachs%26aulast%3DKieltyka%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DVath%26aufirst%3DM.%26aulast%3DBaglieri%26aufirst%3DC.%26aulast%3DFerraro%26aufirst%3DC.%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DDrexler%26aufirst%3DD.%2BM.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26aulast%3DShou%26aufirst%3DW.%2BZ.%26atitle%3DA%2520High-Throughput%2520Bioanalytical%2520Platform%2520Using%2520Automated%2520Infusion%2520for%2520Tandem%2520Mass%2520Spectrometric%2520Method%2520Optimization%2520and%2520its%2520Application%2520in%2520a%2520Metabolic%2520Stability%2520Screen%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2009%26volume%3D23%26spage%3D1579%26epage%3D1591%26doi%3D10.1002%2Frcm.4037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="note"><p class="first last">LE = pIC<sub>50</sub> (bind)/#non-H atoms; LLE = pIC<sub>50</sub> (bind) – log <i>P</i>(or clogP). For a discussion of ligand efficiency pertaining to drug discovery, see:</p></div><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The Role of Ligand Efficiency Metrics in Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+Role+of+Ligand+Efficiency+Metrics+in+Drug+Discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lhQ4Kg3bx_2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520Role%2520of%2520Ligand%2520Efficiency%2520Metrics%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="note"><p class="first last">The other four kinases were JAK1 JH2 (19 nM), cKit (26 nM), FLT3 (412 nM), and Tyro (881 nM).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="note"><p class="first last">Trb3, Trio, Tnik, Mink, Hgk, Cot, Tyro3, Bmpr2, and Cygd (based on a sequence alignment of kinase domains).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanzlik, R. P.</span></span> <span> </span><span class="NLM_article-title">Kinetic Deuterium Isotope Effects on the N-Demethylation of Tertiary Amides by Cytochrome P-450</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>265</i></span>,  <span class="NLM_fpage">12349</span>– <span class="NLM_lpage">12355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=2373695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK3cXlsVOqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1990&pages=12349-12355&author=L.+R.+Hallauthor=R.+P.+Hanzlik&title=Kinetic+Deuterium+Isotope+Effects+on+the+N-Demethylation+of+Tertiary+Amides+by+Cytochrome+P-450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic deuterium isotope effects on the N-demethylation of tertiary amides by cytochrome P-450</span></div><div class="casAuthors">Hall, Larry R.; Hanzlik, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12349-55</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Liver microsomal cytochrome P 450 (tertiary methylamide demethylase) readily N-dealkylates N,N-dimethylamides.  N-Methyl-N-hydroxymethyl amides were isolated as intermediates and characterized by gas chromatograph-mass spectrometry as their trimethylsilyl ethers.  Intramol. kinetic deuterium isotope effects measured for the enzymic N-demethylation of a series of 12 arom. and aliph. N-methyl-N-trideuteriomethyl amides, RCON(CH3)CD3, varied from 3.6 to 6.9 but were independent of both amide bond rotation rate and substrate oxidn. potential.  These values, which represent a lower limit to the intrinsic isotope effect (Dkintrinsic), are significantly larger than those obsd. for anodic N-demethylation and are consistent with a mechanism involving H atom abstraction.  On the other hand, with N,N-dimethylbenzamide the intermol. kinetic deuterium isotope effects on Vmax and Vmax/Km were found to be much smaller (1.23 and 1.75, resp.) indicating substantial suppression of the intrinsic isotope effect.  Such suppression indicates the occurrence of a rate-limiting step other than the isotopically sensitive step together with a strong commitment to catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzuI60P-pveLVg90H21EOLACvtfcHk0lhQ4Kg3bx_2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlsVOqs78%253D&md5=66fb98eeae0b9936464b4eada4bb4fbc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DL.%2BR.%26aulast%3DHanzlik%26aufirst%3DR.%2BP.%26atitle%3DKinetic%2520Deuterium%2520Isotope%2520Effects%2520on%2520the%2520N-Demethylation%2520of%2520Tertiary%2520Amides%2520by%2520Cytochrome%2520P-450%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1990%26volume%3D265%26spage%3D12349%26epage%3D12355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">Using CD<sub>3</sub> to significantly reduce formation of the primary amide metabolite in vivo was generally applicable, proving successful for all nicotinamides and pyridazine amides tested to date.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edling, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">c-Kit--a Hematopoietic Cell Essential Receptor Kinase</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1995</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2006.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.biocel.2006.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=17350321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWmur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=1995-1998&author=C.+E.+Edlingauthor=B.+Hallberg&title=c-Kit%2D%2Da+Hematopoietic+Cell+Essential+Receptor+Kinase&doi=10.1016%2Fj.biocel.2006.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">c-Kit-A hematopoietic cell essential receptor tyrosine kinase</span></div><div class="casAuthors">Edling, Charlotte E.; Hallberg, Bengt</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1995-1998</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase c-Kit is expressed in hematopoietic stem and progenitor cells and in several non-hematopoietic tissues.  In the hematopoietic system, c-Kit is crit. for proliferation, survival and differentiation.  During recent years exploration of the signaling pathways downstream of this receptor has yielded significant new insights in the field.  In this review, we will summarize the c-Kit background, structure, downstream signaling and medical significance with particular focus on its role in hematopoietic progenitor cells and mast cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprkHCEEm6AQrVg90H21EOLACvtfcHk0lhQ4Kg3bx_2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWmur7E&md5=c9c4ceaf53e2c63a8ef0aba712b524fc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2006.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2006.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DEdling%26aufirst%3DC.%2BE.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3Dc-Kit--a%2520Hematopoietic%2520Cell%2520Essential%2520Receptor%2520Kinase%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2007%26volume%3D39%26spage%3D1995%26epage%3D1998%26doi%3D10.1016%2Fj.biocel.2006.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+of+hERG+Optimizations%3A+Highlights+and+Hang-Ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lgTd9qV-NRzMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520of%2520hERG%2520Optimizations%253A%2520Highlights%2520and%2520Hang-Ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirripa, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ransom, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R. S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detwiler, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hettrick, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettibone, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freidinger, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span></span> <span> </span><span class="NLM_article-title">Cyclopropylamino Acid as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B<sub>1</sub> Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.1021/jm0511280</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0511280" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlWmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1231-1234&author=M.+R.+Woodauthor=K.+M.+Schirripaauthor=J.+J.+Kimauthor=B.-L.+Wanauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=R.+S.+L.+Changauthor=C.+Tangauthor=T.+Prueksaritanontauthor=T.+J.+Detwilerauthor=L.+A.+Hettrickauthor=E.+R.+Landisauthor=Y.+M.+Leonardauthor=J.+A.+Kruegerauthor=S.+D.+Lewisauthor=D.+J.+Pettiboneauthor=R.+M.+Freidingerauthor=M.+G.+Bock&title=Cyclopropylamino+Acid+as+a+Pharmacophoric+Replacement+for+2%2C3-Diaminopyridine.+Application+to+the+Design+of+Novel+Bradykinin+B1+Receptor+Antagonists&doi=10.1021%2Fjm0511280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclopropylamino Acid Amide as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B1 Receptor Antagonists</span></div><div class="casAuthors">Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Wan, Bang-Lin; Murphy, Kathy L.; Ransom, Richard W.; Chang, Raymond S. L.; Tang, Cuyue; Prueksaritanont, Thomayant; Detwiler, Theodore J.; Hettrick, Lisa A.; Landis, Elizabeth R.; Leonard, Yvonne M.; Krueger, Julie A.; Lewis, Sidney D.; Pettibone, Douglas J.; Freidinger, Roger M.; Bock, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1231-1234</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonism of the bradykinin B1 receptor represents a potential treatment for chronic pain and inflammation.  Novel antagonists were designed that display low-nanomolar affinity for the human bradykinin B1 receptor and good bioavailability in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHLP_4qFDI8bVg90H21EOLACvtfcHk0lgTd9qV-NRzMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlWmsQ%253D%253D&md5=70df384ebdceb569fadd3bb45f053a07</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm0511280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0511280%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DSchirripa%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DChang%26aufirst%3DR.%2BS.%2BL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DDetwiler%26aufirst%3DT.%2BJ.%26aulast%3DHettrick%26aufirst%3DL.%2BA.%26aulast%3DLandis%26aufirst%3DE.%2BR.%26aulast%3DLeonard%26aufirst%3DY.%2BM.%26aulast%3DKrueger%26aufirst%3DJ.%2BA.%26aulast%3DLewis%26aufirst%3DS.%2BD.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DCyclopropylamino%2520Acid%2520as%2520a%2520Pharmacophoric%2520Replacement%2520for%25202%252C3-Diaminopyridine.%2520Application%2520to%2520the%2520Design%2520of%2520Novel%2520Bradykinin%2520B1%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1231%26epage%3D1234%26doi%3D10.1021%2Fjm0511280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="note"><p class="first last">For reviews on the use of pyridazine in medicinal chemistry, see:</p></div><div class="NLM_citation" id="cit45a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span> <span> </span><span class="NLM_article-title">The Developability of Heteroaromatic and Heteroaliphatic Rings – do Some Have a Better Pedigree as Potential Drug Molecules than Others?</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1062</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1039/c2md20111a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1039%2Fc2md20111a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1062-1069&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=S.+Peaceauthor=S.+D.+Pickettauthor=C.+N.+Luscombe&title=The+Developability+of+Heteroaromatic+and+Heteroaliphatic+Rings+%E2%80%93+do+Some+Have+a+Better+Pedigree+as+Potential+Drug+Molecules+than+Others%3F&doi=10.1039%2Fc2md20111a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">The developability of heteroaromatic and heteroaliphatic rings - do some have a better pedigree as potential drug molecules than others?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Peace, Simon; Pickett, Stephen D.; Luscombe, Christopher N.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1062-1069</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Aq. soly., protein binding and CYP450 inhibition data for compds. contg. a variety of heteroarom. and heteroaliph. rings were analyzed and compared to det. which ring types fared best and worst in these developability screens.  The results suggest that certain heterorings are generally more developable than others: how this information may be used and some caveats to be borne in mind are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCkxdTaUGig7Vg90H21EOLACvtfcHk0lgTd9qV-NRzMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE&md5=6aad4bc48b351d9d20683ee9af1a3354</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1039%2Fc2md20111a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20111a%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26atitle%3DThe%2520Developability%2520of%2520Heteroaromatic%2520and%2520Heteroaliphatic%2520Rings%2520%25E2%2580%2593%2520do%2520Some%2520Have%2520a%2520Better%2520Pedigree%2520as%2520Potential%2520Drug%2520Molecules%2520than%2520Others%253F%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1062%26epage%3D1069%26doi%3D10.1039%2Fc2md20111a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span> <span> </span><span class="NLM_article-title">Are Pyridazines Privileged Structures?</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1039/c1md00074h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1039%2Fc1md00074h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Oqu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=935-941&author=C.+G.+Wermuth&title=Are+Pyridazines+Privileged+Structures%3F&doi=10.1039%2Fc1md00074h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Are pyridazines privileged structures?</span></div><div class="casAuthors">Wermuth, Camille G.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">935-941</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  One can est. that about 50% of all the drug mols. used in medicine contain a Ph ring which can be substituted or not.  The bioisosteric replacement of these Ph rings by the corresponding pyridazine rings opens an access to several thousands of diaza analogs presenting more interaction possibilities, lower Log P values and improved cryst. salts.  The use of pyridazine scaffolds in place of Ph scaffolds entails addnl. interaction possibilities.  Another interest of pyridazines is their capacity to act as original functional surrogates.  Thus, aminopyridazines can be used as carboxamide, as well as amine surrogates.  Finally, the many examples of pyridazines used either as a structural element or as a main scaffold, justify largely their status as privileged structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTuMqekrcmc7Vg90H21EOLACvtfcHk0lgluiwFFJrXpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Oqu7bO&md5=0693fec05e567555cf183e97f0df6852</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1039%2Fc1md00074h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00074h%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DAre%2520Pyridazines%2520Privileged%2520Structures%253F%26jtitle%3DMedChemComm%26date%3D2011%26volume%3D2%26spage%3D935%26epage%3D941%26doi%3D10.1039%2Fc1md00074h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Questel, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, E.</span></span> <span> </span><span class="NLM_article-title">The p<i>K</i><sub><i>BHX</i></sub> Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4073</span>– <span class="NLM_lpage">4086</span>, <span class="refDoi"> DOI: 10.1021/jm801331y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801331y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4073-4086&author=C.+Laurenceauthor=K.+A.+Brameldauthor=J.+Gratonauthor=J.-Y.+Le+Questelauthor=E.+Renault&title=The+pKBHX+Database%3A+Toward+a+Better+Understanding+of+Hydrogen-Bond+Basicity+for+Medicinal+Chemists&doi=10.1021%2Fjm801331y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists</span></div><div class="casAuthors">Laurence, Christian; Brameld, Ken A.; Graton, Jerome; Le Questel, Jean-Yves; Renault, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4073-4086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pKBHX database is presented, which corresponds to three main fields of data: hydrogen bond donor identification, thermodn. data and spectroscopic data.  The pKBHX scale of hydrogen donor basicity differs considerable from the pKBH+ scale of proton transfer basicity.  The hydrogen bond basicities of functional groups relevant to medicinal chem. and drug design is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9OhmMu2VILVg90H21EOLACvtfcHk0lgluiwFFJrXpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D&md5=9ce4bea3e810752baba6ea5784b55ea0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm801331y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801331y%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DC.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DGraton%26aufirst%3DJ.%26aulast%3DLe%2BQuestel%26aufirst%3DJ.-Y.%26aulast%3DRenault%26aufirst%3DE.%26atitle%3DThe%2520pKBHX%2520Database%253A%2520Toward%2520a%2520Better%2520Understanding%2520of%2520Hydrogen-Bond%2520Basicity%2520for%2520Medicinal%2520Chemists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4073%26epage%3D4086%26doi%3D10.1021%2Fjm801331y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="note"><p class="first last">Dosed in 5:5:90 EtOH:TPGS:PEG 300.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhlig, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce-Shaikh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepankova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonocore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tlaskalova-Hogenova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cua, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powrie, F.</span></span> <span> </span><span class="NLM_article-title">Differential Activity of IL-12 and IL-23 in Mucosal and Systemic Innate Immune Pathology</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2006.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.immuni.2006.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=16919486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVGjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=309-318&author=H.+H.+Uhligauthor=B.+S.+McKenzieauthor=S.+Hueauthor=C.+Thompsonauthor=B.+Joyce-Shaikhauthor=R.+Stepankovaauthor=N.+Robinsonauthor=S.+Buonocoreauthor=H.+Tlaskalova-Hogenovaauthor=D.+J.+Cuaauthor=F.+Powrie&title=Differential+Activity+of+IL-12+and+IL-23+in+Mucosal+and+Systemic+Innate+Immune+Pathology&doi=10.1016%2Fj.immuni.2006.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology</span></div><div class="casAuthors">Uhlig, Holm H.; McKenzie, Brent S.; Hue, Sophie; Thompson, Claire; Joyce-Shaikh, Barbara; Stepankova, Renata; Robinson, Nicolas; Buonocore, Sofia; Tlaskalova-Hogenova, Helena; Cua, Daniel J.; Powrie, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">309-318</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The CD40-CD154 pathway is important in the pathogenesis of inflammatory bowel disease.  Here we show that injection of an agonistic CD40 mAb to T and B cell-deficient mice was sufficient to induce a pathogenic systemic and intestinal innate inflammatory response that was functionally dependent on tumor necrosis factor-α and interferon-γ as well as interleukin-12 p40 and interleukin-23 p40 secretion.  CD40-induced colitis, but not wasting disease or serum proinflammatory cytokine prodn., depended on interleukin-23 p19 secretion, whereas interleukin-12 p35 secretion controlled wasting disease and serum cytokine prodn. but not mucosal immunopathol.  Intestinal inflammation was assocd. with IL-23 (p19) mRNA-producing intestinal dendritic cells and IL-17A mRNA within the intestine.  Our expts. identified IL-23 as an effector cytokine within the innate intestinal immune system.  The differential role of IL-23 in local but not systemic inflammation suggests that it may make a more specific target for the treatment of IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj3dkf8LiElLVg90H21EOLACvtfcHk0lgluiwFFJrXpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVGjsrk%253D&md5=25d70c2a9cdd7ea34fce7981a14340c6</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2006.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2006.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DUhlig%26aufirst%3DH.%2BH.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DHue%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DJoyce-Shaikh%26aufirst%3DB.%26aulast%3DStepankova%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DN.%26aulast%3DBuonocore%26aufirst%3DS.%26aulast%3DTlaskalova-Hogenova%26aufirst%3DH.%26aulast%3DCua%26aufirst%3DD.%2BJ.%26aulast%3DPowrie%26aufirst%3DF.%26atitle%3DDifferential%2520Activity%2520of%2520IL-12%2520and%2520IL-23%2520in%2520Mucosal%2520and%2520Systemic%2520Innate%2520Immune%2520Pathology%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26spage%3D309%26epage%3D318%26doi%3D10.1016%2Fj.immuni.2006.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lgRme-xqdZ_dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31a','cit31b'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35a','cit35b','cit35c','cit35d','cit35e'],'ref36':['cit36'],'ref37':['cit37'],'ref38':[],'ref39':[],'ref40':['cit40'],'ref41':[],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45a','cit45b'],'ref46':['cit46'],'ref47':[],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, John S. Tokarski, Javed Khan, Max Ruzanov, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, Kathleen M. Gillooly, David Shuster, Yifan Zhang, Anil Thankappan, Kim W. McIntyre, Charu Chaudhry, Paul A. Elzinga, Manoj Chiney, Anjaneya Chimalakonda, Louis J. Lombardo, John E. Macor, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 677-694. <a href="https://doi.org/10.1021/acs.jmedchem.0c01698" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBMS-986202%25253A%252BA%252BClinical%252BTyk2%252BInhibitor%252Bthat%252BBinds%252Bto%252BTyk2%252BJH2%26aulast%3DLiu%26aufirst%3DChunjian%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D28122020%26volume%3D64%26issue%3D1%26spage%3D677%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James J. Crawford, Wendy Lee, Adam R. Johnson, Kelly J. Delatorre, Jacob Chen, Charles Eigenbrot, Julia Heidmann, Satoko Kakiuchi-Kiyota, Arna Katewa, James R. Kiefer, Lichuan Liu, Joseph W. Lubach, Dinah Misner, Hans Purkey, Karin Reif, Jennifer Vogt, Harvey Wong, Christine Yu, <span class="NLM_string-name hlFld-ContribAuthor">Wendy B. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (8)
                                     , 1588-1597. <a href="https://doi.org/10.1021/acsmedchemlett.0c00249" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00249%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStereochemical%252BDifferences%252Bin%252BFluorocyclopropyl%252BAmides%252BEnable%252BTuning%252Bof%252BBtk%252BInhibition%252Band%252BOff-Target%252BActivity%26aulast%3DCrawford%26aufirst%3DJames%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13052020%26date%3D13072020%26date%3D20072020%26date%3D13072020%26volume%3D11%26issue%3D8%26spage%3D1588%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Enza Torre, Silvio Aprile, Erika Del Grosso, Alessandro Gesù, Alessia Griglio, Giorgia Colombo, Cristina Travelli, Salvatore Paiella, Annalisa Adamo, Elena Orecchini, Alice Coletti, Maria Teresa Pallotta, Stefano Ugel, Alberto Massarotti, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Silvia Fallarini</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 3047-3065. <a href="https://doi.org/10.1021/acs.jmedchem.9b01809" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01809</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01809%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BHighly%252BPotent%252BBenzimidazole%252BDerivatives%252Bas%252BIndoleamine%252B2%25252C3-Dioxygenase-1%252B%252528IDO1%252529%252BInhibitors%25253A%252BFrom%252BStructure-Based%252BVirtual%252BScreening%252Bto%252Bin%252BVivo%252BPharmacodynamic%252BActivity%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D31102019%26date%3D17032020%26date%3D09032020%26volume%3D63%26issue%3D6%26spage%3D3047%26epage%3D3065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen T. Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, James Kempson, John S. Tokarski, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, David Shuster, Kathleen Gillooly, Xiaoxia Yang, Elizabeth Heimrich, Kim W. McIntyre, Charu Chaudhry, Javed Khan, Max Ruzanov, Jeffrey Tredup, Dawn Mulligan, Dianlin Xie, Huadong Sun, Christine Huang, Celia D’Arienzo, Nelly Aranibar, Manoj Chiney, Anjaneya Chimalakonda, William J. Pitts, Louis Lombardo, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8973-8995. <a href="https://doi.org/10.1021/acs.jmedchem.9b00444" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BSelective%252BInhibition%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%25253A%252BDiscovery%252Bof%252Bthe%252BAllosteric%252BInhibitor%252BBMS-986165%26aulast%3DWrobleski%26aufirst%3DStephen%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D18072019%26volume%3D62%26issue%3D20%26spage%3D8973%26epage%3D8995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yu Chang, Shilin Xu, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8951-8952. <a href="https://doi.org/10.1021/acs.jmedchem.9b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01612%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252BAllosteric%252BInhibitors%252BTo%252BTreat%252BAutoimmune%252BDiseases%26aulast%3DChang%26aufirst%3DYu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28092019%26date%3D11102019%26volume%3D62%26issue%3D20%26spage%3D8951%26epage%3D8952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Upendra A.  Argikar</span>, <span class="hlFld-ContribAuthor ">James P.  Driscoll</span>, <span class="hlFld-ContribAuthor ">Carley J. S.  Heck</span>, <span class="hlFld-ContribAuthor ">Lloyd  King</span>, <span class="hlFld-ContribAuthor ">Klarissa D.  Jackson</span>, <span class="hlFld-ContribAuthor ">Wenying  Jian</span>, <span class="hlFld-ContribAuthor ">Amit S.  Kalgutkar</span>, <span class="hlFld-ContribAuthor ">Grover P.  Miller</span>, <span class="hlFld-ContribAuthor ">Valerie  Kramlinger</span>, <span class="hlFld-ContribAuthor ">Ivonne M. C. M.  Rietjens</span>, <span class="hlFld-ContribAuthor ">Aaron M.  Teitelbaum</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Cong  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Novel advances in biotransformation and bioactivation research – 2020 year in review. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2021,</strong> <em>48 </em>, 1-50. <a href="https://doi.org/10.1080/03602532.2021.1916028" title="DOI URL">https://doi.org/10.1080/03602532.2021.1916028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2021.1916028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2021.1916028%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DNovel%252Badvances%252Bin%252Bbiotransformation%252Band%252Bbioactivation%252Bresearch%252B%2525E2%252580%252593%252B2020%252Byear%252Bin%252Breview%26aulast%3DKhojasteh%26aufirst%3DS.%2BCyrus%26date%3D2021%26date%3D2021%26volume%3D48%26spage%3D1%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvio  Danese</span>, <span class="hlFld-ContribAuthor ">Laurent  Peyrin-Biroulet</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. </span><span class="cited-content_cbyCitation_journal-name">Inflammatory Bowel Diseases</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1093/ibd/izab135" title="DOI URL">https://doi.org/10.1093/ibd/izab135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ibd/izab135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fibd%2Fizab135%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammatory%2520Bowel%2520Diseases%26atitle%3DSelective%252BTyrosine%252BKinase%252B2%252BInhibition%252Bfor%252BTreatment%252Bof%252BInflammatory%252BBowel%252BDisease%25253A%252BNew%252BHope%252Bon%252Bthe%252BRise%26aulast%3DDanese%26aufirst%3DSilvio%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Andrew  Tebben</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Robert  Borzilleri</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Jonathan  Lippy</span>, <span class="hlFld-ContribAuthor ">Litao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 1115-1125. <a href="https://doi.org/10.1016/j.drudis.2021.01.018" title="DOI URL">https://doi.org/10.1016/j.drudis.2021.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2021.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2021.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DAn%252Binnovative%252Bkinome%252Bplatform%252Bto%252Baccelerate%252Bsmall-molecule%252Binhibitor%252Bdiscovery%252Band%252Boptimization%252Bfrom%252Bhits%252Bto%252Bleads%26aulast%3DChaudhry%26aufirst%3DCharu%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D1115%26epage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Ryan  Moslin</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>. </span><span class="cited-content_cbyCitation_article-title">JAK
              Family Inhibitors for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-86. <a href="https://doi.org/10.1002/0471266949.bmc279" title="DOI URL">https://doi.org/10.1002/0471266949.bmc279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc279%26sid%3Dliteratum%253Aachs%26atitle%3DJAK%252BFamily%252BInhibitors%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DBorzilleri%26aufirst%3DRobert%2BM.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D86%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. Alison  Rinderspacher</span>. </span><span class="cited-content_cbyCitation_article-title">Six-membered ring systems: diazines and benzo derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 431-466. <a href="https://doi.org/10.1016/B978-0-323-89812-6.00013-4" title="DOI URL">https://doi.org/10.1016/B978-0-323-89812-6.00013-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-323-89812-6.00013-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-323-89812-6.00013-4%26sid%3Dliteratum%253Aachs%26atitle%3DSix-membered%252Bring%252Bsystems%25253A%252Bdiazines%252Band%252Bbenzo%252Bderivatives%26aulast%3DRinderspacher%26aufirst%3DK.%2BAlison%26date%3D2021%26spage%3D431%26epage%3D466%26pub%3DElsevier%26date%3D2021%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nayana  Devang</span>, <span class="hlFld-ContribAuthor ">Adyashree  Pani</span>, <span class="hlFld-ContribAuthor ">G.K.  Rajanikant</span>. </span><span class="cited-content_cbyCitation_article-title">Pseudokinases: Prospects for expanding the therapeutic targets armamentarium. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 121-185. <a href="https://doi.org/10.1016/bs.apcsb.2020.09.004" title="DOI URL">https://doi.org/10.1016/bs.apcsb.2020.09.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apcsb.2020.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apcsb.2020.09.004%26sid%3Dliteratum%253Aachs%26atitle%3DPseudokinases%25253A%252BProspects%252Bfor%252Bexpanding%252Bthe%252Btherapeutic%252Btargets%252Barmamentarium%26aulast%3DDevang%26aufirst%3DNayana%26date%3D2021%26spage%3D121%26epage%3D185%26pub%3DElsevier%26atitle%3DProtein%252BKinases%252Bin%252BDrug%252BDiscovery%26date%3D2021%26volume%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandra  Coomans de Brachène</span>, <span class="hlFld-ContribAuthor ">Angela  Castela</span>, <span class="hlFld-ContribAuthor ">Anne  Op de Beeck</span>, <span class="hlFld-ContribAuthor ">Raghavendra G.  Mirmira</span>, <span class="hlFld-ContribAuthor ">Lorella  Marselli</span>, <span class="hlFld-ContribAuthor ">Piero  Marchetti</span>, <span class="hlFld-ContribAuthor ">Craig  Masse</span>, <span class="hlFld-ContribAuthor ">Wenyan  Miao</span>, <span class="hlFld-ContribAuthor ">Silvana  Leit</span>, <span class="hlFld-ContribAuthor ">Carmella  Evans‐Molina</span>, <span class="hlFld-ContribAuthor ">Decio L.  Eizirik</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta‐cell protection in type 1 diabetes. </span><span class="cited-content_cbyCitation_journal-name">Diabetes, Obesity and Metabolism</span><span> <strong>2020,</strong> <em>22 </em>
                                    (10)
                                     , 1827-1836. <a href="https://doi.org/10.1111/dom.14104" title="DOI URL">https://doi.org/10.1111/dom.14104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/dom.14104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fdom.14104%26sid%3Dliteratum%253Aachs%26jtitle%3DDiabetes%252C%2520Obesity%2520and%2520Metabolism%26atitle%3DPreclinical%252Bevaluation%252Bof%252Btyrosine%252Bkinase%252B2%252Binhibitors%252Bfor%252Bhuman%252Bbeta%2525E2%252580%252590cell%252Bprotection%252Bin%252Btype%252B1%252Bdiabetes%26aulast%3DCoomans%2Bde%2BBrach%25C3%25A8ne%26aufirst%3DAlexandra%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D10%26spage%3D1827%26epage%3D1836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Allosterische Kinaseinhibitoren – Erwartungen und Chancen. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (33)
                                     , 13868-13881. <a href="https://doi.org/10.1002/ange.201914525" title="DOI URL">https://doi.org/10.1002/ange.201914525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201914525%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DAllosterische%252BKinaseinhibitoren%252B%2525E2%252580%252593%252BErwartungen%252Bund%252BChancen%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D33%26spage%3D13868%26epage%3D13881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">New Promise and Opportunities for Allosteric Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (33)
                                     , 13764-13776. <a href="https://doi.org/10.1002/anie.201914525" title="DOI URL">https://doi.org/10.1002/anie.201914525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201914525%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DNew%252BPromise%252Band%252BOpportunities%252Bfor%252BAllosteric%252BKinase%252BInhibitors%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D33%26spage%3D13764%26epage%3D13776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua B.  Sheetz</span>, <span class="hlFld-ContribAuthor ">Sebastian  Mathea</span>, <span class="hlFld-ContribAuthor ">Hanna  Karvonen</span>, <span class="hlFld-ContribAuthor ">Ketan  Malhotra</span>, <span class="hlFld-ContribAuthor ">Deep  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Wilhelmiina  Niininen</span>, <span class="hlFld-ContribAuthor ">Robert  Perttilä</span>, <span class="hlFld-ContribAuthor ">Franziska  Preuss</span>, <span class="hlFld-ContribAuthor ">Krishna  Suresh</span>, <span class="hlFld-ContribAuthor ">Steven E.  Stayrook</span>, <span class="hlFld-ContribAuthor ">Yuko  Tsutsui</span>, <span class="hlFld-ContribAuthor ">Ravi  Radhakrishnan</span>, <span class="hlFld-ContribAuthor ">Daniela  Ungureanu</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Mark A.  Lemmon</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cell</span><span> <strong>2020,</strong> <em>79 </em>
                                    (3)
                                     , 390-405.e7. <a href="https://doi.org/10.1016/j.molcel.2020.06.018" title="DOI URL">https://doi.org/10.1016/j.molcel.2020.06.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molcel.2020.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molcel.2020.06.018%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cell%26atitle%3DStructural%252BInsights%252Binto%252BPseudokinase%252BDomains%252Bof%252BReceptor%252BTyrosine%252BKinases%26aulast%3DSheetz%26aufirst%3DJoshua%2BB.%26date%3D2020%26volume%3D79%26issue%3D3%26spage%3D390%26epage%3D405.e7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean Jacques  Vanden Eynde</span>, <span class="hlFld-ContribAuthor ">Arduino A.  Mangoni</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Jérôme  Leprince</span>, <span class="hlFld-ContribAuthor ">Yasu-Taka  Azuma</span>, <span class="hlFld-ContribAuthor ">Alfonso T.  García-Sosa</span>, <span class="hlFld-ContribAuthor ">Christopher  Hulme</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Paula A. C.  Gomes</span>, <span class="hlFld-ContribAuthor ">Dimitra  Hadjipavlou-Litina</span>, <span class="hlFld-ContribAuthor ">Raffaele  Capasso</span>, <span class="hlFld-ContribAuthor ">Athina  Geronikaki</span>, <span class="hlFld-ContribAuthor ">Laura  Cerchia</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Andrea  Trabocchi</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Winum</span>, <span class="hlFld-ContribAuthor ">F. Javier  Luque</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Mariana  Spetea</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Ivan  Kosalec</span>, <span class="hlFld-ContribAuthor ">Catherine  Guillou</span>, <span class="hlFld-ContribAuthor ">M. Helena  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>, <span class="hlFld-ContribAuthor ">Maria Emília  de Sousa</span>, <span class="hlFld-ContribAuthor ">Clementina  Manera</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>, <span class="hlFld-ContribAuthor ">Stefano  Mangani</span>, <span class="hlFld-ContribAuthor ">Carlo  Siciliano</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>, <span class="hlFld-ContribAuthor ">Cristóbal  de los Ríos</span>, <span class="hlFld-ContribAuthor ">Luigi A.  Agrofoglio</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Rita C.  Guedes</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (1)
                                     , 119. <a href="https://doi.org/10.3390/molecules25010119" title="DOI URL">https://doi.org/10.3390/molecules25010119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25010119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25010119%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525936%26aulast%3DVanden%2BEynde%26aufirst%3DJean%2BJacques%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D1%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katharina  Wöss</span>, <span class="hlFld-ContribAuthor ">Natalija  Simonović</span>, <span class="hlFld-ContribAuthor ">Birgit  Strobl</span>, <span class="hlFld-ContribAuthor ">Sabine  Macho-Maschler</span>, <span class="hlFld-ContribAuthor ">Mathias  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">TYK2: An Upstream Kinase of STATs in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (11)
                                     , 1728. <a href="https://doi.org/10.3390/cancers11111728" title="DOI URL">https://doi.org/10.3390/cancers11111728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11111728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11111728%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTYK2%25253A%252BAn%252BUpstream%252BKinase%252Bof%252BSTATs%252Bin%252BCancer%26aulast%3DW%25C3%25B6ss%26aufirst%3DKatharina%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D11%26spage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrada  Tomoni</span>, <span class="hlFld-ContribAuthor ">Jonathan  Lees</span>, <span class="hlFld-ContribAuthor ">Andrés G.  Santana</span>, <span class="hlFld-ContribAuthor ">Victor M.  Bolanos-Garcia</span>, <span class="hlFld-ContribAuthor ">Agatha  Bastida</span>. </span><span class="cited-content_cbyCitation_article-title">Pseudokinases: From Allosteric Regulation of Catalytic Domains and the Formation of Macromolecular Assemblies to Emerging Drug Targets. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2019,</strong> <em>9 </em>
                                    (9)
                                     , 778. <a href="https://doi.org/10.3390/catal9090778" title="DOI URL">https://doi.org/10.3390/catal9090778</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal9090778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal9090778%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DPseudokinases%25253A%252BFrom%252BAllosteric%252BRegulation%252Bof%252BCatalytic%252BDomains%252Band%252Bthe%252BFormation%252Bof%252BMacromolecular%252BAssemblies%252Bto%252BEmerging%252BDrug%252BTargets%26aulast%3DTomoni%26aufirst%3DAndrada%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D9%26spage%3D778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Previously reported TYK2 JH2 ligands and deck hit <b>4</b>. (a) SPA-binding assay. (b) HTRF displacement assay potency reported throughout the remainder of the communication. (c) <i>K</i><sub><i>i</i>,app</sub> determined using a Morrison titration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) NaHMDS, THF, room temperature 1 h; (b) Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 145 °C, 30–60 min; (c) RR′NH hydrochloride salt, <i>N</i>,<i>N</i>-diisopropylethylamine, HATU, DMF, 1 h (12–39%).</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of <b>5</b> bound to TYK2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZE">6NZE</a>). (a) Close-up of the binding site, highlighting hinge interactions. TYK2 JH2 ribbon and carbons in green. Carbons of <b>5</b> in magenta. Hydrogen bonds shown as dashed lines. (b) Rotated view of the binding site highlighting interactions of C2′ amide and the location of Ala671.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) (COCl)<sub>2</sub>, DMF, chloroform, 0 °C, 1 h; (b) (i) methylamine, chloroform, 0 °C, (76%), (ii) methyl-<i>d</i><sub>3</sub>-amine hydrochloride, triethylamine, DCM, 0 °C, 30 min, (74%), (iii) NH<sub>3</sub>, chloroform, 0 °C, (80%); (c) NaHMDS, THF, room temperature 1 h, (80%); (d) arylamine, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 145 °C, (12–33%).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) LiOH, THF, MeOH, rt 1 h; (b) Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 145 °C, 30 min; (c) HBr, AcOH, 110 °C, 4 h; (d) POCl<sub>3</sub>, NEt<sub>3</sub>, 110 °C, 2 h; (e) methylamine, THF, 0 °C, 1 h; (f) arylamine, NMP, HCl (for <b>20</b> and <b>22</b>), 120 °C, 16 h, (15–51%).</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) NaHMDS, THF, 15 min, (62–80%); (b) sodium tungstate dihydrate, AcOH, H<sub>2</sub>O<sub>2</sub>, 30 min, (68–89%); (c) NH<sub>2</sub>R″, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 145 °C, (7–62%).</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure of TYK2 JH2 bound with <b>23</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZF">6NZF</a>). (a) Close-up of the binding site, highlighting interactions between the C4 aniline and C2′ sulfone group. TYK2 JH2 ribbon and carbons in green. Carbons of <b>23</b> in magenta. Hydrogen bonds shown as dashed lines. (b) Surface representation of protein highlighting C2′sulfone methyl pocket. (c) Superposition of TYK2 JH2 structures bound with <b>5</b> (cyan) and <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of TYK2 JH2 bound with <b>40</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZH">6NZH</a>). (a) View mainly of hinge area. TYK2 JH2 ribbon and carbons in green. Carbons of <b>40</b> in magenta. Distances between the α-hydrogen of the cyclopropyl ring and the protein that are approximately 3 Å or less (and likely are favorable) are shown as dashed lines. (b) Cyclopropylamide as an isostere for 2-aminopyridine. Superposition of TYK2 JH2 structures bound with <b>23</b> (green) and <b>40</b>, only protein from complex with <b>40</b> is shown. (c) Surface representation of protein highlighting complementary binding groove for the cyclopropyl group (<b>40</b> shown in spherical representation).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) MeCN, 1 h; (b) PPh<sub>3</sub>, Et<sub>2</sub>O, 16 h; (c) AcOH, H<sub>2</sub>O, reflux, 6 h; (d) LiOH, THF, MeOH, H<sub>2</sub>O, 16 h; (e) POCl<sub>3</sub>, NEt<sub>3</sub>, 110 °C, 2 h; (f) methyl-<i>d</i><sub>3</sub>-amine hydrochloride, <i>N</i>,<i>N</i>′-diisopropylethylamine, THF, rt; (g) 2-(methylthio)aniline, NaHMDS, THF, 15 min; (h) sodium tungstate dihydrate, AcOH, H<sub>2</sub>O<sub>2</sub>, 30 min; (i) NH<sub>2</sub>R, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 130 °C, (44–88%).</p></p></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Dose–response of <b>48</b> in IL-12/IL-18 induced serum IFNγ production; vehicle, 5:5:90 EtOH:TPGS:PEG 300. (b) Exposures, multiples (mWB IC<sub>50</sub> = 130 nM), and % suppression relative to vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/medium/jm-2019-00443e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Dose-dependent response of inhibitor <b>48</b> in α-CD40 Ab induced IBD in SCID mice. (b) Histological evaluation dose–response of <b>48</b> in α-CD40 Ab induced colitis.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a><b>48</b> was dosed as a nanosuspension at 6, 19.2, and 60 mg/mL at the 25, 80, and 250 mg/kg doses, respectively. N/group = 5; *** <i>p</i> < 0.01 using one-way ANOVA and Dunnett’s post-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00443/20191018/images/large/jm-2019-00443e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00443&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i71">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34618" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34618" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lgMP1SOvYwI6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=R.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+Inhibition+as+a+Therapeutic+Strategy+for+Immune+and+Inflammatory+Diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lgMP1SOvYwI6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DR.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520Inhibition%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Immune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Type I/II Cytokines, JAKs, and New Strategies for Treating Autoimmune Diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+M.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Type+I%2FII+Cytokines%2C+JAKs%2C+and+New+Strategies+for+Treating+Autoimmune+Diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0lhYe81sAMIIWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DType%2520I%252FII%2520Cytokines%252C%2520JAKs%252C%2520and%2520New%2520Strategies%2520for%2520Treating%2520Autoimmune%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span>; <span class="NLM_string-name">Moslin, R.</span>; <span class="NLM_string-name">Lin, S.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Spergel, S.</span>; <span class="NLM_string-name">Kempson, J.</span>; <span class="NLM_string-name">Pitts, W. J.</span>; <span class="NLM_string-name">Tokarski, J.</span>; <span class="NLM_string-name">Strnad, J.</span>; <span class="NLM_string-name">Shuster, D.</span>; <span class="NLM_string-name">Gillooly, K.</span>; <span class="NLM_string-name">McIntyre, K. W.</span>; <span class="NLM_string-name">Zupa-Fernandez, A.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Chaudhry, C.</span>; <span class="NLM_string-name">Huang, C.</span>; <span class="NLM_string-name">D’Arienzo, C.</span>; <span class="NLM_string-name">Heimrich, E.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Muckelbauer, J. K.</span>; <span class="NLM_string-name">Chang, C.</span>; <span class="NLM_string-name">Tredup, J.</span>; <span class="NLM_string-name">Mulligan, D.</span>; <span class="NLM_string-name">Xia, D.</span>; <span class="NLM_string-name">Aranibar, N.</span>; <span class="NLM_string-name">Chimalakonda, A.</span>; <span class="NLM_string-name">Chiney, M.</span>; <span class="NLM_string-name">Carter, P. H.</span>; <span class="NLM_string-name">Burke, J. R.</span>; <span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span> <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00443</span> .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+T.+Wrobleski&author=R.+Moslin&author=S.+Lin&author=Y.+Zhang&author=S.+Spergel&author=J.+Kempson&author=W.+J.+Pitts&author=J.+Tokarski&author=J.+Strnad&author=D.+Shuster&author=K.+Gillooly&author=K.+W.+McIntyre&author=A.+Zupa-Fernandez&author=L.+Cheng&author=H.+Sun&author=C.+Chaudhry&author=C.+Huang&author=C.+D%E2%80%99Arienzo&author=E.+Heimrich&author=X.+Yang&author=J.+K.+Muckelbauer&author=C.+Chang&author=J.+Tredup&author=D.+Mulligan&author=D.+Xia&author=N.+Aranibar&author=A.+Chimalakonda&author=M.+Chiney&author=P.+H.+Carter&author=J.+R.+Burke&author=D.+S.+Weinstein&title=Highly+Selective+Inhibition+of+Tyrosine+Kinase+2+%28TYK2%29+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of+the+Allosteric+Inhibitor+BMS-986165&doi=10.1021%2Facs.jmedchem.9b00443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26atitle%3DHighly%2520Selective%2520Inhibition%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2520the%2520Allosteric%2520Inhibitor%2520BMS-986165%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26doi%3D10.1021%2Facs.jmedchem.9b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span> JAK1 deficient
mice die perinatally and suffer from neurological deficits:<span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meraz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampe, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, K. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennica, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R. D.</span></span> <span> </span><span class="NLM_article-title">Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">383</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81166-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2FS0092-8674%2800%2981166-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=9590172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=373-383&author=S.+J.+Rodigauthor=M.+A.+Merazauthor=J.+M.+Whiteauthor=P.+A.+Lampeauthor=J.+K.+Rileyauthor=C.+D.+Arthurauthor=K.+L.+Kingauthor=K.+C.+F.+Sheehanauthor=L.+Yinauthor=D.+Pennicaauthor=E.+M.+Johnsonauthor=R.+D.+Schreiber&title=Disruption+of+the+Jak1+Gene+Demonstrates+Obligatory+and+Nonredundant+Roles+of+the+Jaks+in+Cytokine-Induced+Biologic+Responses&doi=10.1016%2FS0092-8674%2800%2981166-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</span></div><div class="casAuthors">Rodig, Scott J.; Meraz, Marco A.; White, J. Michael; Lampe, Pat A.; Riley, Joan K.; Arthur, Cora D.; King, Kathleen L.; Sheehan, Kathleen C. F.; Yin, Li; Pennica, Diane; Johnson, Eugene M., Jr.; Schreiber, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">373-383</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Herein we report the generation of mice lacking the ubiquitously expressed Janus kinase, Jak1.  Jak1-/- mice are runted at birth, fail to nurse, and die perinatally.  Although Jak1-/- cells are responsive to many cytokines, they fail to manifest biol. responses to cytokines that bind to three distinct families of cytokine receptors.  These include all class II cytokine receptors, cytokine receptors that utilize the γc subunit for signaling, and the family of cytokine receptors that depend on the gp130 subunit for signaling.  Our results thus demonstrate that Jak1 plays an essential and nonredundant role in promoting biol. responses induced by a select subset of cytokine receptors, including those in which Jak utilization was thought to be nonspecific.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxGavQ7H-weLVg90H21EOLACvtfcHk0lhYe81sAMIIWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLs%253D&md5=c96007f46457346d3446a6ed2c2e0e07</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981166-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981166-6%26sid%3Dliteratum%253Aachs%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMeraz%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DLampe%26aufirst%3DP.%2BA.%26aulast%3DRiley%26aufirst%3DJ.%2BK.%26aulast%3DArthur%26aufirst%3DC.%2BD.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSheehan%26aufirst%3DK.%2BC.%2BF.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DPennica%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DDisruption%2520of%2520the%2520Jak1%2520Gene%2520Demonstrates%2520Obligatory%2520and%2520Nonredundant%2520Roles%2520of%2520the%2520Jaks%2520in%2520Cytokine-Induced%2520Biologic%2520Responses%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D373%26epage%3D383%26doi%3D10.1016%2FS0092-8674%2800%2981166-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span> JAK2 deficient mouse embryos are anemic
and die 12–13 days postcoitum:<span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffstadt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, K.</span></span> <span> </span><span class="NLM_article-title">Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81168-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2FS0092-8674%2800%2981168-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=9590174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+M%C3%BCllerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+Deficiency+Defines+an+Essential+Developmental+Checkpoint+in+Definitive+Hematopoiesis&doi=10.1016%2FS0092-8674%2800%2981168-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span></div><div class="casAuthors">Neubauer, Hans; Cumano, Ana; Muller, Mathias; Wu, Hong; Huffstadt, Ulrike; Pfeffer, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors.  A targeted inactivation of Jak2 was performed.  Jak2-/- embryos are anemic and die around day 12.5 postcoitum.  Primitive erythrocytes are found, but definitive erythropoiesis is absent.  Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe.  Fetal liver BFU-E and CFU-E colonies are completely absent.  However, multilineage hematopoietic stem cells (CD34low, c-kitpos) can be found, and B lymphopoiesis appears intact.  In contrast to IFNα stimulation, Jak2-/- cells do not respond to IFNγ.  Jak2-/- embryonic stem cells are competent for LIF signaling.  The data provided demonstrate that Jak2 has pivotal functions for signal transduction of a set of cytokine receptors required in definitive erythropoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8oeTh0n3FcbVg90H21EOLACvtfcHk0liCRQljcj4vpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D&md5=74275b73c807331170c096145e69af94</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981168-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981168-X%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520Deficiency%2520Defines%2520an%2520Essential%2520Developmental%2520Checkpoint%2520in%2520Definitive%2520Hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D397%26epage%3D409%26doi%3D10.1016%2FS0092-8674%2800%2981168-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Deursen, J. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thierfelder, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witthuhn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMickle, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosveld, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, J. N.</span></span> <span> </span><span class="NLM_article-title">Defective Lymphoid Development in Mice Lacking Jak3</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">800</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1126/science.270.5237.800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1126%2Fscience.270.5237.800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=7481769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK2MXptV2isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=800-802&author=T.+Nosakaauthor=J.+M.+A.+van+Deursenauthor=R.+A.+Trippauthor=W.+E.+Thierfelderauthor=B.+A.+Witthuhnauthor=A.+P.+McMickleauthor=P.+C.+Dohertyauthor=G.+C.+Grosveldauthor=J.+N.+Ihle&title=Defective+Lymphoid+Development+in+Mice+Lacking+Jak3&doi=10.1126%2Fscience.270.5237.800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Defective lymphoid development in mice lacking Jak3</span></div><div class="casAuthors">Nosaka, Tetsuya; van Deursen, Jan M. A.; Tripp, Ralph A.; Thierfelder, William E.; Witthuhn, Bruce A.; McMickle, Anthony P.; Doherty, Peter C.; Grosveld, Gerard; Ihle, James N.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5237</span>),
    <span class="NLM_cas:pages">800-2</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The Janus tyrosine kinases (Jaks) play a central role in signaling through cytokine receptors.  Although Jak1, Jak2, and Tyk2 are widely expressed, Jak3 is predominantly expressed in hematopoietic cells and is known to assoc. only with the common γ (γc) chain of the interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15 receptors.  Homozygous mutant mice in which the Jak3 gene had been disrupted were generated by gene targeting.  Jak3-deficient mice had profound redns. in thymocytes and severe B cell and T cell lymphopenia similar to severe combined immunodeficiency disease (SCID), and the residual T cells and B cells were functionally deficient.  Thus, Jak3 plays a crit. role in γc signaling and lymphoid development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop_pvDKJAxprVg90H21EOLACvtfcHk0liCRQljcj4vpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptV2isr0%253D&md5=5b96bcb02a748be8b4df4a3ea7337867</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5237.800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5237.800%26sid%3Dliteratum%253Aachs%26aulast%3DNosaka%26aufirst%3DT.%26aulast%3Dvan%2BDeursen%26aufirst%3DJ.%2BM.%2BA.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26aulast%3DThierfelder%26aufirst%3DW.%2BE.%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DMcMickle%26aufirst%3DA.%2BP.%26aulast%3DDoherty%26aufirst%3DP.%2BC.%26aulast%3DGrosveld%26aufirst%3DG.%2BC.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DDefective%2520Lymphoid%2520Development%2520in%2520Mice%2520Lacking%2520Jak3%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D800%26epage%3D802%26doi%3D10.1126%2Fscience.270.5237.800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyamada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikebe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itsumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiwai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, H.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">7539</span>– <span class="NLM_lpage">7546</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0902740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.4049%2Fjimmunol.0902740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=19917699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVehtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2009&pages=7539-7546&author=A.+Oyamadaauthor=H.+Ikebeauthor=M.+Itsumiauthor=H.+Saiwaiauthor=S.+Okadaauthor=K.+Shimodaauthor=Y.+Iwakuraauthor=K.+I.+Nakayamaauthor=Y.+Iwamotoauthor=Y.+Yoshikaiauthor=H.+Yamada&title=Tyrosine+Kinase+2+Plays+Critical+Roles+in+the+Pathogenic+CD4+T+Cell+Responses+for+the+Development+of+Experimental+Autoimmune+Encephalomyelitis&doi=10.4049%2Fjimmunol.0902740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase 2 Plays Critical Roles in the Pathogenic CD4 T Cell Responses for the Development of Experimental Autoimmune Encephalomyelitis</span></div><div class="casAuthors">Oyamada, Akiko; Ikebe, Hiori; Itsumi, Momoe; Saiwai, Hirokazu; Okada, Seiji; Shimoda, Kazuya; Iwakura, Yoichiro; Nakayama, Keiichi I.; Iwamoto, Yukihide; Yoshikai, Yasunobu; Yamada, Hisakata</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7539-7546</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2), a member of the JAK family, is involved in IL-12- and IL-23-mediated signaling.  In the present study, we examd. the roles of Tyk2 in the development of myelin oligodendrocyte glycoprotein (MOG)-induced exptl. autoimmune encephalomyelitis (EAE) by using Tyk2 knockout (KO) mice.  In vitro differentiation of Th1 but not Th17 cells was severely impaired in Tyk2 KO CD4 T cells, although Tyk2 KO Th17 cells did not respond to IL-23.  Tyk2 KO mice showed complete resistance against EAE with no infiltration of CD4 T cells in the spinal cord.  Surprisingly, the no. of MOG-specific Th17 cells in the periphery was comparable between KO and wild-type (WT) mice, whereas Th1 cells were greatly reduced in Tyk2 KO mice.  Adoptive transfer of MOG-primed WT T cells induced EAE in Tyk2 KO recipients, indicating that Tyk2 in the environment was dispensable for the infiltration of effector T cells into the spinal cord.  A reduced but significant no. of Tyk2 KO T cells were detected in the spinal cord of mice with EAE, which had been reconstituted with bone marrow cells of WT and KO mice.  Furthermore, MOG-immunized Tyk2 KO mice developed EAE after adoptive transfer of MOG-primed WT Th1 cells, which might trigger local inflammation that recruits Th17 cells.  Taken together, these results indicate that Tyk2 is critically involved in the pathogenic CD4 T cell responses and thus could be a target mol. for the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0gM6rPFuApLVg90H21EOLACvtfcHk0lhEgFlD2_kzzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVehtrrE&md5=05bba19010fbdffbb10b751a1dda16fb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902740%26sid%3Dliteratum%253Aachs%26aulast%3DOyamada%26aufirst%3DA.%26aulast%3DIkebe%26aufirst%3DH.%26aulast%3DItsumi%26aufirst%3DM.%26aulast%3DSaiwai%26aufirst%3DH.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DIwakura%26aufirst%3DY.%26aulast%3DNakayama%26aufirst%3DK.%2BI.%26aulast%3DIwamoto%26aufirst%3DY.%26aulast%3DYoshikai%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DH.%26atitle%3DTyrosine%2520Kinase%25202%2520Plays%2520Critical%2520Roles%2520in%2520the%2520Pathogenic%2520CD4%2520T%2520Cell%2520Responses%2520for%2520the%2520Development%2520of%2520Experimental%2520Autoimmune%2520Encephalomyelitis%26jtitle%3DJ.%2520Immunol.%26date%3D2009%26volume%3D183%26spage%3D7539%26epage%3D7546%26doi%3D10.4049%2Fjimmunol.0902740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeltz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevach, E. M.</span></span> <span> </span><span class="NLM_article-title">A Heritable Defect in IL-12 Signaling in B10.Q/J Mice. I. In Vitro Analysis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">5712</span>– <span class="NLM_lpage">5719</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.166.9.5712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.4049%2Fjimmunol.166.9.5712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=11313413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFyqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2001&pages=5712-5719&author=R.+Ortmannauthor=R.+Smeltzauthor=G.+Yapauthor=A.+Sherauthor=E.+M.+Shevach&title=A+Heritable+Defect+in+IL-12+Signaling+in+B10.Q%2FJ+Mice.+I.+In+Vitro+Analysis&doi=10.4049%2Fjimmunol.166.9.5712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis</span></div><div class="casAuthors">Ortmann, Robert; Smeltz, Ronald; Yap, George; Sher, Alan; Shevach, Ethan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5712-5719</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">B10.Q mice are normally susceptible to the induction of collagen-induced arthritis.  The authors noted that one subline of B10.Q mice, B10.Q/J, was completely resistant to disease induction when immunized with collagen in CFA.  B10.Q/J mice have a global defect in the generation of Th1 responses, and antigen-specific T cells derived from this strain failed to produce IFN-γ.  Because T cells from these mice could produce normal amts. of IFN-γ when activated by IL-12/IL-18-independent stimuli, the defect appeared to be a failure to respond to IL-12.  This defect extended to NK cells, which also failed to produce IFN-γ when stimulated by IL-12.  The capacity of NK cells, but not activated T cells, to produce IFN-γ in response to IL-12 could be partially restored by IL-18.  The expression of the IL-12R β1- and β2-chains on T cells and NK cells from B10.Q/J mice was normal.  However, activated T cells from B10.Q/J mice did not signal normally through the IL-12R and manifested a defect in their capacity to phosphorylate Stat4.  This defect was partial in that it could be overcome by increasing both the concn. of IL-12 and the incubation times in the Stat4 phosphorylation assays.  Because Stat4 function is apparently intact in B10.Q/J mice, the defect in IL-12 signaling can be localized between the IL-12R complex and Stat4.  This subtle abnormality in IL-12 responsiveness results in a profound defect in the generation of Th1 cells and the development of autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnzWn-o1wME7Vg90H21EOLACvtfcHk0lhEgFlD2_kzzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFyqsr4%253D&md5=bf724d444e9db709a3a40fc251b73d40</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.166.9.5712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.166.9.5712%26sid%3Dliteratum%253Aachs%26aulast%3DOrtmann%26aufirst%3DR.%26aulast%3DSmeltz%26aufirst%3DR.%26aulast%3DYap%26aufirst%3DG.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DShevach%26aufirst%3DE.%2BM.%26atitle%3DA%2520Heritable%2520Defect%2520in%2520IL-12%2520Signaling%2520in%2520B10.Q%252FJ%2520Mice.%2520I.%2520In%2520Vitro%2520Analysis%26jtitle%3DJ.%2520Immunol.%26date%3D2001%26volume%3D166%26spage%3D5712%26epage%3D5719%26doi%3D10.4049%2Fjimmunol.166.9.5712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agematsu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuge, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yachie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessho, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujieda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakiguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abinun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belohradsky, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyawaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karasuyama, H.</span></span> <span> </span><span class="NLM_article-title">Human Tyrosine Kinase 2 Deficiency Reveals its Requisite Roles in Multiple Cytokine Signals Involved in Innate and Acquired Immunity</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2006.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.immuni.2006.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=17088085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=745-755&author=Y.+Minegishiauthor=M.+Saitoauthor=T.+Morioauthor=K.+Watanabeauthor=K.+Agematsuauthor=S.+Tsuchiyaauthor=H.+Takadaauthor=T.+Haraauthor=N.+Kawamuraauthor=T.+Arigaauthor=H.+Kanekoauthor=N.+Kondoauthor=I.+Tsugeauthor=A.+Yachieauthor=Y.+Sakiyamaauthor=T.+Iwataauthor=F.+Besshoauthor=T.+Ohishiauthor=K.+Johauthor=K.+Imaiauthor=K.+Kogawaauthor=M.+Shinoharaauthor=M.+Fujiedaauthor=H.+Wakiguchiauthor=S.+Pasicauthor=M.+Abinunauthor=H.+D.+Ochsauthor=E.+D.+Rennerauthor=A.+Janssonauthor=B.+H.+Belohradskyauthor=A.+Metinauthor=N.+Shimizuauthor=S.+Mizutaniauthor=T.+Miyawakiauthor=S.+Nonoyamaauthor=H.+Karasuyama&title=Human+Tyrosine+Kinase+2+Deficiency+Reveals+its+Requisite+Roles+in+Multiple+Cytokine+Signals+Involved+in+Innate+and+Acquired+Immunity&doi=10.1016%2Fj.immuni.2006.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity</span></div><div class="casAuthors">Minegishi, Yoshiyuki; Saito, Masako; Morio, Tomohiro; Watanabe, Ken; Agematsu, Kazunaga; Tsuchiya, Shigeru; Takada, Hidetoshi; Hara, Toshiro; Kawamura, Nobuaki; Ariga, Tadashi; Kaneko, Hideo; Kondo, Naomi; Tsuge, Ikuya; Yachie, Akihiro; Sakiyama, Yukio; Iwata, Tsutomu; Bessho, Fumio; Ohishi, Tsutomu; Joh, Kosuke; Imai, Kohsuke; Kogawa, Kazuhiro; Shinohara, Miwa; Fujieda, Mikiya; Wakiguchi, Hiroshi; Pasic, Srdjan; Abinun, Mario; Ochs, Hans D.; Renner, Eleonore D.; Jansson, Annette; Belohradsky, Bernd H.; Metin, Ayse; Shimizu, Norio; Mizutani, Shuki; Miyawaki, Toshio; Nonoyama, Shigeaki; Karasuyama, Hajime</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tyrosine kinase 2 (Tyk2) is a nonreceptor tyrosine kinase that belongs to the Janus kinase (Jak) family.  Here we identified a homozygous Tyk2 mutation in a patient who had been clin. diagnosed with hyper-IgE syndrome.  This patient showed unusual susceptibility to various microorganisms including virus, fungi, and mycobacteria and suffered from atopic dermatitis with elevated serum IgE.  The patient's cells displayed defects in multiple cytokine signaling pathways including those for type I interferon (IFN), interleukin (IL)-6, IL-10, IL-12, and IL-23.  The cytokine signals were successfully restored by transducing the intact Tyk2 gene.  Thus, the Tyk2 deficiency is likely to account for the patient's complex clin. manifestations, including the phenotype of impaired T helper 1 (Th1) differentiation and accelerated Th2 differentiation.  This study identifies human Tyk2 deficiency and demonstrates that Tyk2 plays obligatory roles in multiple cytokine signals involved in innate and acquired immunity of humans, which differs substantially from Tyk2 function in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TTbAIzXM-bVg90H21EOLACvtfcHk0li-2cIAEnoVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Gnt7zI&md5=debec30b44a7e1dc111d7cfb1c92f7dd</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2006.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2006.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DMorio%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAgematsu%26aufirst%3DK.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DN.%26aulast%3DAriga%26aufirst%3DT.%26aulast%3DKaneko%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DN.%26aulast%3DTsuge%26aufirst%3DI.%26aulast%3DYachie%26aufirst%3DA.%26aulast%3DSakiyama%26aufirst%3DY.%26aulast%3DIwata%26aufirst%3DT.%26aulast%3DBessho%26aufirst%3DF.%26aulast%3DOhishi%26aufirst%3DT.%26aulast%3DJoh%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DKogawa%26aufirst%3DK.%26aulast%3DShinohara%26aufirst%3DM.%26aulast%3DFujieda%26aufirst%3DM.%26aulast%3DWakiguchi%26aufirst%3DH.%26aulast%3DPasic%26aufirst%3DS.%26aulast%3DAbinun%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DRenner%26aufirst%3DE.%2BD.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DBelohradsky%26aufirst%3DB.%2BH.%26aulast%3DMetin%26aufirst%3DA.%26aulast%3DShimizu%26aufirst%3DN.%26aulast%3DMizutani%26aufirst%3DS.%26aulast%3DMiyawaki%26aufirst%3DT.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DKarasuyama%26aufirst%3DH.%26atitle%3DHuman%2520Tyrosine%2520Kinase%25202%2520Deficiency%2520Reveals%2520its%2520Requisite%2520Roles%2520in%2520Multiple%2520Cytokine%2520Signals%2520Involved%2520in%2520Innate%2520and%2520Acquired%2520Immunity%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26spage%3D745%26epage%3D755%26doi%3D10.1016%2Fj.immuni.2006.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kreins, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciancanelli, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramírez-Alejo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Baghdadi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonoyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahdaviani, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ailal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousfiha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nievas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehn, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deveau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Azbaoui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halwani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogunovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moncada-Velez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Barricarte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migaud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deswarte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotlarz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Fleckenstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleckenstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cormier-Daire, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose-John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarstrom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Muhsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaussabel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangye, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustamante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisson-Dupuis, S.</span></span> <span> </span><span class="NLM_article-title">Human TYK2 Deficiency: Mycobacterial and Viral Infections Without Hyper-IgE Syndrome</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">1641</span>– <span class="NLM_lpage">1662</span>, <span class="refDoi"> DOI: 10.1084/jem.20140280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1084%2Fjem.20140280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=26304966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Wjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=1641-1662&author=A.+Y.+Kreinsauthor=M.+J.+Ciancanelliauthor=S.+Okadaauthor=X.-F.+Kongauthor=N.+Ram%C3%ADrez-Alejoauthor=S.+S.+Kilicauthor=J.+El+Baghdadiauthor=S.+Nonoyamaauthor=S.+A.+Mahdavianiauthor=F.+Ailalauthor=A.+Bousfihaauthor=D.+Mansouriauthor=E.+Nievasauthor=C.+S.+Maauthor=G.+Raoauthor=A.+Bernasconiauthor=H.+S.+Kuehnauthor=J.+Niemelaauthor=J.+Stoddardauthor=P.+Deveauauthor=A.+Cobatauthor=S.+El+Azbaouiauthor=A.+Sabriauthor=C.+K.+Limauthor=M.+Sundinauthor=D.+T.+Averyauthor=R.+Halwaniauthor=A.+V.+Grantauthor=B.+Boissonauthor=D.+Bogunovicauthor=Y.+Itanauthor=M.+Moncada-Velezauthor=R.+Martinez-Barricarteauthor=M.+Migaudauthor=C.+Deswarteauthor=L.+Alsinaauthor=D.+Kotlarzauthor=C.+Kleinauthor=I.+Muller-Fleckensteinauthor=B.+Fleckensteinauthor=V.+Cormier-Daireauthor=S.+Rose-Johnauthor=C.+Picardauthor=L.+Hammarstromauthor=A.+Puelauthor=S.+Al-Muhsenauthor=L.+Abelauthor=D.+Chaussabelauthor=S.+D.+Rosenzweigauthor=Y.+Minegishiauthor=S.+G.+Tangyeauthor=J.+Bustamanteauthor=J.-L.+Casanovaauthor=S.+Boisson-Dupuis&title=Human+TYK2+Deficiency%3A+Mycobacterial+and+Viral+Infections+Without+Hyper-IgE+Syndrome&doi=10.1084%2Fjem.20140280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome</span></div><div class="casAuthors">Kreins, Alexandra Y.; Ciancanelli, Michael J.; Okada, Satoshi; Kong, Xiao-Fei; Ramirez-Alejo, Noe; Kilic, Sara Sebnem; El Bagjhdadi, Jamila; Nonoyama, Shigeaki; Mahdaviani, Seyed Alireza; Ailal, Fatima; Bousfiha, Aziz; Mansouri, Davood; Nievas, Elma; Ma, Cindy S.; Rao, Geetha; Bernasconi, Andrea; Kuehn, Hye Sun; Niemela, Julie; Stoddard, Jennifer; Deveau, Paul; Cobat, Aurelie; El Azbaoui, Safe; Sabri, Ayoub; lim, Che Kang; Sundin, Mikael; Avery, Danielle T.; Halwani, Rabih; Grant, Audrey V.; Boisson, Bertrand; Bogunovic, Dusan; Itan, Yuval; Moncada-Velez, Marcela; Martinez-Barricarte, Ruben; Migaud, Melanie; Deswarte, Caroline; Alsina, Laia; Kotlarz, Daniel; Klein, Christoph; Muller-Fleckenstein, Ingrid; Fleckenstein, Bernhard; Cormier-Daire, Valerie; Rose-John, Stefen; Picard, Capucine; Hammarstrom, Lennart; Puel, Anne; Al-Muhsen, Saleh; Abel, Laurent; Chaussabel, Damien; Rosenzweig, Sergio D.; Minegishi, Yoshiyuki; Tangye, Stuart G.; Bustamante, Jacinta; Casanova, Jean-Laurent; Boisson-Dupuis, Stephanie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1641-1662</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Autosomal recessive, complete TYK2 deficiency was previously described in a patient (P1) with intracellular bacterial and viral infections and features of hyper-IgE syndrome (HIES), including atopic dermatitis, high serum IgE levels, and staphylococcal abscesses.  We identified seven other TYK2-deficient patients from five families and four different ethnic groups.  These patients were homozygous for one of five null mutations, different from that seen in P1.  They displayed mycobacterial and/or viral infections, but no HIES.  All eight TYK2-deficient patients displayed impaired but not abolished cellular responses to (a) IL-12 and IFN-α/ β, accounting for mycobacterial and viral infections, resp.; (b) IL-23, with normal proportions of circulating IL-17+ T cells, accounting for their apparent lack of mucocutaneous candidiasis; and (c) IL-10, with no overt clin. consequences, including a lack of inflammatory bowel disease.  Cellular responses to IL-21, IL-27, IFN-γ, IL-28/29 (IFN-λ), and leukemia inhibitory factor (LIF) were normal.  The leukocytes and fibroblasts of all seven newly identified TYK2-deficient patients, unlike those of P1, responded normally to IL-G, possibly accounting for the lack of HIES in these patients.  The expression of exogenous wild-type TYK2 or the silencing of endogenous TYK2 did not rescue IL-6 hyporesponsiveness, suggesting that this phenotype was not a consequence of the TYK2 genotype.  The core clin. phenotype of TYK2 deficiency is mycobacterial and/or viral infections, caused by impaired responses to IL-12 and IFN-α/β.  Moreover, impaired IL-6 responses and HIES do not appear to be intrinsic features of TYK2 deficiency in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqcrqmRKkmKbVg90H21EOLACvtfcHk0li-2cIAEnoVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Wjtbo%253D&md5=d5916cdd4b0ebe7f613a824292cf1c6c</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1084%2Fjem.20140280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20140280%26sid%3Dliteratum%253Aachs%26aulast%3DKreins%26aufirst%3DA.%2BY.%26aulast%3DCiancanelli%26aufirst%3DM.%2BJ.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DX.-F.%26aulast%3DRam%25C3%25ADrez-Alejo%26aufirst%3DN.%26aulast%3DKilic%26aufirst%3DS.%2BS.%26aulast%3DEl%2BBaghdadi%26aufirst%3DJ.%26aulast%3DNonoyama%26aufirst%3DS.%26aulast%3DMahdaviani%26aufirst%3DS.%2BA.%26aulast%3DAilal%26aufirst%3DF.%26aulast%3DBousfiha%26aufirst%3DA.%26aulast%3DMansouri%26aufirst%3DD.%26aulast%3DNievas%26aufirst%3DE.%26aulast%3DMa%26aufirst%3DC.%2BS.%26aulast%3DRao%26aufirst%3DG.%26aulast%3DBernasconi%26aufirst%3DA.%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DNiemela%26aufirst%3DJ.%26aulast%3DStoddard%26aufirst%3DJ.%26aulast%3DDeveau%26aufirst%3DP.%26aulast%3DCobat%26aufirst%3DA.%26aulast%3DEl%2BAzbaoui%26aufirst%3DS.%26aulast%3DSabri%26aufirst%3DA.%26aulast%3DLim%26aufirst%3DC.%2BK.%26aulast%3DSundin%26aufirst%3DM.%26aulast%3DAvery%26aufirst%3DD.%2BT.%26aulast%3DHalwani%26aufirst%3DR.%26aulast%3DGrant%26aufirst%3DA.%2BV.%26aulast%3DBoisson%26aufirst%3DB.%26aulast%3DBogunovic%26aufirst%3DD.%26aulast%3DItan%26aufirst%3DY.%26aulast%3DMoncada-Velez%26aufirst%3DM.%26aulast%3DMartinez-Barricarte%26aufirst%3DR.%26aulast%3DMigaud%26aufirst%3DM.%26aulast%3DDeswarte%26aufirst%3DC.%26aulast%3DAlsina%26aufirst%3DL.%26aulast%3DKotlarz%26aufirst%3DD.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DMuller-Fleckenstein%26aufirst%3DI.%26aulast%3DFleckenstein%26aufirst%3DB.%26aulast%3DCormier-Daire%26aufirst%3DV.%26aulast%3DRose-John%26aufirst%3DS.%26aulast%3DPicard%26aufirst%3DC.%26aulast%3DHammarstrom%26aufirst%3DL.%26aulast%3DPuel%26aufirst%3DA.%26aulast%3DAl-Muhsen%26aufirst%3DS.%26aulast%3DAbel%26aufirst%3DL.%26aulast%3DChaussabel%26aufirst%3DD.%26aulast%3DRosenzweig%26aufirst%3DS.%2BD.%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DTangye%26aufirst%3DS.%2BG.%26aulast%3DBustamante%26aufirst%3DJ.%26aulast%3DCasanova%26aufirst%3DJ.-L.%26aulast%3DBoisson-Dupuis%26aufirst%3DS.%26atitle%3DHuman%2520TYK2%2520Deficiency%253A%2520Mycobacterial%2520and%2520Viral%2520Infections%2520Without%2520Hyper-IgE%2520Syndrome%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2015%26volume%3D212%26spage%3D1641%26epage%3D1662%26doi%3D10.1084%2Fjem.20140280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Couturier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucciarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurtdinov, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debouverie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebrun-Frenay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Confavreux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukusic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cournu-Rebeix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goertsches, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zettl, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comabella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieckmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Myhsok, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mars, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saoudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksenberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clanet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liblau, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassat, D.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2 Variant Influences T Lymphocyte Polarization and Multiple Sclerosis Susceptibility</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1093/brain/awr010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1093%2Fbrain%2Fawr010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=21354972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A280%3ADC%252BC3M3it1alsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2011&pages=693-703&author=N.+Couturierauthor=F.+Bucciarelliauthor=R.+N.+Nurtdinovauthor=M.+Debouverieauthor=C.+Lebrun-Frenayauthor=G.+Deferauthor=T.+Moreauauthor=C.+Confavreuxauthor=S.+Vukusicauthor=I.+Cournu-Rebeixauthor=R.+H.+Goertschesauthor=U.+K.+Zettlauthor=M.+Comabellaauthor=X.+Montalbanauthor=P.+Rieckmannauthor=F.+Weberauthor=B.+M%C3%BCller-Myhsokauthor=G.+Edanauthor=B.+Fontaineauthor=L.+T.+Marsauthor=A.+Saoudiauthor=J.+R.+Oksenbergauthor=M.+Clanetauthor=R.+S.+Liblauauthor=D.+Brassat&title=Tyrosine+Kinase+2+Variant+Influences+T+Lymphocyte+Polarization+and+Multiple+Sclerosis+Susceptibility&doi=10.1093%2Fbrain%2Fawr010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility</span></div><div class="casAuthors">Couturier Nicolas; Bucciarelli Florence; Nurtdinov Ramil N; Debouverie Marc; Lebrun-Frenay Christine; Defer Gilles; Moreau Thibault; Confavreux Christian; Vukusic Sandra; Cournu-Rebeix Isabelle; Goertsches Robert H; Zettl Uwe K; Comabella Manuel; Montalban Xavier; Rieckmann Peter; Weber Frank; Muller-Myhsok Bertram; Edan Gilles; Fontaine Bertrand; Mars Lennart T; Saoudi Abdelhadi; Oksenberg Jorge R; Clanet Michel; Liblau Roland S; Brassat David</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">Pt 3</span>),
    <span class="NLM_cas:pages">693-703</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tyrosine kinase 2 variant rs34536443 has been established as a genetic risk factor for multiple sclerosis in a variety of populations.  However, the functional effect of this variant on disease pathogenesis remains unclear.  This study replicated the genetic association of tyrosine kinase 2 with multiple sclerosis in a cohort of 1366 French patients and 1802 controls.  Furthermore, we assessed the functional consequences of this polymorphism on human T lymphocytes by comparing the reactivity and cytokine profile of T lymphocytes isolated from individuals expressing the protective TYK2(GC) genotype with the disease-associated TYK2(GG) genotype.  Our results demonstrate that the protective C allele infers decreased tyrosine kinase 2 activity, and this reduction of activity is associated with a shift in the cytokine profile favouring the secretion of Th2 cytokines.  These findings suggest that the rs34536443 variant effect on multiple sclerosis susceptibility might be mediated by deviating T lymphocyte differentiation toward a Th2 phenotype.  This impact of tyrosine kinase 2 on effector differentiation is likely to be of wider importance because other autoimmune diseases also have been associated with polymorphisms within tyrosine kinase 2.  The modulation of tyrosine kinase 2 activity might therefore represent a new therapeutic approach for the treatment of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAUtIRbYJEbJp6t8nS6Nc3fW6udTcc2ebBcHbFsmb5j7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3it1alsA%253D%253D&md5=f5a12ce5f485067a22d821552f1a1bde</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawr010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawr010%26sid%3Dliteratum%253Aachs%26aulast%3DCouturier%26aufirst%3DN.%26aulast%3DBucciarelli%26aufirst%3DF.%26aulast%3DNurtdinov%26aufirst%3DR.%2BN.%26aulast%3DDebouverie%26aufirst%3DM.%26aulast%3DLebrun-Frenay%26aufirst%3DC.%26aulast%3DDefer%26aufirst%3DG.%26aulast%3DMoreau%26aufirst%3DT.%26aulast%3DConfavreux%26aufirst%3DC.%26aulast%3DVukusic%26aufirst%3DS.%26aulast%3DCournu-Rebeix%26aufirst%3DI.%26aulast%3DGoertsches%26aufirst%3DR.%2BH.%26aulast%3DZettl%26aufirst%3DU.%2BK.%26aulast%3DComabella%26aufirst%3DM.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DRieckmann%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DM%25C3%25BCller-Myhsok%26aufirst%3DB.%26aulast%3DEdan%26aufirst%3DG.%26aulast%3DFontaine%26aufirst%3DB.%26aulast%3DMars%26aufirst%3DL.%2BT.%26aulast%3DSaoudi%26aufirst%3DA.%26aulast%3DOksenberg%26aufirst%3DJ.%2BR.%26aulast%3DClanet%26aufirst%3DM.%26aulast%3DLiblau%26aufirst%3DR.%2BS.%26aulast%3DBrassat%26aufirst%3DD.%26atitle%3DTyrosine%2520Kinase%25202%2520Variant%2520Influences%2520T%2520Lymphocyte%2520Polarization%2520and%2520Multiple%2520Sclerosis%2520Susceptibility%26jtitle%3DBrain%26date%3D2011%26volume%3D134%26spage%3D693%26epage%3D703%26doi%3D10.1093%2Fbrain%2Fawr010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 Locus Genotype-to-Phenotype Differences in Autoimmunity</span>. <i>Science Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=27807284" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.+A.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+Locus+Genotype-to-Phenotype+Differences+in+Autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520Locus%2520Genotype-to-Phenotype%2520Differences%2520in%2520Autoimmunity%26jtitle%3DScience%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span> For a review of the use of Ustekinumab in psoriasis and psoriatic
arthritis, see:<span class="NLM_contrib-group"><span class="NLM_string-name">Croxtall, J. D.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab: A Review of its use in the Management of Moderate to Severe Plaque Psoriasis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1733</span>– <span class="NLM_lpage">1753</span>, <span class="refDoi"> DOI: 10.2165/11207530-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.2165%2F11207530-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=21902296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1733-1753&author=J.+D.+Croxtall&title=Ustekinumab%3A+A+Review+of+its+use+in+the+Management+of+Moderate+to+Severe+Plaque+Psoriasis&doi=10.2165%2F11207530-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis</span></div><div class="casAuthors">Croxtall, Jamie D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1733-1753</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Ustekinumab (Stelara) is a human monoclonal antibody that binds to the p40 subunit common to both interleukin (IL)-12 and IL-23.  It is indicated in the US for use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.  In the EU, it is indicated for those who failed to respond to, have a contraindication to or are intolerant of other systemic therapies or phototherapy.  This article reviews the efficacy and tolerability of ustekinumab in patients with moderate to severe plaque psoriasis, as well as summarizing its pharmacol. properties.  Ustekinumab attenuates the immune cell activation properties of IL-12 and IL-23.  It interrupts the abnormal activation of signalling and cytokine cascades that underlie the pathol. of psoriasis by reducing the expression of IL-12- and IL-23-induced cell surface markers that mediate skin homing, activation and cytokine release.  In well designed, randomized clin. trials, regimens of s.c. ustekinumab 45 or 90 mg provided a rapid and durable improvement in psoriasis area severity index (PASI) scores for patients with moderate to severe plaque psoriasis.  A significantly greater proportion of patients receiving ustekinuman 45 or 90 mg compared with those receiving placebo achieved a ≥75% improvement from baseline in PASI score following 12 wk' treatment (primary endpoint).  Improvements in PASI scores were evident following 2 wk' treatment with ustekinumab and were sustained for up to 3 years.  Treatment with ustekinumab 45 or 90 mg also improved health-related quality-of-life scores from baseline.  Following 12 wk' treatment, ustekinumab 45 or 90 mg was more effective than etanercept 50 mg twice weekly in providing symptomatic relief for patients with moderate to severe plaque psoriasis.  Furthermore, ustekinumab treatment provided effective symptomatic improvement for almost half of the patients who showed no response to 12 wk' treatment with etanercept.  More limited data indicate that ustekinumab also improves the symptoms of arthritis in patients with plaque psoriasis and psoriatic arthritis.  S.c. ustekinumab was generally well tolerated in clin. trials; most adverse events were mild in intensity and did not require dosage adjustment.  A pooled anal. of clin. trial data indicated no specific patterns of infection for recipients of ustekinumab and that infection rates remained stable following cumulative exposure to the agent.  In conclusion, s.c. ustekinumab provides an effective and well tolerated alternative for the symptomatic treatment of patients with moderate to severe plaque psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_Ypb6QpOVSrVg90H21EOLACvtfcHk0lhCIlt0XQLd8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtr7E&md5=adc553a889d647c9fd00aea59040c01b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2165%2F11207530-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11207530-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DCroxtall%26aufirst%3DJ.%2BD.%26atitle%3DUstekinumab%253A%2520A%2520Review%2520of%2520its%2520use%2520in%2520the%2520Management%2520of%2520Moderate%2520to%2520Severe%2520Plaque%2520Psoriasis%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D1733%26epage%3D1753%26doi%3D10.2165%2F11207530-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feagan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johanns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adedokun, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanauer, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Targan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Villiers, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombel, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulassay, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzberg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desreumaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loftus, E. V.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieleman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutgeerts, P.</span></span> <span> </span><span class="NLM_article-title">Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">1946</span>– <span class="NLM_lpage">1960</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1056%2FNEJMoa1602773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=27959607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=1946-1960&author=B.+G.+Feaganauthor=W.+J.+Sandbornauthor=C.+Gasinkauthor=D.+Jacobsteinauthor=Y.+Langauthor=J.+R.+Friedmanauthor=M.+A.+Blankauthor=J.+Johannsauthor=L.-L.+Gaoauthor=Y.+Miaoauthor=O.+J.+Adedokunauthor=B.+E.+Sandsauthor=S.+B.+Hanauerauthor=S.+Vermeireauthor=S.+Targanauthor=S.+Ghoshauthor=W.+J.+de+Villiersauthor=J.-F.+Colombelauthor=Z.+Tulassayauthor=U.+Seidlerauthor=B.+A.+Salzbergauthor=P.+Desreumauxauthor=S.+D.+Leeauthor=E.+V.+Loftusauthor=L.+A.+Dielemanauthor=S.+Katzauthor=P.+Rutgeerts&title=Ustekinumab+as+Induction+and+Maintenance+Therapy+for+Crohn%E2%80%99s+Disease&doi=10.1056%2FNEJMoa1602773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ustekinumab as induction and maintenance therapy for Crohn's disease</span></div><div class="casAuthors">Feagan, B. G.; Sandborn, W. J.; Gasink, C.; Jacobstein, D.; Lang, Y.; Friedman, J. R.; Blank, M. A.; Johanns, J.; Gao, L.-L.; Miao, Y.; Adedokun, O. J.; Sands, B. E.; Hanauer, S. B.; Vermeire, S.; Targan, S.; Ghosh, S.; de Villiers, W. J.; Colombel, J.-F.; Tulassay, Z.; Seidler, U.; Salzberg, B. A.; Desreumaux, P.; Lee, S. D.; Loftus, E. V. Jr.; Dieleman, L. A.; Katz, S.; Rutgeerts, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1946-1960</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin- 23, was evaluated as an i.v. induction therapy in two populations with moderately to severely active Crohn's disease.  Ustekinumab was also evaluated as s.c. maintenance therapy.  Methods: We randomly assigned patients to receive a single i.v. dose of ustekinumab (either 130 mg or approx. 6 mg per kg of body wt.) or placebo in two induction trials.  The UNITI-1 trial included 741 patients who met the criteria for primary or secondary nonresponse to tumor necrosis factor (TNF) antagonists or had unacceptable side effects.  The UNITI-2 trial included 628 patients in whom conventional therapy failed or unacceptable side effects occurred.  Patients who completed these induction trials then participated in IM-UNITI, in which the 397 patients who had a response to ustekinumab were randomly assigned to receive s.c. maintenance injections of 90 mg of ustekinumab (either every 8 wk or every 12 wk) or placebo.  The primary end point for the induction trials was a clin. response at week 6 (defined as a decrease from baseline in the Crohn's Disease Activity Index [CDAI] score of ≥100 points or a CDAI score <150).  The primary end point for the maintenance trial was remission at week 44 (CDAI score <150).  Results: The rates of response at week 6 among patients receiving i.v. ustekinumab at a dose of either 130 mg or approx. 6 mg per kg were significantly higher than the rates among patients receiving placebo (in UNITI-1, 34.3%, 33.7%, and 21.5%, resp., with P≤0.003 for both comparisons with placebo; in UNITI-2, 51.7%, 55.5%, and 28.7%, resp., with P<0.001 for both doses).  In the groups receiving maintenance doses of ustekinumab every 8 wk or every 12 wk, 53.1% and 48.8%, resp., were in remission at week 44, as compared with 35.9% of those receiving placebo (P = 0.005 and P = 0.04, resp.).  Within each trial, adverse-event rates were similar among treatment groups.  Conclusions: Among patients with moderately to severely active Crohn's disease, those receiving i.v. ustekinumab had a significantly higher rate of response than did those receiving placebo.  S.c. ustekinumab maintained remission in patients who had a clin. response to induction therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmRR8xWwu5_7Vg90H21EOLACvtfcHk0lhCIlt0XQLd8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ksrfO&md5=fe0fe2ba66261e94acdd1ce816d40ab8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602773%26sid%3Dliteratum%253Aachs%26aulast%3DFeagan%26aufirst%3DB.%2BG.%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DGasink%26aufirst%3DC.%26aulast%3DJacobstein%26aufirst%3DD.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFriedman%26aufirst%3DJ.%2BR.%26aulast%3DBlank%26aufirst%3DM.%2BA.%26aulast%3DJohanns%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DL.-L.%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DAdedokun%26aufirst%3DO.%2BJ.%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DHanauer%26aufirst%3DS.%2BB.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DTargan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3Dde%2BVilliers%26aufirst%3DW.%2BJ.%26aulast%3DColombel%26aufirst%3DJ.-F.%26aulast%3DTulassay%26aufirst%3DZ.%26aulast%3DSeidler%26aufirst%3DU.%26aulast%3DSalzberg%26aufirst%3DB.%2BA.%26aulast%3DDesreumaux%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DS.%2BD.%26aulast%3DLoftus%26aufirst%3DE.%2BV.%26aulast%3DDieleman%26aufirst%3DL.%2BA.%26aulast%3DKatz%26aufirst%3DS.%26aulast%3DRutgeerts%26aufirst%3DP.%26atitle%3DUstekinumab%2520as%2520Induction%2520and%2520Maintenance%2520Therapy%2520for%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D1946%26epage%3D1960%26doi%3D10.1056%2FNEJMoa1602773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van Vollenhoven, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsokos, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werth, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevrier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Ustekinumab, an IL-12 and IL-23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Multicenter, Double-blind, Phase 2, Randomised, Controlled Study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1330</span>– <span class="NLM_lpage">1339</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)32167-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2FS0140-6736%2818%2932167-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=30249507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOhurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1330-1339&author=R.+F.+van+Vollenhovenauthor=B.+H.+Hahnauthor=G.+C.+Tsokosauthor=C.+L.+Wagnerauthor=P.+Lipskyauthor=Z.+Toumaauthor=V.+P.+Werthauthor=R.+M.+Gordonauthor=B.+Zhouauthor=B.+Hsuauthor=M.+Chevrierauthor=M.+Triebelauthor=J.+L.+Jordanauthor=S.+Rose&title=Efficacy+and+Safety+of+Ustekinumab%2C+an+IL-12+and+IL-23+Inhibitor%2C+in+Patients+with+Active+Systemic+Lupus+Erythematosus%3A+Results+of+a+Multicenter%2C+Double-blind%2C+Phase+2%2C+Randomised%2C+Controlled+Study&doi=10.1016%2FS0140-6736%2818%2932167-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study</span></div><div class="casAuthors">van Vollenhoven, Ronald F.; Hahn, Bevra H.; Tsokos, George C.; Wagner, Carrie L.; Lipsky, Peter; Touma, Zahi; Werth, Victoria P.; Gordon, Robert M.; Zhou, Bei; Hsu, Benjamin; Chevrier, Marc; Triebel, Manon; Jordan, Jarrat L.; Rose, Shawn</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10155</span>),
    <span class="NLM_cas:pages">1330-1339</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease.  IL-12 and IL-23 have been implicated in systemic lupus erythematosus.  We aimed to assess the efficacy and safety of ustekinumab for the treatment of systemic lupus erythematosus in patients with moderate-to-severe disease activity despite conventional treatment.  This was a multicentre, double-blind, phase 2, randomised, controlled trial of adult patients with active, seropos. systemic lupus erythematosus, done at 44 private practices and academic centers in Argentina, Australia, Germany, Hungary, Mexico, Poland, Spain, Taiwan, and the USA.  Eligible adults were aged 18-75 years, weighed at least 35 kg, and had a diagnosis of systemic lupus erythematosus at least 3 mo before the first administration of study drug.  Eligible patients were randomly assigned (3:2) to the ustekinumab or placebo group using an interactive web response system with stratification by skin biopsy, lupus nephritis presence, baseline systemic lupus erythematosus medications and systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score combined factor, site, region, and race.  Patients and investigators were masked to treatment allocation.  Patients received an i.v. infusion of ustekinumab (260 mg for patients weighing 35-55 kg, 390 mg for patients weighing >55 kg and ≤85 kg, and 520 mg for patients weighing >85 kg) followed by s.c. injections of ustekinumab 90 mg every 8 wk or i.v. infusion of placebo at week 0 followed by s.c. injections of placebo every 8 wk, both in addn. to std.-of-care therapy.  The primary endpoint was the proportion of patients achieving a SLEDAI-2K responder index-4 (SRI-4) response at week 24.  Efficacy analyses were done in a modified intention-to-treat population of patients who received at least one dose (partial or complete, i.v. or s.c.) of their randomly assigned study treatment.  Safety analyses were done in all patients who received at least one dose of study treatment, regardless of group assignment.  This study is registered at ClinicalTrials.gov, no. NCT02349061.  Between Oct 6, 2015, and Nov 30, 2016, 166 patients were screened, of whom 102 were randomly assigned to receive ustekinumab (n=60) or placebo (n=42).  At week 24, 37 (62%) of 60 patients in the ustekinumab group and 14 (33%) of 42 patients in the placebo group achieved an SRI-4 response (percentage difference 28% [95% CI 10-47], p=0·006).  Between week 0 and week 24, 47 (78%) of 60 patients in the ustekinumab group and 28 (67%) of 42 patients in the placebo group had at least one adverse event.  Infections were the most common type of adverse event (27 [45%] in the ustekinumab group vs 21 [50%] in the placebo group).  No deaths or treatment-emergent opportunistic infections, herpes zoster, tuberculosis, or malignancies occurred between weeks 0-24.  The addn. of ustekinumab to std.-of-care treatment resulted in better efficacy in clin. and lab. parameters than placebo in the treatment of active systemic lupus erythematosus and had a safety profile consistent with ustekinumab therapy in other diseases.  The results of this study support further development of ustekinumab as a novel treatment in systemic lupus erythematosus.  Janssen Research & Development, LLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKMNv-uXP8PbVg90H21EOLACvtfcHk0lgS-YclXos4qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOhurzE&md5=f037f3161cea1b76fb83e68e12ed9e48</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2932167-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252932167-6%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BVollenhoven%26aufirst%3DR.%2BF.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DTsokos%26aufirst%3DG.%2BC.%26aulast%3DWagner%26aufirst%3DC.%2BL.%26aulast%3DLipsky%26aufirst%3DP.%26aulast%3DTouma%26aufirst%3DZ.%26aulast%3DWerth%26aufirst%3DV.%2BP.%26aulast%3DGordon%26aufirst%3DR.%2BM.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHsu%26aufirst%3DB.%26aulast%3DChevrier%26aufirst%3DM.%26aulast%3DTriebel%26aufirst%3DM.%26aulast%3DJordan%26aufirst%3DJ.%2BL.%26aulast%3DRose%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Ustekinumab%252C%2520an%2520IL-12%2520and%2520IL-23%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Active%2520Systemic%2520Lupus%2520Erythematosus%253A%2520Results%2520of%2520a%2520Multicenter%252C%2520Double-blind%252C%2520Phase%25202%252C%2520Randomised%252C%2520Controlled%2520Study%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1330%26epage%3D1339%26doi%3D10.1016%2FS0140-6736%2818%2932167-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blauvelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randazzo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasfi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimball, A. B.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared with Adalimumab for the Continuous Treatment of Patients with Moderate to Severe Psoriasis: Results from the Phase III, Double-blinded, Placebo- and Active Comparator-Controlled VOYAGE 1 Trial</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2016.11.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.jaad.2016.11.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=28057360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1SksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=405-417&issue=3&author=A.+Blauveltauthor=K.+A.+Pappauthor=C.+E.+M.+Griffithsauthor=B.+Randazzoauthor=Y.+Wasfiauthor=Y.-K.+Shenauthor=S.+Liauthor=A.+B.+Kimball&title=Efficacy+and+Safety+of+Guselkumab%2C+an+Anti-Interleukin-23+Monoclonal+Antibody%2C+Compared+with+Adalimumab+for+the+Continuous+Treatment+of+Patients+with+Moderate+to+Severe+Psoriasis%3A+Results+from+the+Phase+III%2C+Double-blinded%2C+Placebo-+and+Active+Comparator-Controlled+VOYAGE+1+Trial&doi=10.1016%2Fj.jaad.2016.11.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial</span></div><div class="casAuthors">Blauvelt, Andrew; Papp, Kim A.; Griffiths, Christopher E. M.; Randazzo, Bruce; Wasfi, Yasmine; Shen, Yaung-Kaung; Li, Shu; Kimball, Alexa B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-417</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial.  We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 yr.  Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 wk; n = 329); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20, then every 8 wk; n = 174); or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 wk through week 47; n = 334).  Physician-reported outcomes (Investigator Global Assessment, Psoriasis Area and Severity Index [PASI]), patient-reported outcomes (Dermatol. Life Quality Index, Psoriasis Symptoms and Signs Diary), and safety were evaluated through week 48.  Guselkumab was superior (P < .001) to placebo at week 16 (85.1% vs 6.9% [Investigator Global Assessment score of 0/1 (cleared/minimal)] and 73.3% vs 2.9% [90% or greater improvement in PASI score from baseline (PASI 90)]).  Guselkumab was also superior (P < .001) to adalimumab for Investigator Global Assessment 0/1 and PASI 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4% and 76.3% vs 47.9%).  Furthermore, guselkumab significantly improved patient-reported outcomes through week 48.  Adverse event rates were comparable between treatments.  Analyses were limited to 48 wk.  Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 yr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_St0MQ2YFlrVg90H21EOLACvtfcHk0lgS-YclXos4qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1SksA%253D%253D&md5=296388a810106b5dbced2f689be04fc3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.11.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.11.041%26sid%3Dliteratum%253Aachs%26aulast%3DBlauvelt%26aufirst%3DA.%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DRandazzo%26aufirst%3DB.%26aulast%3DWasfi%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.-K.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKimball%26aufirst%3DA.%2BB.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Guselkumab%252C%2520an%2520Anti-Interleukin-23%2520Monoclonal%2520Antibody%252C%2520Compared%2520with%2520Adalimumab%2520for%2520the%2520Continuous%2520Treatment%2520of%2520Patients%2520with%2520Moderate%2520to%2520Severe%2520Psoriasis%253A%2520Results%2520from%2520the%2520Phase%2520III%252C%2520Double-blinded%252C%2520Placebo-%2520and%2520Active%2520Comparator-Controlled%2520VOYAGE%25201%2520Trial%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2017%26volume%3D76%26issue%3D3%26spage%3D405%26epage%3D417%26doi%3D10.1016%2Fj.jaad.2016.11.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sozzani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosisio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tincani, A.</span></span> <span> </span><span class="NLM_article-title">Type I Interferons in Systemic Immunity</span>. <i>Autoimmunity</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.3109/08916930903510872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.3109%2F08916930903510872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=20298124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFehtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=196-203&author=S.+Sozzaniauthor=D.+Bosisioauthor=M.+Scarsiauthor=A.+Tincani&title=Type+I+Interferons+in+Systemic+Immunity&doi=10.3109%2F08916930903510872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Type I interferons in systemic autoimmunity</span></div><div class="casAuthors">Sozzani, Silvano; Bosisio, Daniela; Scarsi, Mirko; Tincani, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Autoimmunity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">196-203</span>CODEN:
                <span class="NLM_cas:coden">AUIMEI</span>;
        ISSN:<span class="NLM_cas:issn">0891-6934</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Type I IFN (IFN-I) was firstly described in 1957 as a sol. factor responsible for viral resistance in vitro.  Today, it is well known that the IFN-I family comprises a wide no. of cytokines with different modulatory effects on angiogenesis, cell growth, fibrosis, and apoptosis.  However, one of the most important functions of IFN-I is the capability to trigger a complex array of cellular responses that result in a host-protective antiviral response.  For this reason, IFN-I can be considered a "director" of protective immune responses.  The recent finding of the so-called interferon signature in patients suffering from different autoimmune diseases has underlined its possible role in the pathogenesis of these diseases.  On the other hand, IFN-α/β is reported to be efficacious in the treatment of some autoimmune and infectious diseases not responsive to conventional therapy.  On these occasions, the treated patients often start or increase autoantibody prodn. supporting the role of IFN as inducer of an autoimmune response.  In this review, we will underline recent acquisitions about IFN-I biol., with a focus on the relevance of the induction of some autoimmune diseases, such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, dermato/polymiositis, and Sjogren's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOfl71Vv3xQbVg90H21EOLACvtfcHk0litHAGglbk9VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFehtrw%253D&md5=1571043015d55361f6412b1dfe0659e3</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3109%2F08916930903510872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08916930903510872%26sid%3Dliteratum%253Aachs%26aulast%3DSozzani%26aufirst%3DS.%26aulast%3DBosisio%26aufirst%3DD.%26aulast%3DScarsi%26aufirst%3DM.%26aulast%3DTincani%26aufirst%3DA.%26atitle%3DType%2520I%2520Interferons%2520in%2520Systemic%2520Immunity%26jtitle%3DAutoimmunity%26date%3D2010%26volume%3D43%26spage%3D196%26epage%3D203%26doi%3D10.3109%2F08916930903510872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khamashta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werth, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalunian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illei, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drappa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greth, W.</span></span> <span> </span><span class="NLM_article-title">Sifalimumab, An Anti-Interferon-α Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus: A Randomised, Double-Blind, Placebo-Controlled Study</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1909</span>– <span class="NLM_lpage">1916</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2015-208562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1136%2Fannrheumdis-2015-208562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=27009916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFahtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2016&pages=1909-1916&issue=11&author=M.+Khamashtaauthor=J.+T.+Merrillauthor=V.+P.+Werthauthor=R.+Furieauthor=K.+Kalunianauthor=G.+G.+Illeiauthor=J.+Drappaauthor=L.+Wangauthor=W.+Greth&title=Sifalimumab%2C+An+Anti-Interferon-%CE%B1+Monoclonal+Antibody%2C+in+Moderate+to+Severe+Systemic+Lupus+Erythematosus%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Study&doi=10.1136%2Fannrheumdis-2015-208562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study</span></div><div class="casAuthors">Khamashta, Munther; Merrill, Joan T.; Werth, Victoria P.; Furie, Richard; Kalunian, Kenneth; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei; Greth, Warren</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1909-1916</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: The efficacy and safety of sifalimumab were assessed in a phase IIb, randomized, double-blind, placebo-controlled study (NCT01283139) of adults with moderate to severe active systemic lupus erythematosus (SLE).  Methods: 431 patients were randomized and received monthly i.v. sifalimumab (200 mg, 600 mg or 1200 mg) or placebo in addn. to std.-of-care medications.  Patients were stratified by disease activity, interferon gene-signature test (high vs low based on the expression of four genes) and geog. region.  The primary efficacy end point was the percentage of patients achieving an SLE responder index response at week 52.  Results: Compared with placebo, a greater percentage of patients who received sifalimumab (all dosages) met the primary end point (placebo: 45.4%; 200 mg: 58.3%; 600 mg: 56.5%; 1200 mg 59.8%).  Other improvements were seen in Cutaneous Lupus Erythematosus Disease Area and Severity Index score (200 mg and 1200 mg monthly), Physician's Global Assessment (600 mg and 1200 mg monthly), British Isles Lupus Assessment Group-based Composite Lupus Assessment (1200 mg monthly), 4-point redns. in the SLE Disease Activity Index-2000 score and redns. in counts of swollen joints and tender joints.  Serious adverse events occurred in 17.6% of patients on placebo and 18.3% of patients on sifalimumab.  Herpes zoster infections were more frequent with sifalimumab treatment.  Conclusions: Sifalimumab is a promising treatment for adults with SLE.  Improvement was consistent across various clin. end points, including global and organ specific measures of disease activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDXKlIdXLL6bVg90H21EOLACvtfcHk0litHAGglbk9VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFahtL4%253D&md5=13decd12e183bf27cb0dc808d23ff345</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2015-208562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2015-208562%26sid%3Dliteratum%253Aachs%26aulast%3DKhamashta%26aufirst%3DM.%26aulast%3DMerrill%26aufirst%3DJ.%2BT.%26aulast%3DWerth%26aufirst%3DV.%2BP.%26aulast%3DFurie%26aufirst%3DR.%26aulast%3DKalunian%26aufirst%3DK.%26aulast%3DIllei%26aufirst%3DG.%2BG.%26aulast%3DDrappa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGreth%26aufirst%3DW.%26atitle%3DSifalimumab%252C%2520An%2520Anti-Interferon-%25CE%25B1%2520Monoclonal%2520Antibody%252C%2520in%2520Moderate%2520to%2520Severe%2520Systemic%2520Lupus%2520Erythematosus%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Study%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2016%26volume%3D75%26issue%3D11%26spage%3D1909%26epage%3D1916%26doi%3D10.1136%2Fannrheumdis-2015-208562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werth, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamashta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalunian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohawn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drappa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S.</span></span> <span> </span><span class="NLM_article-title">Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">376</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1002/art.39962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1002%2Fart.39962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=28130918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=376-386&author=R.+Furieauthor=J.+Merrillauthor=V.+Werthauthor=M.+Khamashtaauthor=K.+Kalunianauthor=P.+Brohawnauthor=G.+Illeiauthor=J.+Drappaauthor=L.+Wangauthor=S.+Yoo&title=Anifrolumab%2C+an+Anti-Interferon-%CE%B1+Receptor+Monoclonal+Antibody%2C+in+Moderate-to-Severe+Systemic+Lupus+Erythematosus&doi=10.1002%2Fart.39962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus</span></div><div class="casAuthors">Furie, Richard; Khamashta, Munther; Merrill, Joan T.; Werth, Victoria P.; Kalunian, Kenneth; Brohawn, Philip; Illei, Gabor G.; Drappa, Jorn; Wang, Liangwei; Yoo, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">376-386</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE).  Methods: Patients (n = 305) were randomized to receive i.v. anifrolumab (300 mg or 1,000 mg) or placebo, in addn. to std. therapy, every 4 wk for 48 wk.  Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or ≥10), oral corticosteroid dosage (<10 or ≥10 mg/day), and type I IFN gene signature test status (high or low) based on a 4-gene expression assay.  The primary end point was the percentage of patients achieving an SLE Responder Index (SRI[4]) response at week 24 with sustained redn. of oral corticosteroids (<10 mg/day and less than or equal to the dose at week 1 from week 12 through 24).  Other end points (including SRI[4], British Isles Lupus Assessment Group [BILAG]-based Composite Lupus Assessment [BICLA], modified SRI[6], and major clin. response) were assessed at week 52.  The primary end point was analyzed in the modified intent-to-treat (ITT) population and type I IFN-high subpopulation.  The study result was considered pos. if the primary end point was met in either of the 2 study populations.  The Type I error rate was controlled at 0.10 (2-sided), within each of the 2 study populations for the primary end point anal.  Results: The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, vs. placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo-treated patients vs. 36.0% [P = 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, resp.  At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% vs. 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, resp.), BICLA (25.7% vs. 53.5% [P < 0.001] and 41.2% [P = 0.018], resp.), modified SRI(6) (28.4% vs. 49.5% [P = 0.002] and 44.7% [P = 0.015], resp.), major clin. response (BILAG 2004 C or better in all organ domains from week 24 through week 52) (6.9% vs. 19.2% [P = 0.012] and 17.3% [P = 0.025], resp.), and several other global and organ-specific end points.  Herpes zoster was more frequent in the anifrolumab-treated patients (2.0% with placebo treatment vs. 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, resp.), as were cases reported as influenza (2.0% vs. 6.1% and 7.6%, resp.), in the anifrolumab treatment groups.  Incidence of serious adverse events was similar between groups (18.8% vs. 16.2% and 17.1%, resp.).  Conclusion: Anifrolumab substantially reduced disease activity compared with placebo across multiple clin. end points in the patients with moderate-to-severe SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOnuGe2pgO6LVg90H21EOLACvtfcHk0lieWe-uXtx1KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrs7Y%253D&md5=c7f5b70586a8cbc0fafb2651a5f98b32</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fart.39962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39962%26sid%3Dliteratum%253Aachs%26aulast%3DFurie%26aufirst%3DR.%26aulast%3DMerrill%26aufirst%3DJ.%26aulast%3DWerth%26aufirst%3DV.%26aulast%3DKhamashta%26aufirst%3DM.%26aulast%3DKalunian%26aufirst%3DK.%26aulast%3DBrohawn%26aufirst%3DP.%26aulast%3DIllei%26aufirst%3DG.%26aulast%3DDrappa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYoo%26aufirst%3DS.%26atitle%3DAnifrolumab%252C%2520an%2520Anti-Interferon-%25CE%25B1%2520Receptor%2520Monoclonal%2520Antibody%252C%2520in%2520Moderate-to-Severe%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D376%26epage%3D386%26doi%3D10.1002%2Fart.39962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span> </span><span class="NLM_article-title">Update on TULIP 1 Phase III Trial for Anifrolumab
in Systemic Lupus Erythematosus</span>.  <i>AstraZeneca
News Release</i>; <span class="NLM_publisher-name">AstraZenica</span>, Aug 31, <span class="NLM_year">2018</span>; <a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html" class="extLink">https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html</a> (accessed Oct 17, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Update+on+TULIP+1+Phase+III+Trial+for+Anifrolumab%0Ain+Systemic+Lupus+Erythematosus.+AstraZeneca%0ANews+Release%3B+AstraZenica%2C+Aug+31%2C+2018%3B+https%3A%2F%2Fwww.astrazeneca.com%2Fcontent%2Fastraz%2Fmedia-centre%2Fpress-releases%2F2018%2Fupdate-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html+%28accessed+Oct+17%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DUpdate%2520on%2520TULIP%25201%2520Phase%2520III%2520Trial%2520for%2520Anifrolumab%250Ain%2520Systemic%2520Lupus%2520Erythematosus%26jtitle%3DAstraZeneca%250ANews%2520Release%26pub%3DAstraZenica%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delarosa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halladay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menghrajani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, Am.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold to Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4521</span>– <span class="NLM_lpage">4536</span>, <span class="refDoi"> DOI: 10.1021/jm400266t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400266t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4521-4536&author=J.+Liangauthor=A+van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=J.+Halladayauthor=A.+Johnsonauthor=P.+B.+Kohliauthor=Y.+Laiauthor=Y.+Liuauthor=J.+Lyssikatosauthor=P.+Mantikauthor=K.+Menghrajaniauthor=J.+Murrayauthor=I.+Pengauthor=Am.+Sambroneauthor=S.+Shiaauthor=Y.+Shinauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=L.+C.+Wuauthor=Y.+Xiaoauthor=W.+Yangauthor=J.+Youngauthor=B.+Zhangauthor=B.-y.+Zhuauthor=S.+Magnuson&title=Lead+Optimization+of+a+4-Aminopyridine+Benzamide+Scaffold+to+Identify+Potent%2C+Selective%2C+and+Orally+Bioavailable+TYK2+Inhibitors&doi=10.1021%2Fjm400266t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors</span></div><div class="casAuthors">Liang, Jun; van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade; Chang, Christine; Delarosa, Donnie; DeVoss, Jason; Driscoll, Jim; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Halladay, Jason; Johnson, Adam; Kohli, Pawan Bir; Lai, Yingjie; Liu, Yanzhou; Lyssikatos, Joseph; Mantik, Priscilla; Menghrajani, Kapil; Murray, Jeremy; Peng, Ivan; Sambrone, Amy; Shia, Steven; Shin, Young; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Wu, Lawren C.; Xiao, Yisong; Yang, Wenqian; Young, Judy; Zhang, Birong; Zhu, Bing-yan; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4521-4536</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the authors' lead optimization effort to identify potent, selective, and orally bioavailable TYK2 inhibitors, starting with lead mol. 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  The authors used structure-based design to discover 2,6-dichloro-4-cyanophenyl and (1R,2R)-2-fluorocyclopropylamide modifications, each of which exhibited improved TYK2 potency and JAK1 and JAK2 selectivity relative to 2,6-dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide.  Further optimization eventually led to 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-fluorocyclopropanecarboxamido)pyridin-4-yl)benzamide that showed good TYK2 enzyme and interleukin-12 (IL-12) cell potency, as well as acceptable cellular JAK1 and JAK2 selectivity and excellent oral exposure in mice.  When tested in a mouse IL-12 PK/PD model, 2-Chloro-4-cyano-6-fluoro-N-(2-((1R,2R)-2-ffluorocyclopropanecarboxamido)pyridin-4-yl)benzamide showed statistically significant knockdown of cytokine interferon-γ (IFNγ), suggesting that selective inhibition of TYK2 kinase activity might be sufficient to block the IL-12 pathway in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCinZ75WrtObVg90H21EOLACvtfcHk0lgV9XSnX_p_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFakuro%253D&md5=290ee5f1e3e093136ac5fbb418323421</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400266t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400266t%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLyssikatos%26aufirst%3DJ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DAm.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DB.-y.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DLead%2520Optimization%2520of%2520a%25204-Aminopyridine%2520Benzamide%2520Scaffold%2520to%2520Identify%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520TYK2%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4521%26epage%3D4536%26doi%3D10.1021%2Fjm400266t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagamiya, H.</span>; <span class="NLM_string-name">Yoshida, M.</span>; <span class="NLM_string-name">Seto, M.</span>; <span class="NLM_string-name">Marui, S.</span>; <span class="NLM_string-name">Oda, T.</span>; <span class="NLM_string-name">Ishichi, Y.</span>; <span class="NLM_string-name">Suzuki, H.</span>; <span class="NLM_string-name">Kusumoto, T.</span>; <span class="NLM_string-name">Yogo, T.</span>; <span class="NLM_string-name">Rhim, C. Y.</span>; <span class="NLM_string-name">Yoon, C.</span>; <span class="NLM_string-name">Lee, G. N.</span>; <span class="NLM_string-name">Kang, H. B.</span>; <span class="NLM_string-name">Kim, K. O.</span>; <span class="NLM_string-name">Jeoh, H. S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazolopyridines as Tyrosine Kinase 2 (Tyk2) Inhibitors and Pharmaceuticals Containing them</span>. PCT Int. Appl. <span class="NLM_patent">WO2013/125543 A1</span>,  <span class="NLM_patent">20130829</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Nagamiya&author=M.+Yoshida&author=M.+Seto&author=S.+Marui&author=T.+Oda&author=Y.+Ishichi&author=H.+Suzuki&author=T.+Kusumoto&author=T.+Yogo&author=C.+Y.+Rhim&author=C.+Yoon&author=G.+N.+Lee&author=H.+B.+Kang&author=K.+O.+Kim&author=H.+S.+Jeoh&title=Preparation+of+Pyrazolopyridines+as+Tyrosine+Kinase+2+%28Tyk2%29+Inhibitors+and+Pharmaceuticals+Containing+them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNagamiya%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520Pyrazolopyridines%2520as%2520Tyrosine%2520Kinase%25202%2520%2528Tyk2%2529%2520Inhibitors%2520and%2520Pharmaceuticals%2520Containing%2520them%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berezhkovsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delarosa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodacre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeod, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menghrajani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span> <span> </span><span class="NLM_article-title">Identification of an Imidazopyridine Scaffold to Generate Potent and Selective TYK2 Inhibitors that Demonstrate Activity in an In Vivo Psoriasis Model</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4370</span>– <span class="NLM_lpage">4376</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.bmcl.2017.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=28830649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOku7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=4370-4376&author=J.+Liangauthor=A.+Van+Abbemaauthor=M.+Balazsauthor=K.+Barrettauthor=L.+Berezhkovskyauthor=W.+S.+Blairauthor=C.+Changauthor=D.+Delarosaauthor=J.+DeVossauthor=J.+Driscollauthor=C.+Eigenbrotauthor=S.+Goodacreauthor=N.+Ghilardiauthor=C.+MacLeodauthor=A.+Johnsonauthor=P.+Bir+Kohliauthor=Y.+Laiauthor=Z.+Linauthor=P.+Mantikauthor=K.+Menghrajaniauthor=H.+Nguyenauthor=I.+Pengauthor=A.+Sambroneauthor=S.+Shiaauthor=J.+Smithauthor=S.+Sohnauthor=V.+Tsuiauthor=M.+Ultschauthor=K.+Williamsauthor=L.+C.+Wuauthor=W.+Yangauthor=B.+Zhangauthor=S.+Magnuson&title=Identification+of+an+Imidazopyridine+Scaffold+to+Generate+Potent+and+Selective+TYK2+Inhibitors+that+Demonstrate+Activity+in+an+In+Vivo+Psoriasis+Model&doi=10.1016%2Fj.bmcl.2017.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model</span></div><div class="casAuthors">Liang, Jun; Van Abbema, Anne; Balazs, Mercedesz; Barrett, Kathy; Berezhkovsky, Leo; Blair, Wade S.; Chang, Christine; Delarosa, Donnie; De Voss, Jason; Driscoll, Jim; Eigenbrot, Charles; Goodacre, Simon; Ghilardi, Nico; MacLeod, Calum; Johnson, Adam; Bir Kohli, Pawan; Lai, Yingjie; Lin, Zhonghua; Mantik, Priscilla; Menghrajani, Kapil; Nguyen, Hieu; Peng, Ivan; Sambrone, Amy; Shia, Steven; Smith, Jan; Sohn, Sue; Tsui, Vickie; Ultsch, Mark; Williams, Karen; Wu, Lawren C.; Yang, Wenqian; Zhang, Birong; Magnuson, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4370-4376</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compd. 1.  Further optimization led to generation of compd. 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties.  In mice, compd. 30 demonstrated dose-dependent redn. of IL-17 prodn. in a PK/PD model as well as in an imiquimod-induced psoriasis model.  In this efficacy model, the IL-17 decrease was accompanied by a redn. of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe2FqArjLnebVg90H21EOLACvtfcHk0lh1IpqnN7gZrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOku7bJ&md5=d132566f504626660c52c680399c9a09</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBerezhkovsky%26aufirst%3DL.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDelarosa%26aufirst%3DD.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGoodacre%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DMacLeod%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DMantik%26aufirst%3DP.%26aulast%3DMenghrajani%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DI.%26aulast%3DSambrone%26aufirst%3DA.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DL.%2BC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMagnuson%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520an%2520Imidazopyridine%2520Scaffold%2520to%2520Generate%2520Potent%2520and%2520Selective%2520TYK2%2520Inhibitors%2520that%2520Demonstrate%2520Activity%2520in%2520an%2520In%2520Vivo%2520Psoriasis%2520Model%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D4370%26epage%3D4376%26doi%3D10.1016%2Fj.bmcl.2017.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.-B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+Inhibition+of+TYK2+and+JAK1+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29-pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lh1IpqnN7gZrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520Inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529-pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">For reviews of TYK2 selective inhibitors, see:</p></div><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span> <span> </span><span class="NLM_article-title">Toward Selective TYK2 Inhibitors as Therapeutic Agents for the Treatment of Inflammatory Diseases</span>. <i>Pharm. Pat. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.4155/ppa.14.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.4155%2Fppa.14.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=25291316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=449-466&issue=4&author=C.+J.+Menet&title=Toward+Selective+TYK2+Inhibitors+as+Therapeutic+Agents+for+the+Treatment+of+Inflammatory+Diseases&doi=10.4155%2Fppa.14.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Menet, Christel J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Patent Analyst</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-466</span>CODEN:
                <span class="NLM_cas:coden">PPAHCN</span>;
        ISSN:<span class="NLM_cas:issn">2046-8954</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The family of JAK comprises four members and has received significant attention in recent years from the pharmaceutical industry as a therapeutic target.  The role of JAK is central to cytokine signaling pathways.  It is believed that selective modulation of one specific JAK can lead to the inhibition of a restricted set of cytokines, which should avoid undesired side effects and get closer to the profile of biol. therapies.  Consequently, selective JAK inhibition has become a major focus area of drug discovery research.  A review of the TYK2 patents indicates that industry attention has recently turned toward the development of specific inhibitors.  Importantly, despite the increasing no. of published patents, none of these drugs have yet made it to the clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmMgH3Z8Ff7Vg90H21EOLACvtfcHk0lg4h4mnZOiQBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF&md5=0a79df697117246c840c559260d8e7ba</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.4155%2Fppa.14.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fppa.14.23%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26atitle%3DToward%2520Selective%2520TYK2%2520Inhibitors%2520as%2520Therapeutic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DPharm.%2520Pat.%2520Anal.%26date%3D2014%26volume%3D3%26issue%3D4%26spage%3D449%26epage%3D466%26doi%3D10.4155%2Fppa.14.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span></span> <span> </span><span class="NLM_article-title">Advances in the Discovery and Development of Selective Tyrosine Kinase 2 (TYK2) Inhibitors</span>. <i>Medicinal Chemistry Reviews</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.29200/acsmedchemrev-v53.ch10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.29200%2Facsmedchemrev-v53.ch10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlyjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=177-200&author=D.+W.+Weinsteinauthor=R.+M.+Moslin&title=Advances+in+the+Discovery+and+Development+of+Selective+Tyrosine+Kinase+2+%28TYK2%29+Inhibitors&doi=10.29200%2Facsmedchemrev-v53.ch10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery and development of selective tyrosine kinase 2 (TYK2) inhibitors</span></div><div class="casAuthors">Weinstein, David S.; Moslin, Ryan M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-200</span>CODEN:
                <span class="NLM_cas:coden">MCREGD</span>;
        ISSN:<span class="NLM_cas:issn">2575-9175</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society, Division of Medicinal Chemistry</span>)
        </div><div class="casAbstract">A review discussing the advances in the discovery and development of selective tyrosine kinase 2 (TYK2) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm_EO5ig1UTrVg90H21EOLACvtfcHk0lg4h4mnZOiQBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlyjsb8%253D&md5=1ae794f8190d9c312e67fcdd2e06b793</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.29200%2Facsmedchemrev-v53.ch10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.29200%252Facsmedchemrev-v53.ch10%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DD.%2BW.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26atitle%3DAdvances%2520in%2520the%2520Discovery%2520and%2520Development%2520of%2520Selective%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%2520Inhibitors%26jtitle%3DMedicinal%2520Chemistry%2520Reviews%26date%3D2018%26volume%3D53%26spage%3D177%26epage%3D200%26doi%3D10.29200%2Facsmedchemrev-v53.ch10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure of a Pseudokinase Domain Switch that Controls Oncogenic Activation of Jak Kinases</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1223</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnsmb.2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24013208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2ktrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1221-1223&issue=10&author=A.+V.+Tomsauthor=A.+Deshpandeauthor=R.+McNallyauthor=Y.+Jeongauthor=J.+M.+Rogersauthor=C.+U.+Kimauthor=S.+M.+Grunerauthor=S.+B.+Ficarroauthor=J.+A.+Martoauthor=M.+Sattlerauthor=J.+D.+Griffinauthor=M.+J.+Eck&title=Structure+of+a+Pseudokinase+Domain+Switch+that+Controls+Oncogenic+Activation+of+Jak+Kinases&doi=10.1038%2Fnsmb.2673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases</span></div><div class="casAuthors">Toms, Angela V.; Deshpande, Anagha; McNally, Randall; Jeong, Youngjee; Rogers, Julia M.; Kim, Chae Un; Gruner, Sol M.; Ficarro, Scott B.; Marto, Jarrod A.; Sattler, Martin; Griffin, James D.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1221-1223</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The V617F mutation in the Jak2 pseudokinase domain causes myeloproliferative neoplasms, and the equiv. mutation in Jak1 (V658F) is found in T-cell leukemias.  Crystal structures of wild-type and V658F-mutant human Jak1 pseudokinase reveal a conformational switch that remodels a linker segment encoded by exon 12, which is also a site of mutations in Jak2.  This switch is required for V617F-mediated Jak2 activation and possibly for physiol. Jak activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH5DpUPWQk57Vg90H21EOLACvtfcHk0lg3Z6InmujJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2ktrnO&md5=e38a60cb1460c113ba8460319902c493</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2673%26sid%3Dliteratum%253Aachs%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DDeshpande%26aufirst%3DA.%26aulast%3DMcNally%26aufirst%3DR.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DRogers%26aufirst%3DJ.%2BM.%26aulast%3DKim%26aufirst%3DC.%2BU.%26aulast%3DGruner%26aufirst%3DS.%2BM.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructure%2520of%2520a%2520Pseudokinase%2520Domain%2520Switch%2520that%2520Controls%2520Oncogenic%2520Activation%2520of%2520Jak%2520Kinases%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2013%26volume%3D20%26issue%3D10%26spage%3D1221%26epage%3D1223%26doi%3D10.1038%2Fnsmb.2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bandaranayake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of the JAK2 Pseudokinase Domain and the Pathogenic Mutant V617F</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">754</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnsmb.2348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=22820988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=754-759&issue=8&author=R.+M.+Bandaranayakeauthor=D.+Ungureanuauthor=Y.+Shanauthor=D.+E.+Shawauthor=O.+Silvennoinenauthor=S.+R.+Hubbard&title=Crystal+Structures+of+the+JAK2+Pseudokinase+Domain+and+the+Pathogenic+Mutant+V617F&doi=10.1038%2Fnsmb.2348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F</span></div><div class="casAuthors">Bandaranayake, Rajintha M.; Ungureanu, Daniela; Shan, Yibing; Shaw, David E.; Silvennoinen, Olli; Hubbard, Stevan R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">754-759</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The protein tyrosine kinase JAK2 mediates signaling through numerous cytokine receptors.  JAK2 possesses a pseudokinase domain (JH2) and a tyrosine kinase domain (JH1).  Through unknown mechanisms, JH2 regulates the catalytic activity of JH1, and hyperactivating mutations in the JH2 region of human JAK2 cause myeloproliferative neoplasms (MPNs).  We showed previously that JAK2 JH2 is, in fact, catalytically active.  Here we present crystal structures of human JAK2 JH2, including both wild type and the most prevalent MPN mutant, V617F.  The structures reveal that JH2 adopts the fold of a prototypical protein kinase but binds Mg-ATP noncanonically.  The structural and biochem. data indicate that the V617F mutation rigidifies α-helix C in the N lobe of JH2, facilitating trans-phosphorylation of JH1.  The crystal structures of JH2 afford new opportunities for the design of novel JAK2 therapeutics targeting MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGj9DoN3fj37Vg90H21EOLACvtfcHk0lg3Z6InmujJZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKntLbM&md5=da64398430cd3279e131b2569cdc7391</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2348%26sid%3Dliteratum%253Aachs%26aulast%3DBandaranayake%26aufirst%3DR.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DCrystal%2520Structures%2520of%2520the%2520JAK2%2520Pseudokinase%2520Domain%2520and%2520the%2520Pathogenic%2520Mutant%2520V617F%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26issue%3D8%26spage%3D754%26epage%3D759%26doi%3D10.1038%2Fnsmb.2348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the Pseudokinase-Kinase Domains from Protein Kinase TYK2 Reveals a Mechanism for Janus Kinase (JAK) Autoinhibition</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8025</span>– <span class="NLM_lpage">8030</span>, <span class="refDoi"> DOI: 10.1073/pnas.1401180111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1073%2Fpnas.1401180111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24843152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8025-8030&issue=22&author=P.+J.+Lupardusauthor=M.+Ultschauthor=H.+Wallweberauthor=P.+Bir+Kohliauthor=A.+R.+Johnsonauthor=C.+Eigenbrot&title=Structure+of+the+Pseudokinase-Kinase+Domains+from+Protein+Kinase+TYK2+Reveals+a+Mechanism+for+Janus+Kinase+%28JAK%29+Autoinhibition&doi=10.1073%2Fpnas.1401180111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition</span></div><div class="casAuthors">Lupardus Patrick J; Ultsch Mark; Wallweber Heidi; Eigenbrot Charles; Bir Kohli Pawan; Johnson Adam R</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8025-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinases (JAKs) are receptor-associated multidomain tyrosine kinases that act downstream of many cytokines and interferons.  JAK kinase activity is regulated by the adjacent pseudokinase domain via an unknown mechanism.  Here, we report the 2.8-ÅA structure of the two-domain pseudokinase-kinase module from the JAK family member TYK2 in its autoinhibited form.  We find that the pseudokinase and kinase interact near the kinase active site and that most reported mutations in cancer-associated JAK alleles cluster in or near this interface.  Mutation of residues near the TYK2 interface that are analogous to those in cancer-associated JAK alleles, including the V617F and "exon 12" JAK2 mutations, results in increased kinase activity in vitro.  These data indicate that JAK pseudokinases are autoinhibitory domains that hold the kinase domain inactive until receptor dimerization stimulates transition to an active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsxgEXiV6j3TQLBVDQn4bCfW6udTcc2ebUSPy7NGOoQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D&md5=47f1d528f736376c9e02add92839ac67</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1401180111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1401180111%26sid%3Dliteratum%253Aachs%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Pseudokinase-Kinase%2520Domains%2520from%2520Protein%2520Kinase%2520TYK2%2520Reveals%2520a%2520Mechanism%2520for%2520Janus%2520Kinase%2520%2528JAK%2529%2520Autoinhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26issue%3D22%26spage%3D8025%26epage%3D8030%26doi%3D10.1073%2Fpnas.1401180111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edavettal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2-Mediated Signal Transduction in T Lymphocytes is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">11061</span>– <span class="NLM_lpage">11074</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.619502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1074%2Fjbc.M114.619502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=25762719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=11061-11074&author=J.+S.+Tokarskiauthor=A.+Zupa-Fernandezauthor=J.+A.+Tredupauthor=K.+Pikeauthor=C.+Changauthor=D.+Xieauthor=L.+Chengauthor=D.+Pedicordauthor=J.+Muckelbauerauthor=S.+R.+Johnsonauthor=S.+Wuauthor=S.+C.+Edavettalauthor=Y.+Hongauthor=M.+R.+Witmerauthor=L.+L.+Elkinauthor=Y.+Blatauthor=W.+J.+Pittsauthor=D.+S.+Weinsteinauthor=J.+R.+Burke&title=Tyrosine+Kinase+2-Mediated+Signal+Transduction+in+T+Lymphocytes+is+Blocked+by+Pharmacological+Stabilization+of+Its+Pseudokinase+Domain&doi=10.1074%2Fjbc.M114.619502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain</span></div><div class="casAuthors">Tokarski, John S.; Zupa-Fernandez, Adriana; Tredup, Jeffrey A.; Pike, Kristen; Chang, Chieh Ying; Xie, Dianlin; Cheng, Lihong; Pedicord, Donna; Muckelbauer, Jodi; Johnson, Stephen R.; Wu, Sophie; Edavettal, Suzanne C.; Hong, Yang; Witmer, Mark R.; Elkin, Lisa L.; Blat, Yuval; Pitts, William J.; Weinstein, David S.; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11061-11074</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibition of signal transduction downstream of the IL-23 receptor represents an intriguing approach to the treatment of autoimmunity.  Using a chemogenomics approach marrying kinome-wide inhibitory profiles of a compd. library with the cellular activity against an IL-23-stimulated transcriptional response in T lymphocytes, a class of inhibitors was identified that bind to and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of receptor-mediated activation of the adjacent catalytic domain.  These Tyk2 pseudokinase domain stabilizers were also shown to inhibit Tyk2-dependent signaling through the Type I interferon receptor but not Tyk2-independent signaling and transcriptional cellular assays, including stimulation through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high functional selectivity of this approach.  A crystal structure of the pseudokinase domain liganded with a representative example showed the compd. bound to a site analogous to the ATP-binding site in catalytic kinases with features consistent with high ligand selectivity.  The results support a model where the pseudokinase domain regulates activation of the catalytic domain by forming receptor-regulated inhibitory interactions.  Tyk2 pseudokinase stabilizers, therefore, represent a novel approach to the design of potent and selective agents for the treatment of autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwSl_Zer56d7Vg90H21EOLACvtfcHk0lgX8vikampzRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D&md5=49e10a7c3e430c8be198c119b26bb16b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.619502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.619502%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DTredup%26aufirst%3DJ.%2BA.%26aulast%3DPike%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DMuckelbauer%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DEdavettal%26aufirst%3DS.%2BC.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DElkin%26aufirst%3DL.%2BL.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DTyrosine%2520Kinase%25202-Mediated%2520Signal%2520Transduction%2520in%2520T%2520Lymphocytes%2520is%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520Its%2520Pseudokinase%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D11061%26epage%3D11074%26doi%3D10.1074%2Fjbc.M114.619502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillert, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">27261</span>– <span class="NLM_lpage">27270</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.672048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1074%2Fjbc.M115.672048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=26359499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=27261-27270&issue=45&author=X.+Minauthor=D.+Ungureanuauthor=S.+Maxwellauthor=H.+Hammar%C3%A9nauthor=S.+Thibaultauthor=E.-K.+Hillertauthor=M.+Ayresauthor=B.+Greenfieldauthor=J.+Eksterowiczauthor=C.+Gabelauthor=N.+Walkerauthor=O.+Silvennoinenauthor=Z.+Wang&title=Structural+and+Functional+Characterization+of+the+JH2+Pseudokinase+Domain+of+JAK+Family+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1074%2Fjbc.M115.672048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span></div><div class="casAuthors">Min, Xiaoshan; Ungureanu, Daniela; Maxwell, Sarah; Hammaren, Henrik; Thibault, Steve; Hillert, Ellin-Kristina; Ayres, Merrill; Greenfield, Brad; Eksterowicz, John; Gabel, Chris; Walker, Nigel; Silvennoinen, Olli; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">27261-27270</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation.  JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2).  The majority of disease-assocd. mutations in JAKs map to JH2, demonstrating its central regulatory function.  JH2s were considered catalytically inactive, but JAK2 JH2 was found to have low autoregulatory catalytic activity.  Whether the other JAK JH2s share ATP binding and enzymic activity has been unclear.  Here we report the crystal structure of TYK2 JH2 in complex with adenosine 5'-O-(thiotriphosphate) (ATP-γS) and characterize its nucleotide binding by biochem. and biophys. methods.  TYK2 JH2 did not show phosphotransfer activity, but it binds ATP and the nucleotide binding stabilizes the protein without inducing major conformational changes.  Mutation of the JH2 ATP-binding pocket increased basal TYK2 phosphorylation and downstream signaling.  The overall structural characteristics of TYK2 JH2 resemble JAK2 JH2, but distinct stabilizing mol. interactions around helix αAL in the activation loop provide a structural basis for differences in substrate access and catalytic activities among JAK family JH2s.  The structural and biochem. data suggest that ATP binding is functionally important for both TYK2 and JAK2 JH2s, whereas the regulatory phosphorylation appears to be a unique property of JAK2.  Finally, the co-crystal structure of TYK2 JH2 complexed with a small mol. inhibitor demonstrates that JH2 is accessible to ATP-competitive compds., which offers novel approaches for targeting cytokine signaling as well as potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ZJIkM0pXXbVg90H21EOLACvtfcHk0limlR60x_nIig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO&md5=2933fa07a5bdbea19f3d434591613070</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.672048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.672048%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DX.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DMaxwell%26aufirst%3DS.%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DHillert%26aufirst%3DE.-K.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DGreenfield%26aufirst%3DB.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGabel%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructural%2520and%2520Functional%2520Characterization%2520of%2520the%2520JH2%2520Pseudokinase%2520Domain%2520of%2520JAK%2520Family%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26issue%3D45%26spage%3D27261%26epage%3D27270%26doi%3D10.1074%2Fjbc.M115.672048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dondi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzé, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">A Dual Role for the Kinase-Like Domain of the Tyrosine Kinase Tyk2 in Interferon-α Signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">8991</span>– <span class="NLM_lpage">8996</span>, <span class="refDoi"> DOI: 10.1073/pnas.160130297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1073%2Fpnas.160130297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10908660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls12lu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=8991-8996&issue=16&author=T.+C.+Yehauthor=E.+Dondiauthor=G.+Uz%C3%A9author=S.+Pellegrini&title=A+Dual+Role+for+the+Kinase-Like+Domain+of+the+Tyrosine+Kinase+Tyk2+in+Interferon-%CE%B1+Signaling&doi=10.1073%2Fpnas.160130297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-α signaling</span></div><div class="casAuthors">Yeh, Tammie C.; Dondi, Elisabetta; Uze, Gilles; Pellegrini, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8991-8996</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tyrosine kinases of the Janus kinase family initiate cellular responses through their assocn. with receptors for α-helical cytokines.  In addn. to a tyrosine kinase domain, these enzymes possess a kinase-like (KL) domain, whose function remains elusive.  To investigate the role of the KL domain of Tyk2 in interferon-α/β signaling, we transfected a library of Tyk2 cDNAs contg. random point mutations in KL into Tyk2-neg. cells and selected for loss-of-function Tyk2 mutants.  Four such mutants, V584D, G596V, H669P, and R856G, were identified through this screen.  Like the wild-type Tyk2, the mutant proteins were able to sustain the level of IFNAR1 receptor protein.  However, all four mutants were incapable of restoring high-affinity interferon-α binding in Tyk2-neg. cells and were also catalytically impaired, even when transiently overexpressed.  Interferon-α induced phosphorylation, and gene expression could be detected in V584D- or G596V-expressing cells, but not in H669P- or R856G-expressing cells.  Furthermore, H669P and R856G proteins were constitutively highly phosphorylated.  All together, these our findings demonstrate that an intact KL domain is essential for the intrinsic catalytic activity of Tyk2 and for the establishment of a high-affinity interferon-α receptor complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Si0cKeITxbVg90H21EOLACvtfcHk0limlR60x_nIig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls12lu74%253D&md5=da8f555ea9811971e6f4734e1d73de79</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.160130297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.160130297%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DT.%2BC.%26aulast%3DDondi%26aufirst%3DE.%26aulast%3DUz%25C3%25A9%26aufirst%3DG.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DA%2520Dual%2520Role%2520for%2520the%2520Kinase-Like%2520Domain%2520of%2520the%2520Tyrosine%2520Kinase%2520Tyk2%2520in%2520Interferon-%25CE%25B1%2520Signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26issue%3D16%26spage%3D8991%26epage%3D8996%26doi%3D10.1073%2Fpnas.160130297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogensen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzé, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">Distinct Domains of the Protein Tyrosine Kinase Tyk2 Required for Binding of Interferon-alpha/beta and for Signal Transduction</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3327</span>– <span class="NLM_lpage">3334</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.7.3327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1074%2Fjbc.270.7.3327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=7531704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK2MXjslagsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=3327-3334&issue=7&author=L.+Velazquezauthor=K.+E.+Mogensenauthor=G.+Barbieriauthor=M.+Fellousauthor=G.+Uz%C3%A9author=S.+Pellegrini&title=Distinct+Domains+of+the+Protein+Tyrosine+Kinase+Tyk2+Required+for+Binding+of+Interferon-alpha%2Fbeta+and+for+Signal+Transduction&doi=10.1074%2Fjbc.270.7.3327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-α/β and for signal transduction</span></div><div class="casAuthors">Velazquez, Laura; Mogensen, Knud E.; Barbieri, Giovanna; Fellous, Marc; Uze, Gilles; Pellegrini, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3327-34</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tyk2 belongs to the JAK family of nonreceptor protein tyrosine kinases recently found implicated in signaling through a large no. of cytokine receptors.  These proteins are characterized by a large amino-terminal region and two tandemly arranged kinase domains, a kinase-like and a tyrosine kinase domain.  Genetic and biochem. evidence supports the requirement for tyk2 in interferon-α/β binding and signaling.  To study the role of the distinct domains of tyk2, constructs lacking one or both kinase domains were stably transfected in recipient cells lacking the endogenous protein.  Removal of either or both kinase domains resulted in loss of the in vitro kinase activity.  The mutant form truncated of the tyrosine kinase domain was found to reconstitute binding of interferon-α8 and partial signaling.  While no contribution of this protein toward interferon-β binding was evident, increased signaling could be measured.  The mutant form lacking both kinase domains did not exhibit any detectable activity.  Altogether, thus, a sequential deletion of domains engenders a sequential loss of function and that the different domains of tyk2 have distinct functions, all essential for full interferon-α and -β binding and signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhuTslOF05xrVg90H21EOLACvtfcHk0limlR60x_nIig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjslagsrs%253D&md5=7da85d93af787ea1b643f284a9935d31</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.7.3327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.7.3327%26sid%3Dliteratum%253Aachs%26aulast%3DVelazquez%26aufirst%3DL.%26aulast%3DMogensen%26aufirst%3DK.%2BE.%26aulast%3DBarbieri%26aufirst%3DG.%26aulast%3DFellous%26aufirst%3DM.%26aulast%3DUz%25C3%25A9%26aufirst%3DG.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DDistinct%2520Domains%2520of%2520the%2520Protein%2520Tyrosine%2520Kinase%2520Tyk2%2520Required%2520for%2520Binding%2520of%2520Interferon-alpha%252Fbeta%2520and%2520for%2520Signal%2520Transduction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26issue%3D7%26spage%3D3327%26epage%3D3334%26doi%3D10.1074%2Fjbc.270.7.3327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of Imidazo[1,2-b]pyridazine TYK2 Pseudokinase Ligands as Potent and Selective Allosteric Inhibitors of TYK2 Signalling</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1039/C6MD00560H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1039%2FC6MD00560H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=30108788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=700-712&author=R.+Moslinauthor=D.+Gardnerauthor=J.+Santellaauthor=Y.+Zhangauthor=J.+V.+Dunciaauthor=C.+Liuauthor=J.+Linauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=D.+Pedicordauthor=J.+Chenauthor=Y.+Blatauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=H.+Sunauthor=C.+Chaudhryauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=D.+S.+Weinstein&title=Identification+of+Imidazo%5B1%2C2-b%5Dpyridazine+TYK2+Pseudokinase+Ligands+as+Potent+and+Selective+Allosteric+Inhibitors+of+TYK2+Signalling&doi=10.1039%2FC6MD00560H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</span></div><div class="casAuthors">Moslin, R.; Gardner, D.; Santella, J.; Zhang, Y.; Duncia, J. V.; Liu, C.; Lin, J.; Tokarski, J. S.; Strnad, J.; Pedicord, D.; Chen, J.; Blat, Y.; Zupa-Fernandez, A.; Cheng, L.; Sun, H.; Chaudhry, C.; Huang, C.; D'Arienzo, C.; Sack, J. S.; Muckelbauer, J. K.; Chang, C.; Tredup, J.; Xie, D.; Aranibar, N.; Burke, J. R.; Carter, P. H.; Weinstein, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">700-712</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">As a member of the Janus (JAK) family of non-receptor tyrosine kinases, TYK2 mediates the signaling of pro-inflammatory cytokines including IL-12, IL-23 and type 1 interferon (IFN), and therefore represents an attractive potential target for treating the various immuno-inflammatory diseases in which these cytokines have been shown to play a role.  Following up on our previous report that ligands to the pseudokinase domain (JH2) of TYK2 suppress cytokine-mediated receptor activation of the catalytic (JH1) domain, the imidazo[1,2-b]pyridazine (IZP) 7 was identified as a promising hit compd.  Through iterative modification of each of the substituents of the IZP scaffold, the cellular potency was improved while maintaining selectivity over the JH1 domain.  These studies led to the discovery of the JH2-selective TYK2 inhibitor 29, which provided encouraging systemic exposures after oral dosing in mice.  Phosphodiesterase 4 (PDE4) was identified as an off-target and potential liability of the IZP ligands, and selectivity for TYK2 JH2 over this enzyme was obtained by elaborating along selectivity vectors detd. from analyses of X-ray co-crystal structures of representative ligands of the IZP class bound to both proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobX5_XfvLHsLVg90H21EOLACvtfcHk0li_Gryq-zjqIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN&md5=67b06413866ee6096810903f62edd901</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1039%2FC6MD00560H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00560H%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DD.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520TYK2%2520Pseudokinase%2520Ligands%2520as%2520Potent%2520and%2520Selective%2520Allosteric%2520Inhibitors%2520of%2520TYK2%2520Signalling%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D700%26epage%3D712%26doi%3D10.1039%2FC6MD00560H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mückelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=383-388&author=C+Liuauthor=J.+Linauthor=R.+Moslinauthor=J.+S.+Tokarskiauthor=J.+M%C3%BCckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=H.+Parkauthor=P.+Liauthor=D.-R.+Wuauthor=J.+Strnadauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=C.+Chaudryauthor=J.+Chenauthor=C.+Chenauthor=H.+Sunauthor=P.+Elzingaauthor=C.+D%27arienzoauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=L.+J.+Lombardoauthor=P.+H.+Carterauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=D.+S.+Weinstein&title=Identification+of+Imidazo%5B1%2C2-b%5Dpyridazine+Derivatives+as+Potent%2C+Selective%2C+and+Orally+Active+Tyk2+JH2+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors</span></div><div class="casAuthors">Liu, Chunjian; Lin, James; Moslin, Ryan; Tokarski, John S.; Muckelbauer, Jodi; Chang, ChiehYing; Tredup, Jeffrey; Xie, Dianlin; Park, Hyunsoo; Li, Peng; Wu, Dauh-Rurng; Strnad, Joann; Zupa-Fernandez, Adriana; Cheng, Lihong; Chaudhry, Charu; Chen, Jing; Chen, Cliff; Sun, Huadong; Elzinga, Paul; Darienzo, Celia; Gillooly, Kathleen; Taylor, Tracy L.; McIntyre, Kim W.; Salter-Cid, Luisa; Lombardo, Louis J.; Carter, Percy H.; Aranibar, Nelly; Burke, James R.; Weinstein, David S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-388</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stability.  The N1-substituent on 2-oxo-1,2-dihydropyridine ring can be a variety of alkyl, aryl, and heteroaryl groups, but among them, 2-pyridyl provided much enhanced Caco-2 permeability, attributed to its ability to form intramol. hydrogen bonds.  Further structure-activity relationship studies at the C3 position led to the identification of highly potent and selective Tyk2 JH2 inhibitor 6, which proved to be highly effective in inhibiting IFNγ prodn. in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKahxaaZZWtbVg90H21EOLACvtfcHk0lgDDUkkhzCiwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsV2qu7w%253D&md5=65c8d8dccfcc2cf73175aef902df9fa2</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DM%25C3%25BCckelbauer%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DChaudry%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DElzinga%26aufirst%3DP.%26aulast%3DD%2527arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520Derivatives%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Active%2520Tyk2%2520JH2%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D383%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauzzi, M.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKendry, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogensen, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">Interferon-α-Dependent Activation of Tyk2 Requires Phosphorylation of Positive Regulatory Tyrosines by Another Kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">20494</span>– <span class="NLM_lpage">20500</span>, <span class="refDoi"> DOI: 10.1074/jbc.271.34.20494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1074%2Fjbc.271.34.20494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=8702790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK28Xlt1ygu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=20494-20500&author=M.%0AC.+Gauzziauthor=L.+Velazquezauthor=R.+McKendryauthor=K.+E.+Mogensenauthor=M.+Fellousauthor=S.+Pellegrini&title=Interferon-%CE%B1-Dependent+Activation+of+Tyk2+Requires+Phosphorylation+of+Positive+Regulatory+Tyrosines+by+Another+Kinase&doi=10.1074%2Fjbc.271.34.20494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon-α-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase</span></div><div class="casAuthors">Gauzzi, M. Cristina; Velazquez, Laura; McKendry, Roslyn; Mogensen, Knud E.; Fellous, Marc; Pellegrini, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20494-20500</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tyk2 and JAK1, members of the Janus kinase (JAK) family of protein tyrosine kinases, are required for interferon-α/β binding and signaling.  Both enzymes are assocd. with the interferon-α/β receptor, and upon ligand binding, they undergo tyrosine phosphorylation and catalytic activation in an interdependent manner.  To identify residues involved in Tyk2 regulation and to understand the basis of the interdependence of Tyk2 and JAK1, six mutated versions of Tyk2 bearing single or multiple point mutations in the tyrosine kinase domain were studied in a cell line lacking endogenous Tyk2.  The Y1054F/Y1055F substitutions in the putative activation loop prevented ligand-dependent activation of Tyk2, without abolishing its catalytic potential.  The K930R mutation in the ATP binding site generated a kinase-neg. protein, which however, still became phosphorylated upon interferon-α treatment.  The Y1054F/Y1055F substitutions in this kinase-neg. Tyk2 abolished the induced phosphorylation.  These results indicate that Tyk2 is activated by phosphorylation on Tyr-1054 and/or Tyr-1055 and that this phosphorylation requires another kinase, most likely JAK1.  While the Tyk2 forms mutated on Tyr-1054 and Tyr-1055 or on Lys-930 allowed some inducible gene expression, the combination of the three point mutations totally abolished signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPWGWPmMOHpbVg90H21EOLACvtfcHk0lgDDUkkhzCiwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xlt1ygu7w%253D&md5=934c554dfd8648a157193f82d4166dcd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.34.20494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.34.20494%26sid%3Dliteratum%253Aachs%26aulast%3DGauzzi%26aufirst%3DM.%2BC.%26aulast%3DVelazquez%26aufirst%3DL.%26aulast%3DMcKendry%26aufirst%3DR.%26aulast%3DMogensen%26aufirst%3DK.%2BE.%26aulast%3DFellous%26aufirst%3DM.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DInterferon-%25CE%25B1-Dependent%2520Activation%2520of%2520Tyk2%2520Requires%2520Phosphorylation%2520of%2520Positive%2520Regulatory%2520Tyrosines%2520by%2520Another%2520Kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D20494%26epage%3D20500%26doi%3D10.1074%2Fjbc.271.34.20494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of Small Molecules Targeting the Pseudokinase Her3</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3382</span>– <span class="NLM_lpage">3389</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.bmcl.2015.04.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=26094118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3382-3389&author=S.+M.+Limauthor=T.+Xieauthor=K.+D.+Westoverauthor=S.+B.+Ficarroauthor=H.+S.+Taeauthor=D.+Gurbaniauthor=T.+Simauthor=J.+A.+Martoauthor=P.+A.+J%C3%A4nneauthor=C.+M.+Crewsauthor=N.+S.+Gray&title=Development+of+Small+Molecules+Targeting+the+Pseudokinase+Her3&doi=10.1016%2Fj.bmcl.2015.04.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of small molecules targeting the pseudokinase Her3</span></div><div class="casAuthors">Lim, Sang Min; Xie, Ting; Westover, Kenneth D.; Ficarro, Scott B.; Tae, Hyun Seop; Gurbani, Deepak; Sim, Taebo; Marto, Jarrod A.; Janne, Pasi A.; Crews, Craig M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3382-3389</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Her3 is a member of the human epidermal growth factor receptor (EGFR) tyrosine kinase family, and it is often either overexpressed or deregulated in many types of human cancer.  Her3 has not been the subject of small-mol. inhibitor development because it is a pseudokinase and does not possess appreciable kinase activity.  We recently reported on the development of the first selective irreversible Her3 ligand (TX1-85-1) that forms a covalent bond with cysteine 721 which is unique to Her3 among all kinases.  We also developed a bi-functional compd. (TX2-121-1) contg. a hydrophobic adamantane moiety and the same warhead of TX1-85-1 that is capable of inhibiting Her3-dependent signaling and growth.  Here we report on the structure-based medicinal chem. effort that resulted in the discovery of these two compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTq9SbGZsuHLVg90H21EOLACvtfcHk0ljqwOMzZUMNlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGmtr0%253D&md5=3c96eda91b3747000aaf0796fc20e357</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.103%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BM.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DTae%26aufirst%3DH.%2BS.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520Small%2520Molecules%2520Targeting%2520the%2520Pseudokinase%2520Her3%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3382%26epage%3D3389%26doi%3D10.1016%2Fj.bmcl.2015.04.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Novel Approaches for Targeting Kinases: Allosteric Inhibition, Allosteric Activation and Pseudokinases</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.4155/fmc.13.216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.4155%2Ffmc.13.216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24649957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=541-561&author=S.+W.+Cowan-Jacobauthor=W.+Jahnkeauthor=S.+Knapp&title=Novel+Approaches+for+Targeting+Kinases%3A+Allosteric+Inhibition%2C+Allosteric+Activation+and+Pseudokinases&doi=10.4155%2Ffmc.13.216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases</span></div><div class="casAuthors">Cowan-Jacob, Sandra W.; Jahnke, Wolfgang; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">541-561</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in many essential cellular processes and their deregulation can lead to a variety of diseases, including cancer.  The pharmaceutical industry has invested heavily in the identification of kinase inhibitors to modulate these disease-promoting pathways, resulting in several successful drugs.  However, the field is challenging as it is difficult to identify novel selective inhibitors with good pharmacokinetic/pharmacodynamic properties.  In addn., resistance to kinase inhibitor treatment frequently arises.  The identification of non-ATP site targeting ('allosteric') inhibitors, the identification of kinase activators and the expansion of kinase target space to include the less studied members of the family, including atypical- and pseudo-kinases, are potential avenues to overcome these challenges.  In this perspective, the opportunities and challenges of following these approaches and others will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtQaQbATcjnLVg90H21EOLACvtfcHk0ljqwOMzZUMNlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyiurk%253D&md5=74a540a959200628a065e287ea6e48d3</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.13.216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.13.216%26sid%3Dliteratum%253Aachs%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DNovel%2520Approaches%2520for%2520Targeting%2520Kinases%253A%2520Allosteric%2520Inhibition%252C%2520Allosteric%2520Activation%2520and%2520Pseudokinases%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D541%26epage%3D561%26doi%3D10.4155%2Ffmc.13.216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reiterer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhan, H.</span></span> <span> </span><span class="NLM_article-title">Day of the Dead: Pseudokinases and Pseudophosphatases in Physiology and Disease</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2014.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.tcb.2014.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24818526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVals7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=489-505&author=V.+Reitererauthor=P.+A.+Eyersauthor=H.+Farhan&title=Day+of+the+Dead%3A+Pseudokinases+and+Pseudophosphatases+in+Physiology+and+Disease&doi=10.1016%2Fj.tcb.2014.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">Day of the dead: pseudokinases and pseudophosphatases in physiology and disease</span></div><div class="casAuthors">Reiterer, Veronika; Eyers, Patrick A.; Farhan, Hesso</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">489-505</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pseudophosphatases and pseudokinases are increasingly viewed as integral elements of signaling pathways, and there is mounting evidence that they have frequently retained the ability to interact with cellular 'substrates', and can exert important roles in different diseases.  However, these pseudoenzymes have traditionally received scant attention compared to classical kinases and phosphatases.  In this review we explore new findings in the emerging pseudokinase and pseudophosphatase fields, and discuss their different modes of action which include exciting new roles as scaffolds, anchors, spatial modulators, traps, and ligand-driven regulators of canonical kinases and phosphatases.  Thus, it is now apparent that pseudokinases and pseudophosphatases both support and drive a panoply of signaling networks.  Finally, we highlight recent evidence on their involvement in human pathologies, marking them as potential novel drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQhlAbeCzFT7Vg90H21EOLACvtfcHk0ljqwOMzZUMNlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVals7Y%253D&md5=ab7719e24a3080439997957ba889ffd7</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2014.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2014.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DReiterer%26aufirst%3DV.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DFarhan%26aufirst%3DH.%26atitle%3DDay%2520of%2520the%2520Dead%253A%2520Pseudokinases%2520and%2520Pseudophosphatases%2520in%2520Physiology%2520and%2520Disease%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2014%26volume%3D24%26spage%3D489%26epage%3D505%26doi%3D10.1016%2Fj.tcb.2014.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span> <span> </span><span class="NLM_article-title">Dawn of the Dead: Protein Pseudokinases Signal New Adventures in Cell Biology</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">969</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1042/BST20130115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1042%2FBST20130115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=23863165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2msrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=969-974&author=P.+A.+Eyersauthor=J.+M.+Murphy&title=Dawn+of+the+Dead%3A+Protein+Pseudokinases+Signal+New+Adventures+in+Cell+Biology&doi=10.1042%2FBST20130115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35cR"><div class="casContent"><span class="casTitleNuber">35c</span><div class="casTitle"><span class="NLM_cas:atitle">Dawn of the dead: protein pseudokinases signal new adventures in cell biology</span></div><div class="casAuthors">Eyers, Patrick A.; Murphy, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">969-974</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent studies of proteins contg. kinase-like domains that lack catalytic residue(s) classically required for phosphotransfer, termed pseudokinases, have uncovered important roles in cell signalling across the kingdoms of life.  Addnl., mutations within pseudokinase domains are known to underlie human diseases, suggesting that these proteins may represent new and unexplored therapeutic targets.  To date, few pseudokinases have been studied in intricate detail, but as described in the present article and in the subsequent papers in this issue of Biochem. Society Transactions, several new studies have provided an advanced template and an improved framework for interrogating the roles of pseudokinases in signal transduction.  In the present article, the authors review landmarks in the establishment of this field of study, highlight some exptl. challenges and propose a simple scheme for definition of these domains based on their primary sequences, rather than exptl. defined nucleotide-binding or catalytic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJmZ4zTA9gZbVg90H21EOLACvtfcHk0littmaaSOryPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2msrrL&md5=8fd95f237debc9da4f61cd303fde39b0</span></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=10.1042%2FBST20130115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20130115%26sid%3Dliteratum%253Aachs%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26atitle%3DDawn%2520of%2520the%2520Dead%253A%2520Protein%2520Pseudokinases%2520Signal%2520New%2520Adventures%2520in%2520Cell%2520Biology%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2013%26volume%3D41%26spage%3D969%26epage%3D974%26doi%3D10.1042%2FBST20130115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span> <span> </span><span class="NLM_article-title">Kinase Drug Discovery--What’s Next in the Field?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/cb300610s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvF2q" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&issue=1&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+Drug+Discovery%2D%2DWhat%E2%80%99s+Next+in+the+Field%3F&doi=10.1021%2Fcb300610s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35dR"><div class="casContent"><span class="casTitleNuber">35d</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Drug Discovery - What's Next in the Field?</span></div><div class="casAuthors">Cohen, Philip; Alessi, Dario R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-104</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Over the past 15 years protein kinases have become the pharmaceutical industry's most important class of drug target in the field of cancer.  Some 20 drugs that target kinases have been approved for clin. use over the past decade, and hundreds more are undergoing clin. trials.  However, the recent approval of the first protein kinase inhibitors for the treatment of inflammatory diseases, coupled with an enhanced understanding of the signaling networks that control the immune system, suggests that there will be a surge of interest in this area over the next 10 years.  In this connection, we discuss opportunities for targeting protein kinases in the MyD88 signaling network for the development of drugs to treat chronic inflammatory and autoimmune diseases.  Activating mutations in protein kinases underlie many other diseases and conditions, and we also discuss why the protein kinases SPAK/OSR1 and LRRK2 have recently become interesting targets for the treatment of hypertension and Parkinson's disease, resp., and the progress that has been made in developing LRRK2 inhibitors.  Finally we suggest that more focus on the identification of inhibitors of kinase activation, rather than kinase activity, may pay dividends in identifying exquisitely specific inhibitors of signal transduction cascades, and we also highlight "pseudo-kinases" as an attractive and unexplored area for drug development that merits much more attention in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qmfkcqZ3ILVg90H21EOLACvtfcHk0littmaaSOryPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvF2q&md5=5bf2ced4163b6ae70e604b2916a6a068</span></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520Drug%2520Discovery--What%25E2%2580%2599s%2520Next%2520in%2520the%2520Field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26issue%3D1%26spage%3D96%26epage%3D104%26doi%3D10.1021%2Fcb300610s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span> <span> </span><span class="NLM_article-title">Prospects for Pharmacological Targeting of Pseudokinases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">526</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fs41573-019-0018-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=30850748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1GjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=501-526&author=J.+E.+Kungauthor=N.+Jura&title=Prospects+for+Pharmacological+Targeting+of+Pseudokinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35eR"><div class="casContent"><span class="casTitleNuber">35e</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for pharmacological targeting of pseudokinases</span></div><div class="casAuthors">Kung, Jennifer E.; Jura, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">501-526</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Pseudokinases are members of the protein kinase superfamily but signal primarily through noncatalytic mechanisms.  Many pseudokinases contribute to the pathologies of human diseases, yet they remain largely unexplored as drug targets owing to challenges assocd. with modulation of their biol. functions.  Our understanding of the structure and physiol. roles of pseudokinases has improved substantially over the past decade, revealing intriguing similarities between pseudokinases and their catalytically active counterparts.  Pseudokinases often adopt conformations that are analogous to those seen in catalytically active kinases and, in some cases, can also bind metal cations and/or nucleotides.  Several clin. approved kinase inhibitors have been shown to influence the noncatalytic functions of active kinases, providing hope that similar properties in pseudokinases could be pharmacol. regulated.  In this Review, we discuss known roles of pseudokinases in disease, their unique structural features and the progress that has been made towards developing pseudokinase-directed therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUFxQnlHTnn7Vg90H21EOLACvtfcHk0littmaaSOryPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1GjtLw%253D&md5=f3414770154e8d6449b454f9bc3f19bd</span></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0018-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0018-3%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DJ.%2BE.%26aulast%3DJura%26aufirst%3DN.%26atitle%3DProspects%2520for%2520Pharmacological%2520Targeting%2520of%2520Pseudokinases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D501%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kieltyka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W. Z.</span></span> <span> </span><span class="NLM_article-title">A High-Throughput Bioanalytical Platform Using Automated Infusion for Tandem Mass Spectrometric Method Optimization and its Application in a Metabolic Stability Screen</span>. <i>Rapid Commun. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1579</span>– <span class="NLM_lpage">1591</span>, <span class="refDoi"> DOI: 10.1002/rcm.4037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1002%2Frcm.4037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=19399765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1579-1591&author=K.+Kieltykaauthor=J.+Zhangauthor=S.+Liauthor=M.+Vathauthor=C.+Baglieriauthor=C.+Ferraroauthor=T.+A.+Zvyagaauthor=D.+M.+Drexlerauthor=H.+N.+Wellerauthor=W.+Z.+Shou&title=A+High-Throughput+Bioanalytical+Platform+Using+Automated+Infusion+for+Tandem+Mass+Spectrometric+Method+Optimization+and+its+Application+in+a+Metabolic+Stability+Screen&doi=10.1002%2Frcm.4037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span></div><div class="casAuthors">Kieltyka, Kasia; Zhang, Jun; Li, Shu; Vath, Marianne; Baglieri, Chris; Ferraro, Cheryl; Zvyaga, Tatyana A.; Drexler, Dieter M.; Weller, Harold N.; Shou, Wilson Z.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1579-1591</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Liq. chromatog./tandem mass spectrometry (LC/MS/MS) is the bioanal. method of choice to support plate-based, in vitro early ADME (Absorption, Distribution, Metab. and Excretion) screens such as metabolic stability (Metstab) assessment.  MS/MS method optimization has historically been the bottleneck in this environment, where samples from thousands of discrete compds. are analyzed on a monthly basis, mainly due to the lack of a high-quality com. available platform to handle the necessary MS/MS method optimization steps for sample anal. by selected reaction monitoring (SRM) on triple quadrupole mass spectrometers.  To address this challenge, we recently developed a highly automated bioanal. platform by successfully integrating QuickQuan 2.0, a unique high-throughput soln. featuring MS/MS method optimization by automated infusion, with a customized inhouse software tool in support of a Metstab screen.  In this platform, a dual-column setup running parallel chromatog. was also implemented to reduce the bioanal. cycle time for LC/MS/MS sample anal.  A set of 45 validation compds. was used to demonstrate the speed, quality and reproducibility of MS/MS method optimization, sample anal., and data processing using this automated platform.  Metstab results for the validation compds. in microsomes from multiple species (human, rat, mouse) showed good consistency within each batch, and also between batches conducted on different days.  We have achieved and maintained a monthly throughput of 1300 compd. assays representing 500 discrete compds. per instrument per mo on this platform, and it has been used to generate metabolic stability data for more than 25 000 compds. to date with an overall success rate of more than 95%.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8W1PNTqYnALVg90H21EOLACvtfcHk0ljhMqwVHlZE7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D&md5=57977322942dc41955c1d9cf015e5b05</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Frcm.4037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.4037%26sid%3Dliteratum%253Aachs%26aulast%3DKieltyka%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DVath%26aufirst%3DM.%26aulast%3DBaglieri%26aufirst%3DC.%26aulast%3DFerraro%26aufirst%3DC.%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DDrexler%26aufirst%3DD.%2BM.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26aulast%3DShou%26aufirst%3DW.%2BZ.%26atitle%3DA%2520High-Throughput%2520Bioanalytical%2520Platform%2520Using%2520Automated%2520Infusion%2520for%2520Tandem%2520Mass%2520Spectrometric%2520Method%2520Optimization%2520and%2520its%2520Application%2520in%2520a%2520Metabolic%2520Stability%2520Screen%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2009%26volume%3D23%26spage%3D1579%26epage%3D1591%26doi%3D10.1002%2Frcm.4037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="note"><p class="first last">LE = pIC<sub>50</sub> (bind)/#non-H atoms; LLE = pIC<sub>50</sub> (bind) – log <i>P</i>(or clogP). For a discussion of ligand efficiency pertaining to drug discovery, see:</p></div><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The Role of Ligand Efficiency Metrics in Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+Role+of+Ligand+Efficiency+Metrics+in+Drug+Discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0ljhMqwVHlZE7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520Role%2520of%2520Ligand%2520Efficiency%2520Metrics%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="note"><p class="first last">The other four kinases were JAK1 JH2 (19 nM), cKit (26 nM), FLT3 (412 nM), and Tyro (881 nM).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="note"><p class="first last">Trb3, Trio, Tnik, Mink, Hgk, Cot, Tyro3, Bmpr2, and Cygd (based on a sequence alignment of kinase domains).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanzlik, R. P.</span></span> <span> </span><span class="NLM_article-title">Kinetic Deuterium Isotope Effects on the N-Demethylation of Tertiary Amides by Cytochrome P-450</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>265</i></span>,  <span class="NLM_fpage">12349</span>– <span class="NLM_lpage">12355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=2373695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADyaK3cXlsVOqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1990&pages=12349-12355&author=L.+R.+Hallauthor=R.+P.+Hanzlik&title=Kinetic+Deuterium+Isotope+Effects+on+the+N-Demethylation+of+Tertiary+Amides+by+Cytochrome+P-450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic deuterium isotope effects on the N-demethylation of tertiary amides by cytochrome P-450</span></div><div class="casAuthors">Hall, Larry R.; Hanzlik, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12349-55</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Liver microsomal cytochrome P 450 (tertiary methylamide demethylase) readily N-dealkylates N,N-dimethylamides.  N-Methyl-N-hydroxymethyl amides were isolated as intermediates and characterized by gas chromatograph-mass spectrometry as their trimethylsilyl ethers.  Intramol. kinetic deuterium isotope effects measured for the enzymic N-demethylation of a series of 12 arom. and aliph. N-methyl-N-trideuteriomethyl amides, RCON(CH3)CD3, varied from 3.6 to 6.9 but were independent of both amide bond rotation rate and substrate oxidn. potential.  These values, which represent a lower limit to the intrinsic isotope effect (Dkintrinsic), are significantly larger than those obsd. for anodic N-demethylation and are consistent with a mechanism involving H atom abstraction.  On the other hand, with N,N-dimethylbenzamide the intermol. kinetic deuterium isotope effects on Vmax and Vmax/Km were found to be much smaller (1.23 and 1.75, resp.) indicating substantial suppression of the intrinsic isotope effect.  Such suppression indicates the occurrence of a rate-limiting step other than the isotopically sensitive step together with a strong commitment to catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzuI60P-pveLVg90H21EOLACvtfcHk0lhFkXNhJQTG3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlsVOqs78%253D&md5=66fb98eeae0b9936464b4eada4bb4fbc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DL.%2BR.%26aulast%3DHanzlik%26aufirst%3DR.%2BP.%26atitle%3DKinetic%2520Deuterium%2520Isotope%2520Effects%2520on%2520the%2520N-Demethylation%2520of%2520Tertiary%2520Amides%2520by%2520Cytochrome%2520P-450%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1990%26volume%3D265%26spage%3D12349%26epage%3D12355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">Using CD<sub>3</sub> to significantly reduce formation of the primary amide metabolite in vivo was generally applicable, proving successful for all nicotinamides and pyridazine amides tested to date.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edling, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallberg, B.</span></span> <span> </span><span class="NLM_article-title">c-Kit--a Hematopoietic Cell Essential Receptor Kinase</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1995</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2006.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.biocel.2006.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=17350321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWmur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=1995-1998&author=C.+E.+Edlingauthor=B.+Hallberg&title=c-Kit%2D%2Da+Hematopoietic+Cell+Essential+Receptor+Kinase&doi=10.1016%2Fj.biocel.2006.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">c-Kit-A hematopoietic cell essential receptor tyrosine kinase</span></div><div class="casAuthors">Edling, Charlotte E.; Hallberg, Bengt</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1995-1998</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase c-Kit is expressed in hematopoietic stem and progenitor cells and in several non-hematopoietic tissues.  In the hematopoietic system, c-Kit is crit. for proliferation, survival and differentiation.  During recent years exploration of the signaling pathways downstream of this receptor has yielded significant new insights in the field.  In this review, we will summarize the c-Kit background, structure, downstream signaling and medical significance with particular focus on its role in hematopoietic progenitor cells and mast cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprkHCEEm6AQrVg90H21EOLACvtfcHk0lhFkXNhJQTG3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWmur7E&md5=c9c4ceaf53e2c63a8ef0aba712b524fc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2006.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2006.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DEdling%26aufirst%3DC.%2BE.%26aulast%3DHallberg%26aufirst%3DB.%26atitle%3Dc-Kit--a%2520Hematopoietic%2520Cell%2520Essential%2520Receptor%2520Kinase%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2007%26volume%3D39%26spage%3D1995%26epage%3D1998%26doi%3D10.1016%2Fj.biocel.2006.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+of+hERG+Optimizations%3A+Highlights+and+Hang-Ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lhFkXNhJQTG3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520of%2520hERG%2520Optimizations%253A%2520Highlights%2520and%2520Hang-Ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirripa, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ransom, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R. S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detwiler, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hettrick, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettibone, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freidinger, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bock, M. G.</span></span> <span> </span><span class="NLM_article-title">Cyclopropylamino Acid as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B<sub>1</sub> Receptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1234</span>, <span class="refDoi"> DOI: 10.1021/jm0511280</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0511280" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlWmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1231-1234&author=M.+R.+Woodauthor=K.+M.+Schirripaauthor=J.+J.+Kimauthor=B.-L.+Wanauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=R.+S.+L.+Changauthor=C.+Tangauthor=T.+Prueksaritanontauthor=T.+J.+Detwilerauthor=L.+A.+Hettrickauthor=E.+R.+Landisauthor=Y.+M.+Leonardauthor=J.+A.+Kruegerauthor=S.+D.+Lewisauthor=D.+J.+Pettiboneauthor=R.+M.+Freidingerauthor=M.+G.+Bock&title=Cyclopropylamino+Acid+as+a+Pharmacophoric+Replacement+for+2%2C3-Diaminopyridine.+Application+to+the+Design+of+Novel+Bradykinin+B1+Receptor+Antagonists&doi=10.1021%2Fjm0511280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclopropylamino Acid Amide as a Pharmacophoric Replacement for 2,3-Diaminopyridine. Application to the Design of Novel Bradykinin B1 Receptor Antagonists</span></div><div class="casAuthors">Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Wan, Bang-Lin; Murphy, Kathy L.; Ransom, Richard W.; Chang, Raymond S. L.; Tang, Cuyue; Prueksaritanont, Thomayant; Detwiler, Theodore J.; Hettrick, Lisa A.; Landis, Elizabeth R.; Leonard, Yvonne M.; Krueger, Julie A.; Lewis, Sidney D.; Pettibone, Douglas J.; Freidinger, Roger M.; Bock, Mark G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1231-1234</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antagonism of the bradykinin B1 receptor represents a potential treatment for chronic pain and inflammation.  Novel antagonists were designed that display low-nanomolar affinity for the human bradykinin B1 receptor and good bioavailability in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHLP_4qFDI8bVg90H21EOLACvtfcHk0li6mQKBe0etzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlWmsQ%253D%253D&md5=70df384ebdceb569fadd3bb45f053a07</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm0511280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0511280%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DSchirripa%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DChang%26aufirst%3DR.%2BS.%2BL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DDetwiler%26aufirst%3DT.%2BJ.%26aulast%3DHettrick%26aufirst%3DL.%2BA.%26aulast%3DLandis%26aufirst%3DE.%2BR.%26aulast%3DLeonard%26aufirst%3DY.%2BM.%26aulast%3DKrueger%26aufirst%3DJ.%2BA.%26aulast%3DLewis%26aufirst%3DS.%2BD.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DFreidinger%26aufirst%3DR.%2BM.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DCyclopropylamino%2520Acid%2520as%2520a%2520Pharmacophoric%2520Replacement%2520for%25202%252C3-Diaminopyridine.%2520Application%2520to%2520the%2520Design%2520of%2520Novel%2520Bradykinin%2520B1%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1231%26epage%3D1234%26doi%3D10.1021%2Fjm0511280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="note"><p class="first last">For reviews on the use of pyridazine in medicinal chemistry, see:</p></div><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span> <span> </span><span class="NLM_article-title">The Developability of Heteroaromatic and Heteroaliphatic Rings – do Some Have a Better Pedigree as Potential Drug Molecules than Others?</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1062</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1039/c2md20111a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1039%2Fc2md20111a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1062-1069&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=S.+Peaceauthor=S.+D.+Pickettauthor=C.+N.+Luscombe&title=The+Developability+of+Heteroaromatic+and+Heteroaliphatic+Rings+%E2%80%93+do+Some+Have+a+Better+Pedigree+as+Potential+Drug+Molecules+than+Others%3F&doi=10.1039%2Fc2md20111a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">The developability of heteroaromatic and heteroaliphatic rings - do some have a better pedigree as potential drug molecules than others?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Peace, Simon; Pickett, Stephen D.; Luscombe, Christopher N.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1062-1069</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Aq. soly., protein binding and CYP450 inhibition data for compds. contg. a variety of heteroarom. and heteroaliph. rings were analyzed and compared to det. which ring types fared best and worst in these developability screens.  The results suggest that certain heterorings are generally more developable than others: how this information may be used and some caveats to be borne in mind are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCkxdTaUGig7Vg90H21EOLACvtfcHk0li6mQKBe0etzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE&md5=6aad4bc48b351d9d20683ee9af1a3354</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1039%2Fc2md20111a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20111a%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26atitle%3DThe%2520Developability%2520of%2520Heteroaromatic%2520and%2520Heteroaliphatic%2520Rings%2520%25E2%2580%2593%2520do%2520Some%2520Have%2520a%2520Better%2520Pedigree%2520as%2520Potential%2520Drug%2520Molecules%2520than%2520Others%253F%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1062%26epage%3D1069%26doi%3D10.1039%2Fc2md20111a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span> <span> </span><span class="NLM_article-title">Are Pyridazines Privileged Structures?</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">941</span>, <span class="refDoi"> DOI: 10.1039/c1md00074h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1039%2Fc1md00074h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Oqu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=935-941&author=C.+G.+Wermuth&title=Are+Pyridazines+Privileged+Structures%3F&doi=10.1039%2Fc1md00074h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Are pyridazines privileged structures?</span></div><div class="casAuthors">Wermuth, Camille G.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">935-941</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  One can est. that about 50% of all the drug mols. used in medicine contain a Ph ring which can be substituted or not.  The bioisosteric replacement of these Ph rings by the corresponding pyridazine rings opens an access to several thousands of diaza analogs presenting more interaction possibilities, lower Log P values and improved cryst. salts.  The use of pyridazine scaffolds in place of Ph scaffolds entails addnl. interaction possibilities.  Another interest of pyridazines is their capacity to act as original functional surrogates.  Thus, aminopyridazines can be used as carboxamide, as well as amine surrogates.  Finally, the many examples of pyridazines used either as a structural element or as a main scaffold, justify largely their status as privileged structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTuMqekrcmc7Vg90H21EOLACvtfcHk0li_x1kpWfaunQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Oqu7bO&md5=0693fec05e567555cf183e97f0df6852</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1039%2Fc1md00074h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1md00074h%26sid%3Dliteratum%253Aachs%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26atitle%3DAre%2520Pyridazines%2520Privileged%2520Structures%253F%26jtitle%3DMedChemComm%26date%3D2011%26volume%3D2%26spage%3D935%26epage%3D941%26doi%3D10.1039%2Fc1md00074h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brameld, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Questel, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, E.</span></span> <span> </span><span class="NLM_article-title">The p<i>K</i><sub><i>BHX</i></sub> Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4073</span>– <span class="NLM_lpage">4086</span>, <span class="refDoi"> DOI: 10.1021/jm801331y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801331y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4073-4086&author=C.+Laurenceauthor=K.+A.+Brameldauthor=J.+Gratonauthor=J.-Y.+Le+Questelauthor=E.+Renault&title=The+pKBHX+Database%3A+Toward+a+Better+Understanding+of+Hydrogen-Bond+Basicity+for+Medicinal+Chemists&doi=10.1021%2Fjm801331y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists</span></div><div class="casAuthors">Laurence, Christian; Brameld, Ken A.; Graton, Jerome; Le Questel, Jean-Yves; Renault, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4073-4086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pKBHX database is presented, which corresponds to three main fields of data: hydrogen bond donor identification, thermodn. data and spectroscopic data.  The pKBHX scale of hydrogen donor basicity differs considerable from the pKBH+ scale of proton transfer basicity.  The hydrogen bond basicities of functional groups relevant to medicinal chem. and drug design is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9OhmMu2VILVg90H21EOLACvtfcHk0li_x1kpWfaunQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D&md5=9ce4bea3e810752baba6ea5784b55ea0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm801331y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801331y%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DC.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DGraton%26aufirst%3DJ.%26aulast%3DLe%2BQuestel%26aufirst%3DJ.-Y.%26aulast%3DRenault%26aufirst%3DE.%26atitle%3DThe%2520pKBHX%2520Database%253A%2520Toward%2520a%2520Better%2520Understanding%2520of%2520Hydrogen-Bond%2520Basicity%2520for%2520Medicinal%2520Chemists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4073%26epage%3D4086%26doi%3D10.1021%2Fjm801331y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="note"><p class="first last">Dosed in 5:5:90 EtOH:TPGS:PEG 300.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhlig, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce-Shaikh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepankova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonocore, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tlaskalova-Hogenova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cua, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powrie, F.</span></span> <span> </span><span class="NLM_article-title">Differential Activity of IL-12 and IL-23 in Mucosal and Systemic Innate Immune Pathology</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2006.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=10.1016%2Fj.immuni.2006.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=16919486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVGjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=309-318&author=H.+H.+Uhligauthor=B.+S.+McKenzieauthor=S.+Hueauthor=C.+Thompsonauthor=B.+Joyce-Shaikhauthor=R.+Stepankovaauthor=N.+Robinsonauthor=S.+Buonocoreauthor=H.+Tlaskalova-Hogenovaauthor=D.+J.+Cuaauthor=F.+Powrie&title=Differential+Activity+of+IL-12+and+IL-23+in+Mucosal+and+Systemic+Innate+Immune+Pathology&doi=10.1016%2Fj.immuni.2006.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology</span></div><div class="casAuthors">Uhlig, Holm H.; McKenzie, Brent S.; Hue, Sophie; Thompson, Claire; Joyce-Shaikh, Barbara; Stepankova, Renata; Robinson, Nicolas; Buonocore, Sofia; Tlaskalova-Hogenova, Helena; Cua, Daniel J.; Powrie, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">309-318</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The CD40-CD154 pathway is important in the pathogenesis of inflammatory bowel disease.  Here we show that injection of an agonistic CD40 mAb to T and B cell-deficient mice was sufficient to induce a pathogenic systemic and intestinal innate inflammatory response that was functionally dependent on tumor necrosis factor-α and interferon-γ as well as interleukin-12 p40 and interleukin-23 p40 secretion.  CD40-induced colitis, but not wasting disease or serum proinflammatory cytokine prodn., depended on interleukin-23 p19 secretion, whereas interleukin-12 p35 secretion controlled wasting disease and serum cytokine prodn. but not mucosal immunopathol.  Intestinal inflammation was assocd. with IL-23 (p19) mRNA-producing intestinal dendritic cells and IL-17A mRNA within the intestine.  Our expts. identified IL-23 as an effector cytokine within the innate intestinal immune system.  The differential role of IL-23 in local but not systemic inflammation suggests that it may make a more specific target for the treatment of IBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj3dkf8LiElLVg90H21EOLACvtfcHk0li_x1kpWfaunQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVGjsrk%253D&md5=25d70c2a9cdd7ea34fce7981a14340c6</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2006.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2006.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DUhlig%26aufirst%3DH.%2BH.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DHue%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DJoyce-Shaikh%26aufirst%3DB.%26aulast%3DStepankova%26aufirst%3DR.%26aulast%3DRobinson%26aufirst%3DN.%26aulast%3DBuonocore%26aufirst%3DS.%26aulast%3DTlaskalova-Hogenova%26aufirst%3DH.%26aulast%3DCua%26aufirst%3DD.%2BJ.%26aulast%3DPowrie%26aufirst%3DF.%26atitle%3DDifferential%2520Activity%2520of%2520IL-12%2520and%2520IL-23%2520in%2520Mucosal%2520and%2520Systemic%2520Innate%2520Immune%2520Pathology%26jtitle%3DImmunity%26date%3D2006%26volume%3D25%26spage%3D309%26epage%3D318%26doi%3D10.1016%2Fj.immuni.2006.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0ljtLKRZWVfWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZE','PDB','6NZE'); return false;">PDB: 6NZE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZF','PDB','6NZF'); return false;">PDB: 6NZF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZH','PDB','6NZH'); return false;">PDB: 6NZH</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i66"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00443">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_63464"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00443">10.1021/acs.jmedchem.9b00443</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">X-ray crystallographic data and refinement statistics for compounds <b>5</b>, <b>23</b>, and <b>40</b> in TYK2 JH2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00443/suppl_file/jm9b00443_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings available for all compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00443/suppl_file/jm9b00443_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00443/suppl_file/jm9b00443_si_001.pdf">jm9b00443_si_001.pdf (147.33 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00443/suppl_file/jm9b00443_si_002.csv">jm9b00443_si_002.csv (2.72 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structures of compound <b>5</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZE">6NZE</a>), <b>23</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZF">6NZF</a>), and <b>40</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZH">6NZH</a>) in TYK2 JH2 are available from the RCSB Protein Data Bank (<a href="http://www.rscb.org" class="extLink">www.rscb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00443%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00443" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797c4e8d29d1bf","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
